0001104659-15-055905.txt : 20150804 0001104659-15-055905.hdr.sgml : 20150804 20150804162800 ACCESSION NUMBER: 0001104659-15-055905 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20150630 FILED AS OF DATE: 20150804 DATE AS OF CHANGE: 20150804 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ABBOTT LABORATORIES CENTRAL INDEX KEY: 0000001800 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 360698440 STATE OF INCORPORATION: IL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-02189 FILM NUMBER: 151025921 BUSINESS ADDRESS: STREET 1: 100 ABBOTT PARK ROAD STREET 2: D-322 AP6D CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 BUSINESS PHONE: 8479376100 10-Q 1 a15-11917_110q.htm 10-Q

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2015

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File No. 1-2189

ABBOTT LABORATORIES

An Illinois Corporation				I.R.S. Employer Identification No.
				36-0698440

100 Abbott Park Road

Abbott Park, Illinois 60064-6400

Telephone: (224) 667-6100

Indicate by check mark whether the registrant: (l) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of l934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large Accelerated Filer x	Accelerated Filer o

Non-Accelerated Filer o	Smaller reporting company o
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

As of June 30, 2015, Abbott Laboratories had 1,490,441,465 common shares without par value outstanding.

Table of Contents

Abbott Laboratories

Table of Contents

Part I - Financial Information

	Page
Item 1. Financial Statements and Supplementary Data

Condensed Consolidated Statement of Earnings	3
Condensed Consolidated Statement of Comprehensive Income	4
Condensed Consolidated Balance Sheet	5
Condensed Consolidated Statement of Cash Flows	6
Notes to the Condensed Consolidated Financial Statements	7

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	18

Item 3. Quantitative and Qualitative Disclosures about Market Risk	25

Item 4. Controls and Procedures	25

Part II - Other Information

Item 1. Legal Proceedings	25

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	26

Item 6. Exhibits	26

Signature	27

Table of Contents

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Earnings

(Unaudited)

(dollars in millions except per share data; shares in thousands)

	Three Months Ended						Six Months Ended
	June 30						June 30
	2015			2014			2015			2014
Net sales	$	5,170		$	5,057		$	10,067		$	9,812

Cost of products sold, excluding amortization of intangible assets	2,218			2,288			4,299			4,562
Amortization of intangible assets	151			133			307			260
Research and development	345			310			658			679
Selling, general and administrative	1,727			1,649			3,464			3,269
Total operating cost and expenses	4,441			4,380			8,728			8,770

Operating earnings	729			677			1,339			1,042

Interest expense	44			36			81			72
Interest (income)	(27		)	(19		)	(48		)	(35		)
Net foreign exchange loss (gain)	5			—			(49		)	1
Other (income) expense, net	(279		)	2			(284		)	5
Earnings from continuing operations before taxes	986			658			1,639			999
Taxes on earnings from continuing operations	200			233			324			350
Earnings from continuing operations	786			425			1,315			649

Earnings (loss) from discontinued operations, net of taxes	(1		)	41			25			192
Gain (loss) on sale of discontinued operations, net of tax	(1		)	—			1,736			—
Net earnings (loss) from discontinued operations, net of tax	(2		)	41			1,761			192
Net Earnings	$	784		$	466		$	3,076		$	841

Basic Earnings Per Common Share —
Continuing operations	$	0.52		$	0.28		$	0.87		$	0.42
Discontinued operations	—			0.03			1.17			0.13
Net earnings	$	0.52		$	0.31		$	2.04		$	0.55

Diluted Earnings Per Common Share —
Continuing operations	$	0.52		$	0.28		$	0.87		$	0.42
Discontinued operations	—			0.02			1.16			0.13
Net earnings	$	0.52		$	0.30		$	2.03		$	0.55

Cash Dividends Declared Per Common Share	$	0.24		$	0.22		$	0.48		$	0.44

Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share	1,493,771			1,506,595			1,500,285			1,521,668
Dilutive Common Stock Options	10,444			10,451			10,676			10,605

Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options	1,504,215			1,517,046			1,510,961			1,532,273

Outstanding Common Stock Options Having No Dilutive Effect	658			544			658			544

The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.

Table of Contents

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Comprehensive Income

(Unaudited)

(dollars in millions)

	Three Months Ended						Six Months Ended
	June 30						June 30
	2015			2014			2015			2014
Net Earnings	$	784		$	466		$	3,076		$	841
Foreign currency translation (loss) gain adjustments	84			(19		)	(827		)	43
Net actuarial gains (losses) and amortization of net actuarial (losses) and prior service (cost) and credits, net of taxes of $10 and $25 in 2015 and $7 and $15 in 2014	22			12			53			28
Unrealized gains (losses) on marketable equity securities, net of taxes of $256 and $344 in 2015 and $(2) and $(2) in 2014	522			(4		)	695			(4		)
Net adjustments for derivative instruments designated as cash flow hedges and other, net of taxes of $(6) and nil in 2015 and $(2) and $(2) in 2014	(25		)	(7		)	1			(7		)
Other comprehensive income (loss)	603			(18		)	(78		)	60
Comprehensive Income	$	1,387		$	448		$	2,998		$	901

Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax:							June 30, 2015			December 31, 2014
Cumulative foreign currency translation (loss) adjustments							$	(3,643	)	$	(2,924	)
Net actuarial (losses) and prior service cost and credits							(2,157		)	(2,229		)
Cumulative unrealized gains on marketable equity securities							696			1
Cumulative gains (losses) on derivative instruments designated as cash flow hedges and other							100			99

The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.

Table of Contents

Abbott Laboratories and Subsidiaries

Condensed Consolidated Balance Sheet

(Unaudited)

(dollars in millions)

	June 30, 2015			December 31, 2014
Assets
Current Assets:
Cash and cash equivalents	$	4,048		$	4,063
Short-term investments	7,129			397
Trade receivables, less allowances of $362 in 2015 and $310 in 2014	3,553			3,586
Inventories:
Finished products	1,869			1,807
Work in process	303			278
Materials	563			558
Total inventories	2,735			2,643
Prepaid expenses, deferred income taxes, and other receivables	3,573			3,680
Current assets held for disposition	93			892
Total Current Assets	21,131			15,261
Investments	243			229
Property and equipment, at cost	12,433			12,632
Less: accumulated depreciation and amortization	6,695			6,697
Net property and equipment	5,738			5,935
Intangible assets, net of amortization	5,785			6,198
Goodwill	9,896			10,067
Deferred income taxes and other assets	1,330			1,651
Non-current assets held for disposition	2			1,934
	$	44,125		$	41,275
Liabilities and Shareholders’ Investment
Current Liabilities:
Short-term borrowings	$	2,867		$	4,382
Trade accounts payable	1,000			1,064
Salaries, wages and commissions	759			776
Other accrued liabilities	3,288			2,943
Dividends payable	358			362
Income taxes payable	589			270
Current portion of long-term debt	32			55
Current liabilities held for disposition	292			680
Total Current Liabilities	9,185			10,532
Long-term debt	5,862			3,408
Post-employment obligations, deferred income taxes and other long-term liabilities	5,952			5,588
Non-current liabilities held for disposition	—			108
Commitments and Contingencies
Shareholders’ Investment:
Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued	—			—
Common shares, without par value Authorized - 2,400,000,000 shares Issued at stated capital amount - Shares: 2015: 1,699,703,688; 2014: 1,694,929,949	12,566			12,383
Common shares held in treasury, at cost - Shares: 2015: 209,262,223; 2014: 186,894,515	(9,716		)	(8,678		)
Earnings employed in the business	25,162			22,874
Accumulated other comprehensive income (loss)	(5,004		)	(5,053		)
Total Abbott Shareholders’ Investment	23,008			21,526
Noncontrolling Interests in Subsidiaries	118			113
Total Shareholders’ Investment	23,126			21,639
	$	44,125		$	41,275

The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.

Table of Contents

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Cash Flows

(Unaudited)

(dollars in millions)

	Six Months Ended June 30
	2015			2014
Cash Flow From (Used in) Operating Activities:
Net earnings	$	3,076		$	841
Adjustments to reconcile net earnings to net cash from operating activities -
Depreciation	416			463
Amortization of intangibles	307			335
Share-based compensation	205			168
Gain on sale of discontinued operations	(2,820		)	—
Gain on sale of Mylan shares	(207		)	—
Trade receivables	(125		)	(76		)
Inventories	(210		)	(141		)
Other, net	301			(354		)
Net Cash From Operating Activities	943			1,236

Cash Flow From (Used in) Investing Activities:
Acquisitions of property and equipment	(451		)	(513		)
Proceeds from business disposition	230			—
Acquisitions of businesses and technologies, net of cash acquired	(4		)	—
Proceeds from the sale of Mylan shares	2,290			—
(Purchases) Sales of other investment securities, net	(2,056		)	1,119
Other	28			27
Net Cash From Investing Activities	37			633

Cash Flow From (Used in) Financing Activities:
Net (repayments of ) proceeds from issuance of short-term debt and other	(1,518		)	872
Proceeds from the issuance of long-term debt	2,485			—
Repayments of long-term debt	(33		)	—
Purchases of common shares	(1,347		)	(2,193		)
Proceeds from stock options exercised, including income tax benefit	213			226
Dividends paid	(724		)	(676		)
Net Cash (Used in) Financing Activities	(924		)	(1,771		)

Effect of exchange rate changes on cash and cash equivalents	(71		)	(3		)

Net Increase (Decrease) in Cash and Cash Equivalents	(15		)	95
Cash and Cash Equivalents, Beginning of Year	4,063			3,475
Cash and Cash Equivalents, End of Period	$	4,048		$	3,570

The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

June 30, 2015

(Unaudited)

Note 1 — Basis of Presentation

The accompanying unaudited, condensed consolidated financial statements have been prepared pursuant to rules and regulations of the Securities and Exchange Commission and, therefore, do not include all information and footnote disclosures normally included in audited financial statements. However, in the opinion of management, all adjustments (which include only normal adjustments) necessary to present fairly the results of operations, financial position and cash flows have been made. It is suggested that these statements be read in conjunction with the financial statements included in Abbott’s Annual Report on Form 10-K for the year ended December 31, 2014. The consolidated financial statements include the accounts of the parent company and subsidiaries, after elimination of intercompany transactions.

Note 2 — Discontinued Operations

On February 27, 2015, Abbott completed the sale of its developed markets branded generics pharmaceuticals business to Mylan Inc. (Mylan) for 110 million shares (or approximately 22%) of a newly formed entity (Mylan N.V.) that combined Mylan’s existing business and Abbott’s developed markets branded generics pharmaceuticals business. Mylan N.V. is publicly traded. Historically, this business was included in Abbott’s Established Pharmaceutical Products segment. Abbott retained its branded generics pharmaceuticals business in emerging markets. At the date of closing, the 110 million Mylan N.V. shares that Abbott received were valued at $5.77 billion and Abbott recorded an after-tax gain on the sale of the business of approximately $1.6 billion. The shareholder agreement with Mylan N.V. includes voting and other restrictions that prevent Abbott from exercising significant influence over the operating and financial policies of Mylan N.V.

At the close of this transaction, Abbott and Mylan entered into transition services agreements pursuant to which Abbott and Mylan are providing various back office support services to each other on an interim transitional basis. Transition services may be provided for up to 2 years. Charges by Abbott under these transition services agreements are recorded as a reduction of the costs to provide the respective service in the applicable expense category in the Condensed Consolidated Statement of Earnings. This transition support does not constitute significant continuing involvement in Mylan’s operations. Abbott also entered into manufacturing supply agreements with Mylan related to certain products, with the supply term ranging from 3 to 10 years and requiring a 2 year notice prior to termination. The cash flows associated with these transition service and manufacturing supply agreements are not expected to be significant and therefore, these cash flows are not direct cash flows of the disposed component under Accounting Standards Codification 205.

In April 2015, Abbott sold 40.3 million of the 110 million ordinary shares of Mylan N.V. received in the sale of the developed markets branded generics pharmaceuticals business to Mylan. In the second quarter of 2015, Abbott recorded a pretax gain of $207 million on $2.29 billion in net proceeds from the sale of these shares. The gain is recognized in the Other (income) expense line of the Condensed Consolidated Statement of Earnings. The proceeds from the sale were invested in short-term investments.

On February 10, 2015, Abbott completed the sale of its animal health business to Zoetis Inc. Abbott received cash proceeds of $230 million and reported an after tax gain on the sale of approximately $130 million.

As a result of the disposition of the above businesses, the current and prior year operating results of these businesses up to the date of sale are reported as part of discontinued operations on the Earnings from Discontinued Operations, net of tax line in the Condensed Consolidated Statement of Earnings. Discontinued operations include an allocation of interest expense assuming a uniform ratio of consolidated debt to equity for all of Abbott’s historical operations.

On January 1, 2013, Abbott completed the separation of AbbVie Inc. (AbbVie), which was formed to hold Abbott’s research-based proprietary pharmaceuticals business. For a small portion of AbbVie’s operations, the legal transfer of AbbVie’s assets (net of liabilities) did not occur with the separation of AbbVie on January 1, 2013 due to the time required to transfer marketing authorizations and other regulatory requirements in each of these countries. Under the terms of the separation agreement with Abbott, AbbVie is subject to the risks and entitled to the benefits generated by these operations and assets. The majority of these operations were transferred to AbbVie in 2013 and 2014. These assets and liabilities have been presented as held for disposition in the Condensed Consolidated Balance Sheet. Abbott has recorded a prepaid asset of $210 million for its obligation to transfer these net liabilities held for disposition to AbbVie.

Table of Contents

Abbott has retained all liabilities for all U.S. federal and foreign income taxes on income prior to the separation, as well as certain non-income taxes attributable to AbbVie’s business prior to the separation. AbbVie generally will be liable for all other taxes attributable to its business. Earnings from discontinued operations in the first six months of 2015 and 2014 reflect the recognition of $17 million and $42 million, respectively, of net tax benefits primarily as a result of the resolution of various tax positions related to AbbVie’s operations for years prior to the separation. The following table summarizes the components of discontinued operations:

	Three Months Ended June 30						Six Months Ended June 30
(in millions)	2015			2014			2015			2014
Net Sales
Developed markets generics pharmaceuticals and animal health businesses	$	—		$	494		$	256		$	983
AbbVie	—			—			—			—
Total	$	—		$	494		$	256		$	983
Earnings (Loss) Before Tax
Developed markets generics pharmaceuticals and animal health businesses	$	(5	)	$	79		$	20		$	161
AbbVie	—			—			—			—
Total	$	(5	)	$	79		$	20		$	161
Income Tax Expense (Benefit)
Developed markets generics pharmaceuticals and animal health businesses	$	—		$	44		$	12		$	11
AbbVie	(4		)	(6		)	(17		)	(42		)
Total	$	(4	)	$	38		$	(5	)	$	(31	)
Net Earnings
Developed markets generics pharmaceuticals and animal health businesses	$	(5	)	$	35		$	8		$	150
AbbVie	4			6			17			42
Total	$	(1	)	$	41		$	25		$	192

The sale of the developed markets branded generics pharmaceuticals and animal health businesses in the first six months of 2015 resulted in the recognition of a pretax gain of $2.820 billion, tax expense of $1.084 billion and an after tax gain of $1.736 billion.

The assets of the operations held for disposition and the liabilities to be assumed in the disposition related to the businesses noted above, as well as the AbbVie assets and liabilities are classified as held for disposition in the Condensed Consolidated Balance Sheet as of June 30, 2015 and December 31, 2014. The cash flows associated with the developed markets branded generics pharmaceuticals and animal health businesses are included in Abbott’s Condensed Consolidated Statement of Cash Flows up to the date of disposition.

The following is a summary of the assets and liabilities held for disposition:

(in millions)	June 30, 2015		December 31, 2014
Trade receivables, net	$	39	$	498
Total inventories	23		254
Prepaid expenses, deferred income taxes, and other receivables	31		140
Current assets held for disposition	93		892
Net property and equipment	2		125
Intangible assets, net of amortization	—		804
Goodwill	—		950
Deferred income taxes and other assets	—		55
Non-current assets held for disposition	2		1,934
Total assets held for disposition	$	95	$	2,826

Trade accounts payable	$	279	$	423
Salaries, wages, commissions and other accrued liabilities	13		257
Current liabilities held for disposition	292		680
Post-employment obligations, deferred income taxes and other long-term liabilities	—		108
Total liabilities held for disposition	$	292	$	788

Table of Contents

Note 3 — Supplemental Financial Information

Shares of unvested restricted stock that contain non-forfeitable rights to dividends are treated as participating securities and are included in the computation of earnings per share under the two-class method. Under the two-class method, net earnings are allocated between common shares and participating securities. Earnings from Continuing Operations allocated to common shares for the three months ended June 30, 2015 and 2014 were $783 million and $423 million, respectively and for the six months ended June 30, 2015 and 2014 were $1,309 million and $646 million, respectively. Net earnings allocated to common shares for the three months ended June 30, 2015 and 2014 were $780 million and $463 million, respectively, and for the six months ended June 30, 2015 and 2014 were $3,061 million and $837 million, respectively.

Other (income) expense, net in the second quarter of 2015 primarily relates to a $207 million gain on the sale of a portion of Abbott’s position in Mylan stock and $79 million of income resulting from a decrease in the fair value of contingent consideration related to a business acquisition. In the second quarter of 2015, Abbott sold 40.3 million of the 110 million ordinary shares of Mylan N.V. received in the sale of the developed markets branded generics pharmaceuticals business to Mylan. Abbott received $2.29 billion in net proceeds from the sale of these shares. As a result of this sale, Abbott’s ownership interest in Mylan N.V. decreased from approximately 22% to approximately 14%.

Other, net in Net cash from operating activities in the Condensed Consolidated Statement of Cash Flows for the first six months of 2015 and 2014 includes the effects of contributions to defined benefit plans of $547 million and $330 million, respectively, and to the post-employment medical and dental benefit plans of $24 million and $40 million in the six month periods of 2015 and 2014, respectively. The first six months of 2015 also includes the non-cash impact of approximately $1.1 billion of tax expense associated with the gain on the sale of businesses. The first six months of 2014 includes approximately $70 million of tax benefits, net of cash refunded by taxing authorities, resulting from the resolution of various tax positions pertaining to prior years.

The components of short-term and long-term investments as of June 30, 2015 and December 31, 2014 are as follows:

Short-term Investments	June 30,		December 31,
(in millions)	2015		2014
Equity securities	$	4,672	$	—
Other, primarily bank time deposits	2,457		397
Total	$	7,129	$	397

Long-term Investments
(in millions)
Equity securities	$	226	$	212
Other	17		17
Total	$	243	$	229

The short-term investments in equity securities reflect the market value as of June 30, 2015 of 69.7 million of ordinary shares of Mylan N.V.

In March 2015, Abbott issued $2.5 billion of long-term debt consisting of $750 million of 2.00% Senior Notes due March 15, 2020; $750 million of 2.55% Senior Notes due March 15, 2022; and $1.0 billion of 2.95% Senior Notes due March 15, 2025. Abbott also entered into interest rate swap contracts totaling $2.5 billion. These contracts have the effect of changing Abbott’s obligation from a fixed interest rate to a variable interest rate obligation.

Table of Contents

Note 4 — Changes in Accumulated Other Comprehensive Income (Loss)

The changes in accumulated other comprehensive income (loss), net of income taxes, are as follows:

	Three Months Ended June 30
	Cumulative Foreign Currency Translation Adjustments						Net Actuarial Losses and Prior Service Costs and Credits						Cumulative Unrealized Gains on Marketable Equity Securities						Cumulative Gains on Derivative Instruments Designated as Cash Flow Hedges
(in millions)	2015			2014			2015			2014			2015			2014			2015			2014
Balance at March 31	$	(3,727	)	$	(656	)	$	(2,179	)	$	(1,296	)	$	174		$	13		$	125		$	5
Other comprehensive income (loss) before reclassifications	84			(19		)	—			—			660			1			5			—
Amounts reclassified from accumulated other comprehensive income	—			—			22			12			(138		)	(5		)	(30		)	(7		)
Net current period comprehensive income	84			(19		)	22			12			522			(4		)	(25		)	(7		)
Balance at June 30	$	(3,643	)	$	(675	)	$	(2,157	)	$	(1,284	)	$	696		$	9		$	100		$	(2	)

	Six Months Ended June 30
	Cumulative Foreign Currency Translation Adjustments						Net Actuarial Losses and Prior Service Costs and Credits						Cumulative Unrealized Gains on Marketable Equity Securities						Cumulative Gains on Derivative Instruments Designated as Cash Flow Hedges
(in millions)	2015			2014			2015			2014			2015			2014			2015			2014
Balance at December 31, 2014 and 2013	$	(2,924	)	$	(718	)	$	(2,229	)	$	(1,312	)	$	1		$	13		$	99		$	5
Impact of business dispositions	108			—			19			—			—			—			—			—
Other comprehensive income (loss) before reclassifications	(827		)	43			—			—			833			2			48			(1		)
Amounts reclassified from accumulated other comprehensive income	—			—			53			28			(138		)	(6		)	(47		)	(6		)
Net current period comprehensive income	(827		)	43			53			28			695			(4		)	1			(7		)
Balance at June 30	$	(3,643	)	$	(675	)	$	(2,157	)	$	(1,284	)	$	696		$	9		$	100		$	(2	)

Reclassified amounts for foreign currency translation are recorded in the Condensed Consolidated Statement of Earnings as Net foreign exchange loss (gain); gains on marketable equity securities as Other (income) expense, net and cash flow hedges as Cost of products sold. Net actuarial losses and prior service cost are included as a component of net periodic benefit plan costs; see Note 11 for additional details.

Note 5 — Business Acquisitions

In September 2014, Abbott completed the acquisition of the controlling interest in CFR Pharmaceuticals S.A. (CFR) for approximately $2.9 billion in cash ($2.8 billion net of CFR cash on hand at closing). Including the assumption of approximately $570 million of debt, the total cost of the acquisition was $3.4 billion. The acquisition of CFR more than doubles Abbott’s branded generics pharmaceutical presence in Latin America and further expands its presence in emerging markets. CFR’s financial results are included in Abbott’s financial statements beginning on September 26, 2014, the date that Abbott acquired control of this business. Abbott owns 99.9% of the outstanding ordinary shares of CFR. The fair value of the non-controlling interest at the acquisition date was approximately $3 million. The acquisition was funded with cash and cash equivalents and short-term investments. The preliminary allocation of the fair value of the acquisition is shown in the table below. The allocation of the fair value of the acquisition will be finalized when the valuation is completed.

(in billions)
Acquired intangible assets, non-deductible	$	1.80
Goodwill, non-deductible	1.60
Acquired net tangible assets	0.06
Deferred income taxes recorded at acquisition	(0.54		)
Total preliminary allocation of fair value	$	2.92

Table of Contents

Acquired intangible assets consist primarily of product rights for currently marketed products and are amortized over 12 to 16 years (average of 15 years). The goodwill is primarily attributable to intangible assets that do not qualify for separate recognition. The goodwill is identifiable to the Established Pharmaceutical Products segment. The acquired tangible assets consist primarily of cash and cash equivalents of approximately $94 million, trade accounts receivable of approximately $179 million, inventory of approximately $169 million, other current assets of approximately $51 million, property and equipment of approximately $209 million, and other long-term assets of approximately $138 million. Assumed liabilities consist of borrowings of approximately $570 million, trade accounts payable and other current liabilities of approximately $200 million and other noncurrent liabilities of approximately $15 million.

Annualized net sales for CFR Pharmaceuticals are expected to total approximately $750 million at current exchange rates. Had the acquisition of CFR Pharmaceuticals taken place on January 1, 2013, the consolidated net sales and earnings of Abbott would not have been significantly different from the reported amounts.

In December 2014, Abbott acquired control of Veropharm, a leading Russian pharmaceutical company for approximately $315 million, excluding assumed debt, plus a subsequent $5 million payment related to a working capital adjustment. Through this acquisition, Abbott establishes a manufacturing footprint in Russia and obtains a portfolio of medicines that is well aligned with Abbott’s current pharmaceutical therapeutic areas of focus. Abbott acquired control of Veropharm through its purchase of Limited Liability Company Garden Hills, the holding company that owns approximately 98 percent of Veropharm. Including the assumption of approximately $90 million of debt and a minority interest with a fair value of $5 million, the total value of the acquired business was approximately $415 million. The preliminary allocation of the fair value of the acquisition resulted in definite-lived non-deductible intangible assets of approximately $100 million, non-deductible goodwill of approximately $115 million, and net deferred tax liabilities of approximately $25 million. Non-deductible goodwill is identifiable with the Established Pharmaceutical Products segment. Additionally, Abbott acquired property, plant, and equipment of approximately $165 million, accounts receivable of approximately $45 million, inventory of approximately $25 million, and net other liabilities of approximately $10 million. Acquired intangible assets consist of developed technology and are being amortized over 16 years. In 2015, Abbott acquired the remaining shares of Veropharm, increasing its ownership to 100 percent.

In December 2014, Abbott completed the acquisition of Topera, Inc. for approximately $250 million in cash, plus additional payments up to $300 million to be made upon completion of certain regulatory and sales milestones. The acquisition of Topera provides Abbott a foundational entry in the electrophysiology market. The final allocation of the fair value of the acquisition resulted in non-deductible acquired in-process research and development of approximately $20 million, which is accounted for as an indefinite-lived intangible asset until regulatory approval or discontinuation, non-deductible definite-lived intangibles assets of approximately $325 million, non-deductible goodwill of approximately $175 million, net deferred tax liabilities of approximately $105 million, and contingent consideration of approximately $165 million. The fair value of the contingent consideration was determined based on an independent appraisal. Acquired intangible assets consist of developed technology and trademarks, and are being amortized over 16 years.

The preliminary allocations of fair value of the acquisitions of CFR Pharmaceuticals and Veropharm will be finalized when valuations are completed. Had the aggregate of the above acquisitions taken place on January 1, 2013, consolidated net sales and earnings would not have been significantly different from reported amounts.

Note 6 — Goodwill and Intangible Assets

The total amount of goodwill reported was $9.896 billion at June 30, 2015 and $10.067 billion at December 31, 2014, which excluded goodwill classified as held for disposition. As part of the disposal of the developed markets branded generics pharmaceuticals business in the first six months of 2015, $894 million of goodwill was included as part of the net assets sold. In the first six months of 2015, foreign currency translation adjustments decreased goodwill by approximately $235 million, while purchase price allocation adjustments associated with recent acquisitions increased goodwill by approximately $67 million. The amount of goodwill related to reportable segments at June 30, 2015 was $3.3 billion for the Established Pharmaceutical Products segment, $286 million for the Nutritional Products segment, $443 million for the Diagnostic Products segment, and $2.9 billion for the Vascular Products segment. There was no reduction of goodwill relating to impairments.

The gross amount of amortizable intangible assets, primarily product rights and technology was $10.8 billion as of June 30, 2015 and December 31, 2014, and accumulated amortization was $5.1 billion as of June 30, 2015 and $4.9 billion as of December 31, 2014. The December 31, 2014 amounts exclude the intangibles that were classified as held for disposition. $738 million of intangibles were included in the net assets transferred as part of the disposal of the developed markets branded generics pharmaceuticals business in the first six months of 2015. Indefinite-lived intangible assets, which relate to in-process research and development acquired in a business combination, was approximately $134 million at June 30, 2015 and December 31, 2014. Abbott’s estimated annual amortization

Table of Contents

expense for intangible assets is approximately $680 million in 2015, $660 million in 2016, $650 million in 2017, $570 million in 2018 and $530 million in 2019. Amortizable intangible assets are amortized over 2 to 20 years (weighted average 12 years).

Note 7 — Restructuring Plans

In 2014, Abbott management approved plans to streamline operations in order to reduce costs and improve efficiencies in various Abbott businesses including nutritional and established pharmaceuticals businesses. In the first six months of 2015, charges of approximately $19 million were recognized, of which approximately $1 million is recognized in Cost of products sold and approximately $18 million is recognized in Selling, general and administrative expense. Additional charges of approximately $25 million were recorded primarily for accelerated depreciation. The following summarizes the activity for the first six months of 2015 related to these restructuring actions and the status of the related accrual as of June 30, 2015:

(in millions)
Accrued balance at December 31, 2014	$	118
Restructuring charges recorded in 2015	19
Payments and other adjustments	(44		)
Accrued balance at June 30, 2015	$	93

From 2013 to 2015, Abbott management approved various plans to reduce costs and improve efficiencies across various functional areas. In the first six months of 2015, charges of approximately $25 million were recognized, of which approximately $9 million is recorded in Cost of products sold, approximately $2 million is recorded in Research and Development, and approximately $14 million is recorded in Selling, general and administrative expense. In 2013, Abbott management also approved plans to streamline certain manufacturing operations in order to reduce costs and improve efficiencies in Abbott’s established pharmaceuticals business. In 2012, Abbott management approved plans to streamline various commercial operations in order to reduce costs and improve efficiencies in Abbott’s core diagnostics, established pharmaceuticals and nutritionals businesses. The following summarizes the activity for the first six months of 2015 related to these restructuring actions and the status of the related accrual as of June 30, 2015:

(in millions)
Accrued balance at December 31, 2014	$	135
Restructuring charges recorded in 2015	25
Payments and other adjustments	(42		)
Accrued balance at June 30, 2015	$	118

In 2013 and prior years, Abbott management approved plans to realign its vascular manufacturing operations and core diagnostics business in order to reduce costs. The following summarizes the activity for the first six months of 2015 related to these restructuring actions and the status of the related accrual as of June 30, 2015:

(in millions)
Accrued balance at December 31, 2014	$	39
Payments and other adjustments	(7		)
Accrued balance at June 30, 2015	$	32

Note 8 — Incentive Stock Programs

In the first six months of 2015, Abbott granted 5,518,363 stock options, 660,787 restricted stock awards and 5,774,560 restricted stock units under its incentive stock programs. At June 30, 2015, approximately 86 million shares were reserved for future grants. Information regarding the number of stock options outstanding and exercisable at June 30, 2015 is as follows:

	Outstanding		Exercisable
Number of shares	37,098,123		27,421,775
Weighted average remaining life (years)	4.9		3.4
Weighted average exercise price	$	31.06	$	26.83
Aggregate intrinsic value (in millions)	$	669	$	611

The total unrecognized share-based compensation cost at June 30, 2015 amounted to approximately $249 million which is expected to be recognized over the next three years.

Table of Contents

Note 9 — Financial Instruments, Derivatives and Fair Value Measures

Certain Abbott foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates for anticipated intercompany purchases by those subsidiaries whose functional currencies are not the U.S. dollar. These contracts, with notional amounts totaling $1.6 billion at June 30, 2015 and $1.5 billion at December 31, 2014 are designated as cash flow hedges of the variability of the cash flows due to changes in foreign exchange rates and are recorded at fair value. Accumulated gains and losses as of June 30, 2015 will be included in Cost of products sold at the time the products are sold, generally through the next twelve to eighteen months. The amount of hedge ineffectiveness was not significant in 2015 and 2014.

Abbott enters into foreign currency forward exchange contracts to manage currency exposures for foreign currency denominated third-party trade payables and receivables, and for intercompany loans and trade accounts payable where the receivable or payable is denominated in a currency other than the functional currency of the entity. For intercompany loans, the contracts require Abbott to sell or buy foreign currencies, primarily European currencies and Japanese yen, in exchange for primarily U.S. dollars and other European currencies. For intercompany and trade payables and receivables, the currency exposures are primarily the U.S. dollar, European currencies and Japanese yen. At June 30, 2015 and December 31, 2014, Abbott held $14.1 billion of such foreign currency forward exchange contracts.

Abbott has designated foreign denominated short-term debt as a hedge of the net investment in a foreign subsidiary of approximately $431 million and approximately $445 million as of June 30, 2015 and December 31, 2014, respectively. Accordingly, changes in the reported value of this debt due to changes in exchange rates are recorded in Accumulated other comprehensive income (loss), net of tax.

Abbott is a party to interest rate hedge contracts totaling approximately $4.0 billion at June 30, 2015 and $1.5 billion at December 31, 2014 to manage its exposure to changes in the fair value of fixed-rate debt. These contracts are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates. The effect of the hedge is to change a fixed-rate interest obligation to a variable rate for that portion of the debt. Abbott records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount. No hedge ineffectiveness was recorded in income in 2015 or 2014 for these hedges.

The following table summarizes the amounts and location of certain derivative financial instruments as of June 30, 2015 and December 31, 2014:

	Fair Value - Assets					Fair Value - Liabilities
(in millions)	June 30, 2015		Dec. 31, 2014		Balance Sheet Caption	June 30, 2015		Dec. 31, 2014		Balance Sheet Caption

Interest rate swaps designated as fair value hedges	$	103	$	101	Deferred income taxes and other assets	$	17	$	—	Post-employment obligations, deferred income taxes and other long-term liabilities

Foreign currency forward exchange contracts:
Hedging instruments	87		107		Prepaid expenses, deferred income taxes, and other receivables	9		—		Other accrued liabilities
Others not designated as hedges	270		150		Prepaid expenses, deferred income taxes, and other receivables	66		130		Other accrued liabilities

Debt designated as a hedge of net investment in a foreign subsidiary	—		—		n/a	431		445		Short-term borrowings
	$	460	$	358		$	523	$	575

The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges, debt designated as a hedge of net investment in a foreign subsidiary and certain other derivative financial instruments, as well as the amounts and location of income (expense) and gain (loss) reclassified into income for the three months and six months ended June 30, 2015 and 2014. The amount of hedge ineffectiveness was not significant in 2015 and 2014 for these hedges.

Table of Contents

	Gain (loss) Recognized in Other Comprehensive Income (loss)												Income (expense) and Gain (loss) Reclassified into Income
	Three Months Ended June 30						Six Months Ended June 30						Three Months Ended June 30						Six Months Ended June 30						Income Statement
(in millions)	2015			2014			2015			2014			2015			2014			2015			2014			Caption

Foreign currency forward exchange contracts designated as cash flow hedges	$	5		$	(3	)	$	48		$	(1	)	$	30		$	2		$	47		$	5		Cost of products sold

Debt designated as a hedge of net investment in a foreign subsidiary	(11		)	(7		)	(14		)	(18		)	n/a			n/a			n/a			n/a			n/a

Interest rate swaps designated as fair value hedges	n/a			n/a			n/a			n/a			(63		)	8			(14		)	19			Interest expense

Foreign currency forward exchange contracts not designated as hedges	n/a			n/a			n/a			n/a			(85		)	(11		)	(101		)	(25		)	Net foreign exchange loss (gain)

The interest rate swaps are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates. The hedged debt is marked to market, offsetting the effect of marking the interest rate swaps to market.

The carrying values and fair values of certain financial instruments as of June 30, 2015 and December 31, 2014 are shown in the following table. The carrying values of all other financial instruments approximate their estimated fair values. The counterparties to financial instruments consist of select major international financial institutions. Abbott does not expect any losses from nonperformance by these counterparties.

	June 30, 2015						December 31, 2014
(in millions)	Carrying Value			Fair Value			Carrying Value			Fair Value

Investment Securities:
Equity securities	$	4,898		$	4,898		$	212		$	212
Other	17			17			17			17
Total Long-term Debt	(5,894		)	(6,323		)	(3,463		)	(4,113		)
Foreign Currency Forward Exchange Contracts:
Receivable position	357			357			263			263
(Payable) position	(75		)	(75		)	(135		)	(135		)
Interest Rate Hedge Contracts:
Receivable position	103			103			101			101
Payable position	(17		)	(17		)	—			—

The fair value of the debt was determined based on significant other observable inputs, including current interest rates.

Table of Contents

The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet:

			Basis of Fair Value Measurement
(in millions)	Outstanding Balances		Quoted Prices in Active Markets		Significant Other Observable Inputs		Significant Unobservable Inputs
June 30, 2015:
Equity securities	$	4,682	$	10	$	4,672	$	—
Interest rate swap derivative financial instruments	103		—		103		—
Foreign currency forward exchange contracts	357		—		357		—
Total Assets	$	5,142	$	10	$	5,132	$	—

Fair value of hedged long-term debt	$	4,104	$	—	$	4,104	$	—
Foreign currency forward exchange contracts	75		—		75		—
Interest rate swap derivative financial instruments	17		—		17		—
Contingent consideration related to business combinations	169		—		—		169
Total Liabilities	$	4,365	$	—	$	4,196	$	169

December 31, 2014:
Equity securities	$	9	$	9	$	—	$	—
Interest rate swap derivative financial instruments	101		—		101		—
Foreign currency forward exchange contracts	263		—		263		—
Total Assets	$	373	$	9	$	364	$	—

Fair value of hedged long-term debt	$	1,637	$	—	$	1,637	$	—
Foreign currency forward exchange contracts	135		—		135		—
Contingent consideration related to business combinations	243		—		—		243
Total Liabilities	$	2,015	$	—	$	1,772	$	243

Equity securities are principally comprised of Mylan N.V. ordinary shares. The fair value of the Mylan equity securities was determined based on the value of the publicly-traded ordinary shares adjusted for the restrictions related to the resale of these shares. The fair value of debt was determined based on the face value of the debt adjusted for the fair value of the interest rate swaps, which is based on a discounted cash flow analysis. The fair value of foreign currency forward exchange contracts is determined using a market approach, which utilizes values for comparable derivative instruments. The fair value of the contingent consideration was determined based on an independent appraisal adjusted for the time value of money and other changes in fair value primarily resulting from changes in regulatory timelines.

Note 10 — Litigation and Environmental Matters

Abbott has been identified as a potentially responsible party for investigation and cleanup costs at a number of locations in the United States and Puerto Rico under federal and state remediation laws and is investigating potential contamination at a number of company-owned locations. Abbott has recorded an estimated cleanup cost for each site for which management believes Abbott has a probable loss exposure. No individual site cleanup exposure is expected to exceed $4 million, and the aggregate cleanup exposure is not expected to exceed $15 million.

Abbott is involved in various claims and legal proceedings, and Abbott estimates the range of possible loss for its legal proceedings and environmental exposures to be from approximately $40 million to $55 million. The recorded accrual balance at June 30, 2015 for these proceedings and exposures was approximately $50 million. This accrual represents management’s best estimate of probable loss, as defined by FASB ASC No. 450, “Contingencies.” Within the next year, legal proceedings may occur that may result in a change in the estimated loss accrued by Abbott. While it is not feasible to predict the outcome of all such proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on Abbott’s financial position, cash flows, or results of operations.

Table of Contents

Note 11 — Post-Employment Benefits

Retirement plans consist of defined benefit, defined contribution, and medical and dental plans. Net cost recognized in continuing operations for the three months and six months ended June 30 for Abbott’s major defined benefit plans and post-employment medical and dental benefit plans is as follows:

	Defined Benefit Plans												Medical and Dental Plans
	Three Months						Six Months						Three Months						Six Months
	Ended June 30						Ended June 30						Ended June 30						Ended June 30
( in millions)	2015			2014			2015			2014			2015			2014			2015			2014
Service cost — benefits earned during the period	$	68		$	62		$	150		$	128		$	6		$	9		$	15		$	18
Interest cost on projected benefit obligations	77			75			156			152			11			16			25			32
Expected return on plan assets	(128		)	(113		)	(257		)	(226		)	(10		)	(9		)	(19		)	(19		)
Net amortization of:
Actuarial loss, net	42			24			89			49			1			4			10			9
Prior service cost (credit)	—			—			—			1			(12		)	(9		)	(24		)	(18		)
Total Cost	59			48			138			104			(4		)	11			7			22
Less: Discontinued operations	—			4			1			8			—			—			—			—
Net cost - continuing operations	$	59		$	44		$	137		$	96		$	(4	)	$	11		$	7		$	22

Abbott funds its domestic defined benefit plans according to IRS funding limitations. International pension plans are funded according to similar regulations. In the first six months of 2015 and 2014, $547 million and $330 million, respectively, were contributed to defined benefit plans and $24 million and $40 million were contributed to the post-employment medical and dental benefit plans in the first six months of 2015 and 2014, respectively.

Note 12 — Taxes on Earnings

Taxes on earnings from continuing operations reflect the estimated annual effective rates and include charges for interest and penalties. In the first six months of 2015, taxes on earnings from continuing operations include a tax cost of $69 million related to the disposal of shares of Mylan stock. Taxes on earnings from continuing operations were not affected by any adjustments as the result of the resolution of various tax positions pertaining to prior years. Tax expense related to discontinued operations includes $665 million of tax expense on certain current-year funds earned outside the U. S. that were not designated as permanently reinvested overseas. Earnings from discontinued operations, net of tax, in the first six months of 2015 also reflects the recognition of $17 million of net tax benefits primarily as a result of the resolution of various tax positions related to AbbVie’s operations for years prior to the separation. The conclusion of these tax matters decreased the gross amount of unrecognized tax benefits by approximately $35 million. Taxes on earnings from continuing operations, in the first six months of 2014, reflect a tax cost of $7 million, primarily as a result of the resolution of various tax positions related to the branded generics pharmaceutical business. Earnings from discontinued operations, net of tax, in the first six months of 2014 reflects the recognition of $109 million of net tax benefits primarily as a result of the resolution of various tax positions related to the developed markets branded generics pharmaceuticals business, as well as AbbVie’s operations, for years prior to the separation. The conclusion of these tax matters decreased the gross amount of unrecognized tax benefits by approximately $134 million.

Tax authorities in various jurisdictions regularly review Abbott’s income tax filings. Abbott believes that it is reasonably possible that the recorded amount of gross unrecognized tax benefits may decrease by $525 million to $635 million, including cash adjustments, within the next twelve months as a result of concluding various domestic and international tax matters. In the U.S., Abbott’s federal income tax returns through 2011 are settled except for two issues.

Table of Contents

Note 13 — Segment Information

Abbott’s principal business is the discovery, development, manufacture and sale of a broad line of health care products. Abbott’s products are generally sold directly to retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices and government agencies throughout the world. Abbott’s reportable segments are as follows:

Established Pharmaceutical Products — International sales of a broad line of branded generic pharmaceutical products.

Nutritional Products — Worldwide sales of a broad line of adult and pediatric nutritional products.

Diagnostic Products — Worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. For segment reporting purposes, the Core Laboratories Diagnostics, Molecular Diagnostics, Point of Care and Ibis diagnostic divisions are aggregated and reported as the Diagnostic Products segment.

Vascular Products — Worldwide sales of coronary, endovascular, structural heart, vessel closure and other medical device products. For segment reporting purposes, the Vascular and Electrophysiology Products divisions are aggregated and reported as the Vascular Products segment.

Non-reportable segments include the Diabetes Care and Medical Optics segments.

On February 27, 2015, Abbott completed the sale of its developed markets branded generics pharmaceuticals business to Mylan N.V. This business was previously included in the Established Pharmaceutical Products segment for the first six months of 2014; therefore, the 2014 segment information below has been adjusted to reflect the classification of the developed markets branded generics pharmaceuticals business as part of discontinued operations in the Condensed Consolidated Statement of Earnings.

Abbott’s underlying accounting records are maintained on a legal entity basis for government and public reporting requirements. Segment disclosures are on a performance basis consistent with internal management reporting. Intersegment transfers of inventory are recorded at standard cost and are not a measure of segment operating earnings. The cost of some corporate functions and the cost of certain employee benefits are charged to segments at predetermined rates that approximate cost. Remaining costs, if any, are not allocated to segments. In addition, intangible asset amortization is not allocated to operating segments, and intangible assets and goodwill are not included in the measure of each segment’s assets. The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and are not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.

	Net Sales to External Customers								Operating Earnings
	Three Months				Six Months				Three Months						Six Months
	Ended June 30				Ended June 30				Ended June 30						Ended June 30
(in millions)	2015		2014		2015		2014		2015			2014			2015			2014
Established Pharmaceutical Products	$	977	$	744	$	1,874	$	1,425	$	172		$	160		$	339		$	281
Nutritional Products	1,717		1,731		3,386		3,362		389			302			739			585
Diagnostic Products	1,177		1,189		2,270		2,306		304			279			580			501
Vascular Products	722		765		1,420		1,503		280			303			564			524
Total Reportable Segments	4,593		4,429		8,950		8,596		1,145			1,044			2,222			1,891
Other	577		628		1,117		1,216
Net Sales	$	5,170	$	5,057	$	10,067	$	9,812
Corporate functions and benefit plans costs									(104		)	(103		)	(221		)	(161		)
Non-reportable segments									62			106			117			172
Net interest expense									(17		)	(17		)	(33		)	(37		)
Share-based compensation (a)									(57		)	(48		)	(205		)	(164		)
Amortization of intangible assets									(151		)	(133		)	(307		)	(260		)
Other, net (b)									108			(191		)	66			(442		)
Consolidated Earnings from Continuing Operations Before Taxes									$	986		$	658		$	1,639		$	999

(a) Approximately 40 to 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards.

(b) Other, net in 2015 includes a gain on the sale of a portion of Abbott’s position in Mylan stock and a decrease in the fair value of contingent consideration related to a business acquisition, which was partially offset by charges associated with cost reduction initiatives.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Financial Review - Results of Operations

The following table details sales by reportable segment for the three months and six months ended June 30. Percent changes are versus the prior year and are based on unrounded numbers.

	Net Sales to External Customers
(in millions)	Three Months ended June 30, 2015		Three Months ended June 30, 2014		Total Change		Impact of Foreign Exchange		Total Change Excl. Foreign Exchange

Established Pharmaceutical Products	$	977	$	744	31.3	%	(14.7	)%	46.0	%
Nutritional Products	1,717		1,731		(0.8	)	(4.7	)	3.9
Diagnostic Products	1,177		1,189		(1.0	)	(9.7	)	8.7
Vascular Products	722		765		(5.6	)	(8.8	)	3.2
Total Reportable Segments	4,593		4,429		3.7		(8.4	)	12.1
Other	577		628		(8.0	)	(9.5	)	1.5
Net Sales	$	5,170	$	5,057	2.2		(8.6	)	10.8

Total U.S.	$	1,592	$	1,544	3.1		—		3.1

Total International	$	3,578	$	3,513	1.8		(12.4	)	14.2

	Net Sales to External Customers
(in millions)	Six Months ended June 30, 2015		Six Months ended June 30, 2014		Total Change		Impact of Foreign Exchange		Total Change Excl. Foreign Exchange

Established Pharmaceutical Products	$	1,874	$	1,425	31.5	%	(13.0	)%	44.5	%
Nutritional Products	3,386		3,362		0.7		(4.3	)	5.0
Diagnostic Products	2,270		2,306		(1.6	)	(8.9	)	7.3
Vascular Products	1,420		1,503		(5.5	)	(8.1	)	2.6
Total Reportable Segments	8,950		8,596		4.1		(7.7	)	11.8
Other	1,117		1,216		(8.1	)	(8.6	)	0.5
Net Sales	$	10,067	$	9,812	2.6		(7.8	)	10.4

Total U.S.	$	3,094	$	3,018	2.5		—		2.5

Total International	$	6,973	$	6,794	2.6		(11.3	)	13.9

Net sales growth in the second quarter and first six months of 2015 was negatively impacted by changes in foreign currency exchange rates. The relatively stronger U.S. dollar decreased total international sales by 12.4 percent and total sales by 8.6 percent in the second quarter. Excluding the unfavorable impact of foreign exchange and including the impact of the 2014 acquisitions of CFR Pharmaceuticals and Veropharm, total net sales increased 10.8 percent in the second quarter of 2015, driven by higher revenues across all four reportable segments. Double-digit growth in emerging market sales was a significant contributor to the 14.2 percent increase in total international sales excluding the impact of foreign exchange for the second quarter of 2015.

Table of Contents

The table below provides detail by sales category for the six months ended June 30. Percent changes are versus the prior year and are based on unrounded numbers.

(in millions)	June 30, 2015		June 30, 2014		Total Change		Impact of Foreign Exchange		Total Change Excl. Foreign Exchange
Established Pharmaceutical Products sales —
Key Emerging Markets	$	1,380	$	1,062	29.9	%	(14.0	)%	43.9	%
Other	494		363		36.1		(10.3	)	46.4

Nutritionals —
U.S. Pediatric Nutritionals	786		761		3.2		—		3.2
International Pediatric Nutritionals	1,144		1,118		2.3		(6.1	)	8.4
U.S. Adult Nutritionals	628		652		(3.8	)	—		(3.8	)
International Adult Nutritionals	828		831		(0.3	)	(9.5	)	9.2

Diagnostics —
Immunochemistry	1,723		1,774		(2.9	)	(9.9	)	7.0

Vascular Products (1) —
Coronary Devices	1,099		1,186		(7.4	)	(8.8	)	1.4
Endovascular	257		257		(0.2	)	(7.2	)	7.0

(1) Coronary Devices include DES / BVS product portfolio, structural heart, guidewires, balloon catheters, and other coronary products. Endovascular includes vessel closure, carotid stents and other peripheral products.

Key Emerging Markets for the Established Pharmaceutical Products business include India, Russia, China, Brazil and Colombia, along with several other markets that represent the most attractive long-term growth opportunities for Abbott’s branded generics product portfolio. Excluding the unfavorable effect of foreign exchange, sales in the Key Emerging Markets increased 43.9 percent compared to the first six months of 2014. Excluding the impact of the 2014 acquisitions of CFR Pharmaceuticals and Veropharm and the effect of foreign exchange, sales in the Key Emerging Markets for Established Pharmaceuticals increased in the low double digits driven by growth across multiple markets.

Excluding the effect of foreign exchange, the 8.4 percent increase in International Pediatric Nutritional sales was primarily driven by double-digit growth in China and several countries in Latin America as a result of recently launched infant formula products and an increase in market share, partially offset by market dynamics in certain Asian countries. Excluding the effect of foreign exchange, the 9.2 percent increase in International Adult Nutritional sales reflects double-digit growth in Latin America and continued expansion of the adult nutrition category internationally. The 3.8 percent decrease in U.S. Adult Nutritional sales reflects weakness in the retail and institutional categories due to the negative effects of increased competition and market dynamics.

Excluding the effect of foreign exchange, the 7.3 percent increase in total Diagnostics sales was primarily driven by sales growth in emerging markets and by share gains in the core laboratory markets in the U.S. and internationally. In the Vascular Products segment, double digit growth in sales of Abbott’s MitraClip structural heart device for the treatment of mitral regurgitation was partially offset by continued pricing pressures on DES products. The increase in the Endovascular business was driven by higher Supera and vessel closure sales.

The gross profit margin percentage was 54.2 percent for the second quarter 2015 compared to 52.1 percent for the second quarter 2014. The gross profit margin percentage was 54.2 percent for the first six months of 2015 compared to 50.9 percent for the first six months of 2014. The increase primarily reflects the impact of gross margin initiatives and, in part, the impact of foreign exchange, in the Diagnostics and Nutritional businesses.

Research and development expenses increased by $35 million, or 11.1 percent, in the second quarter 2015 due primarily to higher spending across various businesses and a milestone payment recorded in the second quarter of 2015, while research and development expenses decreased by $21 million, or 3.0 percent, in the first six months of 2015 due primarily to the impact of higher restructuring costs recorded in the first six months of 2014 than in the first six months of 2015. For the six months ended June 30, 2015, research and development expenditures totaled $120 million for the Vascular Products segment, $211 million for the Diagnostic Products segment, $68 million for the Established Pharmaceutical Products segment and $103 million for the Nutritional Products segment.

Selling, general and administrative expenses for the second quarter and first six months of 2015 increased 4.8 percent and 6.0 percent, respectively, due primarily to the impact of the acquisition of CFR Pharmaceuticals in the third quarter of 2014 and Veropharm in the fourth quarter of 2014.

Table of Contents

Business Acquisitions

(in billions)
Acquired intangible assets, non-deductible	$	1.80
Goodwill, non-deductible	1.60
Acquired net tangible assets	0.06
Deferred income taxes recorded at acquisition	(0.54		)
Total preliminary allocation of fair value	$	2.92

The preliminary allocations of fair value of CFR Pharmaceuticals and Veropharm will be finalized when valuations are completed. Had the aggregate of the above acquisitions taken place on January 1, 2013, consolidated net sales and earnings would not have been significantly different from reported amounts.

Table of Contents

Goodwill

At June 30, 2015, goodwill recorded as a result of business combinations totaled approximately $10 billion. Goodwill is reviewed for impairment annually in the third quarter or when an event that could result in an impairment occurs, using a quantitative assessment to determine whether it is more likely than not that the fair value of any reporting unit is less than its carrying amount. The income and market approaches are used to calculate the fair value of each reporting unit. The results of the last impairment test indicated that the fair value of each reporting unit was substantially in excess of its carrying value except for the Medical Optics reporting unit. Goodwill related to the Medical Optics unit totals approximately $2 billion. Abbott updated its impairment analysis as of June 30, 2015 for Medical Optics. While the fair value of the Medical Optics business exceeds its carrying value by approximately 15%, various factors could develop and result in a valuation in the future where the fair value of the Medical Optics unit has declined below its carrying value, thereby triggering the requirement to estimate the implied fair value of the goodwill and measure for impairment. These factors include a lower than projected growth rate for the business, longer regulatory approval timelines for products currently under development, and the negative impact of foreign currency movements as well as an increase in the discount rate used in the quantitative assessment.

Restructuring Plans

The results for the first six months of 2015 reflect charges recognized for actions associated with the company’s plans to streamline various operations in order to reduce costs and improve efficiencies. Abbott recorded employee related severance and other charges of approximately $44 million in 2015 related to these initiatives. Approximately $10 million is recognized in Cost of products sold, approximately $2 million is recognized in Research and Development, and approximately $32 million is recognized in Selling, general and administrative expense. See Note 7 to the financial statements, “Restructuring Plans,” for additional information regarding these charges.

Interest Expense (Income), net

Interest expense (income), net of $17 million for the second quarter of 2015 was unchanged from the prior year as higher interest expense related to higher debt levels was offset by higher interest income. Interest expense (income), net of $33 million in the first six months of 2015 decreased compared to 2014 as higher interest expense in 2015, due to higher debt levels, was more than offset by higher interest income.

Taxes on Earnings from Continuing Operations

Table of Contents

Separation of AbbVie Inc.

Abbott has retained all liabilities for all U.S. federal and foreign income taxes on income prior to the separation, as well as certain non-income taxes attributable to AbbVie’s business. AbbVie generally will be liable for all other taxes attributable to its business. Earnings from discontinued operations in the first six months of 2015 and 2014 reflect the recognition of $17 million and $42 million, respectively, of net tax benefits primarily as a result of the resolution of various tax positions related to AbbVie’s operations for years prior to the separation.

Discontinued Operations

As a result of the disposition of Abbott’s developed markets branded generics pharmaceuticals and animal health businesses, the current and prior year operating results of these businesses up to the date of sale are reported as part of discontinued operations on the Earnings from discontinued operations, net of tax line in the Condensed Consolidated Statement of Earnings. Discontinued operations include an allocation of interest expense assuming a uniform ratio of consolidated debt to equity for all of Abbott’s historical operations. Earnings from discontinued operations in the first six months of 2015 and 2014 reflect the recognition of $17 million and $42 million, respectively, of net tax benefits primarily as a result of the resolution of various tax positions related to AbbVie’s operations for years prior to the separation.

The operating results of Abbott’s developed markets branded generics pharmaceuticals, animal health and AbbVie businesses, which are being reported as discontinued operations are as follows:

	Three Months Ended June 30						Six Months Ended June 30
(in millions)	2015			2014			2015			2014
Net Sales
Developed markets generics pharmaceuticals and animal health businesses	$	—		$	494		$	256		$	983
AbbVie	—			—			—			—
Total	$	—		$	494		$	256		$	983
Earnings Before Tax
Developed markets generics pharmaceuticals and animal health businesses	$	(5	)	$	79		$	20		$	161
AbbVie	—			—			—			—
Total	$	(5	)	$	79		$	20		$	161
Income Tax Expense (Benefit)
Developed markets generics pharmaceuticals and animal health businesses	$	—		$	44		$	12		$	11
AbbVie	(4		)	(6		)	(17		)	(42		)
Total	$	(4	)	$	38		$	(5	)	$	(31	)
Net Earnings
Developed markets generics pharmaceuticals and animal health businesses	$	(5	)	$	35		$	8		$	150
AbbVie	4			6			17			42
Total	$	(1	)	$	41		$	25		$	192

The sale of the developed markets branded generics pharmaceuticals and animal health businesses in the first quarter of 2015 resulted in the recognition of a pretax gain of $2.820 billion, tax expense of $1.084 billion and an after tax gain of $1.736 billion.

Table of Contents

The assets of the operations held for disposition and the liabilities to be assumed in the disposition related to the businesses previously noted, as well as the AbbVie assets and liabilities are classified as held for disposition in the Condensed Consolidated Balance Sheet as of June 30, 2015 and December 31, 2014. The cash flows associated with the developed markets branded generics pharmaceuticals and animal health businesses are included in Abbott’s Condensed Consolidated Statement of Cash Flows up to the date of disposition.

The following is a summary of the assets and liabilities held for disposition:

(in millions)	June 30, 2015		December 31, 2014
Trade receivables, net	$	39	$	498
Total inventories	23		254
Prepaid expenses, deferred income taxes, and other receivables	31		140
Current assets held for disposition	93		892
Net property and equipment	2		125
Intangible assets, net of amortization	—		804
Goodwill	—		950
Deferred income taxes and other assets	—		55
Non-current assets held for disposition	2		1,934
Total assets held for disposition	$	95	$	2,826

Trade accounts payable	$	279	$	423
Salaries, wages, commissions and other accrued liabilities	13		257
Current liabilities held for disposition	292		680
Post-employment obligations, deferred income taxes and other long-term liabilities	—		108
Total liabilities held for disposition	$	292	$	788

Liquidity and Capital Resources June 30, 2015 Compared with December 31, 2014

The $4.0 billion of cash and cash equivalents at June 30, 2015 was virtually unchanged from December 31, 2014 as the cash generated by operations, as well as, the issuance of additional debt was offset by the impact of share repurchases and dividends paid.

Net cash from operating activities for the first six months of 2015 totaled $943 million. Other, net in Net cash from operating activities for the first six months of 2015 of $301 million reflects the non-cash impact of approximately $1.1 billion of tax expense associated with the gain on the sale of businesses. Other, net cash from operating activities also includes the contributions to defined benefit pension plans of $547 million in 2015, as well as approximately $95 million related to cost reduction and business disposal activities. Other, net in Net cash from operating activities for the first six months of 2014 of $(354) million reflects contributions to defined benefit pension plans of $330 million in 2014, as well as the non-cash impact of approximately $70 million of tax benefits, net of cash refunds by tax authorities, from the resolution of various tax positions pertaining to prior years. Abbott expects to fund cash dividends, capital expenditures and its other investments in its businesses with cash flow from operating activities, cash on hand, short-term investments and borrowings.

Working capital was $11.9 billion at June 30, 2015 and $4.7 billion at December 31, 2014. The $7.2 billion increase in working capital in 2015 primarily reflects the $4.7 billion of Mylan N.V. ordinary shares held by Abbott at June 30, 2015, as well as the proceeds from the sale of a portion of the shares received in the sale of Abbott’s developed markets branded generics pharmaceuticals business to Mylan. In April 2015, Abbott sold 40.3 million of the 110 million Mylan N.V. ordinary shares, which generated cash proceeds of $2.29 billion that were invested in short-term investments.

A majority of Abbott’s trade receivables in Italy, Spain, Portugal, and Greece are with governmental health systems. Governmental receivables in these four countries accounted for approximately 1% of Abbott’s total assets and 8% of total net trade receivables as of June 30, 2015 as compared to approximately 1% of total assets and 9% of total net receivables as of December 31, 2014. With the exception of Greece, Abbott historically has collected almost all of the outstanding receivables in these countries. Revenue from operations in Greece represented less than 0.5% of Abbott’s total net sales in the first six months of 2015 and the first six months of 2014. Abbott closely monitors economic conditions and budgetary and other fiscal developments in these countries. Abbott regularly communicates with its customers regarding the status of receivable balances, including their payment plans and obtains positive confirmation of the validity of the receivables. Abbott also monitors the potential for and periodically has utilized factoring arrangements to mitigate risk although such arrangements were not material in the first six months of 2015.

Table of Contents

Since January 2010, Venezuela has been designated as a highly inflationary economy under U.S. Generally Accepted Accounting Principles. In 2014 and in the first six months of 2015, the government of Venezuela operated multiple mechanisms to exchange bolivars into U.S. dollars. In the first six months of 2015, Abbott continued to use the official rate of 6.3 Venezuelan bolivars to the U.S. dollar to report the results, financial position, and cash flows related to its operations in Venezuela since Abbott continued to qualify for this exchange rate to pay for the import of various products into Venezuela. Abbott cannot predict whether there will be a devaluation of the Venezuelan bolivar or whether it will continue to be able to exchange bolivars at the 6.3 rate. As of June 30, 2015, Abbott had net monetary assets that are subject to revaluation in Venezuela of approximately $380 million. In the first six months of 2015, revenue from operations in Venezuela represented approximately 2% of Abbott’s total net sales.

At June 30, 2015 Abbott’s long-term debt rating was A+ by Standard & Poor’s Corporation and A2 by Moody’s Investors Service. Abbott has readily available financial resources, including unused lines of credit of $5.0 billion that support commercial paper borrowing arrangements which expire in 2019.

Under a registration statement filed with the Securities and Exchange Commission in March 2015, Abbott issued $2.5 billion of long-term debt in the first six months of 2015 that matures in 2020, 2022 and 2025 with fixed interest rates of 2.0 percent, 2.55 percent, and 2.95 percent, respectively. Proceeds from this debt were used to pay down short-term borrowings. Abbott also entered into interest rate swap contracts totaling $2.5 billion. These contracts have the effect of changing Abbott’s obligation from a fixed interest rate to a variable interest rate obligation.

In September 2014, the board of directors authorized the repurchase of up to $3.0 billion of Abbott’s common shares from time to time, which was in addition to the $512 million unused portion of a previous program announced in June 2013. In the first six months of 2015, Abbott repurchased 11.3 million shares at a cost of $512 million under the unused portion of the 2013 authorization and 15.6 million shares at a cost of $738 million under the program authorized in 2014 for a total of 26.9 million shares at a cost of $1.25 billion. In the first six months of 2014, 54.6 million shares were purchased at a cost of $2.1 billion under the June 2013 authorization.

In each of the first two quarters of 2015, Abbott declared a quarterly dividend of $0.24 per share on its common shares, which represents a 9% increase over the $0.22 per share quarterly dividend declared in each of the first two quarters of 2014.

Recently Issued Accounting Standards

In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers, which provides a single comprehensive model for accounting for revenue from contracts with customers and will supersede most existing revenue recognition guidance. The standard becomes effective for Abbott in the first quarter of 2018. Abbott is currently evaluating the effect, if any, that the standard will have on its consolidated financial statements and related disclosures.

Legislative Issues

Abbott’s primary markets are highly competitive and subject to substantial government regulations throughout the world. Abbott expects debate to continue over the availability, method of delivery, and payment for health care products and services. It is not possible to predict the extent to which Abbott or the health care industry in general might be adversely affected by these factors in the future. A more complete discussion of these factors is contained in Item 1, Business, and Item 1A, Risk Factors, in the 2014 Annual Report on Form 10-K.

Private Securities Litigation Reform Act of 1995 — A Caution Concerning Forward-Looking Statements

Under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, Abbott cautions investors that any forward-looking statements or projections made by Abbott, including those made in this document, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, Risk Factors, in the 2014 Annual Report on Form 10-K.

Table of Contents

PART I. FINANCIAL INFORMATION

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Market Price Sensitive Investments

The market value of the available-for-sale equity securities held by Abbott was approximately $4.682 billion as of June 30, 2015 and $9 million as of December 31, 2014. The increase is due primarily to the shares of Mylan N.V. that Abbott received in the sale of its developed markets branded generics pharmaceuticals business and that it continued to hold at June 30, 2015. All available-for-sale equity securities are subject to potential changes in market value. A hypothetical 20 percent decrease in the share prices of these investments would decrease their fair value at June 30, 2015 by approximately $936 million. Abbott monitors these investments for other than temporary declines in market value, and charges impairment losses to income when an other than temporary decline in value occurs.

Item 4. Controls and Procedures

(a) Evaluation of disclosure controls and procedures. The Chief Executive Officer, Miles D. White, and Chief Financial Officer, Brian B. Yoor, evaluated the effectiveness of Abbott Laboratories’ disclosure controls and procedures as of the end of the period covered by this report, and concluded that Abbott Laboratories’ disclosure controls and procedures were effective to ensure that information Abbott is required to disclose in the reports that it files or submits with the Securities and Exchange Commission (the “Commission”) under the Securities Exchange Act of 1934 (the “Exchange Act”) is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms, and to ensure that information required to be disclosed by Abbott in the reports that it files or submits under the Exchange Act is accumulated and communicated to Abbott’s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

(b) Changes in internal control over financial reporting. During the quarter ended June 30, 2015, there were no changes in Abbott’s internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, Abbott’s internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

Abbott is involved in various claims, legal proceedings and investigations, including those described in our Annual Report on Form 10-K for the year ended December 31, 2014.

Table of Contents

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Period	(a) Total Number of Shares (or Units) Purchased		(b) Average Price Paid per Share (or Unit)		(c) Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs	(d) Maximum Number (or Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs
April 1, 2015 – April 30, 2015	32,025	(1)	$	47.941	—	$	2,261,537,480	(2)
May 1, 2015 – May 31, 2015	20,924	(1)	$	48.648	—	$	2,261,537,480	(2)
June 1, 2015 – June 30, 2015	31,983	(1)	$	48.598	—	$	2,261,537,480	(2)
Total	84,932	(1)	$	48.362	—	$	2,261,537,480	(2)

(1) These shares include:

(i) the shares deemed surrendered to Abbott to pay the exercise price in connection with the exercise of employee stock options — 12,650 in April, 1,549 in May, and 12,608 in June; and

(ii) the shares purchased on the open market for the benefit of participants in the Abbott Laboratories, Limited Employee Stock Purchase Plan — 19,375 in April, 19,375 in May, and 19,375 in June.

These shares do not include the shares surrendered to Abbott to satisfy tax withholding obligations in connection with the vesting of restricted stock or restricted stock units.

(2) On September 11, 2014, Abbott announced that its board of directors approved the purchase of up to $3 billion of its common shares, from time to time.

Item 6. Exhibits

Incorporated by reference to the Exhibit Index included herewith.

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ABBOTT LABORATORIES

By:	/s/ Brian B. Yoor
	Brian B. Yoor
	Senior Vice President, Finance
	and Chief Financial Officer

	Date: August 4, 2015

Table of Contents

EXHIBIT INDEX

Exhibit No.		Exhibit

12		Statement re: computation of ratio of earnings to fixed charges.

31.1		Certification of Chief Executive Officer Required by Rule 13a-14(a) (17 CFR 240.13a-14(a)).

31.2		Certification of Chief Financial Officer Required by Rule 13a-14(a) (17 CFR 240.13a-14(a)).

Exhibits 32.1 and 32.2 are furnished herewith and should not be deemed to be “filed” under the Securities Exchange Act of 1934.

32.1		Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2		Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101		The following financial statements and notes from the Abbott Laboratories Quarterly Report on Form 10-Q for the quarter and six months ended June 30, 2015, formatted in XBRL: (i) Condensed Consolidated Statement of Earnings; (ii) Condensed Consolidated Statement of Comprehensive Income; (iii) Condensed Consolidated Balance Sheet; (iv) Condensed Consolidated Statement of Cash Flows and (v) the notes to the Condensed Consolidated Financial Statements.

EX-12 2 a15-11917_1ex12.htm EX-12

Exhibit 12

Abbott Laboratories and Subsidiaries

Computation of Ratio of Earnings to Fixed Charges

(Unaudited)

(dollars in millions)

	Six Months Ended
	June 30, 2015
Earnings from Continuing Operations	$	1,315
Add (deduct):
Taxes on earnings	324
Capitalized interest cost, net of amortization	5
Noncontrolling interests	9

Earnings from Continuing Operations, as adjusted	1,653

Fixed Charges:
Interest on long-term and short-term debt	81
Capitalized interest cost	7
Rental expense representative of an interest factor	42

Total Fixed Charges	130

Total adjusted earnings available for payment of fixed charges	$	1,783

Ratio of earnings to fixed charges	13.7

NOTE: For the purpose of calculating this ratio, (i) earnings from continuing operations have been calculated by adjusting earnings for taxes on earnings; interest expense; capitalized interest cost, net of amortization; noncontrolling interests; and the portion of rentals representative of the interest factor, (ii) Abbott considers one-third of rental expense to be the amount representing return on capital, and (iii) fixed charges comprise total interest expense, including capitalized interest and such portion of rentals.

EX-31.1 3 a15-11917_1ex31d1.htm EX-31.1

Exhibit 31.1

Certification of Chief Executive Officer

Required by Rule 13a-14(a) (17 CFR 240.13a-14(a))

I, Miles D. White, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Abbott Laboratories;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of Abbott as of, and for, the periods presented in this report;

4. Abbott’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for Abbott and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to Abbott, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of Abbott’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in Abbott’s internal control over financial reporting that occurred during Abbott’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, Abbott’s internal control over financial reporting; and

5. Abbott’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to Abbott’s auditors and the audit committee of Abbott’s board of directors:

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect Abbott’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in Abbott’s internal control over financial reporting.

Date: August 4, 2015	/s/ Miles D. White
	Miles D. White, Chairman of the Board and
	Chief Executive Officer

EX-31.2 4 a15-11917_1ex31d2.htm EX-31.2

Exhibit 31.2

Certification of Chief Financial Officer

Required by Rule 13a-14(a) (17 CFR 240.13a-14(a))

I, Brian B. Yoor, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Abbott Laboratories;

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in Abbott’s internal control over financial reporting.

Date: August 4, 2015	/s/ Brian B. Yoor
	Brian B. Yoor, Senior Vice President,
	Finance and Chief Financial Officer

EX-32.1 5 a15-11917_1ex32d1.htm EX-32.1

Exhibit 32.1

Certification Pursuant To

18 U.S.C. Section 1350

As Adopted Pursuant To

Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report of Abbott Laboratories (the “Company”) on Form 10-Q for the period ended June 30, 2015 as filed with the Securities and Exchange Commission (the “Report”), I, Miles D. White, Chairman of the Board and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Miles D. White
Miles D. White
Chairman of the Board and
Chief Executive Officer
August 4, 2015

A signed original of this written statement required by Section 906 has been provided to Abbott Laboratories and will be retained by Abbott Laboratories and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 6 a15-11917_1ex32d2.htm EX-32.2

Exhibit 32.2

Certification Pursuant To

18 U.S.C. Section 1350

As Adopted Pursuant To

Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report of Abbott Laboratories (the “Company”) on Form 10-Q for the period ended June 30, 2015 as filed with the Securities and Exchange Commission (the “Report”), I, Brian B. Yoor, Senior Vice President, Finance and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Brian B. Yoor
Brian B. Yoor
Senior Vice President, Finance
and Chief Financial Officer
August 4, 2015

EX-101.INS 7 abt-20150630.xml XBRL INSTANCE DOCUMENT 0000001800 abt:OtherPrimarilyBankTimeDepositsAndUsTreasuryBillsMember 2015-06-30 0000001800 abt:OtherPrimarilyBankTimeDepositsAndUsTreasuryBillsMember 2014-12-31 0000001800 us-gaap:EmployeeStockOptionMember 2015-06-30 0000001800 us-gaap:RestrictedStockUnitsRSUMember 2015-01-01 2015-06-30 0000001800 abt:RestrictedStockAwardsMember 2015-01-01 2015-06-30 0000001800 abt:RestructuringPlan2015And2013Member 2015-01-01 2015-06-30 0000001800 us-gaap:AllOtherSegmentsMember 2015-04-01 2015-06-30 0000001800 us-gaap:AllOtherSegmentsMember 2015-01-01 2015-06-30 0000001800 us-gaap:AllOtherSegmentsMember 2014-04-01 2014-06-30 0000001800 us-gaap:AllOtherSegmentsMember 2014-01-01 2014-06-30 0000001800 abt:RestructuringPlan2015Member 2015-06-30 0000001800 abt:RestructuringPlan2014Member 2015-06-30 0000001800 abt:RestructuringPlan2013AndPriorYearsMember 2015-06-30 0000001800 abt:RestructuringPlan2015Member 2014-12-31 0000001800 abt:RestructuringPlan2014Member 2014-12-31 0000001800 abt:RestructuringPlan2013AndPriorYearsMember 2014-12-31 0000001800 us-gaap:SellingGeneralAndAdministrativeExpensesMember abt:RestructuringPlan2015Member 2015-01-01 2015-06-30 0000001800 us-gaap:SellingGeneralAndAdministrativeExpensesMember abt:RestructuringPlan2014Member 2015-01-01 2015-06-30 0000001800 us-gaap:CostOfSalesMember abt:RestructuringPlan2015Member 2015-01-01 2015-06-30 0000001800 us-gaap:CostOfSalesMember abt:RestructuringPlan2014Member 2015-01-01 2015-06-30 0000001800 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-06-30 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2015-04-01 2015-06-30 0000001800 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2014-04-01 2014-06-30 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2014-04-01 2014-06-30 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2014-01-01 2014-06-30 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2015-04-01 2015-06-30 0000001800 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2015-04-01 2015-06-30 0000001800 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2015-04-01 2015-06-30 0000001800 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2015-01-01 2015-06-30 0000001800 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2015-01-01 2015-06-30 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2014-04-01 2014-06-30 0000001800 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2014-04-01 2014-06-30 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2014-01-01 2014-06-30 0000001800 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2014-01-01 2014-06-30 0000001800 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2014-01-01 2014-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:VascularProductsMember 2015-04-01 2015-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember 2015-04-01 2015-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember 2015-04-01 2015-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember 2015-04-01 2015-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:VascularProductsMember 2015-01-01 2015-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember 2015-01-01 2015-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember 2015-01-01 2015-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember 2015-01-01 2015-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:VascularProductsMember 2014-04-01 2014-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember 2014-04-01 2014-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember 2014-04-01 2014-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember 2014-04-01 2014-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:VascularProductsMember 2014-01-01 2014-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember 2014-01-01 2014-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember 2014-01-01 2014-06-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember 2014-01-01 2014-06-30 0000001800 abt:OtherLegalProceedingsAndEnvironmentalExposuresMember 2015-06-30 0000001800 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:OtherAggregatedInvestmentsMember 2015-06-30 0000001800 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:EquitySecuritiesMember 2015-06-30 0000001800 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:OtherAggregatedInvestmentsMember 2015-06-30 0000001800 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:EquitySecuritiesMember 2015-06-30 0000001800 us-gaap:OtherInvestmentsMember 2015-06-30 0000001800 us-gaap:EquitySecuritiesMember 2015-06-30 0000001800 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:OtherAggregatedInvestmentsMember 2014-12-31 0000001800 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:EquitySecuritiesMember 2014-12-31 0000001800 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:OtherAggregatedInvestmentsMember 2014-12-31 0000001800 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:EquitySecuritiesMember 2014-12-31 0000001800 us-gaap:OtherInvestmentsMember 2014-12-31 0000001800 us-gaap:EquitySecuritiesMember 2014-12-31 0000001800 abt:MyLanNVMember 2015-06-30 0000001800 us-gaap:SubsidiariesMember abt:ProprietaryPharmaceuticalProductsMember 2015-01-01 2015-06-30 0000001800 us-gaap:SubsidiariesMember abt:ProprietaryPharmaceuticalProductsMember 2014-01-01 2014-06-30 0000001800 us-gaap:OperatingSegmentsMember 2015-04-01 2015-06-30 0000001800 us-gaap:OperatingSegmentsMember 2015-01-01 2015-06-30 0000001800 us-gaap:OperatingSegmentsMember 2014-04-01 2014-06-30 0000001800 us-gaap:OperatingSegmentsMember 2014-01-01 2014-06-30 0000001800 abt:CfrPharmaceuticalsSaMember 2014-09-26 2014-09-26 0000001800 abt:VascularProductsMember 2015-06-30 0000001800 abt:NutritionalProductsMember 2015-06-30 0000001800 abt:EstablishedPharmaceuticalProductsMember 2015-06-30 0000001800 abt:DiagnosticProductsMember 2015-06-30 0000001800 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2015-01-01 2015-06-30 0000001800 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2014-01-01 2014-12-31 0000001800 us-gaap:WeightedAverageMember 2015-01-01 2015-06-30 0000001800 abt:VeropharmMember 2014-12-01 2014-12-31 0000001800 abt:ToperaMember 2014-12-01 2014-12-31 0000001800 abt:CfrPharmaceuticalsSaMember us-gaap:WeightedAverageMember 2014-09-25 2014-09-26 0000001800 abt:CfrPharmaceuticalsSaMember us-gaap:MinimumMember 2014-09-25 2014-09-26 0000001800 abt:CfrPharmaceuticalsSaMember us-gaap:MaximumMember 2014-09-25 2014-09-26 0000001800 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-06-30 0000001800 abt:DevelopedMarketsBrandedGenericsPharmaceuticalsBusinessMember 2015-02-27 0000001800 abt:ProprietaryPharmaceuticalProductsMember 2015-01-01 2015-06-30 0000001800 abt:DevelopedMarketsBrandedGenericsPharmaceuticalsBusinessMember 2015-02-27 2015-02-27 0000001800 abt:AnimalHealthBusinessMember 2015-02-10 2015-02-10 0000001800 us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2015-04-01 2015-06-30 0000001800 us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2015-01-01 2015-06-30 0000001800 us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2014-04-01 2014-06-30 0000001800 us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2014-01-01 2014-06-30 0000001800 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2015-04-01 2015-06-30 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2015-04-01 2015-06-30 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:ForeignCurrencyGainLossMember 2015-04-01 2015-06-30 0000001800 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2015-01-01 2015-06-30 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2015-01-01 2015-06-30 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:ForeignCurrencyGainLossMember 2015-01-01 2015-06-30 0000001800 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2014-04-01 2014-06-30 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2014-04-01 2014-06-30 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:ForeignCurrencyGainLossMember 2014-04-01 2014-06-30 0000001800 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2014-01-01 2014-06-30 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2014-01-01 2014-06-30 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:ForeignCurrencyGainLossMember 2014-01-01 2014-06-30 0000001800 abt:PostemploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2015-06-30 0000001800 us-gaap:ShortTermDebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2015-06-30 0000001800 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2015-06-30 0000001800 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2015-06-30 0000001800 us-gaap:ShortTermDebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2014-12-31 0000001800 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2014-12-31 0000001800 abt:DeferredIncomeTaxesAndOtherAssetsMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2015-06-30 0000001800 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2015-06-30 0000001800 us-gaap:ForeignExchangeContractMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2015-06-30 0000001800 abt:PrepaidExpensesDeferredIncomeTaxesAndOtherReceivablesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2015-06-30 0000001800 abt:PrepaidExpensesDeferredIncomeTaxesAndOtherReceivablesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2015-06-30 0000001800 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2015-06-30 0000001800 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2015-06-30 0000001800 abt:DeferredIncomeTaxesAndOtherAssetsMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2014-12-31 0000001800 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2014-12-31 0000001800 us-gaap:ForeignExchangeContractMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2014-12-31 0000001800 abt:PrepaidExpensesDeferredIncomeTaxesAndOtherReceivablesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2014-12-31 0000001800 abt:PrepaidExpensesDeferredIncomeTaxesAndOtherReceivablesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2014-12-31 0000001800 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2014-12-31 0000001800 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2014-12-31 0000001800 us-gaap:PensionPlansDefinedBenefitMember us-gaap:SegmentContinuingOperationsMember 2015-04-01 2015-06-30 0000001800 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember us-gaap:SegmentContinuingOperationsMember 2015-04-01 2015-06-30 0000001800 us-gaap:PensionPlansDefinedBenefitMember us-gaap:SegmentDiscontinuedOperationsMember 2015-01-01 2015-06-30 0000001800 us-gaap:PensionPlansDefinedBenefitMember us-gaap:SegmentContinuingOperationsMember 2015-01-01 2015-06-30 0000001800 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember us-gaap:SegmentContinuingOperationsMember 2015-01-01 2015-06-30 0000001800 us-gaap:PensionPlansDefinedBenefitMember us-gaap:SegmentDiscontinuedOperationsMember 2014-04-01 2014-06-30 0000001800 us-gaap:PensionPlansDefinedBenefitMember us-gaap:SegmentContinuingOperationsMember 2014-04-01 2014-06-30 0000001800 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember us-gaap:SegmentContinuingOperationsMember 2014-04-01 2014-06-30 0000001800 us-gaap:PensionPlansDefinedBenefitMember us-gaap:SegmentDiscontinuedOperationsMember 2014-01-01 2014-06-30 0000001800 us-gaap:PensionPlansDefinedBenefitMember us-gaap:SegmentContinuingOperationsMember 2014-01-01 2014-06-30 0000001800 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember us-gaap:SegmentContinuingOperationsMember 2014-01-01 2014-06-30 0000001800 us-gaap:PensionPlansDefinedBenefitMember 2015-04-01 2015-06-30 0000001800 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2015-04-01 2015-06-30 0000001800 us-gaap:PensionPlansDefinedBenefitMember 2015-01-01 2015-06-30 0000001800 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2015-01-01 2015-06-30 0000001800 us-gaap:PensionPlansDefinedBenefitMember 2014-04-01 2014-06-30 0000001800 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2014-04-01 2014-06-30 0000001800 us-gaap:PensionPlansDefinedBenefitMember 2014-01-01 2014-06-30 0000001800 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2014-01-01 2014-06-30 0000001800 abt:LongTermSeniorNotesDueIn2020At2.95PercentMember 2015-03-31 0000001800 abt:LongTermSeniorNotesDueiN2020At2.55PercentMember 2015-03-31 0000001800 abt:LongTermSeniorNotesDueIn2020At2.00PercentMember 2015-03-31 0000001800 2015-03-31 0000001800 2014-06-30 0000001800 2013-12-31 0000001800 abt:DevelopedMarketsBrandedGenericsPharmaceuticalsBusinessMember 2015-06-30 0000001800 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2015-06-30 0000001800 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2014-12-31 0000001800 abt:ToperaMember 2014-12-31 0000001800 abt:VeropharmMember 2014-01-01 2014-12-31 0000001800 abt:VeropharmMember 2015-06-30 0000001800 abt:VeropharmMember 2014-12-31 0000001800 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2015-06-30 0000001800 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2015-06-30 0000001800 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2015-06-30 0000001800 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2014-12-31 0000001800 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2014-12-31 0000001800 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2014-12-31 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2015-06-30 0000001800 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2015-06-30 0000001800 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2015-06-30 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2015-06-30 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2015-03-31 0000001800 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2015-03-31 0000001800 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2015-03-31 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2015-03-31 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2014-12-31 0000001800 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2014-12-31 0000001800 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2014-12-31 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2014-12-31 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2014-06-30 0000001800 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2014-06-30 0000001800 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2014-06-30 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2014-06-30 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2014-03-31 0000001800 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2014-03-31 0000001800 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2014-03-31 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2014-03-31 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2013-12-31 0000001800 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2013-12-31 0000001800 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2013-12-31 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2013-12-31 0000001800 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2015-06-30 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2015-06-30 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2015-06-30 0000001800 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2014-12-31 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2014-12-31 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2014-12-31 0000001800 abt:RestructuringPlan2015Member 2015-01-01 2015-06-30 0000001800 abt:RestructuringPlan2014Member 2015-01-01 2015-06-30 0000001800 abt:RestructuringPlan2013AndPriorYearsMember 2015-01-01 2015-06-30 0000001800 abt:DevelopedMarketsBrandedGenericsPharmaceuticalsBusinessMember 2015-01-01 2015-06-30 0000001800 abt:DevelopedMarketsBrandedGenericsPharmaceuticalsBusinessMember us-gaap:MinimumMember 2015-01-01 2015-06-30 0000001800 abt:DevelopedMarketsBrandedGenericsPharmaceuticalsBusinessMember us-gaap:MaximumMember 2015-01-01 2015-06-30 0000001800 abt:MyLanNVMember 2015-01-01 2015-06-30 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2015-01-01 2015-06-30 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2015-01-01 2015-06-30 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2015-01-01 2015-06-30 0000001800 us-gaap:SubsidiariesMember 2015-04-01 2015-06-30 0000001800 abt:DevelopedMarketsGenericsPharmaceuticalsAndAnimalHealthBusinessMember 2015-04-01 2015-06-30 0000001800 us-gaap:SubsidiariesMember 2015-01-01 2015-06-30 0000001800 abt:DevelopedMarketsGenericsPharmaceuticalsAndAnimalHealthBusinessMember 2015-01-01 2015-06-30 0000001800 us-gaap:SubsidiariesMember 2014-04-01 2014-06-30 0000001800 abt:DevelopedMarketsGenericsPharmaceuticalsAndAnimalHealthBusinessMember 2014-04-01 2014-06-30 0000001800 us-gaap:SubsidiariesMember 2014-01-01 2014-06-30 0000001800 abt:DevelopedMarketsGenericsPharmaceuticalsAndAnimalHealthBusinessMember 2014-01-01 2014-06-30 0000001800 2015-06-30 0000001800 us-gaap:SubsidiariesMember abt:ProprietaryPharmaceuticalProductsHeldForDisposalMember 2015-06-30 0000001800 2014-12-31 0000001800 us-gaap:InterestRateSwapMember 2015-01-01 2015-03-31 0000001800 us-gaap:CorporateNonSegmentMember 2015-04-01 2015-06-30 0000001800 us-gaap:CorporateNonSegmentMember 2015-01-01 2015-06-30 0000001800 us-gaap:CorporateNonSegmentMember 2014-04-01 2014-06-30 0000001800 us-gaap:CorporateNonSegmentMember 2014-01-01 2014-06-30 0000001800 abt:MyLanNVMember abt:DevelopedMarketsBrandedGenericsPharmaceuticalsBusinessMember 2015-02-27 0000001800 abt:MylanMember 2015-04-01 2015-04-30 0000001800 abt:MylanMember abt:DevelopedMarketsBrandedGenericsPharmaceuticalsBusinessMember 2015-02-26 2015-02-27 0000001800 abt:MylanMember abt:DevelopedMarketsBrandedGenericsPharmaceuticalsBusinessMember 2015-01-01 2015-06-30 0000001800 2014-12-01 2014-12-31 0000001800 abt:CfrPharmaceuticalsSaMember 2014-09-26 0000001800 abt:CfrPharmaceuticalsSaMember 2014-09-25 2014-09-26 0000001800 us-gaap:MinimumMember 2015-01-01 2015-06-30 0000001800 us-gaap:MaximumMember 2015-01-01 2015-06-30 0000001800 us-gaap:MaterialReconcilingItemsMember 2015-04-01 2015-06-30 0000001800 2015-04-01 2015-06-30 0000001800 us-gaap:MaterialReconcilingItemsMember 2015-01-01 2015-06-30 0000001800 2015-01-01 2015-06-30 0000001800 us-gaap:MaterialReconcilingItemsMember 2014-04-01 2014-06-30 0000001800 2014-04-01 2014-06-30 0000001800 us-gaap:MaterialReconcilingItemsMember 2014-01-01 2014-06-30 0000001800 2014-01-01 2014-06-30 iso4217:USD xbrli:shares xbrli:shares xbrli:pure iso4217:USD 260000000 260000000 133000000 133000000 307000000 307000000 151000000 151000000 0.45 0.40 750000000 200000000 60000000 5000000 110000000 110000000 110000000 0.22 161000000 103000000 221000000 104000000 2500000000 55000000 108000000 210000000 140000000 31000000 257000000 13000000 192000000 150000000 42000000 41000000 35000000 6000000 25000000 8000000 17000000 -1000000 -5000000 4000000 646000000 423000000 1309000000 783000000 15000000 4000000 P12M 70000000 172000000 106000000 117000000 62000000 19000000 108000000 442000000 191000000 -66000000 -108000000 0.22 P2Y P10Y P3Y P2Y 7000000 44000000 42000000 <div> <div style="margin-left:0pt;margin-right:0pt;">   <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 90.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:66.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (in millions) </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> June 30, 2015 </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> December 31, 2014 </td> <td valign="bottom" style="width:01.10%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:66.66%;background-color: #CCEEFF;padding:0pt;"> Trade receivables, net </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.08%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>39  </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.08%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>498  </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:66.66%;padding:0pt;"> Total inventories </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>23  </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>254  </td> <td valign="bottom" style="width:01.10%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:66.66%;background-color: #CCEEFF;padding:0pt;"> Prepaid expenses, deferred income taxes, and other receivables </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>31  </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>140  </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:66.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:66.66%;padding:0pt;"> Current assets held for disposition </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>93  </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>892  </td> <td valign="bottom" style="width:01.10%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:66.66%;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:66.66%;background-color: #CCEEFF;padding:0pt;"> Net property and equipment </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2  </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>125  </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:66.66%;padding:0pt;"> Intangible assets, net of amortization </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>804  </td> <td valign="bottom" style="width:01.10%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:66.66%;background-color: #CCEEFF;padding:0pt;"> Goodwill </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>950  </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:66.66%;padding:0pt;"> Deferred income taxes and other assets </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>55  </td> <td valign="bottom" style="width:01.10%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:66.66%;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:66.66%;background-color: #CCEEFF;padding:0pt;"> Non-current assets held for disposition </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2  </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,934  </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:66.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:66.66%;padding:0pt;"> Total assets held for disposition </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.08%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>95  </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.08%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,826  </td> <td valign="bottom" style="width:01.10%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:66.66%;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:66.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:66.66%;padding:0pt;"> Trade accounts payable </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.08%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>279  </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.08%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>423  </td> <td valign="bottom" style="width:01.10%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:66.66%;background-color: #CCEEFF;padding:0pt;"> Salaries, wages, commissions and other accrued liabilities </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13  </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>257  </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:66.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:66.66%;padding:0pt;"> Current liabilities held for disposition </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>292  </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>680  </td> <td valign="bottom" style="width:01.10%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:66.66%;background-color: #CCEEFF;padding:0pt;"> Post-employment obligations, deferred income taxes and other long-term liabilities </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>108  </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:66.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:66.66%;padding:0pt;"> Total liabilities held for disposition </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.08%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>292  </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.08%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>788  </td> <td valign="bottom" style="width:01.10%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:66.66%;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;padding:0pt;">   </td> </tr> </table></div>   </div> </div> 7000000 -17000000 69000000 false --12-31 Q2 2015 2015-06-30 10-Q 0000001800 1490441465 Yes Large Accelerated Filer ABBOTT LABORATORIES 14100000000 1500000000 1500000000 14100000000 1600000000 4000000000

1064000000

1000000000

3586000000

3553000000

270000000

589000000

6697000000

6695000000

1000000

696000000

99000000

100000000

-2229000000

-2157000000

-2924000000

-3643000000

-1312000000

5000000

13000000

-718000000

-1296000000

5000000

13000000

-656000000

-1284000000

-2000000

9000000

-675000000

-5053000000

-2229000000

99000000

1000000

-2924000000

-2179000000

125000000

174000000

-3727000000

-5004000000

-2157000000

100000000

696000000

-3643000000

164000000

48000000

205000000

57000000

310000000

362000000

335000000

307000000

544000

658000

41275000000

44125000000

15261000000

21131000000

373000000

9000000

364000000

5142000000

10000000

5132000000

2826000000

95000000

892000000

93000000

9000000

4682000000

10000000

4672000000

0.999

0.98

3000000

5000000

415000000

3400000000

79000000

300000000

165000000

243000000

169000000

2920000000

94000000

51000000

179000000

45000000

90000000

10000000

540000000

105000000

25000000

20000000

1800000000

738000000

325000000

100000000

169000000

25000000

570000000

15000000

138000000

209000000

165000000

3475000000

3570000000

4063000000

4048000000

95000000

-15000000

0.44

0.22

0.48

0.24

2400000000

1694929949

1699703688

12383000000

12566000000

901000000

448000000

2998000000

1387000000

4562000000

2288000000

4299000000

2218000000

8770000000

4380000000

8728000000

4441000000

2500000000

750000000

1000000000

0.02

0.0255

0.0295

-9000000

-49000000

-4000000

-24000000

-10000000

-89000000

-1000000

-42000000

-18000000

1000000

-9000000

-24000000

-12000000

40000000

330000000

24000000

547000000

19000000

226000000

9000000

113000000

19000000

257000000

10000000

128000000

32000000

152000000

16000000

75000000

25000000

156000000

11000000

77000000

22000000

104000000

22000000

96000000

8000000

11000000

48000000

11000000

44000000

4000000

7000000

138000000

7000000

137000000

1000000

-4000000

59000000

-4000000

59000000

18000000

128000000

9000000

62000000

15000000

150000000

6000000

68000000

463000000

416000000

358000000

263000000

107000000

150000000

263000000

101000000

460000000

357000000

87000000

270000000

357000000

103000000

575000000

135000000

130000000

135000000

445000000

523000000

75000000

9000000

66000000

75000000

431000000

17000000

<div> <div style="margin-left:0pt;margin-right:0pt;">   Note 9 — Financial Instruments, Derivatives and Fair Value Measures   Certain Abbott foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates for anticipated intercompany purchases by those subsidiaries whose functional currencies are not the U.S. dollar.  These contracts, with notional amounts totaling $1.6 billion at June 30, 2015 and $1.5 billion at December 31, 2014 are designated as cash flow hedges of the variability of the cash flows due to changes in foreign exchange rates and are recorded at fair value.   Accumulated gains and losses as of June 30, 2015 will be included in Cost of products sold at the time the products are sold, generally through the next twelve to eighteen months.  The amount of hedge ineffectiveness was not significant in 2015 and 2014.   Abbott enters into foreign currency forward exchange contracts to manage currency exposures for foreign currency denominated third-party trade payables and receivables, and for intercompany loans and trade accounts payable where the receivable or payable is denominated in a currency other than the functional currency of the entity.  For intercompany loans, the contracts require Abbott to sell or buy foreign currencies, primarily European currencies and Japanese yen, in exchange for primarily U.S. dollars and other European currencies.  For intercompany and trade payables and receivables, the currency exposures are primarily the U.S. dollar, European currencies and Japanese yen.  At June 30, 2015 and December 31, 2014, Abbott held $14.1 billion of such foreign currency forward exchange contracts.   Abbott has designated foreign denominated short-term debt as a hedge of the net investment in a foreign subsidiary of approximately $431 million and approximately $445 million as of June 30, 2015 and December 31, 2014, respectively.  Accordingly, changes in the reported value of this debt due to changes in exchange rates are recorded in Accumulated other comprehensive income (loss), net of tax.   Abbott is a party to interest rate hedge contracts totaling approximately $4.0 billion at June 30, 2015 and $1.5 billion at December 31, 2014 to manage its exposure to changes in the fair value of fixed-rate debt.   These contracts are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates.  The effect of the hedge is to change a fixed-rate interest obligation to a variable rate for that portion of the debt.  Abbott records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount.  No hedge ineffectiveness was recorded in income in 2015 or 2014 for these hedges.   The following table summarizes the amounts and location of certain derivative financial instruments as of June 30, 2015 and December 31, 2014:   <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:23.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="7" valign="bottom" style="width:36.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Fair Value - Assets </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="7" valign="bottom" style="width:36.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Fair Value - Liabilities </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:23.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (in millions) </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> June 30, 2015 </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Dec. 31, 2014 </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Balance Sheet Caption </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> June 30, 2015 </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Dec. 31, 2014 </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Balance Sheet Caption </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:23.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:23.00%;background-color: #CCEEFF;padding:0pt;"> Interest rate swaps designated as fair value hedges </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="top" style="width:05.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>103  </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="top" style="width:05.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>101  </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:18.00%;background-color: #CCEEFF;padding:0pt;"> Deferred income taxes and other assets </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="top" style="width:05.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17  </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="top" style="width:05.88%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:18.00%;background-color: #CCEEFF;padding:0pt;"> Post-employment obligations, deferred income taxes and other long-term liabilities </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:23.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:23.00%;background-color: #CCEEFF;padding:0pt;"> Foreign currency forward exchange contracts: </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:23.00%;padding:0pt;"> Hedging instruments </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="top" style="width:07.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>87  </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="top" style="width:07.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>107  </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="top" style="width:18.00%;padding:0pt;"> Prepaid expenses, deferred income taxes, and other receivables </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="top" style="width:07.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9  </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="top" style="width:07.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="top" style="width:18.00%;padding:0pt;"> Other accrued liabilities </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:23.00%;background-color: #CCEEFF;padding:0pt;"> Others not designated as hedges </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="top" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>270  </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="top" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>150  </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:18.00%;background-color: #CCEEFF;padding:0pt;"> Prepaid expenses, deferred income taxes, and other receivables </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="top" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>66  </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="top" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>130  </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:18.00%;background-color: #CCEEFF;padding:0pt;"> Other accrued liabilities </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:23.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:23.00%;background-color: #CCEEFF;padding:0pt;"> Debt designated as a hedge of net investment in a foreign subsidiary </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="top" style="width:07.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="top" style="width:07.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:18.00%;background-color: #CCEEFF;padding:0pt;"> n/a </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="top" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>431  </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="top" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>445  </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:18.00%;background-color: #CCEEFF;padding:0pt;"> Short-term borrowings </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:23.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="top" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="top" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:18.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="top" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="top" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:18.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:23.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>460  </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>358  </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>523  </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.86%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>575  </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:23.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> </table></div>   The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges, debt designated as a hedge of net investment in a foreign subsidiary and certain other derivative financial instruments, as well as the amounts and location of income (expense) and gain (loss) reclassified into income for the three months and six months ended June 30, 2015 and 2014.  The amount of hedge ineffectiveness was not significant in 2015 and 2014 for these hedges.   <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:22.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:28.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Gain (loss) Recognized in Other Comprehensive Income (loss) </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:28.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Income (expense) and Gain (loss) Reclassified into Income </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td valign="bottom" style="width:15.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:22.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:13.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Three Months Ended June 30 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:13.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Six Months Ended June 30 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:13.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Three Months Ended June 30 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:13.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Six Months Ended June 30 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td valign="bottom" style="width:15.00%;padding:0pt;"> Income Statement </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:22.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (in millions) </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2014 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2014 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2014 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2014 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Caption </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:22.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td valign="bottom" style="width:15.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:22.50%;background-color: #CCEEFF;padding:0pt;"> Foreign currency forward exchange contracts designated as cash flow hedges </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:04.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:04.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;"> ) </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:04.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>48 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:04.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;"> ) </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:04.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>30 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:04.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:04.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>47 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:04.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.00%;background-color: #CCEEFF;padding:0pt;"> Cost of products sold </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:22.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td valign="bottom" style="width:15.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:22.50%;background-color: #CCEEFF;padding:0pt;"> Debt designated as a hedge of net investment in a foreign subsidiary </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(14 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(18 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;padding:0pt;"> n/a </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;padding:0pt;"> n/a </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;padding:0pt;"> n/a </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;padding:0pt;"> n/a </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.00%;background-color: #CCEEFF;padding:0pt;"> n/a </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:22.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td valign="bottom" style="width:15.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:22.50%;background-color: #CCEEFF;padding:0pt;"> Interest rate swaps designated as fair value hedges </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;padding:0pt;"> n/a </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;padding:0pt;"> n/a </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;padding:0pt;"> n/a </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;padding:0pt;"> n/a </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(63 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(14 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.00%;background-color: #CCEEFF;padding:0pt;"> Interest expense </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:22.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td valign="bottom" style="width:15.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:22.50%;background-color: #CCEEFF;padding:0pt;"> Foreign currency forward exchange contracts not designated as hedges </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;padding:0pt;"> n/a </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;padding:0pt;"> n/a </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;padding:0pt;"> n/a </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;padding:0pt;"> n/a </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(85 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(101 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(25 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;"> ) </td> <td valign="bottom" style="width:15.00%;background-color: #CCEEFF;padding:0pt;"> Net foreign exchange loss (gain) </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   The interest rate swaps are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates.  The hedged debt is marked to market, offsetting the effect of marking the interest rate swaps to market.   The carrying values and fair values of certain financial instruments as of June 30, 2015 and December 31, 2014 are shown in the following table. The carrying values of all other financial instruments approximate their estimated fair values.  The counterparties to financial instruments consist of select major international financial institutions.  Abbott does not expect any losses from nonperformance by these counterparties.   <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 83.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:38.78%;padding:0pt;">   </td> <td valign="bottom" style="width:02.98%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:27.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> June 30, 2015 </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:27.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> December 31, 2014 </td> <td valign="bottom" style="width:01.20%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:38.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (in millions) </td> <td valign="bottom" style="width:02.98%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Carrying Value </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Fair Value </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Carrying Value </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Fair Value </td> <td valign="bottom" style="width:01.20%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:38.78%;padding:0pt;">   </td> <td valign="bottom" style="width:02.98%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.02%;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:38.78%;background-color: #CCEEFF;padding:0pt;"> Investment Securities: </td> <td valign="bottom" style="width:02.98%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.02%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:38.78%;padding:0pt;"> Equity securities </td> <td valign="bottom" style="width:02.98%;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.66%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,898 </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.68%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,898 </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.66%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>212 </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.64%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>212 </td> <td valign="bottom" style="width:01.20%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:38.78%;background-color: #CCEEFF;padding:0pt;"> Other </td> <td valign="bottom" style="width:02.98%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17 </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.02%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17 </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17 </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17 </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:38.78%;padding:0pt;"> Total Long-term Debt </td> <td valign="bottom" style="width:02.98%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(5,894 </td> <td valign="bottom" style="width:03.00%;"> ) </td> <td colspan="2" valign="bottom" style="width:12.02%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(6,323 </td> <td valign="bottom" style="width:03.00%;"> ) </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,463 </td> <td valign="bottom" style="width:03.00%;"> ) </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,113 </td> <td valign="bottom" style="width:01.20%;"> ) </td> </tr> <tr> <td valign="top" style="width:38.78%;background-color: #CCEEFF;padding:0pt;"> Foreign Currency Forward Exchange Contracts: </td> <td valign="bottom" style="width:02.98%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.02%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:38.78%;padding:0pt;"> Receivable position </td> <td valign="bottom" style="width:02.98%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>357 </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.02%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>357 </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>263 </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>263 </td> <td valign="bottom" style="width:01.20%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:38.78%;background-color: #CCEEFF;padding:0pt;"> (Payable) position </td> <td valign="bottom" style="width:02.98%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(75 </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:12.02%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(75 </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(135 </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(135 </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;"> ) </td> </tr> <tr> <td valign="top" style="width:38.78%;padding:0pt;"> Interest Rate Hedge Contracts: </td> <td valign="bottom" style="width:02.98%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.02%;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:38.78%;background-color: #CCEEFF;padding:0pt;"> Receivable position </td> <td valign="bottom" style="width:02.98%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>103 </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.02%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>103 </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>101 </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>101 </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:38.78%;padding:0pt;"> Payable position </td> <td valign="bottom" style="width:02.98%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(17 </td> <td valign="bottom" style="width:03.00%;"> ) </td> <td colspan="2" valign="bottom" style="width:12.02%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(17 </td> <td valign="bottom" style="width:03.00%;"> ) </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.20%;padding:0pt;">   </td> </tr> </table></div>   The fair value of the debt was determined based on significant other observable inputs, including current interest rates.   The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the   balance sheet:   <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 93.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:45.36%;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="8" valign="bottom" style="width:37.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Basis of Fair Value Measurement </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:45.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (in millions) </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Outstanding Balances </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Quoted Prices in Active Markets </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Significant Other Observable Inputs </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Significant Unobservable Inputs </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;"> June 30, 2015: </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;"> Equity securities </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,682  </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10  </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,672  </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;"> Interest rate swap derivative financial instruments </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>103  </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>103  </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;"> Foreign currency forward exchange contracts </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>357  </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>357  </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;"> Total Assets </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,142  </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10  </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,132  </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;"> Fair value of hedged long-term debt </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,104  </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,104  </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;"> Foreign currency forward exchange contracts </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>75  </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>75  </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;"> Interest rate swap derivative financial instruments </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17  </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17  </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;"> Contingent consideration related to business combinations </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>169  </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>169  </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;"> Total Liabilities </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,365  </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,196  </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>169  </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;"> December 31, 2014: </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;"> Equity securities </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9  </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9  </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;"> Interest rate swap derivative financial instruments </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>101  </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>101  </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;"> Foreign currency forward exchange contracts </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>263  </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>263  </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;"> Total Assets </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>373  </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9  </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>364  </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;"> Fair value of hedged long-term debt </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,637  </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,637  </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;"> Foreign currency forward exchange contracts </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>135  </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>135  </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;"> Contingent consideration related to business combinations </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>243  </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>243  </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;"> Total Liabilities </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,015  </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,772  </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.50%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>243  </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> </table></div>   Equity securities are principally comprised of Mylan N.V. ordinary shares.  The fair value of the Mylan equity securities was determined based on the value of the publicly-traded ordinary shares adjusted for the restrictions related to the resale of these shares. The fair value of debt was determined based on the face value of the debt adjusted for the fair value of the interest rate swaps, which is based on a discounted cash flow analysis. The fair value of foreign currency forward exchange contracts is determined using a market approach, which utilizes values for comparable derivative instruments.  The fair value of the contingent consideration was determined based on an independent appraisal adjusted for the time value of money and other changes in fair value primarily resulting from changes in regulatory timelines. </div> </div>

-25000000

5000000

19000000

-11000000

2000000

8000000

-101000000

47000000

-14000000

-85000000

30000000

-63000000

-18000000

-1000000

-7000000

-3000000

-14000000

48000000

-11000000

5000000

2820000000

1736000000

130000000

1600000000

-1000000

161000000

79000000

20000000

-5000000

192000000

41000000

25000000

-1000000

-31000000

11000000

-42000000

38000000

44000000

-6000000

-5000000

12000000

-17000000

-4000000

1100000000

1084000000

665000000

498000000

39000000

423000000

279000000

1934000000

2000000

5770000000

950000000

804000000

1934000000

2000000

125000000

2000000

983000000

494000000

256000000

362000000

358000000

0.55

0.31

2.04

0.52

0.55

0.30

2.03

0.52

-3000000

-71000000

776000000

759000000

249000000

P3Y

<div> <div style="margin-left:0pt;margin-right:0pt;">   <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 83.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:38.78%;padding:0pt;">   </td> <td valign="bottom" style="width:02.98%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:27.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> June 30, 2015 </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:27.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> December 31, 2014 </td> <td valign="bottom" style="width:01.20%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:38.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (in millions) </td> <td valign="bottom" style="width:02.98%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Carrying Value </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Fair Value </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Carrying Value </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Fair Value </td> <td valign="bottom" style="width:01.20%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:38.78%;padding:0pt;">   </td> <td valign="bottom" style="width:02.98%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.02%;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:38.78%;background-color: #CCEEFF;padding:0pt;"> Investment Securities: </td> <td valign="bottom" style="width:02.98%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.02%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:38.78%;padding:0pt;"> Equity securities </td> <td valign="bottom" style="width:02.98%;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.66%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,898 </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.68%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,898 </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.66%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>212 </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.64%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>212 </td> <td valign="bottom" style="width:01.20%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:38.78%;background-color: #CCEEFF;padding:0pt;"> Other </td> <td valign="bottom" style="width:02.98%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17 </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.02%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17 </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17 </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17 </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:38.78%;padding:0pt;"> Total Long-term Debt </td> <td valign="bottom" style="width:02.98%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(5,894 </td> <td valign="bottom" style="width:03.00%;"> ) </td> <td colspan="2" valign="bottom" style="width:12.02%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(6,323 </td> <td valign="bottom" style="width:03.00%;"> ) </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,463 </td> <td valign="bottom" style="width:03.00%;"> ) </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,113 </td> <td valign="bottom" style="width:01.20%;"> ) </td> </tr> <tr> <td valign="top" style="width:38.78%;background-color: #CCEEFF;padding:0pt;"> Foreign Currency Forward Exchange Contracts: </td> <td valign="bottom" style="width:02.98%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.02%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:38.78%;padding:0pt;"> Receivable position </td> <td valign="bottom" style="width:02.98%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>357 </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.02%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>357 </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>263 </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>263 </td> <td valign="bottom" style="width:01.20%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:38.78%;background-color: #CCEEFF;padding:0pt;"> (Payable) position </td> <td valign="bottom" style="width:02.98%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(75 </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:12.02%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(75 </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(135 </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(135 </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;"> ) </td> </tr> <tr> <td valign="top" style="width:38.78%;padding:0pt;"> Interest Rate Hedge Contracts: </td> <td valign="bottom" style="width:02.98%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.02%;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">   </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:38.78%;background-color: #CCEEFF;padding:0pt;"> Receivable position </td> <td valign="bottom" style="width:02.98%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>103 </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.02%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>103 </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>101 </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>101 </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:38.78%;padding:0pt;"> Payable position </td> <td valign="bottom" style="width:02.98%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(17 </td> <td valign="bottom" style="width:03.00%;"> ) </td> <td colspan="2" valign="bottom" style="width:12.02%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(17 </td> <td valign="bottom" style="width:03.00%;"> ) </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.20%;padding:0pt;">   </td> </tr> </table></div>   </div> </div>

4900000000

5100000000

680000000

530000000

570000000

650000000

660000000

10800000000

P16Y

P12Y

P15Y

P16Y

P20Y

P2Y

P12Y

-1000000

49000000

-5000000

207000000

10067000000

9896000000

894000000

443000000

3300000000

286000000

2900000000

1600000000

175000000

115000000

67000000

235000000

999000000

658000000

1639000000

986000000

649000000

425000000

1315000000

786000000

0.42

0.28

0.87

0.52

0.42

0.28

0.87

0.52

192000000

42000000

41000000

1761000000

17000000

-2000000

0.13

0.03

1.17

0.13

0.02

1.16

350000000

233000000

324000000

200000000

76000000

125000000

141000000

210000000

354000000

-301000000

10605000

10451000

10676000

10444000

134000000

6198000000

5785000000

72000000

36000000

81000000

44000000

-37000000

-17000000

-33000000

-17000000

101000000

103000000

101000000

103000000

17000000

254000000

23000000

1807000000

1869000000

2643000000

2735000000

558000000

563000000

278000000

303000000

35000000

19000000

48000000

27000000

69700000

41275000000

44125000000

10532000000

9185000000

2015000000

1772000000

243000000

4365000000

4196000000

169000000

788000000

292000000

680000000

292000000

108000000

55000000

32000000

3463000000

4113000000

1637000000

5894000000

6323000000

4104000000

3408000000

5862000000

229000000

212000000

17000000

212000000

17000000

212000000

17000000

243000000

226000000

17000000

4898000000

17000000

4898000000

17000000

50000000

55000000

40000000

P18M

113000000

118000000

0.14

-1771000000

-924000000

633000000

37000000

1236000000

943000000

841000000

466000000

3076000000

784000000

837000000

463000000

3061000000

780000000

1042000000

1891000000

501000000

281000000

585000000

524000000

677000000

1044000000

279000000

160000000

302000000

303000000

1339000000

2222000000

580000000

339000000

739000000

564000000

729000000

1145000000

304000000

172000000

389000000

280000000

2943000000

3288000000

3680000000

3573000000

1651000000

1330000000

-4000000

695000000

522000000

-1000000

2000000

43000000

1000000

-19000000

48000000

833000000

-827000000

5000000

660000000

84000000

-7000000

1000000

-25000000

-2000000

-6000000

43000000

-19000000

-827000000

84000000

60000000

-18000000

-78000000

603000000

28000000

-7000000

-4000000

43000000

12000000

-7000000

-4000000

-19000000

53000000

1000000

695000000

-827000000

22000000

-25000000

522000000

84000000

-28000000

-12000000

-53000000

-22000000

15000000

7000000

25000000

10000000

-2000000

344000000

256000000

5588000000

5952000000

-5000000

-2000000

284000000

279000000

-1119000000

2056000000

-27000000

-28000000

2193000000

1347000000

676000000

724000000

2900000000

250000000

315000000

2800000000

4000000

513000000

451000000

<div> <div style="margin-left:0pt;margin-right:0pt;"> Note 11 — Post-Employment Benefits   Retirement plans consist of defined benefit, defined contribution, and medical and dental plans.  Net cost recognized in continuing operations for the three months and six months ended June 30 for Abbott’s major defined benefit plans and post-employment medical and dental benefit plans is as follows:   <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:31.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:32.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Defined Benefit Plans </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:32.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Medical and Dental Plans </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:31.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:15.50%;padding:0pt;"> Three Months </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:15.50%;padding:0pt;"> Six Months </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:15.50%;padding:0pt;"> Three Months </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:15.50%;padding:0pt;"> Six Months </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:31.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:15.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Ended June 30 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:15.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Ended June 30 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:15.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Ended June 30 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:15.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Ended June 30 </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:31.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> ( in millions) </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2014 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2014 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2014 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2014 </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:31.00%;background-color: #CCEEFF;padding:0pt;"> Service cost — benefits earned during the period </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>68 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>62 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>150 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>128 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:31.00%;padding:0pt;"> Interest cost on projected benefit obligations </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>77 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>75 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>156 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>152 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>16 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>32 </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:31.00%;background-color: #CCEEFF;padding:0pt;"> Expected return on plan assets </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(128 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(113 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(257 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(226 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(10 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(9 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(19 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(19 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;"> ) </td> </tr> <tr> <td valign="top" style="width:31.00%;padding:0pt;"> Net amortization of: </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:31.00%;background-color: #CCEEFF;padding:0pt;"> Actuarial loss, net </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>42 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>24 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>89 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>49 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:31.00%;padding:0pt;"> Prior service cost (credit) </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(12 </td> <td valign="bottom" style="width:01.50%;"> ) </td> <td colspan="2" valign="bottom" style="width:07.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(9 </td> <td valign="bottom" style="width:01.50%;"> ) </td> <td colspan="2" valign="bottom" style="width:07.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(24 </td> <td valign="bottom" style="width:01.50%;"> ) </td> <td colspan="2" valign="bottom" style="width:07.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(18 </td> <td valign="bottom" style="width:01.00%;"> ) </td> </tr> <tr> <td valign="top" style="width:31.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:31.00%;background-color: #CCEEFF;padding:0pt;"> Total Cost </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>59 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>48 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>138 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>104 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>22 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:31.00%;padding:0pt;"> Less: Discontinued operations </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:31.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:31.00%;background-color: #CCEEFF;padding:0pt;"> Net cost - continuing operations </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>59 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>44 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>137 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>96 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;"> ) </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.86%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>22 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:31.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   Abbott funds its domestic defined benefit plans according to IRS funding limitations.  International pension plans are funded according to similar regulations.  In the first six months of 2015 and 2014, $547 million and $330 million, respectively, were contributed to defined benefit plans and $24 million and $40 million were contributed to the post-employment medical and dental benefit plans in the first six months of 2015 and 2014, respectively. </div> </div>

1000000

230000000

40300000

230000000

40300000

2290000000

2485000000

872000000

-1518000000

226000000

213000000

12632000000

12433000000

5935000000

5738000000

-28000000

6000000

-12000000

7000000

5000000

-53000000

47000000

138000000

-22000000

30000000

138000000

33000000

679000000

310000000

658000000

345000000

19000000

25000000

2000000

1000000

9000000

18000000

14000000

39000000

118000000

135000000

32000000

93000000

118000000

25000000

22874000000

25162000000

9812000000

1216000000

8596000000

2306000000

1425000000

3362000000

1503000000

5057000000

628000000

4429000000

1189000000

744000000

1731000000

765000000

10067000000

1117000000

8950000000

2270000000

1874000000

3386000000

1420000000

5170000000

577000000

4593000000

1177000000

977000000

1717000000

722000000

<div> <div style="margin-left:0pt;margin-right:0pt;"> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 96.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:24.44%;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="23" valign="bottom" style="width:72.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Three Months Ended June 30 </td> <td valign="bottom" style="width:01.04%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:24.44%;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:17.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Cumulative Foreign Currency Translation Adjustments </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:17.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Net Actuarial Losses and Prior Service Costs and Credits </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:17.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Cumulative Unrealized Gains on Marketable Equity Securities </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:17.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Cumulative Gains on Derivative Instruments Designated as Cash Flow Hedges </td> <td valign="bottom" style="width:01.04%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:24.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (in millions) </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2014 </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2014 </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2014 </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2014 </td> <td valign="bottom" style="width:01.04%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:24.44%;background-color: #CCEEFF;padding:0pt;"> Balance at March 31 </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.58%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,727 </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;"> ) </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.58%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(656 </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;"> ) </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.58%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,179 </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;"> ) </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.58%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,296 </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;"> ) </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.60%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>174 </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.60%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13 </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.60%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>125 </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.62%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5 </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:24.44%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:24.44%;padding:0pt;"> Other comprehensive income (loss) before reclassifications </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>84 </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(19 </td> <td valign="bottom" style="width:01.56%;"> ) </td> <td colspan="2" valign="bottom" style="width:07.74%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.76%;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>660 </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.76%;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1 </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.76%;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5 </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.78%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.04%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:24.44%;background-color: #CCEEFF;padding:0pt;"> Amounts reclassified from accumulated other comprehensive income </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>22 </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12 </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.76%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(138 </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:07.76%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(5 </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:07.76%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(30 </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:07.78%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7 </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;"> ) </td> </tr> <tr> <td valign="top" style="width:24.44%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:24.44%;padding:0pt;"> Net current period comprehensive income </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>84 </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(19 </td> <td valign="bottom" style="width:01.56%;"> ) </td> <td colspan="2" valign="bottom" style="width:07.74%;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>22 </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12 </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.76%;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>522 </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.76%;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4 </td> <td valign="bottom" style="width:01.56%;"> ) </td> <td colspan="2" valign="bottom" style="width:07.76%;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(25 </td> <td valign="bottom" style="width:01.56%;"> ) </td> <td colspan="2" valign="bottom" style="width:07.78%;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7 </td> <td valign="bottom" style="width:01.04%;"> ) </td> </tr> <tr> <td valign="top" style="width:24.44%;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:24.44%;background-color: #CCEEFF;padding:0pt;"> Balance at June 30 </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.58%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,643 </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;"> ) </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.58%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(675 </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;"> ) </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.58%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,157 </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;"> ) </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.58%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,284 </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;"> ) </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.60%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>696 </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.60%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9 </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.60%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>100 </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.62%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2 </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;"> ) </td> </tr> <tr> <td valign="top" style="width:24.44%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:24.44%;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.76%;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.76%;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.76%;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.78%;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:24.44%;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="23" valign="bottom" style="width:72.94%;padding:0pt;"> Six Months Ended June 30 </td> <td valign="bottom" style="width:01.04%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:24.44%;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="23" valign="bottom" style="width:72.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:24.44%;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:17.04%;padding:0pt;"> Cumulative Foreign Currency Translation Adjustments </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:17.04%;padding:0pt;"> Net Actuarial Losses and Prior Service Costs and Credits </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:17.08%;padding:0pt;"> Cumulative Unrealized Gains on Marketable Equity Securities </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:17.10%;padding:0pt;"> Cumulative Gains on Derivative Instruments Designated as Cash Flow Hedges </td> <td valign="bottom" style="width:01.04%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:24.44%;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:17.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:17.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:17.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:17.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:24.44%;padding:0pt;"> (in millions) </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;padding:0pt;"> 2014 </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;padding:0pt;"> 2014 </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.76%;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.76%;padding:0pt;"> 2014 </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.76%;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.78%;padding:0pt;"> 2014 </td> <td valign="bottom" style="width:01.04%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:24.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:24.44%;background-color: #CCEEFF;padding:0pt;"> Balance at December 31, 2014 and 2013 </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.58%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,924 </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;"> ) </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.58%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(718 </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;"> ) </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.58%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,229 </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;"> ) </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.58%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,312 </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;"> ) </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.60%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1 </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.60%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13 </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.60%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>99 </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.62%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5 </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:24.44%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:24.44%;padding:0pt;"> Impact of business dispositions </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>108 </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19 </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.76%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.76%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.76%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.78%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.04%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:24.44%;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:24.44%;background-color: #CCEEFF;padding:0pt;"> Other comprehensive income (loss) before reclassifications </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(827 </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:07.74%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>43 </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.76%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>833 </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.76%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2 </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.76%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>48 </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.78%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1 </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;"> ) </td> </tr> <tr> <td valign="top" style="width:24.44%;padding:0pt;"> Amounts reclassified from accumulated other comprehensive income </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>53 </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>28 </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.76%;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(138 </td> <td valign="bottom" style="width:01.56%;"> ) </td> <td colspan="2" valign="bottom" style="width:07.76%;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(6 </td> <td valign="bottom" style="width:01.56%;"> ) </td> <td colspan="2" valign="bottom" style="width:07.76%;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(47 </td> <td valign="bottom" style="width:01.56%;"> ) </td> <td colspan="2" valign="bottom" style="width:07.78%;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(6 </td> <td valign="bottom" style="width:01.04%;"> ) </td> </tr> <tr> <td valign="top" style="width:24.44%;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:24.44%;background-color: #CCEEFF;padding:0pt;"> Net current period comprehensive income </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(827 </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:07.74%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>43 </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>53 </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>28 </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.76%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>695 </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.76%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4 </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:07.76%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1 </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.78%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7 </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;"> ) </td> </tr> <tr> <td valign="top" style="width:24.44%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:24.44%;padding:0pt;"> Balance at June 30 </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.58%;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,643 </td> <td valign="bottom" style="width:01.56%;"> ) </td> <td valign="bottom" style="width:01.16%;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.58%;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(675 </td> <td valign="bottom" style="width:01.56%;"> ) </td> <td valign="bottom" style="width:01.16%;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.58%;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,157 </td> <td valign="bottom" style="width:01.56%;"> ) </td> <td valign="bottom" style="width:01.16%;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.58%;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,284 </td> <td valign="bottom" style="width:01.56%;"> ) </td> <td valign="bottom" style="width:01.16%;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.60%;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>696 </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.60%;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9 </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.60%;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>100 </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.60%;;font-family:Times New Roman;font-size:7pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2 </td> <td valign="bottom" style="width:01.04%;"> ) </td> </tr> <tr> <td valign="top" style="width:24.44%;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;padding:0pt;">   </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;padding:0pt;">   </td> </tr> </table></div>   </div> </div>

<div> <div style="margin-left:0pt;margin-right:0pt;">   <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:22.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:28.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Gain (loss) Recognized in Other Comprehensive Income (loss) </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:28.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Income (expense) and Gain (loss) Reclassified into Income </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td valign="bottom" style="width:15.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:22.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:13.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Three Months Ended June 30 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:13.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Six Months Ended June 30 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:13.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Three Months Ended June 30 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:13.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Six Months Ended June 30 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td valign="bottom" style="width:15.00%;padding:0pt;"> Income Statement </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:22.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (in millions) </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2014 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2014 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2014 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2014 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Caption </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:22.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td valign="bottom" style="width:15.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:22.50%;background-color: #CCEEFF;padding:0pt;"> Foreign currency forward exchange contracts designated as cash flow hedges </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:04.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:04.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;"> ) </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:04.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>48 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:04.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;"> ) </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:04.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>30 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:04.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:04.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>47 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:04.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.00%;background-color: #CCEEFF;padding:0pt;"> Cost of products sold </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:22.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td valign="bottom" style="width:15.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:22.50%;background-color: #CCEEFF;padding:0pt;"> Debt designated as a hedge of net investment in a foreign subsidiary </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(14 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(18 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;padding:0pt;"> n/a </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;padding:0pt;"> n/a </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;padding:0pt;"> n/a </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;padding:0pt;"> n/a </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.00%;background-color: #CCEEFF;padding:0pt;"> n/a </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:22.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td valign="bottom" style="width:15.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:22.50%;background-color: #CCEEFF;padding:0pt;"> Interest rate swaps designated as fair value hedges </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;padding:0pt;"> n/a </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;padding:0pt;"> n/a </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;padding:0pt;"> n/a </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;padding:0pt;"> n/a </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(63 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(14 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.00%;background-color: #CCEEFF;padding:0pt;"> Interest expense </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:22.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td valign="bottom" style="width:15.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:22.50%;background-color: #CCEEFF;padding:0pt;"> Foreign currency forward exchange contracts not designated as hedges </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;padding:0pt;"> n/a </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;padding:0pt;"> n/a </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;padding:0pt;"> n/a </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;padding:0pt;"> n/a </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(85 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(101 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(25 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;"> ) </td> <td valign="bottom" style="width:15.00%;background-color: #CCEEFF;padding:0pt;"> Net foreign exchange loss (gain) </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   </div> </div>

<div> <div style="margin-left:0pt;margin-right:0pt;">   <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:23.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="7" valign="bottom" style="width:36.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Fair Value - Assets </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="7" valign="bottom" style="width:36.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Fair Value - Liabilities </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:23.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (in millions) </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> June 30, 2015 </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Dec. 31, 2014 </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Balance Sheet Caption </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> June 30, 2015 </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Dec. 31, 2014 </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Balance Sheet Caption </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:23.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:23.00%;background-color: #CCEEFF;padding:0pt;"> Interest rate swaps designated as fair value hedges </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="top" style="width:05.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>103  </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="top" style="width:05.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>101  </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:18.00%;background-color: #CCEEFF;padding:0pt;"> Deferred income taxes and other assets </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="top" style="width:05.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17  </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="top" style="width:05.88%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:18.00%;background-color: #CCEEFF;padding:0pt;"> Post-employment obligations, deferred income taxes and other long-term liabilities </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:23.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:23.00%;background-color: #CCEEFF;padding:0pt;"> Foreign currency forward exchange contracts: </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:23.00%;padding:0pt;"> Hedging instruments </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="top" style="width:07.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>87  </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="top" style="width:07.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>107  </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="top" style="width:18.00%;padding:0pt;"> Prepaid expenses, deferred income taxes, and other receivables </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="top" style="width:07.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9  </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="top" style="width:07.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="top" style="width:18.00%;padding:0pt;"> Other accrued liabilities </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:23.00%;background-color: #CCEEFF;padding:0pt;"> Others not designated as hedges </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="top" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>270  </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="top" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>150  </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:18.00%;background-color: #CCEEFF;padding:0pt;"> Prepaid expenses, deferred income taxes, and other receivables </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="top" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>66  </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="top" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>130  </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:18.00%;background-color: #CCEEFF;padding:0pt;"> Other accrued liabilities </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:23.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:23.00%;background-color: #CCEEFF;padding:0pt;"> Debt designated as a hedge of net investment in a foreign subsidiary </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="top" style="width:07.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="top" style="width:07.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:18.00%;background-color: #CCEEFF;padding:0pt;"> n/a </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="top" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>431  </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="top" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>445  </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:18.00%;background-color: #CCEEFF;padding:0pt;"> Short-term borrowings </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:23.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="top" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="top" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:18.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="top" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="top" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:18.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:23.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>460  </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>358  </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>523  </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.86%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>575  </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:23.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> </table></div>   </div> </div>

<div> <div style="margin-left:0pt;margin-right:0pt;">   <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 93.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:45.36%;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="8" valign="bottom" style="width:37.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Basis of Fair Value Measurement </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:45.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (in millions) </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Outstanding Balances </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Quoted Prices in Active Markets </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Significant Other Observable Inputs </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Significant Unobservable Inputs </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;"> June 30, 2015: </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;"> Equity securities </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,682  </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10  </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,672  </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;"> Interest rate swap derivative financial instruments </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>103  </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>103  </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;"> Foreign currency forward exchange contracts </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>357  </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>357  </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;"> Total Assets </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,142  </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10  </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,132  </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;"> Fair value of hedged long-term debt </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,104  </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,104  </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;"> Foreign currency forward exchange contracts </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>75  </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>75  </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;"> Interest rate swap derivative financial instruments </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17  </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17  </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;"> Contingent consideration related to business combinations </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>169  </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>169  </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;"> Total Liabilities </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,365  </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,196  </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>169  </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;"> December 31, 2014: </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;"> Equity securities </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9  </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9  </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;"> Interest rate swap derivative financial instruments </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>101  </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>101  </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;"> Foreign currency forward exchange contracts </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>263  </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>263  </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;"> Total Assets </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>373  </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9  </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>364  </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;"> Fair value of hedged long-term debt </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,637  </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,637  </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;"> Foreign currency forward exchange contracts </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>135  </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>135  </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;"> Contingent consideration related to business combinations </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>243  </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>243  </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;"> Total Liabilities </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,015  </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,772  </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.50%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>243  </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> </table></div>   </div> </div>

<div> <div style="margin-left:0pt;margin-right:0pt;"> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:31.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:32.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Defined Benefit Plans </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:32.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Medical and Dental Plans </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:31.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:15.50%;padding:0pt;"> Three Months </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:15.50%;padding:0pt;"> Six Months </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:15.50%;padding:0pt;"> Three Months </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:15.50%;padding:0pt;"> Six Months </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:31.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:15.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Ended June 30 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:15.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Ended June 30 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:15.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Ended June 30 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:15.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Ended June 30 </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:31.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> ( in millions) </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2014 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2014 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2014 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2014 </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:31.00%;background-color: #CCEEFF;padding:0pt;"> Service cost — benefits earned during the period </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>68 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>62 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>150 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>128 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:31.00%;padding:0pt;"> Interest cost on projected benefit obligations </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>77 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>75 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>156 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>152 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>16 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>32 </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:31.00%;background-color: #CCEEFF;padding:0pt;"> Expected return on plan assets </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(128 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(113 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(257 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(226 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(10 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(9 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(19 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(19 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;"> ) </td> </tr> <tr> <td valign="top" style="width:31.00%;padding:0pt;"> Net amortization of: </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:31.00%;background-color: #CCEEFF;padding:0pt;"> Actuarial loss, net </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>42 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>24 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>89 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>49 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:31.00%;padding:0pt;"> Prior service cost (credit) </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(12 </td> <td valign="bottom" style="width:01.50%;"> ) </td> <td colspan="2" valign="bottom" style="width:07.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(9 </td> <td valign="bottom" style="width:01.50%;"> ) </td> <td colspan="2" valign="bottom" style="width:07.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(24 </td> <td valign="bottom" style="width:01.50%;"> ) </td> <td colspan="2" valign="bottom" style="width:07.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(18 </td> <td valign="bottom" style="width:01.00%;"> ) </td> </tr> <tr> <td valign="top" style="width:31.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:31.00%;background-color: #CCEEFF;padding:0pt;"> Total Cost </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>59 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>48 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>138 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>104 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>22 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:31.00%;padding:0pt;"> Less: Discontinued operations </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:31.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:31.00%;background-color: #CCEEFF;padding:0pt;"> Net cost - continuing operations </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>59 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>44 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>137 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>96 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;"> ) </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.86%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>22 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:31.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>     </div> </div>

<div> <div style="margin-left:0pt;margin-right:0pt;">   <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 93.00%;margin-left:18pt;"> <tr> <td valign="bottom" style="width:26.32%;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:34.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Net Sales to External Customers </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:34.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Operating Earnings </td> <td valign="bottom" style="width:00.98%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:26.32%;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:16.58%;padding:0pt;"> Three Months </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:16.58%;padding:0pt;"> Six Months </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:16.58%;padding:0pt;"> Three Months </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:16.58%;padding:0pt;"> Six Months </td> <td valign="bottom" style="width:00.98%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:26.32%;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:16.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Ended June 30 </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:16.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Ended June 30 </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:16.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Ended June 30 </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:16.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Ended June 30 </td> <td valign="bottom" style="width:00.98%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:26.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (in millions) </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2014 </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2014 </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2014 </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2014 </td> <td valign="bottom" style="width:00.98%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:26.32%;background-color: #CCEEFF;padding:0pt;"> Established Pharmaceutical Products </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.30%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>977 </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.30%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>744 </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.30%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,874 </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.30%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,425 </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.30%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>172 </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.30%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>160 </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.30%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>339 </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.30%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>281 </td> <td valign="bottom" style="width:00.98%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:26.32%;padding:0pt;"> Nutritional Products </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,717 </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,731 </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,386 </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,362 </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>389 </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>302 </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>739 </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>585 </td> <td valign="bottom" style="width:00.98%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:26.32%;background-color: #CCEEFF;padding:0pt;"> Diagnostic Products </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,177 </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,189 </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,270 </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,306 </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>304 </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>279 </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>580 </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>501 </td> <td valign="bottom" style="width:00.98%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:26.32%;padding:0pt;"> Vascular Products </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>722 </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>765 </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,420 </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,503 </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>280 </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>303 </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>564 </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>524 </td> <td valign="bottom" style="width:00.98%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:26.32%;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.98%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:26.32%;background-color: #CCEEFF;padding:0pt;"> Total Reportable Segments </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,593 </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,429 </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,950 </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,596 </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,145 </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,044 </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,222 </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,891 </td> <td valign="bottom" style="width:00.98%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:26.32%;padding:0pt;"> Other </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>577 </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>628 </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,117 </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,216 </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;padding:0pt;">   </td> <td valign="bottom" style="width:00.98%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:26.32%;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;padding:0pt;">   </td> <td valign="bottom" style="width:00.98%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:26.32%;background-color: #CCEEFF;padding:0pt;"> Net Sales </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.30%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,170 </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.30%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,057 </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.30%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,067 </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.30%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,812 </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.98%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:26.32%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.98%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:26.32%;padding:0pt;"> Corporate functions and benefit plans costs </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(104 </td> <td valign="bottom" style="width:01.58%;"> ) </td> <td colspan="2" valign="bottom" style="width:07.50%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(103 </td> <td valign="bottom" style="width:01.58%;"> ) </td> <td colspan="2" valign="bottom" style="width:07.50%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(221 </td> <td valign="bottom" style="width:01.58%;"> ) </td> <td colspan="2" valign="bottom" style="width:07.50%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(161 </td> <td valign="bottom" style="width:00.98%;"> ) </td> </tr> <tr> <td valign="top" style="width:26.32%;background-color: #CCEEFF;padding:0pt;"> Non-reportable segments </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>62 </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>106 </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>117 </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>172 </td> <td valign="bottom" style="width:00.98%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:26.32%;padding:0pt;"> Net interest expense </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(17 </td> <td valign="bottom" style="width:01.58%;"> ) </td> <td colspan="2" valign="bottom" style="width:07.50%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(17 </td> <td valign="bottom" style="width:01.58%;"> ) </td> <td colspan="2" valign="bottom" style="width:07.50%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(33 </td> <td valign="bottom" style="width:01.58%;"> ) </td> <td colspan="2" valign="bottom" style="width:07.50%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(37 </td> <td valign="bottom" style="width:00.98%;"> ) </td> </tr> <tr> <td valign="top" style="width:26.32%;background-color: #CCEEFF;padding:0pt;"> Share-based compensation (a) </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(57 </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(48 </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(205 </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(164 </td> <td valign="bottom" style="width:00.98%;background-color: #CCEEFF;"> ) </td> </tr> <tr> <td valign="top" style="width:26.32%;padding:0pt;"> Amortization of intangible assets </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(151 </td> <td valign="bottom" style="width:01.58%;"> ) </td> <td colspan="2" valign="bottom" style="width:07.50%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(133 </td> <td valign="bottom" style="width:01.58%;"> ) </td> <td colspan="2" valign="bottom" style="width:07.50%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(307 </td> <td valign="bottom" style="width:01.58%;"> ) </td> <td colspan="2" valign="bottom" style="width:07.50%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(260 </td> <td valign="bottom" style="width:00.98%;"> ) </td> </tr> <tr> <td valign="top" style="width:26.32%;background-color: #CCEEFF;padding:0pt;"> Other, net (b) </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>108 </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(191 </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>66 </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(442 </td> <td valign="bottom" style="width:00.98%;background-color: #CCEEFF;"> ) </td> </tr> <tr> <td valign="top" style="width:26.32%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.98%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:26.32%;padding:0pt;"> Consolidated Earnings from Continuing Operations Before Taxes </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.30%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>986 </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.30%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>658 </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.30%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,639 </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.30%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>999 </td> <td valign="bottom" style="width:00.98%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:26.32%;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.98%;padding:0pt;">   </td> </tr> </table></div>     <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"></td><td valign="top" align="left" style="width: 18.00pt; display: inline;"> (a) </td><td style="width:0pt;"></td><td align="left" valign="top"> Approximately 40 to 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards.</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"></td><td valign="top" align="left" style="width: 18.00pt; display: inline;"> (b) </td><td style="width:0pt;"></td><td align="left" valign="top"> Other, net in 2015 includes a gain on the sale of a portion of Abbott’s position in Mylan stock and a decrease in the fair value of contingent consideration related to a business acquisition, which was partially offset by charges associated with cost reduction initiatives.</td></tr></table></div> </div> </div>

3269000000

1649000000

3464000000

1727000000

168000000

205000000

660787

5774560

86000000

611000000

27421775

26.83

P3Y4M24D

5518363

669000000

37098123

31.06

P4Y10M24D

4382000000

2867000000

397000000

7129000000

2457000000

4672000000

525000000

635000000

21526000000

23008000000

21639000000

23126000000

109000000

186894515

209262223

8678000000

9716000000

134000000

35000000

1532273000

1517046000

1510961000

1504215000

1521668000

1506595000

1500285000

1493771000

Other, net in 2015 includes a gain on the sale of a portion of Abbott’s position in Mylan stock and a decrease in the fair value of contingent consideration related to a business acquisition, which was partially offset by charges associated with cost reduction initiatives. Approximately 40 to 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards.

EX-101.SCH 8 abt-20150630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00100 - Statement - Condensed Consolidated Statement of Earnings link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - Condensed Consolidated Statement of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - Condensed Consolidated Balance Sheet link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - Condensed Consolidated Statement of Cash Flows link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - Discontinued Operations (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Other Comprehensive Income (Details) link:presentationLink link:calculationLink link:definitionLink 40904 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures (Details 4) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Post-Employment Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 41301 - Disclosure - Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00205 - Statement - Condensed Consolidated Statement of Comprehensive Income (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00305 - Statement - Condensed Consolidated Balance Sheet (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Discontinued Operations link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Supplemental Financial Information link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Other Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Business Acquisitions link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Goodwill and Intangible Assets link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Restructuring Plans link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Incentive Stock Programs link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Litigation and Environmental Matters link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Post-Employment Benefits link:presentationLink link:calculationLink link:definitionLink 11201 - Disclosure - Taxes on Earnings link:presentationLink link:calculationLink link:definitionLink 11301 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 30203 - Disclosure - Discontinued Operations (Tables) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - Supplemental Financial Information (Tables) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Other Comprehensive Income (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Business Acquisitions (Tables) link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - Restructuring Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 30803 - Disclosure - Incentive Stock Programs (Tables) link:presentationLink link:calculationLink link:definitionLink 30903 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures (Tables) link:presentationLink link:calculationLink link:definitionLink 31103 - Disclosure - Post-Employment Benefits (Tables) link:presentationLink link:calculationLink link:definitionLink 31303 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 40202 - Disclosure - Discontinued Operations (Details 2) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Supplemental Financial Information (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Business Acquisitions (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Goodwill and Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 40602 - Disclosure - Goodwill and Intangible Assets (Details 2) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Restructuring Plans (Details) link:presentationLink link:calculationLink link:definitionLink 40702 - Disclosure - Restructuring Plans (Details 2) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Incentive Stock Programs (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures (Details) link:presentationLink link:calculationLink link:definitionLink 40902 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures (Details 2) link:presentationLink link:calculationLink link:definitionLink 40903 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures (Details 3) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Litigation and Environmental Matters (Details) link:presentationLink link:calculationLink link:definitionLink 41201 - Disclosure - Taxes on Earnings (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 abt-20150630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.LAB 10 abt-20150630_lab.xml XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT Document and Entity Information Statement [Table] Statement [Line Items] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Current Reporting Status Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus Condensed Consolidated Statement of Earnings Revenue, Net Net Sales Net Sales to External Customers Cost of Goods Sold Cost of products sold, excluding amortization of intangible assets The aggregate expense (excluding discontinued operations) charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. Amortization of Intangible Assets Excluding Discontinued Operations Amortization of intangible assets Amortization of intangible assets Research and Development Expense (Excluding Acquired in Process Cost) Research and development Selling, General and Administrative Expense. Selling, general and administrative Costs and Expenses Total operating cost and expenses Operating Income (Loss) Operating Earnings Operating earnings Interest Expense. Interest expense Investment Income, Interest Interest (income) Foreign Currency Transaction Gain (Loss), before Tax Net foreign exchange loss (gain) Other Nonoperating Income (Expense) Other (income) expense, net Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest Earnings from continuing operations before taxes Income Tax Expense (Benefit) Taxes on earnings from continuing operations Income (Loss) from Continuing Operations, Including Portion Attributable to Noncontrolling Interest Earnings from continuing operations Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax Earnings (loss) from discontinued operations, net of taxes Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax Gain (loss) on sale of discontinued operations, net of tax After Tax Gain Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Earnings from discontinued operations, net tax benefits Net earnings (loss) from discontinued operations, net of tax Net Income (Loss) Attributable to Parent Net Earnings Net Earnings Net earnings Earnings Per Share, Basic [Abstract] Basic Earnings Per Common Share Income (Loss) from Continuing Operations, Per Basic Share Continuing operations (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share Discontinued operations (in dollars per share) Earnings Per Share, Basic Net earnings (in dollars per share) Earnings Per Share, Diluted [Abstract] Diluted Earnings Per Common Share Income (Loss) from Continuing Operations, Per Diluted Share Continuing operations (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share Discontinued operations (in dollars per share) Earnings Per Share, Diluted Net earnings (in dollars per share) Common Stock, Dividends, Per Share, Declared Cash Dividends Declared Per Common Share (in dollars per share) Weighted Average Number of Shares Outstanding, Basic Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Dilutive Common Stock Options (in shares) Weighted Average Number of Shares Outstanding, Diluted Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Outstanding Common Stock Options Having No Dilutive Effect (in shares) Condensed Consolidated Statement of Comprehensive Income Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Foreign currency translation (loss) gain adjustments Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax Net actuarial gains (losses) and amortization of net actuarial (losses) and prior service (cost) and credits, net of taxes of $10 and $25 in 2015 and $7 and $15 in 2014 Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax Unrealized gains (losses) on marketable equity securities, net of taxes of $256 and $344 in 2015 and $(2) and $(2) in 2014 Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax Net adjustments for derivative instruments designated as cash flow hedges and other, net of taxes of $(6) and nil in 2015 and $(2) and $(2) in 2014 Other Comprehensive Income (Loss), Net of Tax Other comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Comprehensive Income Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax Cumulative foreign currency translation (loss) adjustments Accumulated Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Net of Tax Net actuarial (losses) and prior service cost and credits Accumulated Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax Cumulative unrealized gains on marketable equity securities Accumulated Other Comprehensive Income (Loss), Cumulative Changes in Net Gain (Loss) from Cash Flow Hedges, Effect Net of Tax Cumulative gains (losses) on derivative instruments designated as cash flow hedges and other Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Tax Net actuarial gains (losses) and amortization of net actuarial (losses) and prior service (cost) and credits, taxes Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Tax Unrealized gains (losses) on marketable equity securities, taxes Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax Net adjustments for derivative instruments designated as cash flow hedges and other, taxes Condensed Consolidated Balance Sheet Assets [Abstract] Assets Assets, Current [Abstract] Current Assets: Cash and Cash Equivalents, at Carrying Value Cash and Cash Equivalents, End of Period Cash and Cash Equivalents, Beginning of Year Cash and cash equivalents Short-term Investments Short-term Investments, Total Short-term investments Accounts Receivable, Net, Current Trade receivables, less allowances of $362 in 2015 and $310 in 2014 Inventory, Net [Abstract] Inventories: Inventory, Finished Goods, Gross Finished products Inventory, Work in Process, Gross Work in process Inventory, Raw Materials, Gross Materials Inventory, Net Total inventories Other Assets, Current Prepaid expenses, deferred income taxes, and other receivables Assets of Disposal Group, Including Discontinued Operation, Current Current assets held for disposition Current assets held for disposition Assets, Current Total Current Assets Long-term Investments Investments Securities Investments Property, Plant and Equipment, Gross Property and Equipment, at cost Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less: accumulated depreciation and amortization Property, Plant and Equipment, Net Net property and equipment Intangible Assets, Net (Excluding Goodwill) Intangible assets, net of amortization Goodwill Goodwill Other Assets, Noncurrent Deferred income taxes and other assets Disposal Group, Including Discontinued Operation, Other Noncurrent Assets Non-current assets held for disposition Assets Total Assets Liabilities and Equity [Abstract] Liabilities and Shareholders' Investment Liabilities, Current [Abstract] Current Liabilities: Short-term Debt Short-term borrowings Accounts Payable, Trade, Current Trade accounts payable Employee-related Liabilities, Current Salaries, wages and commissions Other Accrued Liabilities, Current Other accrued liabilities Dividends Payable, Current Dividends payable Accrued Income Taxes, Current Income taxes payable Long-term Debt, Current Maturities Current portion of long-term debt Liabilities of Disposal Group, Including Discontinued Operation, Current Current liabilities held for disposition Current liabilities held for disposition Liabilities, Current Total Current Liabilities Long-term Debt, Excluding Current Maturities Long-term debt Other Liabilities, Noncurrent Post-employment Obligations, deferred income taxes and other long - term Liabilities Liabilities of Disposal Group, Including Discontinued Operation, Noncurrent Non-current liabilities held for disposition Non-current liabilities held for disposition Commitments and Contingencies Commitments and Contingencies Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Shareholders' Investment: Preferred Stock, Value, Issued Preferred shares, one dollar par value Authorized - 1,000,000 shares, none issued Common Stock, Value, Issued Common shares, without par value Authorized - 2,400,000,000 shares Issued at stated capital amount - Shares: 2015: 1,699,703,688; 2014: 1,694,929,949 Treasury Stock, Value Common shares held in treasury, at cost - Shares: 2015:209,262,223; 2014: 186,894,515 Retained Earnings (Accumulated Deficit) Earnings employed in the business Accumulated Other Comprehensive Income (Loss), Net of Tax Balance at the end of the period Balance at the beginning of the period Accumulated other comprehensive income (loss) Stockholders' Equity Attributable to Parent Total Abbott Shareholders' Investment Stockholders' Equity Attributable to Noncontrolling Interest Noncontrolling Interests in Subsidiaries Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Total Shareholders' Investment Liabilities and Equity Total Liabilities and Shareholders' Investment Allowance for Doubtful Accounts Receivable, Current Trade receivables, allowances (in dollars) Preferred Stock, Par or Stated Value Per Share Preferred shares, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred shares, Authorized shares Preferred Stock, Shares Issued Preferred shares, issued shares Common Stock, Shares Authorized Common shares, Authorized shares Common Stock, Shares, Issued Common shares, Issued shares Treasury Stock, Shares Common shares held in treasury, shares Condensed Consolidated Statement of Cash Flows Net Cash Provided by (Used in) Operating Activities [Abstract] Cash Flow From (Used in) Operating Activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net earnings to net cash from operating activities - Depreciation Depreciation Amortization of Intangible Assets Amortization of intangibles Share-based Compensation Share-based compensation Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax Gain on sale of discontinued operations Pretax gain on sale of discontinued operations Gain (Loss) on Sale of Equity Investments Gain on sale of Mylan shares Gain on sale of Mylan shares Increase (Decrease) in Accounts Receivable Trade receivables Increase (Decrease) in Inventories Inventories Increase (Decrease) in Other Operating Assets and Liabilities, Net Other, net Net Cash Provided by (Used in) Operating Activities Net Cash From Operating Activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash Flow From (Used in) Investing Activities: Payments to Acquire Property, Plant, and Equipment Acquisitions of property and equipment Proceeds from Divestiture of Businesses Proceeds from the disposition of business Proceeds from business disposition Payments to Acquire Businesses, Net of Cash Acquired Acquisitions of businesses and technology, net of cash acquired Net cash paid, net of cash on hand of acquired company Proceeds from Divestiture of Businesses and Interests in Affiliates Proceeds from the sale of Mylan shares Payments for (Proceeds from) Investments (Purchases) Sales of investment securities, net Payments for (Proceeds from) Other Investing Activities Other Net Cash Provided by (Used in) Investing Activities Net Cash From (Used in) Investing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash Flow From (Used in) Financing Activities: Proceeds from (Repayments of) Short-term Debt Net (repayments of) proceeds from issuance of short-term debt and other Proceeds from Issuance of Long-term Debt Proceeds from the issuance of long-term debt Repayments of Long-term Debt Repayments of long-term debt Payments for Repurchase of Common Stock Purchases of common shares Proceeds from Stock Options Exercised Proceeds from stock options exercised, including income tax benefit Payments of Dividends Dividends paid Net Cash Provided by (Used in) Financing Activities Net Cash (Used in) Financing Activities Effect of Exchange Rate on Cash and Cash Equivalents Effect of exchange rate changes on cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Net Increase (Decrease) in Cash and Cash Equivalents Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Basis of Presentation Discontinued Operations. Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Discontinued Operations Supplemental Financial Information Additional Financial Information Disclosure [Text Block] Supplemental Financial Information Other Comprehensive Income Comprehensive Income (Loss) Note [Text Block] Other Comprehensive Income Business Acquisitions Business Combination Disclosure [Text Block] Business Acquisitions Goodwill and Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] Goodwill and Intangible Assets Restructuring Plans Restructuring and Related Activities Disclosure [Text Block] Restructuring Plans Incentive Stock Programs Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Incentive Stock Programs Financial Instruments, Derivatives and Fair Value Measures Derivative Instruments and Hedging Activities Disclosure [Text Block] Financial Instruments, Derivatives and Fair Value Measures Litigation and Environmental Matters Commitments and Contingencies Disclosure [Text Block] Litigation and Environmental Matters Post-Employment Benefits Postemployment Benefits Disclosure [Text Block] Post-Employment Benefits Taxes on Earnings Income Tax Disclosure [Text Block] Taxes on Earnings Segment Information Segment Reporting Disclosure [Text Block] Segment Information Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block] Components of discontinued operations Tabular disclosure of disposal groups, which may include the classification and carrying value of the assets and liabilities comprising of the disposal group. Schedule of Disposal Groups Including Discontinued Operations Balance Sheet [Table Text Block] Summary of the assets and liabilities held for sale Schedule of Debt [Table Text Block] Components of short-term and long-term investments Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Schedule of the changes in accumulated other comprehensive income (loss), net of income taxes Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Schedule of the allocation of the fair value of the acquisition Schedule of Restructuring and Related Costs [Table] Restructuring Type [Axis] Type Of Restructuring [Domain] Type of Restructuring [Domain] The entity's 2014 restructuring plans to streamline various commercial operations in order to reduce costs and improve efficiencies in the entity's core diagnostics, established pharmaceuticals and nutritionals businesses. Restructuring Plan2014 [Member] Restructuring Plan 2014 The entity's 2015 and 2013 restructuring plan to streamline global manufacturing and commercial operations in order to reduce costs and improve efficiencies in entity's core diagnostics, established pharmaceutical and nutritionals businesses. Restructuring Plan2015 And2013 [Member] Restructuring Plan 2015 and 2013 The entity's 2013 and prior years restructuring plans to realign its worldwide pharmaceutical and vascular manufacturing operations and selected domestic and international commercial and research and development operations in order to reduce costs. Restructuring Plan2013 And Prior Years [Member] Restructuring Plan 2013 and Prior Years Restructuring and Related Cost [Abstract] Restructuring costs Restructuring and Related Costs [Table Text Block] Schedule of restructuring activity Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Stock options outstanding and exercisable Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Summary of the amounts and location of certain derivative financial instruments Derivative Instruments, Gain (Loss) [Table Text Block] Schedule of derivatives gain (loss) in OCI and earnings Fair Value, by Balance Sheet Grouping [Table Text Block] Schedule of carrying values and fair values of certain financial instruments Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of assets and liabilities measured at fair value on a recurring basis Schedule of Net Benefit Costs [Table Text Block] Net cost for the entity's major defined benefit plans and post-employment medical and dental benefit plans Schedule of Segment Reporting Information, by Segment [Table Text Block] Schedule of segment and geographic area information Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Table] Legal Entity [Axis] EX-101.PRE 11 abt-20150630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.DEF 12 abt-20150630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT XML 13 R39.htm IDEA: XBRL DOCUMENT

Incentive Stock Programs (Details) - Jun. 30, 2015 - USD ($) $ / shares in Units, $ in Millions	Total
Share-based Compensation Arrangement by Share-based Payment Award
Incentive stock programs, shares reserved for future grants	86,000,000
Total unrecognized compensation cost	$ 249
Stock options
Share-based Compensation Arrangement by Share-based Payment Award
Grants in period, stock options (in shares)	5,518,363
Stock options outstanding, number of shares	37,098,123
Exercisable options, number of shares	27,421,775
Stock options outstanding, weighted-average remaining life	4 years 10 months 24 days
Exercisable options, weighted-average remaining life	3 years 4 months 24 days
Stock options outstanding, weighted-average exercise price (in dollars per share)	$ 31.06
Exercisable options, weighted-average exercise price (in dollars per share)	$ 26.83
Aggregate intrinsic value of options outstanding	$ 669
Aggregate intrinsic value of options exercisable	$ 611
Total unrecognized compensation cost, recognition period	3 years
Restricted stock awards
Share-based Compensation Arrangement by Share-based Payment Award
Grants in period, restricted stock (in shares)	660,787
Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award
Grants in period, restricted stock (in shares)	5,774,560

EXCEL 14 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0````(`)B#!$>\2RS`W@$``(`=```3````6T-O;G1E;G1?5'EP97-= M+GAM;,V9S4[C,!2%7Z7*%C6N?V`81-D`6T""%_`DMXW5.+9L4\K;8Z>`9JHR M@ADJG4U^>J[O.L3ODV M+)G7S4HOB8G9[(0U;D@TI&DJ/:J+\]LUA6!:FEQNA=)[7FGO>]/H9-S`UD.[ MTW7J%@O34.N:1YN7U"E;TU'6J\F=#NE&V]R";7HV"MLCKXO.OL)^;=YE=7X*8?= MA7]+9FP9FA^6?ZPH]__X+#LO<6W[JZ"?S([!^F!C*N?::C/L&]63"ZM?SJV^ M:J6VJD/N3`DLV>7Y.*[K$:66_^7]]M.:5R@3QF6P@-^%)T.U-ZGD.>[ M_]OXO>!P.[%````*P(```L```!?.0Q(OW[CMB`PD.MQ-*O>X^NO`ZIK`XTHO8<4M?'5$Q^ M#*G*_=ITJK$"2+8CCVG!D4*>-BP>-9?20D0[8$NP+,L5R*V.V:SGVL7.U49V M[M,41Y26M#;3"&>6X9MY6&3I//B)]!=C;IK>TI;MR5/0!_ZS#0//>997'L=V M+YRO+0O]C^AY%.!)T:'B1?4C9@,2[2F]@OIZ`(4QOCLEFI2"(S>C@KN_V/P" M4$L#!!0````(`)B#!$==-=7JS0$``/H<```:````>&PO7W)E;',O=V]R:V)O M;VLN>&UL+G)E;'/%V4M.XT`4A>&M1%X`Y?L@0$08,6%*LP$KJ<11$MMR5:MA M]VTR0.%11PPBG8DMV]*M?_2I5+[O4KUXCH4H'DY:$X)NBD'W5"";LM!MY2@NW+0 M'25(:B!CS4E"6'.T%L"U<+P6`+9PQ!9`MG#,%H"V<-06P+9PW!8`MW#D%D"W M<.P6@+=P]%:@MW+T5J"WDO;::+/-T5N!WLK16X'>RM%;@=[*T5N!WLK16X'> MRM%;@=[*T5N!WLK1VX#>QM';@-[&T=N`WD8Z*T&')1R]#>AM'+T-Z&TAM'+T-Z&TCM'+T=Z.TCMI+-N=-C-T=N! MWL[1VX'>SM';@=[.T=O/]$YM,\;UGSSNNFVZ=,VGX;#H#.^4WP[Q\BFGJ?#G MS9G6>5HIAM/UXBB>IKZ'A&^_.1_^`U!+`P04````"`"8@P1'J^<;1/@"``"% M#```$````&1O8U!R;W!S+V%P<"YX;6R]5U%OVC`0_BL63YNT+A10*R$:J06V M56I5-%CW[#J78-6Q,Y]AL%^_2P(LM$[:\#`>X.+<=[[[[CLGC#1VAS-K,K!. M`K)-JC0.:?&JLW0N&P8!BB6D'#^3BZ:[L;$I=W1ID\#$L10P,6*5@G9!K]N] M"&#C0$<0G66'H)UPE.]RG65*"NZDT>&]%-:@B1V;;@2H4?#2H4!0Y#F(E95N M&W9+G^I2X3,77,&8]@ICKA!*KW^+A<_8I!G7VZ"\NI/Z&7]D"S/A#JJHXQME M]"6W$-&F1]$/BX7/MRW5J7+L>,EU`E'5]_7-/1>/8#&O]+SWN4N?`P7[]3(V M\$CJ9,:EQ7"T=L,U"&?LKDUK=VJ7(B/RIN/C@O+##GOB"+EYU5ES*[EV'8;R M#UWV.N6VY6IAJPR=#7\:^XQ+`(>CX+!8F%7?JBT'X>"R\"#KV#,X5!;N:#NJ M.U]92*<`'^(9M^X_45'4M"=B<-FI5+\/P;B.V%0[DB.[U>56U+PJ)0=K;&@N M-$+$R$*C9$0RB]CP$S,4)N5UZ,3<<)3(3LYD% M),[K&9Y(%(::H5<4\X$&KW!%K^]\1:=-SKOCBGV1FG*69.V;Z,4\N"58EI\F M%I94AEP#`81)P9_X"J4&1'8M?JTDROIDOAH3_99*%7*ZI91T(I\4L&O$%P-V ML+X#?:^$HZ-0)VQ&G/O]*#^J,<]T[HQX)A)-8GGJ=Z[RD(?/Z<%/;`)6KHE+ M+^:.ZDH*HG?#L);6Z!VQ]]R+F1ET9],T4V9;3-$-:(AE3:4+OJ$'$X6?FL*:S3"/BPX,7Z"5GJ]EEHIMGJ_8/:9?7RO#)H!=7K8H=K+HN>? MVKH6-^WCZ6%S,;7-G(#C4K7'],_;"Z#?7@"T51L!E-74<-!\=OB/[D9,WW]T M>Y76F%D3@O7:RK,`MI?GH'L"QJ^"9HQ?!-6S]NK@_6- M?GK'TX=X]3KWXN4M./[3$?X%4$L#!!0````(`)B#!$>$;NZC/P$``&D#```1 M````9&]C4')O<',O8V]R92YX;6S-DTU/PS`,AO\*ZKU+NXUIJKH>`'%B$A)# M(&XA\;:PYD.)IZ[_GLPK+0,NNW&K:[^/7\=)*5PAK(=';QUX5!"N#KHVH1!N MD6P17<%8$%O0/(QBA8G)M?6:8PS]ACDN=GP#;)QE,Z8!N>3(V1&8NIZ85*44 MA?#`T?H.+T6/=WM?$TP*!C5H,!A8/LI94CV;G;&-*=F@K\KHN.8!EU:JM0)Y MTPYEOU.Q,X+7X20'V;>GOW]ZH`Q+NLI#4'U5TS2C9D)U<>".5067,1CC#?Q`0+^_N;&-]>TK]B,Y>5?4)4$L#!!0````(`)B#!$>97)PC$`8` M`)PG```3````>&PO=&AE;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O& M-H&VM!-S:7;;M)F$[4X?A1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5' MY^@X>?/N+F+HAHB4\GA@V2_;UKNW+][@5S(D$4$P&:>O\,`*I4Q>M5II`,,X M?+&A`T%116F]? M(+3E'S/X%/F7/Z3H=,H%N,!M8('_.;Z?D M3EJ(X53"Q,!J9S]6:\?1TDB`@LE]E`6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS* MVG0T;1K@X_%X.+;+THMP'`3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3 M]WW?ZYMHG`J-6T_3:W?=TXZ)QJW0>`V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H M0D;CZWH2%;7E0-,@`%AP=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9I MTAF6-$9RG9`%#@`WQ-%,4'RO0;:*X,*2TER0UL\IM5`:")K(@?5'@B'%W*_] M]9>[R:0S>IU].LYKE']IJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+`GQ^R-;88C'(CN]WV6'WV3T=N M(]>IP+,BUY1&)$6?R"VZY!$XM4D-,A,_")V&F&I0'`*D"3&6H8;XM,:L$>`3 M?;>^",C?C8CWJV^:/5>A6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SCFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0 MKH)[`?_1VC?"J_B"P#E_+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO`J MQ`GH9%LE"0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3- M"S-#MW)+ZK:4OK4F.$KTL@'37[]EUVY".E,%.70[@: M0KX#;;J=W#HXGIB1N0K34I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\ MEAW'B/*B(>ZAAIC/PT.'>7M?F&>5QE`T%&ULK"0L1K=@N-?Q+!3@9&`MH`># MKU$"\E)58#%;Q@,KD*)\3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@3 M9ZO*WF6QP54=SU5;\K"^:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?!8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$! M=$4"(Y4U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_ M6-8>^3+?.7#;.MX#7N83+$.D?L%]BHJ`$:MBOKJO3_DEG#NT>_&!()O\UMND M]MW@#'S4JUJE9"L1/TL'?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC? MAT6:&C/5BZPYC0IO0=5`Y3_;U`UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2. MX>V+OP%02P,$%`````@`F(,$1_;H"GI8`@``2@L```T```!X;"]S='EL97,N M>&ULS59=:]LP%/TK0AFCA1';Z9JVJVT8A)'"A5/TE")I\@1EJQJ+& M7*^40C*D]%1605-+C(K&!#$:3,)P&C!$.$QCWK(94PW(1KV`W#CZ--H%#Z=W^[B9W;A'`+'\:U(8#2]A,'+2"^N!/H@#1NGL$24>T?&?=<4"&!TJ>G M,UB$(X:=QQVB))/$@"5BA*XCQ$NI,WM,NSF&8<^DZRR!(;][^7I M,L]N![,]0NGV]C20QC52"DL^TQ/0V_-5K3?'!<=.I/4[X%U)M(HFEQL!=M!Y M,R$++(?,$5Q#:4QQJ72`)-7"C$K41KI02C!M%`15@B-J*-<1O:%IY4?X.# MKMRG\-@M_T]-;U\UKT9?P?[VDBZO#1V:_3K@C\WUO MS1$2WJ`XIAN>K+3IJ4J[N#E59>:E<++2KO]16M#WK(W&N-46!Q1D+:&*\+4& M9!XR]T8WW>I8OB5JSJ+SW="N*I3IA^U6%DU6X!*U5#V0I5!V,8'>_F[D1]/! M:SY0)-#;/W!!6G9C%?C7<_H'4$L#!!0````(`)B#!$=S&PO=V]R:V)O;VLN>&ULE9=1;]LV$(#_"J&G%=AFBZ*=UJ@+U'7:!6B7 MH`[:9T:B;2(4J9%4DO;7]RC;ZRD^"_&3)5G\2!Z_.Y%OP^S1^?L[Y^[94VUL MF/EYMHVQF8U&H=RJ6H:_7:,L_+=VOI81;OUFY-9K7:JE*]M:V3CBX_%TY)61 M43L;MKH)V9X67D(+C5>R"ENE8FUVL%IJF[U[&V9K;=0WY0.`F6R:?V6MYMF3 MR9B1(5Y6.JIJG@FX=8^J]\"WS:+5)MU,QI-LE&"'J=YX5KI*[6"W6QV^[__( M6*76LC7Q%@9[Z'>>Y5QP/MTQTFO?M'H,&)@>,%E&_:!NY=T\&V=,MM%]U"8J MOY11??*N;;3=`"MC:^U#7*7I=F_6VNI:_TSCAKNP=8__.*]_.ANE697>&=.U M2G]TC:"'\/\3&&/49>_%*.^^II689],Q`!]TT'?:Z/ACGG771J69C)Y-I0O_ M[RMFN^`QG&B[\597O0H5!'YRME`VJ M8G`5G-$51*5BJP@_T`$"<03BYX(*!"H0J#@7)!!(()!X,6@AC;2E8@@T0:#) MN:`I`DT1:'KNU"X0Z`*!+HY!"QET8&[-;KP*H,'S17^-FK\^;K[4H02-M6VA M]^M&^5V!0(`W"/#F&+!JF\8D/R`5V$=M(0X:K@X&8OW&V+_Q,>HZ;I6'>-10 M;+80'$A5X)2N5IC2LYC0>-$&;54(['WY7PO)]'P^.;8W)_3]Y%SUJ(WI$NH* MYF4W*2/9^Q`@_3`)ZYL3_GZ%>N?;,K8>Z@J[`4=ZS;&T.6$MS!W"FJ*PBJZ\ MAQ5V&R_K'@/[FA/"XA5)@TD+%?YD2^7U`RPU1F%C"081*6F!,2$SE`:$R(,YP7'MY5AD M?H;(Q*BPSYSPF5"2#!16FQ-JGW1SJ:+4!G]]L>;%.9HG5)%C%-:\.%?S`FM> M8,V+,S6'@6%4;W_QJ%O<">%X3GPU\-O,4HL.H%H?H@JL";C`*K7A"J MD]E'30^+7A"B#X$8[Z&PZ`4A^NE,[G@8A5TO"-<',UF,\081NRX(UX=1V'6! M71>$Z\,H[+K`K@O"]6$4WDH+[+H@7!_\?(O>9KJWFR9"\)SLGA2(.RYN-B?LGX?K.!L"06A2L?.T'4"Y[8RG47A9[=Y%).T MN4CW7^!\.L_2(1+.BZTQ'^#9M?WL9'?4VI$/I\]WOP!02P,$%`````@`F(,$ M1YX:#]07`@``(0<``!@```!X;"]W;W)K M!"$`:="C;O"K4H^]L:JD%T&Z`;\QCU_Z'K$_!TSHM/>A/P^\=^=6J(&@*H.; MK^YZ//".#A[#S=Y_AKL#C)1$*WYU>.*+MJ>*/U+ZH3H_ZKT/5`V8X)-0$4C> MKO@%$Z*2)/G3AOYC*N.R/:>_ZNG*\H^(XQ=*?G>U:&6UP/=JW*`+$>]T^H[M M'!(5>**$ZZMWNG!!^]GB>SWZ,O=NT/?)/$DR:W,;0FL(;X8PUH4;D"[S&Q*H M*AF=/#XB]?'@3LJ9"I')'M=ILD*N!Y_5Z+4"97!5,581+A0'HX`W12"SG8!P M!D1+0*CMX;8]FNWQTAYI>W1?WU)Q,(IX&Q`[`;&V)_>`1"L&`S`*F`.PS4B< MC$0GI"N3,(IL&Y`Z`:FVYRL`HRBV`9D3D)EW`%8(5O+`CY([$;GQARL(*XFV M$84341A_O(*PDF0;`8&3H8=EPMK7GC4/?&\(W12[*O.5_W;6Q`6(8QBGC\PI M=-/,(H;%<N=/#0NW,O=AC9C'M.>O?NK.;__RQ8['XC.N.?B)V[@7M'*N1& MJG>]AE*!909XDI6W\KRZ=0ANA&IFLLW,#FXZ@H[S@70[%:N_4$L#!!0````( M`)B#!$>BC0!'8@4``,H<```8````>&PO=V]R:W-H965T&UL ME9E-^-KMM_=&5QU/QM?':CZK* MF__BHJPO3QNR,1>^'=\/W7#!WVW]:=S^6!6G]EB?O*9X>]H\D\>,\0$9B7^. MQ:6]^>X-SK_4]8_AQU_[ITTP^%"4Q6LWF,C[C\\B*%@\+4NV_&O]_K1 M=G5EAFR\*O^I/X^G\?.B_Z,"&&8?0&$`G09,\]@',!C`K@,X.H##`.XZ0P@# MPL4,OM8^KER:=_ENV]07KSWG0SR1QQYO!B.]9:\=K?6+UHX7GX>KGSM*M_[G M8`<0>H/$@+!U)`6$3XC?.V#U@FYL4U`]/ER?(@%$(%[7\\-^/Y[7BNQZNYBW)$3GHM-!(2&:Q#"4!!*->A5$.DSP$E6DJ4H3> M%Q5:185:5#2?)+P5!0@E:AU*#*00*-40IQ$R7090*!PT":LF,5I@`:))(R0D MB"1@&$,4F:DD(DA`W`;W]4BK'JDG07R-`>$AHL>80=8EU8P(D5W,@)'1?3W* MJD=I1RBB1R-$4F1A$X`$1\(IAM)#,P7])XR$,'N*0-Q M+/X,=+/*ZZJ8794NV0QQ.`8&V6R`?;N@.ABC-V0,3"10F(O`0@M+"E`1.`)`.:+''(UL3<( M1)=DCG4(P/0G-$P60&B/`!"CZ%8!%+ID:WN;0'1AQLI+#(S$-PL,+;OQN2H) MV9H@5`;4;8E>EV7O%H@";S!9"K(6IDK=79X4&$QX!@R)7+*UO5D@ILICDJ*[ MDE)@B&0.AR)JK_$TN%OG8F"^(%N0&#N8O\`0*;!J:"B7!:;V`D^A>"_V<796 M`T8N,^CLK&8,";$.I0#UIP"$RH!2W*'$T*G*STZPE((W#A;L%97J*L<7%57- M%D8SP4-(UZEDHI9-J)HMC:$4,F,V42X]';677ZIKW;(EB68^\6BD4.D1DZ[82CT%HQ,H")4=IW0(5"9O?PQ76R6#X)F"1&8 M/H`XDA"O%)(VTXE:;O\L(5XIA\>RS%X#F:XWR\V8%79@"(^8E%CS9,`P$&&$ MM857,*`*:Z,FD!(AE(-*^\&7Z9(88JT4,"3@Z&G^BF&/!=,)$\MR/]J_UQZG3+QZFJ]-KN& MH.N&KW)8>?VJ3?_HZK-YCSA31V;W8F4XO=J^I1F4*Q"6Q=O_]AIQ`T4+D1B`^[SGG#2$? MBRNKW_F)4F%]ED7%E_9)B//<0_!U:7F9"/]='AYYIF>R4J M"P>[;N"465[9JX5J>ZE7"W8115[1E]KBE[+,ZG$+=AU:2.[;7C-CR?1-#BK MA=/I]GE)*YZSRJKI86D_H_D6D091Q.^<7GGOWFJ*?V/LO7GXN5_:;E,#+>A. M-"$R>?F@:UH43229^:\.^I6S$?;OV^A;95>6_Y9QNF;%GWPO3K):U[;V])!= M"O'*KC^H]J`JW+&"JU]K=^&"E:W$MLKL$ZYYI:Y7^"=RM6Q8@+4`=X(NS[#` MTP+O2^`;!;X6^%,S$"T@4S,$6A#<"1SH+-75:2:RU:)F5XN?LV8`HKG$ZR:( MC&QQ%4WV,E>-STWKQXH$"^>CB:,1W$,20+`WCJ0:\3O$D04,5H'MH108]&0\ MQ5HCAD+3QU$VCZ-L`2'A8R]>Z\7K]Z@'^NBQWF_U?E_O*[U_YR)42`7=!4@8 M^>/,6H<)@G$F!<9S0P.T`2CRT6-#9-`0@0Z);W.0OB&B8O!B>/F)1EP#LX[U5Q,9S&@F-#";^'[0C]I![J`?U2PC&,9(HAGD1:%A M8M.4[YL\:0C'<628VC05NQ/F-M2MGS>S/8*E+R`3(N#AGH$%YWZBONT98&9> MX!O>=CJ.]6UO6PS'4U9LY`V7#>M<8/A,$LW,,"*FKVD:MNTPC.,)90^OK@B6 ML\`P>)*6B0VO))T";34T97@-KYV(Z"R&W8!FD.N.0^D4:*NA^+Y[G=[.LJ3U M41T"N+5CETK`-JAK[0X:S[C9F=ZU)VB^1@/M*9IOX!CQ%7ZU.&='^BNKCWG% MK3RCH032WH;ROX3`!#X*=V[-1=T!;_0=0 M2P,$%`````@`F(,$1ZF83<W82)Z"U,;6=L/WW M]1>$;(#T$N/AO3=OQF2F=@;SS-VEJ2J\1L'XDPIXG_7F+!VZ05> M%WBO3J74`9AGL.<=*HIK4;$:<'Q<>JM@L4TUP@!^5;@5@V>@O>\8^]";'X>E MYVL+F."]U`I(+1=<8$*TD$K\QVE>4VKB\+E3_V:J5>YW2.""D=_509;*K.^! M`SZB,Y'OK/V.70F)%MPS(LPOV)^%9+2C>("B3[M6M5E;^^;5=[1Q0N@(84_H M\XP3(D>(KH1XEA`[0OR_&1)'2+YD@+9VT[D-DBC/.&N!:)#^G(*%@G,MHI2! M,&JJ:<($5SIZR5_\#%ZTCH.$`\C:0L)H&K)QD+B'0&5@U$7HC:4(+3^93E$X M2#KCXK'*]DYETFC4&8V&[8H,/WE]S(\[?CSDQ[;=P:W%%P.I;2\L)/"G(853 MF49LXM%6#"%;ER=Y7$HR6DIB382W*9)A*8ESD4YC"HMYFI'96$@4Q].8[9W, M9#7I:#6IK2::.1@+>4IG#B8=+>;F9"QDYG2W=R*V%#CX>U/,3V:P"K!GYUK: MS[6/]K-[%>KQ\"6^#A9%,!+?J%EO1_-5/L\:=,(_$3]5M0`[)M50,A/DR)C$ MRJW_K+I:JMNHWQ!\E/KQ1;?;#FB[D:SIKIO^SLO_`5!+`P04````"`"8@P1' MV+?#)MFIK#[IG$)'8-&"^0\>R_7T`MQ\[(;5UB M0Y[$)R0]A+PZM=WW?E=5P^)G4Q_ZQ^5N&(X/2=(_[ZJF[#^WQ^HP_N>E[9IR M&`^[UZ0_=E6YG0LU=8)I:I*FW!^6Z]5\[FNW7K5O0[T_5%^[1?_6-&7WWZ:J MV]/C$I;^Q+?]ZVZ83B3K57(NM]TWU:'?MX=%5[T\+K_`0Z',A,S$W_OJU%]\ M7TSAG]KV^W3PY_9QF4X9JKIZ'J8JRO'C1U54=3W5-%[Y7Z[T_9I3P[]\ M%FQ)-I?/4Z$E#H'<2+?40VG$/@3GM=Q(41R#`"2,[X(QT&@@(D]8 MDN#LEDN69`:5>&\8P@BY0-B3X`272Z)D!L8P8AJ/&8KI*Q/.8[B[I3R.,<:* M4^I,10@/PNX%)TTKR9>9<48)][#PE*6(ISR$_0O.G%82,#,ZDR9>P90!&R._ ML(7!^=-*&O9,;H6Y5S`%XSH[9@D5=C&F=UVR80:(A`XM/&5TQ!3'L(O1&=1* M+F9&N'\%(V!)140)BQA9LI*(F5$*/JYSK^,P!ABS5L6SC:\7NTZA-F)!A6%_ MHM.>E?S)#.9&H`JF%.41QL*P05'S&)?2:#_"Q8'G*1/3VV%_HK.>E?S)3*:E MY:*'LIA^"ML3,]]J*8R#"*5'4,$4VICU$8;UB3G'D?S)$&DQ#4,F9M2$[8G> M>9(^&=+2T[!@"+.(M1J%W4EL/&G9OF&()%\QHV/>9,/B)#9>*IF3(92>/05# M46M8"JN3D,-([F3(@OC$?:\J9G%$-][SR0M"RD,\:(QX=QQ%*HU8`5#8PZ0X MS@?%7F\\*%[X:#&.\B]C,7'"(B:O3W&+XU?H]G7"BB7#542LNNELQJMG(+$9 M(69LAFU&;#.(6*10V$'$#@*4^H\AU$;87RK.&.4QFT=A#RGV$$@>8NB3S4!: M5'IL7`!$=+4*VTBQC4"RD?([A"#..(]AGD4\WE782(HU`I*1&/JD4\FBQ3NF M8[HLK"3%2I+Z8L,04OIQ;EX'\N_@X]MU1*`;.Y`L)1#W(#TDQE&_C,;;8<)* M4OK^=38,(0&*`YHQ,!0A'A5VEV)W@16F/$.!MX&K*>^QP-M`6[FKRNWYH*Y>ANEK-G[OW`\0[F!HC_[W ME/./.NO_`5!+`P04````"`"8@P1'A'E'L!X"```.!P``&````'AL+W=O$,[A^'SWGWU=V6F"`W\:O#`9WU' MN1\I_52#']7>!4H!$WP2*@')YH9+3(@*D@O_L9G_EU2%\_Z8_DWO5MH?$<"CPC)G>UQL2J,@9'1S>(_5C^SN),Q4BDQVNT^26 MN)Y\5;.WPH<@]VXJR#)PQAP,`Z-UI#1(E$R()PT6->"H$I+S9T=6C"_Z)V*7IN'.D0IZ"^L@Z4RJP3`(O,K>6E],T(/@L M5#>1?6;.:S,0M!]OG^D*+/X!4$L#!!0````(`)B#!$?4K*0S[@,``/$2```8 M````>&PO=V]R:W-H965T&ULC9C!CJ,X$(9?!7%GP&4;0BL= MJ6&UVCVL-)K#[IE.G`0-X"R0SNS;+^`RG6ZY*[X$J^K<;ILC_%PZ57U6$):IL8DB2- MVZKNPMUV:?O>[[;Z.C9UI[[WP7!MVZK_KU"-OCV'++0-/^K3>9P;XMTV7N,. M=:NZH=9=T*OC<_C"GDHN9LFB^+M6M^'N/)C-OVK]<[[X\_`<)K,'U:C].*>H MIL.;*E73S)FFRO]BTO>:<^#]N$>]T,RV^POPZC;FU(&+35+W.LN^5X,_]D&PQS!P`&P!JPUG$' M<`S@[P'+T,7&V=*OWZJQVFU[?0N&2S7?;?8TR?LYR90Y&)9L4Y>&I?%E;GW; M,,$ MPB80]PD$)F`?36:+IC/],!J>9.G7HM*(-H(]=B*=79'H!!XG2)U=23$!_^A2 MWG?%:`1+O]:4J$GY8R.9TTB&1@1A)+-C2AA!#9>/C6R<1C9H1!)&C`820E-B MGG3SV$CN-)*C$6+8"Z.)8`,>#S-+G'66YKD0,:P%BB*X&_RO"S%W(>0'WU"% MC"ABGQ'P87"M*O.```.W&T`W.>4&L-LLH=R@BOF\R(R[[2"5!%&H0!%/&.7& MB"(N/2#,W(1CB#A!%"I0E`L"'J7-!-SG5KDIQQ!SP@-SS,TYAJ"CO!8HBH0D MQQ=5DGG`CKEIQQ!W@L(=BL!GHF)NF#&DD*!HAJ+(YW%QHXHAJP3%*A0!Y![] M`3>K`%DE*%;!RBI)35DV%V.YAQ\WT@"1)BBDH0@(36DU'G0%-\\`>28HGJ&( M0GV)FI1[/-[@7F$!PDSZW&DW@0"Y0;V*!8JB244.+JZS,@]^@'3;001)H.Q( M7/QN/%8?X`85(*@D!2H415ZWR$T@0`))BD`HBJ9E&?G$9':6S'T,N5$%B"I) MH0I%P*@IQXI\OA#`#31`H%$`*5`494",86E5J<]:A;NQQQ%5DL(>BJ*/!\[;H9R9&A*?:BB2"2?Y[`/7ZJHXC+[C/3X;B>A M5?UIV6$9@KV^=J/YR%];UUV<%YAW(CZU%^RI-'LQ[VEVVTMU4G]5_:GNAN!5 MCZ-NETV)H]:CFHPEWZ91.ZOJL%XTZCC.I]ETWIL=&7,QZHO=8%IWN7;_`U!+ M`P04````"`"8@P1'6S'9(Z,!``"S`P``&````'AL+W=OZ(XNA1?9 M=CX66%FPE5=+#<9)-,1"L?1?,9I34T(A!^1<< MO\"\A4,4K%"Y]"75X#SJA4*)%F_3*DU:Q^D/YS/M/H'/!+X2/F;)^-0HV?PD MO"@+BR-QO8BSVQT#W$:1H$Q<4@L.72J>8_56[AYYP6Y1:,;P#>8R87B^0EB0 MO]N#TWM\/O$/_^?O%_Y^ZW'_E\=_"N2+0+X5R.]O#I1TX06M MB8+&Q_!#B.UTJ:;$8[\\D?6=EK\!4$L#!!0````(`)B#!$=$ZW1.H@$``+,# M```8````>&PO=V]R:W-H965T&ULC5/;;N,@$/T5Q`<4QW&R MJ\BQE'2UVCY4JOJP^TSLL8T*C!=PW/W[!7R)545J7\S,^)PS!P;R`5=2VR-MG>L.C-FR!<7M`W:@_9\:C>+.IZ9AMC/`JTA2DJ5)LF>*"TV+/-9> M3)%C[Z30\&*([97BYM\9)`Y'NJ%SX54TK0L%5N1LX55"@;8"-3%0'^EI^E>\7A%TQ;V`7!$J6-7U+VUJ&:*90H_CZN M0L=U&/^D,^T^(9T(Z4+XGD3C8Z-H\P=WO,@-#L1V/,QN<_!P$T2\,K%1S3NT ML7@*U6NQV6_QTY.\^YV]G_G;M<3MY_()` M-@MD:X'L_B;7F/.,V7]HPE:GJL`T\?)84F*OW7BH2W6YGZ=A1TOH7M"02:A?";SXVXZ4:$X?=_$26=UK\!U!+ M`P04````"`"8@P1';T)DL:,!``"S`P``&0```'AL+W=O1I"1+DV3+%!>:%GFL/9DBQ]Y)H>')$-LKQ'DL*;'7;CS4N3K?SV,:I_()+_*.-_";FT9H2\[H_&SC(&I$![Y]AI/4O M:$XDU"Z$.Q^;\5*-B<-N>B+S.RT^`%!+`P04````"`"8@P1'I,I4K:4!``"S M`P``&0```'AL+W=OM&KMD3;.=0?&;-&`%O8..VC]GPJ-%LZGIF:V,R#*2-**\22Y9UK(EN99 MK#V;/,/>*=G"LR&VUUJ8]S,H'(YT0^?"BZP;%PHLS]C"*Z6&UDILB8'J2$^; MPSD-B`CX*6&PJY@$[Q?$UY!\+X\T"19`0>&"@O#+%1Y`J2#D&_^>-#];!N(Z MGM4?XVZ]^XNP\(#JERQ=X\TFE)10B5ZY%QR>8-K"+@@6J&S\DJ*W#O5,H42+ MMW&5;5R'\0_?3[3;!#X1^$+XDD3C8Z-H\YMP(L\,#L1V(LQN<_!P$T2\,K%1 MS3NTL7@*U6N^N?^:L6L0FC!\A3F/&)XN$.;E;_;@]!:?C_S=__G;F;]=>]S^ MY?&?`NDLD*X%TMN;7&/.$V:?_-&$K4Y5@ZGCY;&DP+YUXZ$NU>5^GGB M:?X!4$L#!!0````(`)B#!$=&_"YZHP$``+,#```9````>&PO=V]R:W-H965T M)W^?0%?8K5;]<7,C,\Y M.O^G1J.%\ZEIF.T-B"J2M&(\2>Z9%K*C11YKKZ;(<7!*=O!JB!VT%N;7&12. M1YK2I?`FF]:%`BMRMO(JJ:&S$CMBH#[24WHX9P$1`=\EC'83D^#]@O@>DI?J M2)-@`124+B@(OUSA$90*0K[QSUGSLV4@;N-%_2GNUKN_"`N/J'[(RK7>;$)) M!;48E'O#\1GF+>R#8(G*QB\I!^M0+Q1*M/B85MG%=9S^<#[3;A/X3.`KX4L2 MC4^-HLVOPHDB-S@2VXLPN_3@X2:(>&5BHYIW:&/Q%*K7(GU(G-[B\XF__S]_M_!W6X^[OSS^4R!;!+*M0'9[DUO,><'P/YJP MS:EJ,$V\/):4.'1N.M2UNM[/4QPC^X07>2\:^"9,(SM++NC\;.,@:D0'OGUR MMZ>D]2]H3134+H0//C;3I9H2A_WR1-9W6OP&4$L#!!0````(`)B#!$='%F]! MH@$``+,#```9````>&PO=V]R:W-H965T\'I"RPC'()@C=+&+ZE'ZU"M M%$H4?YM7H>,ZS7_R=*'=)V0+(=L('Y-H?&X4;7[BCE>EP8G8@8>S2X\>;H*( M5R8VJGF'-A;/H7JKTL>\9+<@M&"R'>8R8[)B@S`O?[='1N_QLYE_^#\_7_GY MWF/^E\=_"A2K0+$7*.X/N<=<5LR?4[+=KBHP7;P\EM0X:C=OZE;=[NOZ`MD="Z$#[ZV,R7:DX<#NL3 MV=YI]1M02P,$%`````@`F(,$1]J1G*^C`0``LP,``!D```!X;"]W;W)K&ULA5/;;N,@$/T5Q`<4QW':5>182EI5[<-*51]VGXD] MME&!<0''W;]?P)=:W:SZ8F;&YYPY,)`/:-YL"^#(AY+:'FCK7+=GS)8M*&YO ML`/M_]1H%'<^-0VSG0%>19*2+$V26Z:XT+3(8^W%%#GV3@H-+X;87BEN_IQ` MXG"@&SH77D73NE!@1Y!RB#D&[]/FI\M`W$=S^J/<;?>_9E;N$?Y6U2N]683 M2BJH>2_=*PY/,&UA%P1+E#9^2=E;AVJF4*+XQ[@*'==A_),F$^TZ(9T(Z4+X M$0EL;!1M/G#'B]S@0&S'P^PV>P\W0<0K$QO5O$,;B\=0O12;NUW.+D%HPJ0K MS&G$I-D"85[^:H^47N.G(W_W/7\[\[=KC]M_//Y7()L%LK5`=GV3:\QIQMQ^ M:<)6IZK`-/'R6%)BK]UXJ$MUN9_'-$[E$U[D'6_@)S>-T):&ULA5/!CML@ M$/T5Q`182K:JVD.EU1[:,[''-EI@7,#Q]N\+./9:VU2]F)GQ>V\> M#!0CVE?7`7CRII5Q1]IYWQ\8:10N@H/)1083E"D^@5!0*C7_= M--];1N(ZGM6_I-T&]Q?AX`G53UG[+IC-**FA$8/R+SA^A=L6=E&P0N72EU2# M\ZAG"B5:O$VK-&D=IS]\IMTG\!N!+X3'+!F?&B6;GX4796%Q)*X7<7:;0X#; M*!*4B4MJP:%+Q5.L7LO-?E^P:Q2Z8?@*YQIQGS..')FQUJAILFRZ/(Q4.QD^'NE27^WGB M:2KO\++H10O?A6VE<>2"/LPV#:)!]!#:9P\[2KKP@I9$0>-CN`^QG2[5E'CL MYR>RO-/R#U!+`P04````"`"8@P1'YDF)=J4!``"S`P``&0```'AL+W=O:.M*6[^ MGD#B<*`;.A=>1-.Z4&!%SA9>)11H*U`3`_6!'C?[4Q80$?!+P&!7,0G>SXBO M(?E1'6@2+("$T@4%[I<+/(*40<@W_C-IOK<,Q'4\JW^/N_7NS]S"(\K?HG*M M-YM04D'->^E><'B":0N[(%BBM/%+RMXZ5#.%$L7?QE7HN`[CG]W#1+M.2"=" MNA#NDVA\;!1M?N..%[G!@=B.A]EM]AYN@HA7)C:J>8BDV=P\YNP2A M"9.N,*<1DV8+A'GYJSU2>HV?COS=__G;F;]=>]Q^\OBE0#8+9&N![/HFUYC3 MA+E//C1AJU-58)IX>2PIL==N/-2ENMS/8QJG\@XO\HXW\).;1FA+SNC\;.,@ M:D0'OGURLZ.D]2]H2234+H1W/C;CI1H3A]W\1)9W6OP#4$L#!!0````(`)B# M!$>"F=%*HP$``+,#```9````>&PO=V]R:W-H965T)W^?0%?8J5;]<7, MC,\YEN/E]!HGCD:9T*;R(MG.AP,J"K;Q: M*-!6H"8&FB,]I8=S'A`1\%/`:#H7>?-)I34T/!!NA<H8W%4ZA>R_0A+=@U",V8;(,Y3Y@L7R',R]_LD=%;_&SB M[__/WRW\W=;C[B^/_Q3(%X%\*Y#?WN06Z M5M?[>E6#I0H@$``+,#```9````>&PO M=V]R:W-H965TLMB#J1M&(\R^Z9%M+0LDBU5UL6.'@E#;Q: MX@:MA?UU`H7C@6[H7'B3;>=C@94%6WBUU&"<1$,L-`=ZW.Q/>40DP'<)HUO% M)'H_([['Y*4^T"Q:``65CPHB+!=X!*6B4&C\\ZKYV3(2U_&L_I2F#>[/PL$C MJA^R]ETPFU%20R,&Y=]P?(;K"+LH6*%RZ4NJP7G4,X42+3ZF59JTCM,?/M-N M$_B5P!?"0Y:,3XV2S:_"B[*P.!+7BWAVFWV`VR@2E(E+:L&A2\5CK%[*S<.V M8)8T87B^0%B0O]F#TUM\/O%W_^=O9_YV[7'[E\=_"N2S0+X6R&\/ MN<:<9LR?4[+5KFJP;;H\CE0X&#]MZE)=[N>1IU/YA)=%+UKX)FPKC2-G].%L MTT$TB!Y"^^QN1TD77M"2*&A\#+^$V$Z7:DH\]O,36=YI^1M02P,$%`````@` MF(,$1SQU:)&C`0``LP,``!D```!X;"]W;W)K&UL MA5/;;N,@$/T5Q`<4QW&Z4>182KI:M0\K57W8?2;VV$8%Q@LX[O[]`K[4:E/M MBYD9GW/FP$`^H'FU+8`C;TIJ>Z2M<]V!,5NVH+B]PPZT_U.C4=SYU#3,=@9X M%4E*LC1)[IGB0M,BC[5G4^38.RDT/!MB>Z6X^7L&B<.1;NA<>!%-ZT*!%3E; M>)50H*U`30S41WK:',Y90$3`+P<4D>+\@OH;DJ3K2)%@`":4+"MPO5W@` M*8.0;_QGTGQO&8CK>%;_$7?KW5^XA0>4OT7E6F\VH:2"FO?2O>#P"-,6=D&P M1&GCEY2]=:AF"B6*OXVKT'$=IC_[B7:;D$Z$="'LDVA\;!1M?N>.%[G!@=B. MA]EM#AYN@HA7)C:J>8BTV^UW.KD%HPJ0KS'G$I-D"85[^9H^4WN*G M(W_W?_YVYF_7'K>?/'XID,T"V5H@N[W)->8\8^X_-&&K4U5@FGAY+"FQUVX\ MU*6ZW,]3&J?R#B_RCC?PDYM&:$LNZ/QLXR!J1`>^?7*WHZ3U+VA))-0NA-]\ M;,9+-28.N_F)+.^T^`=02P,$%`````@`F(,$1R"H;CNC`0``LP,``!D```!X M;"]W;W)K&ULA5/;;N,@$/T5Q`<4QW':*'(L)5VM MVH=*51]VGXD]ME&!\0*.NW^_@"^UNEGMBYD9GW/FP$`^H'FW+8`C'TIJ>Z2M M<]V!,5NVH+B]PPZT_U.C4=SYU#3,=@9X%4E*LC1)[IGB0M,BC[574^38.RDT MO!IB>Z6X^7T&B<.1;NA<>!--ZT*!%3E;>)50H*U`30S41WK:',Y90$3`#P&# M7<4D>+\@OH?DN3K2)%@`":4+"MPO5W@$*8.0;_QKTOQL&8CK>%;_'G?KW5^X MA4>4/T7E6F\VH:2"FO?2O>'P!-,6=D&P1&GCEY2]=:AF"B6*?XRKT'$=QC]I M,M%N$]*)D"Z$?22PL5&T^8T[7N0&!V(['F:W.7BX"2)>F=BHYAW:6#R%ZK78 M[!]R=@U"$R9=8^W&0UVJR_T\I7$JG_`B[W@#+]PT0EMR M0>=G&P=1(SKP[9.['26M?T%+(J%V(7SPL1DOU9@X[.8GLKS3X@]02P,$%``` M``@`F(,$1^,Q>9FS`0``&`0``!D```!X;"]W;W)K&ULC53;3J0P&'Z5I@]@@1ET!$#>3 M=6]H_[_?J6E+,2K]8CH`B]X$EV:/.VO['2&FZD!0YSX","ALEZ!NN$, M=\"Y%W+&KY/FIZ4GKN>S^GW8K4M_H@;N%/_#:MNYL`E&-31TX/99C0\P;2$D MK!0WX8NJP5@E9@I&@K[%DNK/+MTYN/8B3AF9H.82FM`\^.ZY3&]N"W+V0A,F6V&.$9-M%PAQ\A<],GR) MGT5^_CU_,_,WZXR;F/'Z/P2VL\!V+;"-`K?)UTVN,<<9DWYODE\TR2>![!\F M,V;SEPE9'9T`W88;:E"E!FGCR2W=Y1$H<\]T*3@TUD]_N+F.-S<65O7S.UQ^!N4'4$L#!!0````(`)B# M!$<_BN!>IP$``+,#```9````>&PO=V]R:W-H965T&<>T0`_&(PF4V,O/>+4F\^^=$<<>(M`(?:>@7JEBL\`>=> MR#5^GS5O+3UQ&R_JW\*TSOV%&GA2_#=K;._,)A@UT-*1VUMQ%C_O'SP7R12#?"N3SD,6_0VXQYP6S_Z\)V>RJ`-V%RV-0K49I MXZ:NU?5^GK)P*C=X50ZT@Y]4=TP:=%'6G6TXB%8I"ZY]\E!@U+L7M"8<6NO# M1Q?K>*EB8M6P/)'UG59_`5!+`P04````"`"8@P1'KV(X@:0!``"S`P``&0`` M`'AL+W=O&\9,V8+BY@9[Z-R?&K7BUJ6Z8:;7P*M`4I*E27++%!<=+?)0>]9%CH.5 MHH-G3`0IO9!K_#9I?K3TQ'4\J_\(TSKW M9V[@$>5?4=G6F4THJ:#F@[0O./Z$:82=%RQ1FO`EY6`LJIE"B>+O<15=6,?X MYSZ9:-<)Z41(OQ!8;!1L/G'+BUSC2$S/_=EM]@ZNO8A3)B:H.8BDV M#W(2;,%PIS\U1XIO<9/(W_W/7\[\[=KC]OH\?;A>X%L%LC6 M`MDTY/WG(=>8TXSYVH2M=E6!;L+E,:3$H;-Q4Y?J&=BW6\5#&QV,]/9'FGQ7]02P,$ M%`````@`F(,$1X-']L*F`0``LP,``!D```!X;"]W;W)K&ULA5/;;MP@$/T5Q`<$V^M-JI77TFZJJ'VH%.6A?6;ML8T"C`-XG?Y] M`5_B5"OEQ3#C<\Z<8:`8T;S:#L"1=R6U/=+.N?[`F*TZ4-S>80_:_VG0*.Y\ M:%IF>P.\CB0E698D]TQQH6E9Q-RS*0LZ7*SR"E$'(%WZ;-3]*!N)VOZ@_Q6Z]^PNW\(CRCZA=Y\TFE-30\$&Z%QQ_ MP-S"/@A6*&W\DFJP#M5"H43Q]VD5.J[C].<^GVFW"=E,R%;"MR0:GPI%F]^Y MXV5A<"2VYV%VZ<'#31#QRL1&->_0QN0I9*^EGU?!KD%HQF0;S'G&Y"N$>?F; M-3)ZBY]-_/W7_-W"WVT][B(_?4B_%L@7@7PKD,]-II^;W&+."R;[KPC;G*H" MT\;+8TF%@W;3H:[9]7Z>LCB5#WA9]+R%7]RT0EMR0>=G&P?1(#KPY9.[/26= M?T%K(*%Q8?O@]V:Z5%/@L%^>R/I.RW]02P,$%`````@`F(,$1\8\I@3E`0`` MR`4``!D```!X;"]W;W)K&ULC53;CILP$/T5BP]8 M`X&$1`0IV575/E1:[4/[[,!PT=J8M4W8_GUM8UA:(847[!G..7,&-),.7+S+ M&D"A3T9;>?9JI;H3QC*O@1'YQ#MH]9N2"T:4#D6%92>`%);$*`Y]?X\9:5HO M2VWN560I[Q5M6G@52/:,$?'G"I0/9R_PIL1;4]7*)'"6XIE7-`Q:V?`6"2C/ MWB4X70,+L8A?#0QR<4?&_(WS=Q/\*,Z>;SP`A5P9":*/.SP#I49)5_YPHE\U M#7%YG]2_V7:U_1N1\,SI[Z90M7;K>ZB`DO14O?'A.[@>8B.836O/87P3^8ZV3@@=(9P)B27@L9"U^4(4R5+!!R0[8GY><-)P842T M,I)633N4-GDQV7L6^KL4WXV0PX0+S-5AHAF"M?QJC=!;XXV&@0K)H(@@VM3J#`_Z\.7DP:`U'9 MA2)1SOM6C8,V9^>E=0GMI'[!L[0C%?PDHFI:B6Y&ULA5/+;MLP$/P5@A\0 M2K)<%X8LP$Y0M(<"00[MF996$A&2JY"4E?Y]2>H1M3"0B[B[FIF=Y:,8T;S: M#L"1=R6U/='.N?[(F*TZ4-P^8`_:_VG0*.Y\:EIF>P.\CB0E698D7YCB0M.R MB+5G4Q8X."DT/!MB!Z6X^7,!B>.)IG0IO(BV$!'P2\!H-S$)WJ^(KR'Y49]H$BR`A,H%!>Z7&SR"E$'(-WZ;-3]:!N(V M7M2_Q6F]^RNW\(CRMZA=Y\TFE-30\$&Z%QR_PSS"/@A6*&W\DFJP#M5"H43Q M]VD5.J[C]"?/9MI]0C83LI7P-8G&IT;1YA-WO"P,CL3V/)Q=>O1P$T2\,K%1 MS3NTL7@.U5N9I6G!;D%HQF0;S&7&Y"N$>?F[/3)ZCY]-_/WG_-W"WVT][B(_ M/1P^%\@7@7PKD,]#9O\.N<5<%LSNOR9LLZL*3!LOCR45#MI-F[I6U_MYCL?( M/N!ET?,6?G+3"FW)%9T_VW@0#:(#WSYYV%/2^1>T)A(:%\*#C\UTJ:;$8;\\ MD?6=EG\!4$L#!!0````(`)B#!$&PO=V]R:W-H M965TW9@ M^%%MS-HF=-]^;6,26J%PP3/C[V=&V$X'(3]4#:#1)V>M.@2UUMT>8Y77P*EZ M$!VT9J<4DE-M4EEAU4F@A2-QADD8[C"G31MDJ:N]R2P5O69-"V\2J9YS*O^= M@(GA$$3!5'AOJEK;`LY2?.45#8=6-:)%$LI#<(SVI\0B'.!W`X.:Q;?62D6B;XHL5\A@R MPYP\Y@;!1G[1@P1+?#+RXW7^9N)OYCUN'#]*GM8%MI/`=BZP]4/&7X><8TX3 M9K=N$B^:Q%X@N6,R81[737:+)CLO\'3'Q&-(N&Z2+)HD7B"Z8S)AR#<3/#N$ M'&3E[II"N>A;/9[!:_5ZG8_$'>(;/$L[6L$O*JNF5>@LM+D*[MR60F@P]N%# M'*#:/#C7A$&I;9B86(YW<$RTZ*87Y?JL9?\!4$L#!!0````(`)B#!$??W!)O MHP$``+,#```9````>&PO=V]R:W-H965T&,"*[:&V6=*_KVTN(=%*><$SPSEGSOA2 MC&A>;0?@R)N2VAYIYUQ_8,Q6'2AN[[`'[?\T:!1W/C4ML[T!7D>2DBQ-DF], M<:%I6<3:LRD+')P4&IX-L8-2W/P[@\3Q2'=T*;R(MG.AP,J"K;Q:*-!6H"8& MFB,][0[G/"`BX+>`T6YB$KQ?$%]#\K,^TB18``F5"PK<+U=X`"F#D&_\=]9\ M;QF(VWA1?XS3>O<7;N$!Y1]1N\Z;32BIH>&#="\X/L$\PCX(5BAM_))JL`[5 M0J%$\;=I%3JNX_3G/IEIMPGI3$@_$=C4*-K\P1TO"X,CL3T/9[<[>+@)(EZ9 MV*CF'=I8/(7JM4S3K(#1CT@WF/&/R%<*\_,T>*;W%3R?^_FM^MO"SK<

MRCN\+'K>PB]N6J$MN:#S9QL/HD%TX-LG=WM*.O^"UD1"XT+XW<=FNE13XK!? MGLCZ3LO_4$L#!!0````(`)B#!$<[`"B0IP$``+,#```9````>&PO=V]R:W-H M965T4C']"\V1;`D0\EM3W1UKGNR)@M6U#< M/F`'VO^IT2CN?&H:9CL#O(HD)5F:)(],<:%ID`P:YB$KQ?$=]" M\J,ZT218``FE"PK<+S=X`BF#D&_\/FE^M@S$=3RK?XO3>O=7;N$)Y6]1N=:; M32BIH.:]=*\X?(=IA%T0+%':^"5E;QVJF4*)XA_C*G18S=[S(#0[$=CR;HX2:(>&5BHYIW:&/Q'*JW(DT?NW%3E^IR/\_Q&-DGO,@[WL!/;AJA+;FB\V<; M#Z)&=.#;)P\[2EK_@I9$0NU"N/>Q&2_5F#CLYB>RO-/B+U!+`P04````"`"8 M@P1'43P_UL8$``##&P``&0```'AL+W=OL:JD[5UEZ<_[]`:;'16W: MOHE*GIY^&:;?9F!V*JM?]9KZG0:3F[>F&R)K/S[-TN1Y-U*;^5\8]$_.+G#XW8V^ MZD^WE?^:U699YO_L-\VN5>M/)QNSS3[RYF=Y6ALXAZ`;\*W,Z_[OY.VC;LK" MA4PG1?;;?NX/_>?)_B?V(0P/D!`@SP%"DP$*`A0W0$.`Y@8$$!!P`T(("+D! M$01$W(`8`F)N0`(!"3>@N^;VROE7(9Z]Y/V">7@`))ZPNDT0]<[!2Y1%)!`,Z0FJ-3$2J66D46NK>]"ZGTD3:!X M."M`^*C6_G`KEEAI*V`2:F(93.IR)9*C5^!ZK<-25K`"1E)R[R(I(&+0$@BU MN)L+9]6$B:X`^B+'Z^<[,)I:,,"(*!3C([TXBG<1\/8AK.\GU-H$)O8Y=23P MYB"LJ2?D90(F8!4!;OPB8"Q>RP2LU8"[NK"6G5#&``RY=N\B*2`B4:S9Q[N# M<.TAIO1&,/V4X/M,ZI+%DM,U!=XCA/7NA!0,_AY1'8T#I0#I03W\NM!`-*`8IBEF3G[CR&>SQ#K.01>TFIDSWV9 M"';4O$1XK2HHPX#3K!5>ABJZV1HBCTT`$H3]K!&(4(.7JG(;5=:BQ$M5N=L/ MXD'0&B!!,"_`L-Q=X]6LH9H#CO5HO)JUJV9BO_4-(,&:?(U7LQYY3M=%#3+! MKLU_X*PZC=>S=O7,<4H]\I1-WY^7!4#B>N5>/F:[A0@U>-'K@#%Y:Z"XDX>7 MO8:-$+G``6(^QL2]03MOX/0BC5>TAHH.B5ZT.$-B'%HBD%7C#=X*'+-W\U=6 MO>\/]>2U;)JRZ%\&;,NR,>T@_D-[X7&PO=V]R:W-H M965T=R731KA5; MMID`A#@^>![? M'&A-^#T[TJ;[SXZU-1'=;;OW^+&E9#L$U96'?3_V:E(V[GHY/'MIUTMV$E79 MT)?6X:>Z)NW?)UJQ\\I%KGKPL]P?1/_`6R^]2]RVK&G#2]8X+=VMW$?T4."D M1P;B5TG/?'3M],V_,O;6WWS?KER_[X%6="/Z%*3[>*<9K:H^4U?Y#R3]7[,/ M'%^K[,4@MVO_E7":L>IWN16'KEO?=;9T1TZ5^,G.WRAHB/J$&U;QX:^S.7'! M:A7B.C7YD)]E,WR>Y7]2'\+T`1@"\"4`A<:```("VX`0`D+;@`@"(MN`&`+B MFP!/#M8PU,]$D/6R96>''TD_`=%#A[=]DBZSPX=LW2CSX>%C__1]C6.\]-[[ M1,#@$?,$3.!/,QDPT33RK$I-(_E\EN)3%J_3JA6,E>!@+!A#?#"?(%`)PG&" M`!*$UTTF`]-(J9()%P8FASQ1/,T4DEFD%LV&VF9#:#::+I))YNX&B<9Z))(L MII$<*OG32"$1%*-Y-9%6301JXNDBF63N0H,:B02I04TT.R8%((&%FEBK)@8U MB4&-9.Z008U$0@.2Q]IE=:5&(FB!Y]4DVG65@)IT/D&J'8X47,;090Y,.IIF MDU46VBH+:-,TE26#D&]1!?G:,L/C7HUA'F8`F=YN#@Q*`@O'0TC?#'AF:/%R MD=XU$;9_O4COFRC0#\G8BYX`0K'5V.L]#X$5)38I(KULEK!A!68`&7<+8(S;A2IFVB^`L=HPD-Y4 M4#J_93P#%!I?@F00-O4+C$V[>G="RIY,>P)`YE<@&:.9`F/8!@M`4&2QE+"O M74K8MW<.K/8"A/PTM"BD]T(\X877A8(O6#_6 M>R%67F@Q)['>"_$7O!#KO1#'\ZLP`\CXS4TQACRY8I!A#1678A9;(M;;)4[T M:_7JNS5`IK,"((9C0`[(K:*KHX*J="O(&YT*CV1/?Y!V7S;<>66B.V`.I\$= M8X)V.?S[;HP.E&PO-Q7=B?XRZ:Y;>3J7-X(=U8\-EU\\UO\`4$L#!!0````( M`)B#!$=.!NM]X@0``',<```9````>&PO=V]R:W-H965T9+O3A56WMQ]II$$JT%<8'$/6]_@.EQT?2, M[4U4\NN>[F;^SHV==YMAZ,RB(2C)FHS+:[Z7PV7/M>SV?51UML=_GW>M)\E&56 M_W>?%]7A;LJG[L*/[?NF[2]$\UETM%MORWS7;*O=I,[?[J;?^.W*#,A`_+O- M#\WH^Z0/_J6J?O4_5NN[*>MCR(O\M>U=9-W'9_Z0%T7OJ1OY-SC].V9O./[N MO#\/Z7;AOV1-_E`5/[?K=M-%RZ:3=?Z6?13MC^JPS"$'W3M\K8IF^#MY_6C: MJG0FTTF9_;&?V]WP>;#_21B8X08"#,31@*N@@00#23508*"H!AH,--7`@(&A M&L1@$%,-$C!(J`8I&*1G!I&]?\/=?\S:;#ZKJ\.DV6>])OAMA]>]D\[SI!F\ M=3>^&2Y^ZZ]^SD4L9M%G[P@8,6+N@9',SSPX)N#G$1CM1YY<.-+//`-C_,CB M\DC+RUY6%M'Q$8FZLJ*U%:ZV>+:-$@%E8ADN6^J&EA8PRES-2:$8*,CJ[,WJU/B0+06$2HT`0C,"IA1/MY84S36%'03!S1J&<$""2V^ M,MY`.$,C&2[W/3@@KH6#$D&8C9SC`[DN'9HI`,6$PG*!#R,@5!8:1GQY./G' MD:BZ.+39A!-*S034Q`P@N`."?% MBC<=#ETG4007"9YN0N]\'-P!8;Y%P6X3(53X-D3 M8PPM'&0(CU`2"N8KY`\&U[(`F6K"RD'@,A62/A<$+E.A M$[2;XV.-_D!*,5N""(3^*I`@$YUH.4_`-2)C#`.+F8!8DX(;5;$>%V=3"E3 M#7]>"Y!I&NC43PXBM3^!BUF`F%-"K)*AZ4I&3U?BRI).#Z%N#U"L"=E*7#02 M1),*OSB?CA!ALDK/-@.4E1(:M51X5=455<4E(S6EJOJ*JN*2D89250=IPCCX MXT^"KE)"RY/XXT\F5U055XQ,*56%12RC2%/ACS7%"&4]0H0>KG#Q*1!?2G@8 M*7Q?KMS"DB`9A4M&.J*]:5"M>5 M,GA)3O?D``5.-);`*$HVN/04[$`903<*EYZZ8N6I<.FI%-]UGVP-`5+F_`3N MM&P(Y3^GP`6JV>5=-3#B_%CL)!@*M'(0IP1\5+HY"=@JG2N"TC6N="WH=U'C M2M>24#8X/`OM[PG,ZBOCCQ9O!=JU`DK9\5:@]14UPUN!-H29[R`56B,OO-3) MB1-0I",GC?<,[7H&H0-JO&?H*WJ&QGN&]APGG=;DBK,B@S<#XU;!H9W0`BC: M3LC@SVOCSN(#&=T#--X)?4T;@6PPT>C%QSY[S__)ZO?MKIF\5&U;E<,+C[>J M:O/.";OI7&[R;'W\4>1O;?\U[K[7]IV8_=%6>_>*[_B>&PO=V]R:W-H965TQ]NU=8^W'UF-"JU0%S`1TGY[D-,GZJNJ?S4G*UOI=%E7SLCBU[7EEV\WN),NL^:+.LNI^.:BZ MS-KNL3[:S;F6V7Z85!8V=QS?+K.\6FS6P]BW>K-6E[;(*_FMMII+66;UGZTL MU/5EP19ZX'M^/+7]@+U9V[=Y^[R459.KRJKEX67QRE:I$#UD0/R?RVLS^6[U MR;\I];-_^'?_LG#Z'&0A=VU/D74?[S*61=$S=9%_`>E'S'[B]+MF_SK([=)_ MRQH9J^)'OF]/7;;.PMK+0W8IVN_J^H\$#5Y/N%-%,_RU=I>F5:6>LK#*[/?X MF5?#YW7$=#3S!,X3."W"0R?(&""^)C@HA-8[8CA8AZ2 M`.2#Q>XR,*;!%Z80?)SOS8>(`>(C63QG21]89A,5.E$QK9>`>GG/"5Q-X$X) M7""XTQ$,F&K4,6*6GN.)YV$\8Q@/P@3S8;:>#G/_W_>FR9A0L\GXQF1\2"9\ M3A`8JQ[0JQX:,PC-59\*W8Z8I0@X4K084+Z'4"4`XA%WYZE20`6,4)?(*"L" M61&2RXAAE.(SQQAE&.[",`>I'H!"9"G%@%DR+%\-"N__#5-4"BB7L$$8,ZL" MZV,,4\4(JAA%%2.I8G15W*R*FS?^9U48&PR**G41ZK7L(+-8PQC$[36ALJ9%M_JW3W-FX[FP4"F8T%,[H MAL+-GLTYP5``Q`*L%6D0LB@2C4%J^T@S+\GLU%P[-?;*`"#?1T`Q@)!T$X"$ M`ML+`"+X(C>_N'.78%@`ZAPXQ#3I%WQ,%(4IU2C">8:;NQGW"*8%(`]U+0`M ML/1/.BS#V,ZQZ&V1:`?*SSQ@#">B&%)WW@F9=D[I=<]TN*S]SZ MTV>KTJ<@"H6Y'W#=#U"K@B/'_4'\:>4GF_B?T/1%V_P(@YCCSH!A`2SZ/22A$Z2/1*,J>7!N6 MLCX.%[:-M5.7JAUOP6ZCMTOA5]Y?.]Z-;]DJ9H;QA*W2\&PO=V]R:W-H965T M],3UB>JOIGL\OS-OA=%H?F8;9KV^-] M&#;/N[S,FB_5,3]TOWFIZC)KN[?U:]@VF)_R+_50?-6EEG]WSHOJM/#3,SQ[9&!^'>?GYJ+GX->_%-5_>S?_+U]F$6]AKS(G]L^1-:]O.=) M7A1]I&[F7Q#TSYS]P,N?7?3-D&XG_REK\J0J?NRW[:Y3&\V";?Z2O17M]^KT M5PXYF#[@L?0''?X74?I(L< M-$.T;I6;X<.O_:?O*R7L,GSO`P$C+YBU8V(_DS"8=&0,@3R.B#1^9#.)$G;) MHAE+E[&ZS%B"TOGM`,H%T)-;B9XA1J9"X/-`#4K+"('7AI"?R!:O#J$XV3J(4<4"+Q'A:H11 MQ\+@V1J^%0B+JW!50)C!&B"YB"+&1'BQB!BW!',U$93+G#417C`"*D:1$\W! MA`F#2A#(+V:!BX'J4X):7H`T)VN)UZB$\E/2_]2NSQ#Q:"<(Y!>#%[*$0E:: MR-I!Q!]@@OB%>+;*3]B!Q.U`0J4K0SQ.`(G+YW9")1CEEX.[A@374):::(2$ M94V$;Z\2O$7%5-XC9,FL)XQ?"NY1$CQ*S2DI(W1G-"D&H?QR<">3X&1J0"#6P"PTI67"^)7@9B?//D9)&2$1$ZN7()#_C(L; MH@(;TX(0`Y"PE!@$\HO!#5&!D6E)B8'&@!"<3!F_%(E+`4O4BI(R0C(BUV4* M^<5X.A$P5TT\F&N`!%7^"0+YQ>#6JL!:->7T`$T.#M=BII!?#&Z_"NQ74V4- MD"1W'03RB\$-6($!:VHO`$A\6+VK#7W*^*6&\C2,LZG&KQ_T)^X?-'X2T8P;B+6##&-CUWC% M:*@8P[D/PF\A](+?JAI\1S>N&*A[*P=Q+,;@%6-<]T+T;!N`-&L>O&*,O-VR MI0XRU@\]GJ'8#VV02'[%^'9M7"]$]'6I^7AUB"P>^W;1X&5N7!=$;'PI0`N" MV4P9OQ3\#L88?AD;?'LUKK\A]OH4(,%ZX'"[,*YQF5-_OA&Z^WB%?;UL4\@O M!O<4XRXV">]*'<1Q:H/OPL;3E%PG/4+4R6\S9?SWS;B!649+D@)$+O^4\4O! M/ZRL>375XP?0F(H44L+''4.R6N-A)`:)N`C=3QB\% M+_78M214D3F(W%X0R"\&/]+$8!J6N-Y/`9KL+U=G100:Q807WQ8X9J_Y/UG] MNC\TP5/5ME4Y?$O@I:K:O`L2?>GRV^79]ORFR%_:_LO[4QOFFKH_L2 MROF;,*O_`5!+`P04````"`"8@P1'*7%[EXX"``!A"@``&0```'AL+W=OU#I=4^M,\& M#$2;Q-0VL/W[^I80=KU@7DCLS)DY0SS*JS\.]$(=9%/'U MGG28/]$#Z>63+64=%G+)=A$_,((WNJAK(QC'6=3AI@_K2N^]L+JB1]$V/7EA M`3]V'6;_GDE+S_,0A,/&:[/;"[41U54TUFV:CO2\H7W`R'8>+L!L"9&":,3O MAISYY#Y0S:\H?5.+GYMY&*L>2$O60E%@>3F1)6E;Q225_UK2BZ8JG-X/[-^U M7=G^"G.RI.V?9B/VLMLX##9DBX^M>*7G'\1Z2!7AFK9<_P;K(Q>T&TK"H,/O MYMKT^GHV3XK8EKD+H"V`8\&HXRY`M@!="A+MU'2F?7W#`M<5H^>`'[!ZVV`F MX4R12.:`:S9IB>O-A=H]U2A+JNBDB"P&3C#/!@,OD$C2.S5@Z*J'IC[]6F)I M(&E^7P(-$FAJ`UD;Z7V"9"!(I@2))BCA=8^YAO3&AH449?8U:&E`0";&PTOJ M;"6U7C[(I-->#`8B#[^94R2S(OD-$8/Q,9([-7*K4=S0,)CXOD3AE"CLT83W M"4KGP2G]#PZ(G2WH[<]'Y\JEQ12E1X8`<,L,22UOZ1A0C@H/'>C6,5%$N<<[ M`>XP@@?2"-QQ!.X\7ILU&(1BGU;=60,V;#GPH,C<;K,'W+J#`G(/MP8#B\Q# MQAT64%BS'FD![KB`!_("W7F!'GFQF"1!'C+NO$";E]R'`CK-0OB`6>3N`MW_ MKE@,+#^=XVCR1>$V^E)AP=K>NR%^:"/N^,TM8!Z(KC`Z^J`=^079KNFY\&* M"CE7Z"%@2ZD@LH'X2?[W>SGOC8N6;(6ZS>4],Q.060AZ&`:Z<:JL_P-02P,$ M%`````@`F(,$1P8BE..2`@``#0H``!D```!X;"]W;W)K&ULE5;;;ILP&'X5Q`,4;(ZI"%*2:=HN)E6]V*Z=Q$E0`3/;"=W;SR<( M21WJW@3;?/]W(/)O%SVA;^R$,??>F[IE2__$>?<'A_0N>:OI/^!389$$NY(S=2OMSLS3IJAQ/<:]*Z?5:N>O7Z3AZ;,7@!- M`1P+1AU[060*HFM!K))J9RK7-\1165#2>ZQ#\M\&SP).)8E@]IAB$Y&86ES) MU4L997$17"21P<`)9JTQ\`H)!+U5`_JV>JCKD\<2&PU)LL\EHD$BFL:(5#W( MHL$XH$@GA+$YCO1@^1FULJ(=F$JN9Q)A);V62J1F-2<"] MEREHHT'QPL5*:K62&BO9C!6-`5$\\U4^8AX:R:Q&,F,DGS&B,6GND#:WBN1& M9#$CHC%IZB"RL(HLM$@^\\>M-29-'$1`:%51RU(&S,@84)*YZ`"[CND@.9S9 M.0:41"XZT*ZC6T0$@0.%O4F`+W0)8&\3P/2)/+I-&]_TR]@TS,1!Q]X!@&D! M+DT7I/:TZ1?2VO<T`@O=' M53`Y?1M,C^I6PKP=.;=<'[[CZGCS64%U>E_A9=&A(_Z%Z+%JF;S<5+C`Y?#3(RIOJWH"2?=@!4QM)VS_OKY!V)7;."_! MGIPY,\?X8!<#96^\(D0$[VW3\4U8"=&OHX@?*M)B_D1[TLE_3I2U6,@I.T>\ M9P0?=5+;1"B.EU&+ZRXL"QU[865!+Z*I._+"`GYI6\S^[$A#ATT(X1AXK<^5 M4(&H+*(I[UBWI.,U[0)&3IMP"^L=2A5$(W[69."S<:":WU/ZIB;?CYLP5CV0 MAAR$HL#R<27/I&D4DZS\VY+>:JK$^7AD_ZKERO;WF)-GVORJCZ*2W<9A<"0G M?&G$*QV^$:MAH0@/M.'Z-SAZQ>'JPEG"D2R1QPS28[Y#JX5=%KF:S2(KHJ(HM!,\S. M8-`-$DEZ9PT4NO*1K;&X3Y",!.F\R<00P/W\=,Q/YOFI$1![-+!P-K"P"I8? M5RG3F,ZH-!ATO\3266)I>_18Y#VQI@O;'R>"7@=@<\ M8`]P^P/^89"/6@T(?-Z*VR-@3)+DL0>%VR7P@$W`[1/P,8H%>>UBMU7`>B7W MV!PH=HI%L;]8!,XN$'B(M2"/+8C<7D'6*[G'YQ,E;JW)`UI3=Q>IQV?>@N#S M=SJ:G;XM86=]R>#!@5XZ80[?*3I=9+9(G]XW>%GT^$Q^8':N.Q[LJ9!W`'U@ MGR@51):/G^3"5_*J-4T:&UL ME5=-.:_,X M[!-U'`3?NJ"N36B:+I*.-WU<5V[L<:@K>=)MTXO'(5*GKN/#G[5HY7D5DW@< M>&KV!VT'DKI*IKAMTXE>-;*/!K%;Q??D;LVHA3C$ST:P^LLD_2_EB'[YO M5W%JG=]>S_*=(0!@?0 M$$"G`.H3]T(NS2]<\[H:Y#E21VX7C]P9^&!)#'.D')O)4+G!>SOZ6K.25(25F4O%NH;!;:(IXN0303481.@36&2UUS?L! MA'H=4]AW-/BN1)B*,K!)*,,W"Z?0`@9V"V,(%P90#<%0@8V M"Z.P*2^V2"/HWR9+9EO73@Q[MT-7T4:>>NUWKM/H=`JX=X>`Y!U>5T>^%S_X ML&]Z%3U+;3;0;K>[DU(+(Y_>FIH/YIPR/;1BI^UM8>X'OW/W#UH>QX/(=!JJ M_P)02P,$%`````@`F(,$1]:G(3V5`@``(`H``!D```!X;"]W;W)K&ULC9;?DIHP&,5?A>$!A"]`B#OHS+J=3GO1F9V]:*^C1F46 M""51MV_?_,/B3HKQ0D(\.;\OD1-27?GP+DZ,R>BC;3JQBD]2]D])(G8GUE*Q MX#WKU"\'/K14JMOAF(A^8'1O!K5-@M(4)RVMNWA=F;[785WQLVSJCKT.D3BW M+1W^;%C#KZL8XK'CK3Z>I.Y(UE5R&[>O6]:)FG?1P`ZK^!F>-@AIB5'\K-E5 M3-J1+G[+^;N^^;Y?Q:FN@35L)[4%59<+>V%-HYT4^;^'-KWHO3ZK:-([V[$#/C7SCUV_,S:'0ACO>"/,=[Q(@P! M6RA@/P<[3C[W+&"W-9$`CG]G`+>9'*!W'B M9?W-7E1%JNK'ZN#)4\7376M4Y![X?N05:5:ZZV6[]E*ME^*L\JSD+Y4CST61 M5O^>>2XN*Y>YW<)K=CBJ9L%;+[W>;I<5O)29*)V*[U?N$WO<8-)`6L3OC%_D MX-YIR+\)\=X\_-RM7+_AP'.^58V+M+Y\\`W/\\93'?FOO[?I MUO3?4LDW(O^3[=2Q9NN[SH[OTW.N7L7E!SL;*\7_4WB&S/:`(P!]`9]'-H`C0%^&41MIII9F]>W5*7K924NCCRE3;?9 M8PVO&B>U9T>VWNJ49+OXU*Q^K`.6++V/QI'!P`#SK#$0C$,VG9M%C_%J"B0/ M<*D8H&.$$S$T)(SOA\`N!`Y31)A"21T!"!ZR#AD(C&A(#CF(W!Q.%](A%))#)$\+Z#F.Q);-^3A&20 M6)3"8)!-E,)@`HM2+$@B"T,DN.^`^60MVF7+8C!&DF!&A[8T1U:MBRD-Y#K$VX.8!1E:NJS3KL4NQ&CQLAGJ9;1\F8U^#8C9-(\6)^O4:3.?:'7"#'4" MK4X84>?5`#$@%DVJ$^:H$VAU@E$GW@0:@IY[D,4O#6CQ@1$?PE2<#F0Q2H`> MSV`4BA9;,(1TD\,93:9U!1$M\NLF:U`23[4X,AJW^-E#3',Q`D6+J08)79%D M1D5H\<'"0N,&9*%/],DH:/2)D84+1N:*S#Y7I#6%0$O\*E<#8@&;U#@)&R=$ MBP\[7=G\;:8G'\Z8?$A//K29?`8$\611PF[CLR!#*Q2-0M%B\B$]^7#&Y$-Z M\N'(Y+O:)PPHBL8Q&X-A>,O%&YP'"UX=VG.R=+;B7"I]'.Q7^[/X$[3GR2_X M>GE*#_Q76AVR4CIO0M6GTO8(N1="\3J^_U#WY\C37?^0\[UJ;N/ZOM+G9_V@ MQ*E['="_DUC_!U!+`P04````"`"8@P1'==0HFZH"``"$"@``&0```'AL+W=O M[%)I.Y MV+FN6H4,4)?6BTMC=@E8&0 M(X+X5:`;Z;Q;O/D]QA_\X\=Q;;N\!U2B`^42D#T^T0Z5)5=BE7\KT7M-GMA] MU^K?Q+BL_3TD:(?+]^)(<]:M:UM'=(+7DK[AVW>D9A`='G!)Q*]UN!***YUB M6Q7\DL^B%L^;_"=R59HYP5,)7IO0UC$G^"K!OR<$@PF!2@BF5@A50OA4P9&S M"^=22&$2-_AFD0ODZPFL&-YP$:9L$:'&3",BN.'1SR3PE['SR844XW68K60\ MOQ])%1*TB,,Z,+;AV:82GLP/^TOL%#(?Z&)<)?M'I;=17S<:=/WRI5^!.RX0 M:`&_*Q`H`3`N$!H[")6`]SCE0C"UM%,R,P#ZF9UB%OU(JF6"?B;33#0^S]PX MSUS-XX\++(R.+J8[&AD[B)3`TYAAUU')S.9^/[.33-1/I)'9T"Z3208LQZ=9 M&J=9JFG"<0'@&@T5X8F.`F!L`H`)GBIH%H4#IFKH>2T_^-I"[@"5:!>0]X=%="@]Y*9#:PJ%-=:V!99UIGRD3F30V$ MYO7RL*LIR'<'=C7%#&R.J:XUL/-EBGE>*$[GB*U0N"FRXO2?*#XHN^\[47S^0O4$L#!!0````(`)B#!$=.!'[N M.P,``&80```9````>&PO=V]R:W-H965T=]-WFZ;L_BYY+4[SD(1VX&>UVZM^ M(%K,HG/?>#XW&;_.DQ7VW\I)5^)^G>U47OM-@Z# M#=^6QUK]%*=O'.:0]@G7HI;#9[`^2B4:&Q(&3?ENCE4['$_FFR*&,#R`0@`] M!Y#$&<`@@/T7$!EGP[R^E*I;/&IYUR?1F0,Y9--3DL/@4S_Z MMDB2?!:]]8E`0T>:I='0]+ID923I1Y9(.T!M4&N#C6U0L%'<3L!L@F2<@$&" MZ:7)?-"T9AY&0Q-V7;,"#9W>-I*@1A)C)(TO;Y*.C8`F!2H@P)_/"Z*4<#29XY: M@(;0VT:FJ)$IK(I'`A*CM1B&/8M!"&J"0->GCF5?@FB2%M/$41$K8TG&/`Q1 MW!#UZ!H0L31WV3$BZF4&1PEA'IT#HDF>NLR`B#"/UB$X3X@%BF,1EB`BL:N/ MSR*/-B0X4XB%BF/62Q!-B,?;@.#`(!G<)_-(@2.#W,$,@D.#^%##BHIIX:K] M'>`@.#F(18?/2Q9'![T#'11'!R4>-0$1<37J9\UU*S@TJ(6&SVP87A!V1T'P M_J2V/UTL!=$D8\XWK94EA'C@B^(]2FV/NE@*(C=+0>3%4HHW,K6-[&(IB-PL MM2(OEM(<=Y-[L!1$;I:>11XLI3A=:.'!4A!YL93BW*"6&QX_:1G.#78'-QC. M#>;##2MRLQ147BQE.#H8_?0+_'H*'!WL#G0P'!TL\=FT)"A++SP$MT(HKG/$#[K&>[WI/U_4?*OZTUR?=V8;;"Z4 M.-A=_?FOA<4_4$L#!!0````(`)B#!$?N(XHXB`,``&T2```9````>&PO=V]R M:W-H965T M_V#0_WV.#>?G-OJW:;B#_.>REX6J?U=;?1C4QF&PE;ORM=9/ZO1=XAC2,>!& MU?WT&VQ>>ZT:VR0,FO+='*MV.I[,/XL8F]$-`!O`N0%+G`TX-N`?&D1&V32N MKZ4NU\M.G8+^6([99G<#WHU!ALA!/T4;AM1/-^_'NV_K)&/+Z&T,A`S,F`?# M0'H=*0R2BC,2#0I(&6!E\+D,,#*2Q>T`W`9(Y@&X"0`?QB$FIC7C0":+KS.% M87CJ(20AA20H!"X[2>="#),"O\X4R(CTMI"4%)+B:.%V@(S,2>:?$T$J$&8N M8^:8"H$J%X[Y*@R4W]:Q('4LL`_'=#\8AL6NE%B&W1:2DT)R,X[4H<,@*4M< M\V$@+OAM(2PFE4RWQSE)'%HLQ&('52#%,NZQ^AFCY5@;H&T#8@]+1XC%CAE!QF,P0#L&L-M>BHQ;"/,60GL*H*>(V",$)Q,# M_!.)H5.P)@-Y5@-U6N(HI0NYJ>H8\RBG0;@&9QT.0847EKHJ* M%)_5P^MB:+<`NY5QE50+N4LJ4GXE%6C#`&L8SLE9>)=4H+9/!/;#(X;1L\\]@&(N3>!B+DM0WDM&UP02^@ MRS=708NY?'455\1$LP\#QW(O?Y;=OFK[X%EIK9KI@\!.*2V'(/&787P'66[/ M%[7=^1IB+K0ZVH\[YR],ZW]02P,$%`````@`F(,$1WIIHE72`0`` M204``!D```!X;"]W;W)K&ULC93+CILP&(5?Q>(! MQMPA$4&:3%6UBTJC6;1K)_P$-#:FMA.F;U_?2)D*)=G@"^<_W['!KB8NWF4' MH-`'HX/>R`$?G$1QCTFY8+1I0>BA.6HP#2V")&<1R&.6:D'X*Z MLG.OHJ[X6=%^@%>!Y)DQ(O[L@?)I%T3!//'6GSIE)G!=X6M=TS,89,\')*#= M!<_1=K\Q"BOXV<,D%WUDLA\X?S>#[\TN"$T$H'!4QH'HY@(O0*DQTN#?WO,? MTA0N^[/[5[M:G?Y`)+QP^JMO5*?#A@%JH"5GJM[X]`W\$C)C>.14VB=4-K)9S-[J=,BJ?#%&'E-O-#LG28ILZL&:_]52#Q#DB4D]I#TOD$R M&Z1+@\0;9)]3%E8SN)1>L;F!L-IL@=V'%, M1G*"'T2<^D&B`U?ZQ-GCT7*N0%N$3SITI^^UZX!"JTRWT'WACKH;*#[.%]?U M]JS_`E!+`P04````"`"8@P1'#K9KLO0#``!1%```&0```'AL+W=OGAF- M2BT0%W#<_?8+I,.HT[29BTK\=:?_G:03LKRH^F=SE+)U?I=%U3R[Q[8]+3RO MV1YEF35?U$E6W3][59=9VSW6!Z\YU3+;#49EX7'?GWEEEE?N:CFT?:M72W5N MB[R2WVJG.9=E5O]9RT)=GEWFFH;O^>'8]@W>:NF-=KN\E%63J\JIY?[9?6&+ M5`S(0/R?RTMS]=OI@W]5ZF?_\._NV?7[&&0AMVWO(NN^WF0BBZ+WU/7\"YR^ M]]D;7O\VWK\._:8Q>M[SH[N<_.1?M=7?Z1H"'L'6Y5T0R? MSO;]>!I[4/F-EF;K9:UNCC-*>OG$UMT>-T[Z3P[S>"M2UHS-+[TK6^K(&)+ M[ZUW!`R_8M::X6(:V0`2C(C718"&P5VL"Z[MP^DN$D!F1!2/O:0?O$P&*DR@ MP76^A+:/H\<.`N-`7#L((.'\L8,0C2`$!W?#,1^82J=3,[-H&DD`X=/(1B,L M]*>9%!AND8\9*F<&1!)!P&MG,0,YLFDD-8S$Z=\%\M(^AN>^$&.$U0"$A-AD=$3D#A@D"2@WD6Y1H M-FX5-Y6+F;W"(O6,XWF!\AL3FC<`A0$U0@`)X5L$@Y=R)F`FV;C`BSG[1#5G M>#EGX>.IDAB(REIX-V>1G&G$HE0SO%8S*-:QS#5BD[;9Y8S-`IN5CBQYZP!(O:" M!!!JD0/"B'TR-8S%A.5XO>''UGYO#.E5Y`7HB8DF`H9;KY2D[R/^R^I!7C?.JVE:5PY7, M7JE6=N'Z7[KD'F6V&Q\*N6_[G_,^Z_K&2S^TZF0N\,9;Q-5?4$L#!!0````( M`)B#!$?ACK6TB0(``,\)```9````>&PO=V]R:W-H965T?'D9\K>>4F(\#Z;NN5SOQ3B,`L"OBE)@_D+/9!6_K.CK,%";MD^ MX`=&\%8G-76`PC`-&ERU?I'KV"LK^^!W@;=J M7PH5"(H\Z/.V54-:7M'68V0W]Q;7]NY'ZH: M2$TV0E%@>3F1%:EKQ225/RSI15,E#M<=^P_=KBQ_C3E9T?IOM16EK#;TO2W9 MX6,MWNCY)[$])(IP0VNN?[W-D0O:="F^U^!/ MQYT0V83HDA#K3DUENJ_O6.`B9_3L\0-63QMF$LX4B63VN&:3+7$=7*CHJ8BG M41Z<%)'%H`%F:3`H[B&!I'=J(-^5CTQ^:R1##8,!",/'*JE3);6=)'=4 M#"8:<;`Q`83.5T^' M1[Y[`,XBH'/AY$ZK%O0-LA$ZR*V#K,Z(5QC<1H,GG`9NJT$\P@<6E*9C=-QV M`^.E9(R5('5WFS[1K=LJD-DJX/:7965!$(YY,&ZWP,3M^VL=`X)HQ+<AQU:8(ZR/]C/* M`JES]DM\*6<7,VE<:(K\@/?D-V;[JN7>F@IYBNLC=T>I(+*J\$6^YZ6,!M!#]WXU,]PQ7]02P,$%`````@`F(,$1ZO'8NYX!0``_1X` M`!D```!X;"]W;W)K&ULE9E;IIVS$/4X9N>Z:8OJOIG MLRV*=O:KW!^:Q_FV;8^+(&A>MT69-]^J8W'HGKQ5=9FWW<_Z/6B.=9%OAD[E M/N!AJ(,RWQWFJ^70]KU>+:N/=K\[%-_K6?-1EGG]WW.QKTZ// M\["?0[$O7MM>1-Y]?!;K8K_O)74C_PM"O\;L.YY_=]*S0=UN^B]Y4ZRK_3^[ M3;OM9AO.9YOB+?_8MS^JTQ\%Z*!Z@:_5OAG^SUX_FK8J79?YK,Q_V<_=8?@\ MV2%U+Z23/&L&:9V5FZ'QJ6_]7*F0+X//7A`P_(Q9 M6X:+:20%1(Y(T,T`G0:?8T-PVU]-#Y$`HHE9W):2_29ECJ'.M+&-X/,TDEM'&3#.I99@0A*`,H%!ZJ*11E?0@082$1A9Y8(H1*CE( M"$(G@$1(*)X!Q'5X6R>#ZF2L3H3AU@9\01,J64:KB-#(,DR3;PD&B^/;"D6H M0I$=14:W!<1H/,?^\\%I(J)H(L<92D4E`*5!0K(O0S1ZG8QSIX*6!C M"J=4@Q3.)$$EC@HE8:84*-[]4:J!K"AF'JKA]8"IVYD&&#K5`$3G&H!N)!LW MGD^V87A-8!K>F/$08?"0,'>$!)[T6.03$A:*Z8QC(4-[#239R!!4YBAYMOR: M5BS&%8M]`L)"S!`^G#A($S&<`D0O)`#BD47@,0,U1U249*$`N?%"@AJ`#/1DI[K-0X7B.X\/`;@$1$K3\==+T?NE3, M0H;T&S>GR",<.%X?N*L/'@F+*]QOU!U^@^<\KGW\1D.5(M/-2%'O(`6*\^OM MSZ5]@1(^RQ..+X>Y\?$;6#13^B<`<4,J!L-%I%YN3C[Y!J\/'.H#\]@G<'Q9 MS.]8%PL\ZPF?=3%`AEJ0)`[2Q&M*`>KJ#V5=1_DIAJ^+!?/P&H`X]:X3@$1( M;0W=<)JJO@[R.8$1>'T04!^8A^.)B<.1.TY'!)[SA#O[(!QB#=`#(V/RBR+- M"Q3G1"W+1EG:QSKXFEA`+F8^UM&X@?4=!L9SGH#\PLBPA!T^&96PPP^)ZIXZ MB-RL.LAXK``$GO*$2WED3$;P$JD:Y0.E#J+.=+(1\M@L"'Q!+&`9*Z[4.H>> M`5*,>!%K@!ZN3PLO=0=(4ILM!W$J_V6.8MHC(TF\@LAP?O,(#I@;9W`C11[" M.8H^A7.4US&V>7CTC*>A@>Z"YS@YD;XN8P$@'Y]1>#91(1Y.%^,X MB%^[=W!VN586]?MP#]K,7JN/0VMO$,;6\:[UF?>7LD6&M7>& M7:2=<7]_TAFE>Q)C3U2X2.U%;_`UV=7RF+\7?^7U^^[0S%ZJMJW*X3;PK:K: MHM,^_-8ENFV1;\8?^^*M[;^:[GMM;V?MC[8ZNLOF\<9[]3]02P,$%`````@` MF(,$1Q0Y.9::/```#S4!`!0```!X;"]S:&%R9613=')I;F=S+GAM;.U]V6XC MR;7@\^57)!HRK@10;(K:RW8#*JFJ+=_:7*INPV/,0Y),2=E-9M*Y2"7##_Z( M^W*!F9_SE\Q98CF1$9E,2BIO4VB4+9*9L9PX^Q:_*LLJ^KQ<9.6OO[FMJM6+ M;[\M9[?),BY'^2K)X)?KO%C&%7PL;KXM5T42S\O;)*F6BV\GX_'1M\LXS;Z) MZBS]4YV955:/427&8^9 MYEFT&_VVSD;1_G@83<9[A_"YO(V+I/S5M]5WO_H6Q^!Q/N55O&A^N6;PYN/J MB8_)35I610SOO8N72?.ILY_G^X]FG]Q\O7UVU#'0.4Q?Q`J:< M)Y^C_TH>6M?WZ6'ES;,WWOU=ZPL?DB+-<4_SZ"*NO'PI3\D<=$Z^^[NWF1W?Z\-*FJDC\DJ+ZHT MNXFNJKBJO1/]@W_(:H37Z2(IHG.8^28O/*"^B8N;)#J;S1)X"IZ9\_-MJ\F7 M2T"SJRJ?_3R,K@BWHO=U55:`,["XUA.0@'@-7WJ+;3ZICBSX[.\F'KQS0)JL MA-7#7V6^2.>T%0150J/FU]&KN,A@B240Q0]7%]'VUHXBCBC-HD^W>5W"'LIA MM(6?WZ:+!>"\-_5^]#;/JML23S.9-W\]ZOS5(LKWFN^^2*KJ*%SYZ MG.+)(K+,JF\ M$<\V?>%C4@)"S&Z)X\R3NV21KW`_S>>N$CB-[&88W219@CP"GX_GRS0CUE.E M=QY5$8>+@.GBS["9&>X67TL^KQ"4WEK>FT>3%DA>9E4"Z%+I(5I_WTZS6;Y, M=D)'`>PT26\R!/,M`">)%GE91MLWP/>]Y]]7MT"Y>C0][3#*$@]"!KFOBWP) MFP5RS6K8X5.)WGDND)CM1'DR[A,9Y8;?4#FK-@J MLJ,`[0?.$I`BFN>+15R4$7S+G,Q#H(OPRGN^[0*DYX2+&CE3_]W%Y6UTD=ZE MP-_F9721S&`&&*#Y7L_YS^Y@CT!4[^KE%!Z"PY&#.*(J^@'Y*5!$M.9`:&J6 M%.']`O=Q!&/T?F7!W/+B)@O]L*@!,H^=28X4?/H M?202S`8*[BT\AF->$A<3PK=3S@(B@#C<>[PX#$W>'.>UXL4STK%F#Q&JL>6" MY9?B`,B80=3\5)<5#AT4K_&LJN,B!7F#3ROF`4!C,=40BIGS@O/H"E0>P.RD MN$MG@'8HLOB'&9!$6C4X(?ZQM3>F![8FAPA-TOGI\S'_WY[^VH/A#QG8'HOT MSP"WQJ)AFQ/=FQ?[2L MA"!H`4PD.0?M[X[D.KP%(K[FG^9)">=%AQV7T0QYQ_4BOX]ND_D-K`5GRE%F M!M:X?<0KR=+%YDMD03QS4(JELD(3'T/78]]5O5HM"%\!#T`!KY?U@K;&LP6I M9_L-(:6PRKJDT#D/B>]?]T#UWEC>@;1&S5(HV[&DNHF!:Q"O8R@?@Y^(0,_& M[K8_Q&B^W295"E;-3E_V]_?E*D'%Z@D,(CC>%R'SX$PMA_4R7L090.`*_2U] M#T*;WV=DO[P(JB\$2_P#07$'"FB`@*YNX;QVP3Y8PFQW20N9?2KB>1(5R2R! M<0"X`$OX']CQ`K:/BV=>MG\T<7G8/HB!%M9U";-E55[`P7BK?XWV$P#5F(#- M!WZ?%S_CP/`[S.W]_!;@BO@6=B_11M74S0<^%,DJ3JTQ-H0SOTX*U/P47Z63 M'=JSEE!I.R0V,@%-%JS8@>*^RLLTY+SB%;JG&P)=RT%]*%";!K0G5QD<.YFM ML-R*.*#G9`'@O0#ZM#Q^G@"OF*5,OTV"#I'.2LZ8Z!D#)JAK<1OQT#7^]WD^ MOP<"\)6PP)F((PD;]>_R;'?VV!,)GX0^IS=I/$T7Q&4\9!84-LV+(K\/V5Y, M8'`0Z%H%0R)^0(3RA@).41`GNX\UPP$`+-.R#/$(EM^3R9>CBA7Q`+>P2)O&G?UIO.Z3\`/>PFR]4B M?R!)^7ZZ2&^T!1VD>H%AN#-@U31XQPHDRFVZ3;2)4B63<&*VMV]`20I,1-;9 M;;X`P57^9V09A(>-P.#4SMB`&H+43)0!"R=;1"`GZB0ZJRM`6Q*RN]'><#P> MXS_S3H8O`=;5OC-1F7+ZR?L4!JJKMJ$GPP,>6@P?7=+`R+/*BIC2+%ZE>.;` M*X`\X#4V1E^0I'D!ZSLZ/1T>C_>'1R#$\GI\/3@]/.1?)I@#2I M0+$HZ^+!L,OF3)/QZ7!R-!E.)OMFFI.CX0E,=.A[3HWASDB6\!RW232MRS0+ MB"VI:^>;:O:*34VG>55%;>@0P$_TPQ0YN3$C[2@DS_-5/2W3>1J'Q"1/UG<6 M?EJ0">%SW[=[:4V/5&?[C-U#%Q)JD'`'>4?DTYZEBGYN)'\$04WAB)K_"M-M MR^,-\ET[?./YR]YC!ZBN[:T>)@YJN:_A$,K>)Z_?B%ZC*W6;G&YIMA-9=_O9 M#`R`L$R7'DB/BH4M4>6(*$!D*2@^F71;PB_XF6T(7(&-",1FWFC7UWRL>M8_ MRA$6%[O3&#>-/`;@&U;`T,FTWGN][K6W#T!/;1'?)CEU&`I!!2<8=L`#XB-& MV(;.M#=",&=:@Q!G,]!\68Z7*G;50RO^@.9+,E$83&^5OC"VET`RJ8^1[;]H2YFMS'9W!3!8VS3#+SIDPN>6O>! M=4._]]&!'0EV>&1^T?DV*6`MR&J&6H.*O5?:-IDB77J3>Y M-!Q2#[O,F7:?B*$$1`S+V(N&_R)]J M7"3TQZOV,5H?'$8ODYLTRR@$=DTY!!N\BVD7\!;G$X1B<72B(+Y+],0&F`'F M\[PH5_$L^?4W*WRLN$N^`94.0+47_>VO_QT%!QE\NF5#<[F*LP=<>IW%<-X5 MGOW,R-J9E+77?&J@Q)5:ZH+\CD$EG28)>F$`7U'#6-4%HGA%**94)#?U M(C8L"TGARG`(=E3HYSO,J MP^VCF`(EN48U(\-'%HL'_2;I'&K#P8V-HM_D]\D="A:EK^>K-%,R=1EG8'DK MGPHL03H.M^]OT]FM66&>P:0\NWQL!U@B^JSBX@'!M.*CB:[CM(#G<3KXIEXP MZ`F38)IJ%@4#6A**..IXTB1,[UJ*=!7-T*GXE"K149`I'";P)1*2P9.+9K MX*51LDB7,+30E8`!JG67P'N"8 M3(L:469RS&DZ0VWJX:(7"1^O%=\I>:LI;P5^8:\X'#5L#`%/V2KI#+@V"(HE M,)":S*;2JB"`F:P!`/,<1=OT]PZ=X=[>.%JR4JTU^6WX.EZ!S/R<`C4F@,:3 MR2]VR+D'R'X/GY%.8=Z$D[5XN.C=Z,?1#B,E;&(*$\]Y4D*EY'/**[`J01%;U=)'.%G3R,`!P`)@;-,X9,@[D0JD`S7W%&&0$2+:7W@_##P9JMO=&1'I]906E]!%%\4R1L\!%KDB?(IU%&=SD;4,(W M7U8`1Y8]M$?@MW?D6>>EDRJDE!]\%>,[Z37`.D-1H7L`Y!1:YC!]0KO#,*INE7N'0$Q(`\-KY+29XPEH>]*KK;,Y@!F"M MV3ENRV(=?(9/2%Z*FQ/0\Y(-<+4(+5I7R8SB>CKNJ&0\8"(<(0<..?8#DI4S M4_4CFR0[(OKJLU;;4'">YZ245"3F@!W60*L2ZT2:&IA4^>*.QTXSP1NM6F#8 M"#"'W$4>4%7J:PR]%H38&-1_D#`45%0D['2$MV9@M<8<62-^-;2*@!J"+)$" M/0LP+-'//KX([(5.5JE\:&\2G:@3QRTCN#GHB[@-PR@!K,2^563BLLS1R8$\ M2,T>Q`F::]T^$5<0WGBL,[7+J0MS,IVMJLG3R?6H(>9@0\\J^8M"-K;8E3,E MS_#`&)O/6#M1Z='9/"[`5CK/YS0S;64R/AP-+D&,`&06KFC'O-?H8#S:-XQ; M32=Y.=``@!&P5'%RAP-97I[ZC/@Y]`-0,M7`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`OAOF7Z.EEQ>I=0>@W8`Z^L%T<=MHA42S1.V]HX=R;MU,-&? MA\)000>$RJ,4CGB"";"%%'5=7]C"IQQ3YGDF;?;A^QHW2JGT!_DB`8]5^E;X M(XE>YQC]1N;$(`4AA`O[,WD5$JL1EQT"]\7@TRUP&J=*#2M&DVA_/+@"^`9_ MP)BY@EBY,T#`X_\=G7-=.OU7IQU1*%ZPA>J44B.V7C%P[7Q):.^H_ M=ST[]$]6)WTYR#0A\>GI=E'7`M8R"R9=:Z8T^$3`8AJ=3,;:1*)<8Z,#$E\9 MC4\.'#]=0)>GYX[WK;^-XT(L'A4@!"$BA=E-CLRA(UK4D7MCN1+@NU(;R`[ M15`HH5'@B`Y\3#'Z%O&-ZOUL`3^"6?T\DAO'`"@H3C.T7+TM9M'IO'AVE(K) MN`SZH#=,E_$-)@$Q1@K+X%.4-,S?M4;6JE$%#N!%@V,[T!UXD!T$,JU`##+- M-A.Y!T_+W![T2-4>M*<[#_KE-Q,WU$G-]*%?)C,]VC-]68&FZPD"8##AF'YJ M9!D/98JQ7)J?5SSHF]([:";?YILFW[(G1>M''%P9EUVM/44Z8H%)=)2AH>)CF=&>X?7K)&5=JTAO;MG+/3>9&#$9 M14DL7!WI+%VQ[Z1T`^]-/J(5MKHRIJO)6#-9B=91'U7W^2XQWFB9@&$Z=VS* MQF]#-P$.!U(.#;0%D^H>S2\G@85=0"WK;ZKJHASYO;`GS0SHVW8&UP'IBC1/ M)9,3J6`.&\H\V9M;QR?[3;U]/ZRX:]N)U68K^'M,LC?<'Y^ZTQP='(6G&45. M0?07V?*XL>6CEBT/G[#G_>'X:,^=YV3_N&7/@XX>!,;9'?1)"\N)=1&BG]AU M1`<=G@U7DI:X4K]0:7-$N5SO>BJ=]XJAL<9GXBBY/K>Y.LAF$@2=C//EWL$O%.X:5'VW/@]X`X^RT.TT&:YW4Y@(.CZ> M4/Y=J3&/G"4<0,]1-)/K2+DAHA6`@@,)AP<-=\:^#0B$>(32.E<-10"L!O(Y M<^,5DIW^7).#!CNR2*JQ3V\6Q5::S_T]-WGHITY`8735`1)*8CJT=`DZ0!5, M9M@SR*FB`$3[YD((8YC-?[.]8GS:ZSA>.P0M/`?N?G!17)=$SVB3S;^+#S- MG,7;8%A]74PK=OJ1;R@7P9R2#0O7-20"9&1,&"5/A,OZFV6L7Y3*>"E?#$09 MGJB?-#:(8WZT>I9>-6N*26%&S5.1M)4MTSC[F5WZ\X0@4AK'P];`5J;)M;BS MAN>B><1(G"43"BV2Z[\YAN.09&:LY$P(LO#%T>GH6.)0IQ#`./9;ZIOD2!=5 M<`+\^E!2A)O7S**-4[Z0QH\/'=R=C,;C7T17288XA%IV2:$3G@WGFHPGXU\& M7CL\7/?:Y)>J)\5H+)QC%)>P/)GH]5:E7D@Y92,%2J&X3C_S.L022$M`0B73P?W-CN`G/+:W?>AO M$AV0272N,KC18[%)7PGF%O;E>)-".Z$<5;V^!`,0B; M2RW?-2]V$3_>Q9TW?E'(^M&J/I1 MKC%6"T>;HK-GCY.:^8A,&,24=?T(?]FO,0\.U>4F<,HG3!.7,@HVH&0OBVUE ML[#4%NHT)!UK%*"UF8$JFLNGE=Y6L*B8VMIZ"23_"]6#S<&U]N;2BSU]_;.3( ME]'5Z&P4;<,O7&K0,&9`(9/6/IW<-@;#S+=*T./0]"M\=4MNSDKGPN^@1T37 MMZGP1;UV/#MQ<]@9L<)%+:GL) M2XSF>8UA"*G4K7&1J$P5SF!^@QZ#Z&R)#\;L@JL+PGQ`>.P>&W'*@'W#+QZ` M!=&\-JM=)]IU1)N"Y3E36Q7GX,W14.&."3?)L@-=HZHQQKAE;'*&>C*_!]H_ M/1V=_L)$*D4OP8"%`EM3!K3C5S-V?`A%N53*.35:,AYN`TV,U\P_:,IM8].: M+/W6PD4N5`KGB*H\4U6R!#MS$P%]AV%SX>C;N@6H:7[,_'*:`-M32]YP0)UF M@\?/NL,]R!MZ#-^)]:R&.XQ(V$^-L#_3A^VUXJ7F(KMS3N?GD)2.F'D_F5$X M.\89IR6T9K.P*KDCG9#0`68+$4PE:%V_MF.%*\"*$AVP0>ZFI#;\SB28V'97 M)C:C@H>H$F`)RMZ$,NV/5%K.=JR:=<($8*W3ESLJ"5J!C*J;;*90,_7)6SP1 MI"JU_%,-9WO-^:$JZ<=)3O!GP@A4!?J"'I]R:#>IB3+D0]E\?0#;3E`^.S\] ML`[)RHU_VE!PR)-GG?A#$W-^"#UX)!Y42IP;L0W(F#W[2CBX''AI,A83A0*C MK=/M[9]8;G6FTC1DP%1#&35DTZZJ6S9ZT%319+&R4!.DT+;<.!._"T3?[W6@ M`9N!3I6H1#K('$IJ4X"8'-([D-1D>0B+]Z8O57B68JMT.S7J6#P*C5)ZLPVYT0@FB-V82CHON\7G`ZLLUH%84NL(UY>@ULD2J. MK2=7)\:SCD]N/&-:.=I>2$;_F`#6XLX`$Z-%$I,0_EB#X0!Z34-GT16V`>UN MWYZ>T^M=H2CK7BOL.!Q302^0!^YBR[P5J9X);E3L/B]^IC;KNH64,9^1VQ1Y M?7/+6H8X+[/=Q/`NG-4M-,)B<^!$7)K%VV6!7!J-<18>27MIQR^2!UCL`G MWH#,0YCI)DUTHP(=U?`LVR$;S-.##<*&X$P;B@N6P*IK.+NZS4(,*?"M[&.`\%;GJR. MR80_"J@!Z'<7%--T%9R`@`YPO;%@Q(WWC7`.O";IC1H0`W,QF3=?>D=QX+P7@X+"?_)\$0*HD M<[?@&@N9O%ZS)$K0$77;\L=HC=-$W))A=,N=P M;N/6OM`J.#T5VV/`KWFF5Z.FUT4*HIB&S#(2N3`$L)D\T\'8X-)UM7%I@`O; M`/LO5FN#==F"X@0C<0C:AS+E$V1+0`=[\86G\)8&,X@M9NVJQKFFNDK%V\U% M)T'ES"*WZG12:OI)..<'^28>3(.I-3$YPHK8A0-EG.H.2\T*42*@^XB[VV@= MO&SGD?N2,C?@D\X2KJU&H47:*KN*? M)RM,Q$)[!&:,4\#L)W,YK:*3HN' MPG@G5-*X\4]8O?WF!A!3Y4)7IDK56<$ZQ;V/TKZQJNZIZ9X#6/M):"*1D1SL M7=SA"3XB3W#W:'2&RD[BKJP`+D-*9JWD"CT=G9P>V8*$*I"_`>0R&A\=RX>\ MX(YF.VP#`R>GETSLKI`B M%$R&''^X7#=-=UQ&=*JR:6MF)=,'C]_O'SH,'X[>6`Q@^,P!@WWOE(HUOLKQ$:\Y_@\A"QCST6S_&Y:S&=LU!_UG!+NHL M=UNBN!!3&5F8NY86JA$!.?,*#+)9..OBA:`M(K.=&OY-MQN=Q M*9DB@J/.#1,T\J'(M&L;>.M`0)(?:BGE"0255>Q3,1XZ!*EVD`%,.X?YV#8CIID\JR/0TI]19S=.+8*$H" M'!TUOSW";P^;WQX/W;`C?WO".'RXW_SA%#;21:.A*`(%$2:Z7<_V?8(TBYM7 MT82]B0DE^(U),;E#N\`^8$)NL)_=,6D0@:<';'Q:<]`V5%1&`)KTE.@+BRRQ MCF7)_5F&L`"'S45SV*N\A:=:9-RK,59[\P_I\=[?V MM$RXVLI@J&KY:.I:2[K05C-4_3+5O5&%G2=IF@6.9ZI$;MJ1LC38&KATHL$H MDV@H^^F#]FN(&CR1#!:D1NBW MKU5+4809*GU/(I@0*JTCF-,FKFNPMMPTVYRR[77GEM@+*\:&08H[:!MF(WIC M_KD?/#9,0>YDHMJ_Y48RGLI:74FZEF/J/4PVE@$:H;"H#3LV.JV)GKSV&2;C MS(U&#AI,UV[(O6OE1>G7:GQE5T]G5Y>BC8\H'^F'.937BEUK*N1%RF9J17UV MT;DHX&C$0>3Z=S_K9SC$P%U2&!("8N3K7L&*O2GBY0;^J1/2+MO&&:R5+@IY MX&GR7!\.#_=.AOM'^VY/_&$$.OOP^.38K\F.[ZF/(\+D<'A\?#`\!.W>>ZK. M$/.X6#KEKM5JP?S[2BV8^O8Z0&N*(.%M4%$9)?L(*FQC7M>`*@EOBGBL[8V. M_LS"Q%LS<[.O>P6`S*$C[9>[XG(B1].H2DNG>$+=V#WS>- M#1MO6J372;2MK)(=_TE]10$[G[BAB_'5IEBGF.%UR>HZG4A@>[1C2J788XDW M?!J-MVRY"T4E\GKFY%(%/+S2SJW)@=#F=82DT7943&RZ"F?)YTK59*L07>!" M1-,^P*37#T7:/2/C:W2<_T@`>$N7ZGB7*W10U2E1U>-G&IPK[4*W5E;>2-E] MG2NDN#[*\U;"%TA7-J-&EDLI5H_@5(W]L;K=E@1YZ>*4CL-F1:8:""2J(DHG M+JS,U1G4B@Z;-#N+O:>OA/JJEJI;SJ#S'L^/^J7QY4U>"9?JGXO=;UD#5KXD M6P`FFEZW^<9%W5RXZ@'%5O?=I$I2EPC?1]M1BS#'.JK*PHCJ1S)F$]K+_;=G"5R?#15':? M+.YHD\Q>\*X$D@Y-#S.!#5;!A7>`]R8S!$_=;1/N%A:;7GN$Z^53D-T\;;$^ M6'\Q3[*\1E\)(O"^!>GOX"37:<`IIJ>JF9#QH. MF%\%[T[KAR;$J*;9^AY>U9A#$F<.?=$6_5Q@9N[ZU4T.-&PU[9\W:/-#:\;2*)/&XQ9M[B]K$'8;8#C M3C]*P;GT$!)_O!N7,+>.R5-$RL3U4X1PGO0)Y>L<[+O]1IH_V[R?30(6;E\! M[`!.RABF`W40]LT^?%31[<*+3:Z/9(V;38'`:U]U*`(:?"4,ES[NT6`2@7TSM2TDQP%HQV3E9X+3P M'9N//06"N,5`C`M6)79L=3?E5[+H$1J.+NCF"BY->ETE5V<\0;EUYC@N;-]AY=D/W4LU>=[HCQ M!5J\O>XO85X,L,B8*[K,(3ZU2:`M!`XUOZ-?6#]TP:E@^,3)VR>^(`[D3"DD M9#_I:`J+LV_C0?#*"?9FH^S3?DW4GL^`"3#8[\4./CK!PJ[> M'?2\;C3L@J0Q8`,D_,JC>D(_YAVU0E.._LC&!)J_;L"EUN"[:8TL"_.#9O'S M\`#=5`!Y0//?8Z1&3Y#J7)5CG*)#^AO0WLV8ZCV7%K/HXTP,[(;*Z7V]$25B7TW MLD*Y(5]TDV5W06C0F>;^+4NPU@F."XNWR3YB+_KB2?3L%M1QE!V,X4%%5G1) M.?Q\307#--.I_NZ[>-%7*B_L,O>`L8,X8L\&.<@HW3?+LU52D!,?53AS68:[ MR-':)LHN+SO7("155&BE';_8%F6B#UTAAS*T*77XN:U(GIQ M%:S1Y#Y:-Y-IX;O]@;TE._8K/;;A,!_QU*G7S+K1U&#N6*9S?C`!G^BO+=E> MBE=UC]X4?>TJ26M5HTIA$X]TM5^#W/MH6E/R7]>E8@'LBS=TV=8OW;'OT`Y' MO0060?=MTJW!B@YU6*]$"^+%P-PH[/O_`X)31(5T=_5R\+N:VKQ_*.A./_); MD-[%/8=*D-(6=*Q@NR30.<_\D.7>[XW(9SNFXO'Z@FVM.FA08P/9Y5[$ MH,U"N9#7#HXI-N\VR3//FG<>L8"G;/B\1RO:4-IF<_O2`I9["EC3;:?'K_Q_ M>8)?^A0\D&M7IN@N_9.IL^*WRP)R`EO.3Y(`@J9J+.S M95Q<'\IJ@F&-(N9"/4.#@O*^>$&;#VR*%9K)P)9.'F1K"A'MM*N23<*=WK?B<5'` MB%-@CEH@=O\&4/O&7E+_*KM+BSQ3]P*\C2L,$O:/TN^-*4S?9U`98Z'R,EV+ MKZ=0Z+'"U"26VBD^I#S]D MJ6GTICH3UJ":Y-''=):KU!AYT1@UD<* M?ZL'.0@LY/P@06=?J-UV?\;"[X/&]6S]GA5?EQ;LIKP?'F+,LL( MU)\L M&44'A[#3)##$6)6VCE==Q-[D]1D%2>*!;)B(N*F]<&KB1&YO>$*!G5TKXG@%* M`][TPH!&JN*%&EG!3Y4EO16C7/`H_(/T)PL/Y_RW,Z2KG[_B46%!J0(W0U>:3E2)%5= MT)4%U+A41?]V&O]1TU193I=?OQB<.5U4^5:O#WX3U>T9M2MVVST[]P=2CAA\ M>`.&SHNV*Y2#_7P-4N^&$5D`2%P?2'F-M>ZG.0=F1L6[+=BJ,S^0#UY^O*(W M.=-UF5::85PZ3D-TB:<*I&QUJ>Z1SF`E#(#)[$H!U0-U9YCK\,YPL[LZN*Y5 MLPO6']JIL^MJCM!(A)<;4W3OG;JI.$W>_$G?8ZM[#V_`E"=$;=X(`_--XMQ. M%6:6\C(&KPC5!.Y$SJ6^#%P779CD/>I8BMPQ`2SBZ['6IL%7FRS57$-.K4]T MY]LMV_"P:53+>N3F71&4>#Z*-H(580\*\IC@PAH()=`YK0>T0;_A9;CM-Y70 M#:FZ!ECLL?UJ8'45R]:1[>*B,JWL-9V9<=$JW^\N77+/O$6Q;DS(3U6Y^0^C MZ&HD"LW]0!BL`#0D;B@*]KZ^3RXG+2?N>[.QS`L;KBG?#?.J)[9;<+)+@F@\_.?#8]%S M88123UX8)3T'/X$"6LZMYQ4UEH)XU%V:W$O-WR9!P9EC;JEUTK@&'UN:N`_0 MF:;8?41[%[0]*$Q^VS.&-MN^1;2"S3U\4[3J1:TQNA6.]ITV@"9X1QV(K1#B MB@]IAJNB`VT,N?C&)S;GL#:#S.B5+/*E?BC.TDAX3/IVKJW3'C4!4%;62U,0 M`02TQU'WI*H6"?F"DQ6[N:K[G*]L"IBS5]QIYG'WHNZIBU'],0;R.D4=9A#5 MEZ56*68HSQZ&LFG(4-1T)J9?'SD9@`;S&$.?F0K(T#W*,PYF%9W62>(Y$@OKM^@8 MQHEDLPX[2ZBC4LLDMLXW*A]`5UKJMD6E:M`^7>3YG.YQ%<"'_Q7%6;Z-YR3&D=C:E&`[__5`N$@07G&)0; MHL%VJ-FB@MJX:_N"7^&M! M]RGQ29*^I]].16DSW6%A(UPF]%?ECG'M7LGT'"VR1/>M=DM0$73_RX]&4A!2 M>&S!E19<@X=_ZHH-1!\LG48C4H>&V=//A7,JCP=!+64)\E"*G0NJ4;5S*CRK MQ3-N:R$JS6@&)R6-)E#>9GR#//9*7UE(?[V92KF[]$GJ=F8EIT[KQLK-RE)* M(L*`-5=DJ]I3\@68C"?*Q>-1[0VZVJS2NK'*V4.E"$9?Y5PGHTH0;7,%_:`V MT=DWE2165Z3>H>2#F7.IH>TWB`$/&ZTN5"@LKIQ41)QA%'TTM>\4306E\AH] M&D.[/7F5MV$,J/?I=L=#K^67ZVU5$1EG(`L?/>10:YK-YF&9Z,^H%]4D?'$" M'"#E00F%>1RO24:`D`T)K[!*0K>`(Z&F8XUU`7?M[M(K17H-'X-W8TT(L?S M%4E(>.?59[69,8A'A2!Z,'XOYA!2!D.ZFZ]K*+__ M1RMF%;]2!3(6OB)A/DSJKE.92-"&+<*BG$9/FQGL^J6KMDX2V[$-B)RYP1"? MZLR3XI;P[2E_Y4@0UZ5R;IU&[ZT,>LF7$I*CR0`$EW/F6/,'8\3&@T-Y80.E M%;`K.M/!$NW+59M4?5"(/50/*SQSO/G8Z7+A>''T_?,J`UXEYZ@K?]DC$6?Z M"F!_IM$``>'>GL[M2,S]U\%[M&-9`RGM/1TG3C/IF68^89T!P7+3UGPEY_H1 MJR_(ZT4X=>1>Z1"<@,-9^^AXT,[]9A]=%8/535VQ_6;*+3E\.]T)A0E\V/Y$ MQ60[S>?/G:NX6S0:+W[RB%J;]3S&$O"%IY^UZF5T8AF@\T);WK8?ETALI"#> MCVGBA0/UA=KV04-=?`6QH*1G7-=.OU7IQU2A$GK;7JE(PK:*8^]\26@Y,5>G M)(D#O$92?3'(-"#AN:4H*=Z4W[2DO9M^O,@7FD.LJ<-M5%5\HHX-3I,&#&)3 M>20)**W-ID\O_#QWKQ`+=16F4PC?'C:X#-RPESC=G6D$/'3=\IT^]"SWI6`Z M7J+88Y4,FJXG"(#!MB/T$_"%F#UG]S'5@Z(O)BU+(]/SUB+9\\`58L$E?(&Z M99MQO7;V('*#DIFH=#C9G\EJS_W8NNBDP76K>JWBLDEOCG]U\OI_PF1[.OE]%_P=Y_WYMT;7K(54AW_ M;:XV[M'ROQ6N_K.$^-V/D>.EZX3\3KC86J1;?_^G:V7<#U0F=W&_W_/[@J'^ M`;-#G@4J?\>FO^TDVKO'67^]?N1?.TH\Z]^@E_X%/I61;>:,Z9<4Z<. MQH)]Z%1^&P+V$U%J0:F-^HUXA2F9*$WQA\V MP?([C1<:)_HFV`6SC)I/;5!:*PL>O=X0NK1R3A!=?!9_:CAS:W+OO%U MOT<7B'AH8NI0%<;SJ28V(8UJ5/M7Z%QF,P^,'&)%3U5>H5:D+T5";D<5"2B' MW!LP2TPN>I">L.:HZC;P9X1-]!>@[BQ=ULN6'?#U2OE=2H;^I@O>_R(+CC]W M+!@%"*9!J*Y3K)1Z*]@;AU=VQFF0O^$TR)=M&$29D+`48%4KH+L*PSL?&BNV M<7#KJ1$V&<(,"SRX#,?:%U#B^KD M8%48]^/SCOJ!=9Z8/))AU`P8T(.ZXNR/9].2?!3_.^0*H!+3%EG+8B(0@&Y-G0[-$!ZE;2LFO>J1ZR[/`H1I/#"W- M;4%B&Q(UNI#(8KS/8$R<=>CU['0\K=\.8 MK]-:WUNME>;@6(,=2LCA%VW"9:VLI#:VO80(*;@J[^]Y9,A[F+LH;].5]4)L M[$!21A=U MHK)_L99^,IZ,NU>W,I`-#NY_>7BX;L9)\"7_R].U(WGU35G=F\`<36)#0'`T?K4Y!#KSTF>3UL]C\^I;KC*#;-C>\8ZFFI M\CUSL3>EFJMD-8HF1\-@"O'+@&O3'Z&>ELF?:CIZ3FF5_M'[G&_#FL74V$>D MN`9Q"#>-EK&A2_J&.AX9]CE<=:1>Q[`)NN^7QG70]R:<>[K MQD$OQJ3-,<'YKIY8;W$)G;_^Z#DDKLZ\IS0DNC4E^ZOO:(`3-HGD9DO%N[`5;-H(,*X27#U MO6H%O%S"EL*!UAD"=00!3:%_64'8P]JGQB#LY3;UGM;=[:MFJD-,B[AP*E`# M%D.@.C8\DC5XPF.]-!FC:_:B:E?E;2-^&6IX#7"L/9Z%745D/SM)*6U!X>_. M**1&,B/3;A1S,T0_T>;L!$8IXT='8;'^3'!=E\PCD?=)R'= M?6\\#GW]ON^QO7/HD#-2TBK97:1W?5CS)U+]O`-3?7Z0M'151KTB7D?]O[PT M?M$645Q/H[LBEAAB!_X$IOVZ]0NALDN7-)1(FF5"!@@GSYBY?&NBGQ7_O>DM MA`WK+(24\WICE<$9SV]GU$$87LY4)?1:V6':-E#5C9$\DJP!0K$N#I%C9(]'"]UWX M>1:^0]5+N_#(N)F%\4@LVL"7_7VC+ZY.2.+;&]=`ZDPH]O&Z?`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`7X? M$#QZ"<^?C/I,R]VDQ/_5B>UB'ABR^OM0-#@,,$:LB? M,ON7G^'9P?]%EMC[")Y!=&_@$PM*-.+8W?OWE!K1LR*7C6>>LUV&;QKU$J,] MMB/%1HNEW:*],2[3=LV/$W`]`->+W;\')B]WQNS+1H,]14*HK_! M@^YN$/#5FCS'CC2+#8`Z%+PF:JM)V6B\[56S:X0?C9?M.<(&CUMOWDU;K#%N MMJ6N$3;?`R#9V@0T[PWB**-VS.A(!>@QG?-TRU3/@/('O5'^HVG*(;G@>JZY MM@O"L,4?W:./P3/,WC<.N;:K09@..DS%,$"?I@#),=?T..EZM4?[DR>^_GS; M7-.&I?GJ&SB+&Q5;Q2N^LKNTR#-58O!677G9,^R!.7Z109A9X(RU>:+S):+9 M(HFS>H5?\+UE?!TS7B*X]P)P69_=Z MN);L$G\(6'IXA&&T#.=[/&:D<";(1^U0T)$%[:]'@+;LMFU_[:U%-G57701Z MBE#:#'OCTIGY)>@.EYTI=M?WV6AE?[W:;/A.V*ZN&W[(VNNOX8&UO=U&F%F> M!V`2:N[1!G4G7;U_Q6';Z^>A'&N/.%L2W/N^[UT'OSG2?=(W-Z^]3MW?N2VJ M67/7[1->'4;U"AWTT[S.`A[<#<8!RZ%M'`T$@)]^?N>1]S1[BE9?/&JYU.\O M4;BZ[75\EQ47YO:%.@>T^.1 MM@8S(;&;S5+.7`YA74LCFK!KJ-LI\L<]K[CUCQ/O*\Y/#;5Y<9VZ;D.7[B*T M@V!:Y\%AZ-M_S<8T0<7L:X\:V:/&@NC;LJR^^W]02P$"%`,4````"`"8@P1' MO$LLP-X!``"`'0``$P``````````````@`$`````6T-O;G1E;G1?5'EP97-= M+GAM;%!+`0(4`Q0````(`)B#!$=(=07NQ0```"L"```+``````````````"` M`0\"``!?KYQM$^`(``(4,```0``````````````"``0(%``!D M;V-0&UL4$L!`A0#%`````@`F(,$1X1N[J,_`0``:0,``!$` M`````````````(`!*`@``&1O8U!R;W!S+V-O&UL4$L!`A0#%`````@` MF(,$1YEE@"``!*"P``#0`````````` M````@`'7#P``>&PO&PO=V]R M:W-H965T&UL4$L!`A0#%`````@`F(,$1Z*-`$=B!0``RAP` M`!@``````````````(`![1@``'AL+W=O&^O?5,0,``*P-```8``````````````"``84>``!X M;"]W;W)K&PO=V]R:W-H965T&UL4$L!`A0#%`````@`F(,$1]BWPR7+!```X!D``!@``````````````(`! M520``'AL+W=O$ M>4>P'@(```X'```8``````````````"``58I``!X;"]W;W)K&PO=V]R:W-H965T&UL4$L!`A0#%`````@` MF(,$1ULQV2.C`0``LP,``!@``````````````(`!SB\``'AL+W=O&PO=V]R M:W-H965TDRE2MI0$``+,# M```9``````````````"``5DU``!X;"]W;W)K&UL M4$L!`A0#%`````@`F(,$1T;\+GJC`0``LP,``!D``````````````(`!-3<` M`'AL+W=O&PO=V]R:W-H965T@Z``!X;"]W;W)K&UL4$L!`A0#%`````@` MF(,$1S+BO=FB`0``LP,``!D``````````````(`!PCP``'AL+W=O&PO=V]R:W-H965T"F=%*HP$``+,#```9``````````````"``7=```!X;"]W M;W)K&UL4$L!`A0#%`````@`F(,$1Z58.E"B`0`` MLP,``!D``````````````(`!44(``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`F(,$1^,Q>9FS`0``&`0``!D````````` M`````(`!WD<``'AL+W=O&PO=V]R:W-H M965TO8CB!I`$``+,#```9 M``````````````"``:9+``!X;"]W;W)K&UL4$L! M`A0#%`````@`F(,$1X-']L*F`0``LP,``!D``````````````(`!@4T``'AL M+W=O3P``>&PO=V]R:W-H965T,-0UKIP$``+,#```9``````````````"` M`7I1``!X;"]W;W)K&UL4$L!`A0#%`````@`F(,$ M1S2L"K+-`0``X@0``!D``````````````(`!6%,``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`F(,$1U$\/];&!```PQL` M`!D``````````````(`!%%D``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`F(,$1\Q]+K0Z!```6!<``!D````````````` M`(`!S&8``'AL+W=O&PO=V]R:W-H965T M&UL4$L!`A0# M%`````@`F(,$1P8BE..2`@``#0H``!D``````````````(`!TW,``'AL+W=O M&PO=V]R:W-H965TZ.Q#4T@(``!D-```9``````````````"``4!Y M``!X;"]W;W)K&UL4$L!`A0#%`````@`F(,$1]:G M(3V5`@``(`H``!D``````````````(`!27P``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`F(,$1TX$?NX[`P``9A```!D` M`````````````(`!AH4``'AL+W=O&PO M=V]R:W-H965T,``!X;"]W;W)K&UL4$L!`A0#%`````@`F(,$1PZV:[+T`P``410``!D``````````````(`! MP(X``'AL+W=O&PO=V]R:W-H965TKQV+N>`4``/T>```9```````` M``````"``:N5``!X;"]W;W)K&UL4$L!`A0#%``` M``@`F(,$1Q0Y.9::/```#S4!`!0``````````````(`!6IL``'AL+W-H87)E B9%-T&UL4$L%!@`````X`#@`.@\``";8```````` ` end

XML 15 R46.htm IDEA: XBRL DOCUMENT

Taxes on Earnings (Details) - USD ($) $ in Millions	6 Months Ended
Taxes on Earnings (Details) - USD ($) $ in Millions	Jun. 30, 2015	Jun. 30, 2014
Taxes on Earnings
Tax cost related to the disposal of shares	$ 69
Non-cash impact of tax expense associated with the gain on the sale of businesses	1,100
Decrease in gross unrecognized tax benefits	35
Decrease in gross unrecognized tax benefits, upper bound	635
Decrease in gross unrecognized tax benefits, lower bound	525
AbbVie
Taxes on Earnings
Tax costs (benefits) as a result of the resolution of various tax positions.	(17)
Discontinued operations
Taxes on Earnings
Non-cash impact of tax expense associated with the gain on the sale of businesses	665
Discontinued operations \| AbbVie
Taxes on Earnings
Favorable resolution of various tax positions and other unusual provision items		$ 109
Decrease in gross unrecognized tax benefits		$ 134
Developed markets branded generics pharmaceuticals business
Taxes on Earnings
Tax costs (benefits) as a result of the resolution of various tax positions.	$ 7

XML 16 R33.htm IDEA: XBRL DOCUMENT

Other Comprehensive Income (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Other comprehensive income from continuing operations, net of income taxes
Balance at the beginning of the period			$ (5,053)
Balance at the end of the period	$ (5,004)		(5,004)
Cumulative Foreign Currency Translation Adjustments
Other comprehensive income from continuing operations, net of income taxes
Balance at the beginning of the period	(3,727)	$ (656)	(2,924)	$ (718)
Impact of business dispositions			108
Other comprehensive income (loss) before reclassifications	84	(19)	(827)	43
Net current period comprehensive income	84	(19)	(827)	43
Balance at the end of the period	(3,643)	(675)	(3,643)	(675)
Net Actuarial Losses and Prior Service Costs and Credits
Other comprehensive income from continuing operations, net of income taxes
Balance at the beginning of the period	(2,179)	(1,296)	(2,229)	(1,312)
Impact of business dispositions			19
Amounts reclassified from accumulated other comprehensive income	22	12	53	28
Net current period comprehensive income	22	12	53	28
Balance at the end of the period	(2,157)	(1,284)	(2,157)	(1,284)
Cumulative Unrealized Gains on Marketable Equity Securities
Other comprehensive income from continuing operations, net of income taxes
Balance at the beginning of the period	174	13	1	13
Other comprehensive income (loss) before reclassifications	660	1	833	2
Amounts reclassified from accumulated other comprehensive income	(138)	(5)	(138)	(6)
Net current period comprehensive income	522	(4)	695	(4)
Balance at the end of the period	696	9	696	9
Cumulative Gains on Derivative Instruments Designated as Cash Flow Hedges
Other comprehensive income from continuing operations, net of income taxes
Balance at the beginning of the period	125	5	99	5
Other comprehensive income (loss) before reclassifications	5		48	(1)
Amounts reclassified from accumulated other comprehensive income	(30)	(7)	(47)	(6)
Net current period comprehensive income	(25)	(7)	1	(7)
Balance at the end of the period	$ 100	$ (2)	$ 100	$ (2)

XML 17 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 18 R25.htm IDEA: XBRL DOCUMENT

Restructuring Plans (Tables)

6 Months Ended

Jun. 30, 2015

Restructuring Plan 2014

Restructuring costs

Schedule of restructuring activity

(in millions)
Accrued balance at December 31, 2014	$	118
Restructuring charges recorded in 2015	19
Payments and other adjustments	(44		)

Accrued balance at June 30, 2015	$	93

Restructuring Plan 2015 and 2013

Restructuring costs

Schedule of restructuring activity

(in millions)
Accrued balance at December 31, 2014	$	135
Restructuring charges recorded in 2015	25
Payments and other adjustments	(42		)

Accrued balance at June 30, 2015	$	118

Restructuring Plan 2013 and Prior Years

Restructuring costs

Schedule of restructuring activity

(in millions)
Accrued balance at December 31, 2014	$	39
Payments and other adjustments	(7		)

Accrued balance at June 30, 2015	$	32

XML 19 R42.htm IDEA: XBRL DOCUMENT

Financial Instruments, Derivatives and Fair Value Measures (Details 3) - USD ($) $ in Millions	Jun. 30, 2015	Dec. 31, 2014
Fair value, asset and liability measures
Investments Securities	$ 243	$ 229
Foreign currency forward exchange contracts, receivable position	460	358
Foreign currency forward exchange contracts, (payable) position	(523)	(575)
Equity securities
Fair value, asset and liability measures
Investments Securities	226	212
Carrying value
Fair value, asset and liability measures
Total long-term debt	(5,894)	(3,463)
Foreign currency forward exchange contracts, receivable position	357	263
Foreign currency forward exchange contracts, (payable) position	(75)	(135)
Interest rate hedge contracts, receivable position	103	101
Interest rate hedge contract, (payable) position	(17)
Carrying value \| Equity securities
Fair value, asset and liability measures
Investments Securities	4,898	212
Carrying value \| Other.
Fair value, asset and liability measures
Investments Securities	17	17
Fair value
Fair value, asset and liability measures
Total long-term debt	(6,323)	(4,113)
Foreign currency forward exchange contracts, receivable position	357	263
Foreign currency forward exchange contracts, (payable) position	(75)	(135)
Interest rate hedge contracts, receivable position	103	101
Interest rate hedge contract, (payable) position	(17)
Fair value \| Equity securities
Fair value, asset and liability measures
Investments Securities	4,898	212
Fair value \| Other.
Fair value, asset and liability measures
Investments Securities	$ 17	$ 17

XML 20 R37.htm IDEA: XBRL DOCUMENT

Restructuring Plans (Details) $ in Millions	6 Months Ended
Restructuring Plans (Details) $ in Millions	Jun. 30, 2015 USD ($)
Research and development
Restructuring costs
Restructuring charges	$ 2
Restructuring Plan 2014
Restructuring costs
Restructuring charges	19
Additional charges for accelerated depreciation	25
Restructuring Plan 2014 \| Cost of products sold
Restructuring costs
Restructuring charges	1
Restructuring Plan 2014 \| Selling, general and administrative expense
Restructuring costs
Restructuring charges	18
Restructuring Plan 2015
Restructuring costs
Restructuring charges	25
Restructuring Plan 2015 \| Cost of products sold
Restructuring costs
Restructuring charges	9
Restructuring Plan 2015 \| Selling, general and administrative expense
Restructuring costs
Restructuring charges	$ 14

XML 21 R47.htm IDEA: XBRL DOCUMENT

Segment Information (Details) - USD ($)
$ in Millions

3 Months Ended

6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Segment Reporting Information

Net Sales to External Customers

$ 5,170

$ 5,057

$ 10,067

$ 9,812

Operating Earnings

729

677

1,339

1,042

Amortization of intangible assets

(151)

(133)

(307)

(260)

Earnings from continuing operations before taxes

986

658

1,639

999

Other

Segment Reporting Information

Net Sales to External Customers

577

628

1,117

1,216

Total Reportable Segments

Segment Reporting Information

Net Sales to External Customers

4,593

4,429

8,950

8,596

Operating Earnings

1,145

1,044

2,222

1,891

Earnings from continuing operations before taxes

986

658

1,639

999

Total Reportable Segments | Established Pharmaceutical Products

Segment Reporting Information

Net Sales to External Customers

977

744

1,874

1,425

Operating Earnings

172

160

339

281

Total Reportable Segments | Nutritional Products

Segment Reporting Information

Net Sales to External Customers

1,717

1,731

3,386

3,362

Operating Earnings

389

302

739

585

Total Reportable Segments | Diagnostic Products

Segment Reporting Information

Net Sales to External Customers

1,177

1,189

2,270

2,306

Operating Earnings

304

279

580

501

Total Reportable Segments | Vascular Products

Segment Reporting Information

Net Sales to External Customers

722

765

1,420

1,503

Operating Earnings

280

303

564

524

Corporate functions

Segment Reporting Information

Corporate functions and benefit plans costs

(104)

(103)

(221)

(161)

Reconciling items

Segment Reporting Information

Non-reportable segments

106

117

172

Net interest expense

(17)

(33)

(37)

Share-based compensation

^[1]

(57)

(48)

(205)

(164)

Amortization of intangible assets

(151)

(133)

(307)

(260)

Other, net

^[2]

$ 108

$ (191)

$ 66

$ (442)

Minimum

Segment Reporting Information

Annual share-based awards recognized in first quarter (as a percent)

40.00%

Maximum

Segment Reporting Information

Annual share-based awards recognized in first quarter (as a percent)

45.00%

[1]	Approximately 40 to 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards.
[2]	Other, net in 2015 includes a gain on the sale of a portion of Abbott’s position in Mylan stock and a decrease in the fair value of contingent consideration related to a business acquisition, which was partially offset by charges associated with cost reduction initiatives.

XML 22 R9.htm IDEA: XBRL DOCUMENT

Discontinued Operations

6 Months Ended

Jun. 30, 2015

Discontinued Operations.

Discontinued Operations

Note 2 — Discontinued Operations

	Three Months Ended June 30						Six Months Ended June 30
(in millions)	2015			2014			2015			2014
Net Sales
Developed markets generics pharmaceuticals and animal health businesses	$	—		$	494		$	256		$	983
AbbVie	—			—			—			—

Total	$	—		$	494		$	256		$	983

Earnings (Loss) Before Tax
Developed markets generics pharmaceuticals and animal health businesses	$	(5	)	$	79		$	20		$	161
AbbVie	—			—			—			—

Total	$	(5	)	$	79		$	20		$	161

Income Tax Expense (Benefit)
Developed markets generics pharmaceuticals and animal health businesses	$	—		$	44		$	12		$	11
AbbVie	(4		)	(6		)	(17		)	(42		)

Total	$	(4	)	$	38		$	(5	)	$	(31	)

Net Earnings
Developed markets generics pharmaceuticals and animal health businesses	$	(5	)	$	35		$	8		$	150
AbbVie	4			6			17			42

Total	$	(1	)	$	41		$	25		$	192

The following is a summary of the assets and liabilities held for disposition:

(in millions)	June 30, 2015		December 31, 2014
Trade receivables, net	$	39	$	498
Total inventories	23		254
Prepaid expenses, deferred income taxes, and other receivables	31		140

Current assets held for disposition	93		892

Net property and equipment	2		125
Intangible assets, net of amortization	—		804
Goodwill	—		950
Deferred income taxes and other assets	—		55

Non-current assets held for disposition	2		1,934

Total assets held for disposition	$	95	$	2,826


Trade accounts payable	$	279	$	423
Salaries, wages, commissions and other accrued liabilities	13		257

Current liabilities held for disposition	292		680
Post-employment obligations, deferred income taxes and other long-term liabilities	—		108

Total liabilities held for disposition	$	292	$	788

- Definition

The entire disclosure for the facts and circumstances leading to the completed or expected disposal, manner and timing of disposal, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss), amounts of revenues and pretax profit or loss reported in discontinued operations, the segment in which the disposal group was reported, and the classification (whether sold or classified as held for sale) and carrying value of the assets and liabilities comprising the disposal group. Includes all disposal groups, including those classified as components of the entity (discontinued operations).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1436-107760

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1474-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1510-107760

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e957-107759

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1020-107759

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1012-107759

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=8077374&loc=d3e2443-110228

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2941-110230

+ Details

XML 23 R43.htm IDEA: XBRL DOCUMENT

Financial Instruments, Derivatives and Fair Value Measures (Details 4) - USD ($) $ in Millions	Jun. 30, 2015	Dec. 31, 2014
Fair value, asset and liability measures
Fair Value - Assets	$ 460	$ 358
Fair Value - Liabilities	523	575
Recurring \| Fair value
Fair value, asset and liability measures
Equity securities	4,682	9
Interest rate swap derivative financial instruments, assets	103	101
Total Assets	5,142	373
Fair value of hedged long-term debt	4,104	1,637
Interest rate swap derivative financial instruments	17
Contingent consideration related to business combinations	169	243
Total Liabilities	4,365	2,015
Recurring \| Fair value \| Foreign currency forward exchange contracts
Fair value, asset and liability measures
Fair Value - Assets	357	263
Fair Value - Liabilities	75	135
Recurring \| Quoted Prices in Active Markets
Fair value, asset and liability measures
Equity securities	10	9
Total Assets	10	9
Recurring \| Significant Other Observable Inputs
Fair value, asset and liability measures
Equity securities	4,672
Interest rate swap derivative financial instruments, assets	103	101
Total Assets	5,132	364
Fair value of hedged long-term debt	4,104	1,637
Interest rate swap derivative financial instruments	17
Total Liabilities	4,196	1,772
Recurring \| Significant Other Observable Inputs \| Foreign currency forward exchange contracts
Fair value, asset and liability measures
Fair Value - Assets	357	263
Fair Value - Liabilities	75	135
Recurring \| Significant Unobservable Inputs
Fair value, asset and liability measures
Contingent consideration related to business combinations	169	243
Total Liabilities	$ 169	$ 243

XML 24 R29.htm IDEA: XBRL DOCUMENT

Segment Information (Tables)

6 Months Ended

Jun. 30, 2015

Segment Information

Schedule of segment and geographic area information

	Net Sales to External Customers								Operating Earnings
	Three Months				Six Months				Three Months						Six Months
	Ended June 30				Ended June 30				Ended June 30						Ended June 30
(in millions)	2015		2014		2015		2014		2015			2014			2015			2014
Established Pharmaceutical Products	$	977	$	744	$	1,874	$	1,425	$	172		$	160		$	339		$	281
Nutritional Products	1,717		1,731		3,386		3,362		389			302			739			585
Diagnostic Products	1,177		1,189		2,270		2,306		304			279			580			501
Vascular Products	722		765		1,420		1,503		280			303			564			524

Total Reportable Segments	4,593		4,429		8,950		8,596		1,145			1,044			2,222			1,891
Other	577		628		1,117		1,216

Net Sales	$	5,170	$	5,057	$	10,067	$	9,812

Corporate functions and benefit plans costs									(104		)	(103		)	(221		)	(161		)
Non-reportable segments									62			106			117			172
Net interest expense									(17		)	(17		)	(33		)	(37		)
Share-based compensation (a)									(57		)	(48		)	(205		)	(164		)
Amortization of intangible assets									(151		)	(133		)	(307		)	(260		)
Other, net (b)									108			(191		)	66			(442		)

Consolidated Earnings from Continuing Operations Before Taxes									$	986		$	658		$	1,639		$	999

(a)

Approximately 40 to 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards.

(b)

XML 25 R28.htm IDEA: XBRL DOCUMENT

Post-Employment Benefits (Tables)

6 Months Ended

Jun. 30, 2015

Post-Employment Benefits

Net cost for the entity's major defined benefit plans and post-employment medical and dental benefit plans

	Defined Benefit Plans												Medical and Dental Plans
	Three Months						Six Months						Three Months						Six Months
	Ended June 30						Ended June 30						Ended June 30						Ended June 30
( in millions)	2015			2014			2015			2014			2015			2014			2015			2014
Service cost — benefits earned during the period	$	68		$	62		$	150		$	128		$	6		$	9		$	15		$	18
Interest cost on projected benefit obligations	77			75			156			152			11			16			25			32
Expected return on plan assets	(128		)	(113		)	(257		)	(226		)	(10		)	(9		)	(19		)	(19		)
Net amortization of:
Actuarial loss, net	42			24			89			49			1			4			10			9
Prior service cost (credit)	—			—			—			1			(12		)	(9		)	(24		)	(18		)

Total Cost	59			48			138			104			(4		)	11			7			22
Less: Discontinued operations	—			4			1			8			—			—			—			—

Net cost - continuing operations	$	59		$	44		$	137		$	96		$	(4	)	$	11		$	7		$	22

XML 26 R44.htm IDEA: XBRL DOCUMENT

Litigation and Environmental Matters (Details) $ in Millions	Jun. 30, 2015 USD ($)
Loss Contingencies
Maximum expected cleanup exposure for individual site	$ 4
Maximum expected cleanup exposure in aggregate	15
Other legal proceedings and environmental exposures
Loss Contingencies
Other legal proceedings or environmental exposure, minimum	40
Other legal proceedings or environmental exposure, maximum	55
Recorded reserve balance for legal proceedings and exposures	$ 50

XML 27 R30.htm IDEA: XBRL DOCUMENT

Discontinued Operations (Details) - USD ($) shares in Millions, $ in Millions				1 Months Ended	3 Months Ended		6 Months Ended
	Feb. 27, 2015	Feb. 27, 2015	Feb. 10, 2015	Apr. 30, 2015	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Proceeds from the disposition of business							$ 230.0
Gain on sale of Mylan shares					$ 207.0		207.0
Proceeds from the sale of Mylan shares					2,290.0		2,290.0
After Tax Gain					(1.0)		1,736.0
Pretax gain on sale of discontinued operations							2,820.0
Trade receivables, net					39.0		39.0		$ 498.0
Total inventories					23.0		23.0		254.0
Prepaid expenses, deferred income taxes, and other receivables					31.0		31.0		140.0
Current assets held for disposition					93.0		93.0		892.0
Net property and equipment					2.0		2.0		125.0
Earnings from discontinued operations, net tax benefits					(2.0)	$ 41.0	1,761.0	$ 192.0
Intangible assets, net of amortization									804.0
Goodwill									950.0
Deferred income taxes and other assets									55.0
Non-current assets held for disposition					2.0		2.0		1,934.0
Total assets held for disposition					95.0		95.0		2,826.0
Trade accounts payable					279.0		279.0		423.0
Salaries, wages, commissions and other accrued liabilities					13.0		13.0		257.0
Current liabilities held for disposition					292.0		292.0		680.0
Post-employment obligations, deferred income taxes and other long-term liabilities									108.0
Non-current liabilities held for disposition									108.0
Total liabilities held for disposition					292.0		$ 292.0		$ 788.0
Developed markets branded generics pharmaceuticals business
Amount of shares received for sale of generics pharmaceuticals business to Mylan Inc	$ 5,770.0	$ 5,770.0
Period of notice require to terminate manufacturing supply of products							2 years
After Tax Gain		$ 1,600.0
Developed markets branded generics pharmaceuticals business \| Minimum
Period for providing manufacturing supply of products							3 years
Developed markets branded generics pharmaceuticals business \| Maximum
Period of transition services							2 years
Period for providing manufacturing supply of products							10 years
Animal Health Business
Proceeds from the disposition of business			$ 230.0
After Tax Gain			$ 130.0
AbbVie \| Proprietary Pharmaceuticals Business Assets and Liabilities Held for Disposal
Prepaid assets					$ 210.0		$ 210.0
AbbVie \| Discontinued operations
Earnings from discontinued operations, net tax benefits							$ 17.0	$ 42.0
Mylan
Number of shares received for sale of generics pharmaceuticals business to Mylan Inc				110
Proceeds from the disposition of business				$ 40.3
Mylan \| Developed markets branded generics pharmaceuticals business
Number of shares received for sale of generics pharmaceuticals business to Mylan Inc	110						110
Proceeds from the disposition of business							$ 40.3
Gain on sale of Mylan shares							$ 207.0
Mylan NV \| Developed markets branded generics pharmaceuticals business
Percentage of shares received for sale of generics pharmaceuticals business to Mylan Inc	22.00%	22.00%

XML 28 R31.htm IDEA: XBRL DOCUMENT

Discontinued Operations (Details 2) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
Discontinued Operations (Details 2) - USD ($) $ in Millions	Feb. 27, 2015	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]
Net sales			$ 494	$ 256	$ 983
Pretax income		$ (5)	79	20	161
Income Tax Expense (Benefit)		(4)	38	(5)	(31)
Net income		(1)	41	25	192
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax [Abstract]
Pretax gain on sale of discontinued operations				2,820
Non-cash impact of tax expense associated with the gain on the sale of businesses				1,100
After Tax Gain		(1)		1,736
Developed markets branded generics pharmaceuticals business
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax [Abstract]
After Tax Gain	$ 1,600
Developed markets generics pharmaceuticals and animal health business
Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]
Net sales			494	256	983
Pretax income		(5)	79	20	161
Income Tax Expense (Benefit)			44	12	11
Net income		(5)	35	8	150
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax [Abstract]
Pretax gain on sale of discontinued operations				2,820
Non-cash impact of tax expense associated with the gain on the sale of businesses				1,084
After Tax Gain				1,736
AbbVie
Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]
Income Tax Expense (Benefit)		(4)	(6)	(17)	(42)
Net income		$ 4	$ 6	$ 17	$ 42

XML 29 R8.htm IDEA: XBRL DOCUMENT

Basis of Presentation	6 Months Ended
Basis of Presentation	Jun. 30, 2015
Basis of Presentation
Basis of Presentation	Note 1 — Basis of Presentation The accompanying unaudited, condensed consolidated financial statements have been prepared pursuant to rules and regulations of the Securities and Exchange Commission and, therefore, do not include all information and footnote disclosures normally included in audited financial statements. However, in the opinion of management, all adjustments (which include only normal adjustments) necessary to present fairly the results of operations, financial position and cash flows have been made. It is suggested that these statements be read in conjunction with the financial statements included in Abbott’s Annual Report on Form 10-K for the year ended December 31, 2014. The consolidated financial statements include the accounts of the parent company and subsidiaries, after elimination of intercompany transactions.

XML 30 R32.htm IDEA: XBRL DOCUMENT

Supplemental Financial Information (Details) - USD ($) shares in Millions, $ in Millions		1 Months Ended	3 Months Ended			6 Months Ended
	Feb. 27, 2015	Apr. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Supplemental Financial Information
Earnings from continuing operations allocated to common shares			$ 783.0		$ 423.0	$ 1,309.0	$ 646.0
Net earnings allocated to common shares			780.0		$ 463.0	3,061.0	837.0
Noncash impact of tax benefits from resolution of prior year tax positions included in other, net use of cash in Net cash from operating activities							70.0
Component of long-term investment
Short-term Investments, Total			7,129.0			7,129.0		$ 397.0
Investments			243.0			243.0		229.0
Gain on sale of Mylan shares			$ 207.0			207.0
Pretax gain on sale of discontinued operations						2,820.0
Decrease in fair value of contingent consideration						79.0
Proceeds from Divestiture of Businesses						230.0
Debt and Lines of Credit
Long-term debt issued				$ 2,500.0
Post-employment Obligations and Other Long-term Liabilities:
Non-cash impact of tax expense associated with the gain on the sale of businesses						$ 1,100.0
Mylan NV
Component of long-term investment
Number of shares owned			69.7			69.7
Percentage of shares held before sale of generics pharmaceuticals business to Mylan Inc						22.00%
Ownership interest (as a percent)			14.00%			14.00%
Mylan
Component of long-term investment
Proceeds from Divestiture of Businesses		$ 40.3
Number of shares received for sale of generics pharmaceuticals business to Mylan Inc		110.0
Interest rate swaps
Debt and Lines of Credit
Notional amount of contracts entered during the period				2,500.0
2.00% Senior Notes Due March 15, 2020
Debt and Lines of Credit
Long-term debt issued				$ 750.0
Interest rate percentage				2.00%
2.55% Senior Notes Due March 15, 2022
Debt and Lines of Credit
Long-term debt issued				$ 750.0
Interest rate percentage				2.55%
2.95% Senior Notes Due March 15, 2025
Debt and Lines of Credit
Long-term debt issued				$ 1,000.0
Interest rate percentage				2.95%
Defined Benefit Plans
Post-employment Obligations and Other Long-term Liabilities:
Company contributions						$ 547.0	330.0
Medical and Dental Plans
Post-employment Obligations and Other Long-term Liabilities:
Company contributions						24.0	$ 40.0
Equity securities
Component of long-term investment
Short-term Investments, Total			$ 4,672.0			4,672.0
Investments			226.0			226.0		212.0
Other,
Component of long-term investment
Investments			17.0			17.0		17.0
Other, Primarily Bank Time Deposits and Us Treasury Bills Member
Component of long-term investment
Short-term Investments, Total			$ 2,457.0			2,457.0		$ 397.0
Developed markets branded generics pharmaceuticals business \| Mylan
Component of long-term investment
Gain on sale of Mylan shares						207.0
Proceeds from Divestiture of Businesses						$ 40.3
Number of shares received for sale of generics pharmaceuticals business to Mylan Inc	110.0					110.0

XML 31 R40.htm IDEA: XBRL DOCUMENT

Financial Instruments, Derivatives and Fair Value Measures (Details) - USD ($) $ in Millions	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Derivative instruments, notional amount and fair value
Fair Value - Assets	$ 460	$ 358
Fair Value - Liabilities	523	575
Designated as hedging instrument \| Short-term borrowings \| Net investment hedges
Derivative instruments, notional amount and fair value
Fair Value - Liabilities	431	445
Designated as hedging instrument \| Interest rate swaps \| Fair value hedges
Derivative instruments, notional amount and fair value
Notional amount of cash flow hedge instruments	4,000	1,500
Amount of hedge ineffectiveness recorded in income	0	0
Designated as hedging instrument \| Interest rate swaps \| Deferred income taxes and other assets \| Fair value hedges
Derivative instruments, notional amount and fair value
Fair Value - Assets	103	101
Designated as hedging instrument \| Interest rate swaps \| Post-employment obligations, deferred income taxes and other long-term liabilities \| Fair value hedges
Derivative instruments, notional amount and fair value
Fair Value - Liabilities	17
Designated as hedging instrument \| Foreign currency forward exchange contracts \| Cash flow hedges
Derivative instruments, notional amount and fair value
Notional amount of cash flow hedge instruments	$ 1,600	1,500
Minimum length of time over which accumulated gains and losses will be recognized in Cost of products sold	12 months
Maximum length of time over which accumulated gains and losses will be recognized in Cost of products sold	18 months
Designated as hedging instrument \| Foreign currency forward exchange contracts \| Prepaid expenses, deferred income taxes, and other receivables
Derivative instruments, notional amount and fair value
Fair Value - Assets	$ 87	107
Designated as hedging instrument \| Foreign currency forward exchange contracts \| Other accrued liabilities
Derivative instruments, notional amount and fair value
Fair Value - Liabilities	9
Not designated as hedging instrument \| Foreign currency forward exchange contracts
Derivative instruments, notional amount and fair value
Notional amount of cash flow hedge instruments	14,100	14,100
Not designated as hedging instrument \| Foreign currency forward exchange contracts \| Prepaid expenses, deferred income taxes, and other receivables
Derivative instruments, notional amount and fair value
Fair Value - Assets	270	150
Not designated as hedging instrument \| Foreign currency forward exchange contracts \| Other accrued liabilities
Derivative instruments, notional amount and fair value
Fair Value - Liabilities	$ 66	$ 130

XML 32 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statement of Earnings - USD ($) shares in Thousands, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Condensed Consolidated Statement of Earnings
Net Sales	$ 5,170	$ 5,057	$ 10,067	$ 9,812
Cost of products sold, excluding amortization of intangible assets	2,218	2,288	4,299	4,562
Amortization of intangible assets	151	133	307	260
Research and development	345	310	658	679
Selling, general and administrative	1,727	1,649	3,464	3,269
Total operating cost and expenses	4,441	4,380	8,728	8,770
Operating earnings	729	677	1,339	1,042
Interest expense	44	36	81	72
Interest (income)	(27)	(19)	(48)	(35)
Net foreign exchange loss (gain)	5		(49)	1
Other (income) expense, net	(279)	2	(284)	5
Earnings from continuing operations before taxes	986	658	1,639	999
Taxes on earnings from continuing operations	200	233	324	350
Earnings from continuing operations	786	425	1,315	649
Earnings (loss) from discontinued operations, net of taxes	(1)	41	25	192
Gain (loss) on sale of discontinued operations, net of tax	(1)		1,736
Net earnings (loss) from discontinued operations, net of tax	(2)	41	1,761	192
Net Earnings	$ 784	$ 466	$ 3,076	$ 841
Basic Earnings Per Common Share
Continuing operations (in dollars per share)	$ 0.52	$ 0.28	$ 0.87	$ 0.42
Discontinued operations (in dollars per share)		0.03	1.17	0.13
Net earnings (in dollars per share)	0.52	0.31	2.04	0.55
Diluted Earnings Per Common Share
Continuing operations (in dollars per share)	0.52	0.28	0.87	0.42
Discontinued operations (in dollars per share)		0.02	1.16	0.13
Net earnings (in dollars per share)	0.52	0.30	2.03	0.55
Cash Dividends Declared Per Common Share (in dollars per share)	$ 0.24	$ 0.22	$ 0.48	$ 0.44
Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares)	1,493,771	1,506,595	1,500,285	1,521,668
Dilutive Common Stock Options (in shares)	10,444	10,451	10,676	10,605
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options (in shares)	1,504,215	1,517,046	1,510,961	1,532,273
Outstanding Common Stock Options Having No Dilutive Effect (in shares)	658	544	658	544

XML 33 R45.htm IDEA: XBRL DOCUMENT

Post-Employment Benefits (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
Post-Employment Benefits (Details) - USD ($) $ in Millions	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Defined Benefit Plans
Defined benefit plan net periodic benefit cost
Service cost - benefits earned during the period	$ 68	$ 62	$ 150	$ 128
Interest cost on projected benefit obligations	77	75	156	152
Expected return on plan assets	(128)	(113)	(257)	(226)
Actuarial loss, net	42	24	89	49
Prior service cost (credit)				1
Total Cost	59	48	138	104
Net amortization of:
Company contributions			547	330
Defined Benefit Plans \| Discontinued operations
Defined benefit plan net periodic benefit cost
Total Cost		4	1	8
Defined Benefit Plans \| Continuing operations
Defined benefit plan net periodic benefit cost
Total Cost	59	44	137	96
Medical and Dental Plans
Defined benefit plan net periodic benefit cost
Service cost - benefits earned during the period	6	9	15	18
Interest cost on projected benefit obligations	11	16	25	32
Expected return on plan assets	(10)	(9)	(19)	(19)
Actuarial loss, net	1	4	10	9
Prior service cost (credit)	(12)	(9)	(24)	(18)
Total Cost	(4)	11	7	22
Net amortization of:
Company contributions			24	40
Medical and Dental Plans \| Continuing operations
Defined benefit plan net periodic benefit cost
Total Cost	$ (4)	$ 11	$ 7	$ 22

XML 34 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheet (Parenthetical) - USD ($) $ in Millions	Jun. 30, 2015	Dec. 31, 2014
Condensed Consolidated Balance Sheet
Trade receivables, allowances (in dollars)	$ 362	$ 310
Preferred shares, par value (in dollars per share)	$ 1	$ 1
Preferred shares, Authorized shares	1,000,000	1,000,000
Preferred shares, issued shares	0	0
Common shares, Authorized shares	2,400,000,000	2,400,000,000
Common shares, Issued shares	1,699,703,688	1,694,929,949
Common shares held in treasury, shares	209,262,223	186,894,515

XML 35 R35.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Goodwill and intangible assets information
Goodwill	$ 9,896	$ 10,067
Foreign currency translation adjustments decreased goodwill	235
Purchase price allocation adjustments associated with increased (decreased) goodwill	67
Amount of reduction of goodwill relating to impairments	0
Developed markets branded generics pharmaceuticals business
Goodwill and intangible assets information
Goodwill	894
Increased intangible assets	738
Established Pharmaceutical Products
Goodwill and intangible assets information
Goodwill	3,300
Nutritional Products
Goodwill and intangible assets information
Goodwill	286
Diagnostic Products
Goodwill and intangible assets information
Goodwill	443
Vascular Products
Goodwill and intangible assets information
Goodwill	$ 2,900

XML 36 R22.htm IDEA: XBRL DOCUMENT

Supplemental Financial Information (Tables)

6 Months Ended

Jun. 30, 2015

Supplemental Financial Information

Components of short-term and long-term investments

Short-term Investments	June 30,		December 31,
(in millions)	2015		2014
Equity securities	$	4,672	$	—
Other, primarily bank time deposits	2,457		397

Total	$	7,129	$	397


Long-term Investments
(in millions)

Equity securities	$	226	$	212
Other	17		17

Total	$	243	$	229

XML 37 R36.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets (Details 2) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Goodwill and Intangible Assets
Gross amount of amortizable intangible assets	$ 10,800	$ 10,800
Accumulated amortization of intangible assets	5,100	4,900
Indefinite-lived intangible assets related to in-process research and development acquired in a business combination	134	$ 134
Estimated annual amortization expense, intangible assets, 2015	680
Estimated annual amortization expense, intangible assets, 2016	660
Estimated annual amortization expense, intangible assets, 2017	650
Estimated annual amortization expense, intangible assets, 2018	570
Estimated annual amortization expense, intangible assets, 2019	$ 530
Minimum
Goodwill and Intangible Assets
Average amortization period, intangible assets	2 years
Maximum
Goodwill and Intangible Assets
Average amortization period, intangible assets	20 years
Average
Goodwill and Intangible Assets
Average amortization period, intangible assets	12 years

XML 38 R24.htm IDEA: XBRL DOCUMENT

Business Acquisitions (Tables)

6 Months Ended

Jun. 30, 2015

Business Acquisitions

Schedule of the allocation of the fair value of the acquisition

(in billions)
Acquired intangible assets, non-deductible	$	1.80
Goodwill, non-deductible	1.60
Acquired net tangible assets	0.06
Deferred income taxes recorded at acquisition	(0.54		)

Total preliminary allocation of fair value	$	2.92

XML 39 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 40 R7.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statement of Cash Flows - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Cash Flow From (Used in) Operating Activities:
Net earnings	$ 3,076	$ 841
Adjustments to reconcile net earnings to net cash from operating activities -
Depreciation	416	463
Amortization of intangibles	307	335
Share-based compensation	205	168
Gain on sale of discontinued operations	(2,820)
Gain on sale of Mylan shares	(207)
Trade receivables	(125)	(76)
Inventories	(210)	(141)
Other, net	301	(354)
Net Cash From Operating Activities	943	1,236
Cash Flow From (Used in) Investing Activities:
Acquisitions of property and equipment	(451)	(513)
Proceeds from business disposition	230
Acquisitions of businesses and technology, net of cash acquired	(4)
Proceeds from the sale of Mylan shares	2,290
(Purchases) Sales of investment securities, net	(2,056)	1,119
Other	28	27
Net Cash From (Used in) Investing Activities	37	633
Cash Flow From (Used in) Financing Activities:
Net (repayments of) proceeds from issuance of short-term debt and other	(1,518)	872
Proceeds from the issuance of long-term debt	2,485
Repayments of long-term debt	(33)
Purchases of common shares	(1,347)	(2,193)
Proceeds from stock options exercised, including income tax benefit	213	226
Dividends paid	(724)	(676)
Net Cash (Used in) Financing Activities	(924)	(1,771)
Effect of exchange rate changes on cash and cash equivalents	(71)	(3)
Net Increase (Decrease) in Cash and Cash Equivalents	(15)	95
Cash and Cash Equivalents, Beginning of Year	4,063	3,475
Cash and Cash Equivalents, End of Period	$ 4,048	$ 3,570

XML 41 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statement of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Condensed Consolidated Statement of Comprehensive Income
Net Earnings	$ 784	$ 466	$ 3,076	$ 841
Foreign currency translation (loss) gain adjustments	84	(19)	(827)	43
Net actuarial gains (losses) and amortization of net actuarial (losses) and prior service (cost) and credits, net of taxes of $10 and $25 in 2015 and $7 and $15 in 2014	22	12	53	28
Unrealized gains (losses) on marketable equity securities, net of taxes of $256 and $344 in 2015 and $(2) and $(2) in 2014	522	(4)	695	(4)
Net adjustments for derivative instruments designated as cash flow hedges and other, net of taxes of $(6) and nil in 2015 and $(2) and $(2) in 2014	(25)	(7)	1	(7)
Other comprehensive income (loss)	603	(18)	(78)	60
Comprehensive Income	1,387	$ 448	2,998	$ 901
Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax
Cumulative foreign currency translation (loss) adjustments	(3,643)		(3,643)		$ (2,924)
Net actuarial (losses) and prior service cost and credits	(2,157)		(2,157)		(2,229)
Cumulative unrealized gains on marketable equity securities	696		696		1
Cumulative gains (losses) on derivative instruments designated as cash flow hedges and other	$ 100		$ 100		$ 99

XML 42 R17.htm IDEA: XBRL DOCUMENT

Litigation and Environmental Matters	6 Months Ended
Litigation and Environmental Matters	Jun. 30, 2015
Litigation and Environmental Matters
Litigation and Environmental Matters	Note 10 — Litigation and Environmental Matters Abbott has been identified as a potentially responsible party for investigation and cleanup costs at a number of locations in the United States and Puerto Rico under federal and state remediation laws and is investigating potential contamination at a number of company-owned locations. Abbott has recorded an estimated cleanup cost for each site for which management believes Abbott has a probable loss exposure. No individual site cleanup exposure is expected to exceed $4 million, and the aggregate cleanup exposure is not expected to exceed $15 million. Abbott is involved in various claims and legal proceedings, and Abbott estimates the range of possible loss for its legal proceedings and environmental exposures to be from approximately $40 million to $55 million. The recorded accrual balance at June 30, 2015 for these proceedings and exposures was approximately $50 million. This accrual represents management’s best estimate of probable loss, as defined by FASB ASC No. 450, “Contingencies.” Within the next year, legal proceedings may occur that may result in a change in the estimated loss accrued by Abbott. While it is not feasible to predict the outcome of all such proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on Abbott’s financial position, cash flows, or results of operations.

XML 43 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - Jun. 30, 2015 - shares	Total
Document and Entity Information
Entity Registrant Name	ABBOTT LABORATORIES
Entity Central Index Key	0000001800
Document Type	10-Q
Document Period End Date	Jun. 30, 2015
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding	1,490,441,465
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q2

XML 44 R18.htm IDEA: XBRL DOCUMENT

Post-Employment Benefits

6 Months Ended

Jun. 30, 2015

Post-Employment Benefits

Post-Employment Benefits

Note 11 — Post-Employment Benefits

	Defined Benefit Plans												Medical and Dental Plans
	Three Months						Six Months						Three Months						Six Months
	Ended June 30						Ended June 30						Ended June 30						Ended June 30
( in millions)	2015			2014			2015			2014			2015			2014			2015			2014
Service cost — benefits earned during the period	$	68		$	62		$	150		$	128		$	6		$	9		$	15		$	18
Interest cost on projected benefit obligations	77			75			156			152			11			16			25			32
Expected return on plan assets	(128		)	(113		)	(257		)	(226		)	(10		)	(9		)	(19		)	(19		)
Net amortization of:
Actuarial loss, net	42			24			89			49			1			4			10			9
Prior service cost (credit)	—			—			—			1			(12		)	(9		)	(24		)	(18		)

Total Cost	59			48			138			104			(4		)	11			7			22
Less: Discontinued operations	—			4			1			8			—			—			—			—

Net cost - continuing operations	$	59		$	44		$	137		$	96		$	(4	)	$	11		$	7		$	22

ZIP 45 0001104659-15-055905-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-15-055905-xbrl.zip M4$L#!!0````(`(>#!$?%`6ZX]AX!`-(@(``0`!P`86)T+3(P,34P-C,P+GAM M;%54"0`#72#!55T@P55U>`L``00E#@``!#D!``#L75MSXKBV?C]5YS^P\TZ' M6Y).JKMW02X]J9.$3$CW['E**;8`[386+=E)F%]_))N+#08,V%@2:VH>.K8L MM-;ZUM*W=/WR[X^!4WK#C!/J?CVJ?JHMDNOH](]9HPX3NF2LB%ER!,5E,KE<<'_M)[N2C:U_`%VO9(U M_NJ=>/WI=RU&[!XNE4X^5>N?SLX^569?MQ`7I45]036U3]7IF\GO4_>B]/FX M<5RK5$]*YQ?UDXMZI=2\#\M]O#*G).1R^=>CON<-+XZ/W]_?/\G'GRCKB8\J M]6/B<@^Y%CX*2UXXQ/VUHKA\_2J:-2G^L5#^O1Z4KIZ?GQ\';Z=%144VF9:- MUGMZ'+Z<%$6O7JQ.]/I*/>^310>!I)73>F52E'#:J%7/5DD8EIA$(S90V@X M_:"+^&M0>/Q"_D*C7*F6Z]5HR\D&.K3QG)@<6Y]Z].U8O$BHGKAOF'O)7X3O MY$?UN39QDJ1VT9[J\7_N[SI6'P]0>=HR@8=2Z8LTQP4/7CWA;BDPSX4W&N*O M1YP,AHZ4('C69[C[]4B8H3S1]ZSQXQ2R43/RRJ(YXH_%?XF]B MRR==@EDID!C'U#71[^7M_QU]JP3_53]7*E^.9Y_-JN*X)UL[?2`>A7B]P!]# MAUC$"]M2LD6#W3"$C(6]6!3VZ)N0]F([:;\<)_[PK*G'\;9^.8ZIYM7>RCCA1[FC(ES]&WR>*D\ZKKGE1]2 MDY?J2S4TV3--;;\G@6E&+$$X`HE_N`*S3YT?6MMPI4Q9VU%8C'E7@K&-+5D5 M_XLZID^G!;%K1XJ%!I\\VX/!96">4TQ00)/H.V=J&7A72',X1@Z4X%N>ST0Z MJEI*T M?$Y-,!L(SM"B$8],L"O%865NG M'"6Y=2TZP--,XHY:P5>Q[*B#'4>HX3MV,4..T$+3'A"7"`V)LF_X^F,H=(S' M&CF4N+]"<;/4:R/-K<.2SKV2NA,(ZCF`)MVDH0Z04R>NMP-(!;:['>1`E$\` M^8)VE``R1/*]`-FD:*TFD"$B)P!9:@XQJR^4>(7?L$.'LNBX/S4(DBGD-`D8 M*5XV&X)^M4EGO0GWK3_ZX?+./5` MR4J9(Y-<&PEMTBJ(E%/@:2'S@+WOB+AWE/,;1@=7F).>*U^TV9\^T>UF3<9W,@;:T*DZ;7,X871*0"(I*:*S(`,FI#9@\K./+B/<], MZ,L)Z:3Q4%DAK($$RN(B,[]A\NPZ,;_P?9L;].DPS<5+*G$!M@`/=:5'JNY M!AVBDOI129T!0(A*!D8E!;=%`)U6B$[K/:X#'5=!'9?>8SL06L,&*+'*E%BI$>9+ZG+J$#LH>ROT&\=56_R8>.7VXGLH4^XRE4N'?B)N M"6NP1T9MW])EAVFR6F8@6Z*7+)<-K=GD*A<-)>O6I%&F@L'[X'N,R,J1`_C- M'K]+U0L0S@S"UT+*5X?P/K8?^X@-D(5]CU@`Z#P`G5+9`._,X'U%4,^E7"@9 M\)P]GI=IUR0`KYZ1`'ZL,7R+XP`_UAN_Q?#CPX(P\.,#X\>'!6_@Q\;Q8Z46!@(_ MUAB^Q?!C==:>`3_6&[^%\>,#@C#PX\/CQP<$;^#')O+C`N\HD8NQA7&DZK%K M$/CUN@^N#4W]!W$23RFB3Z`#`0>V]WI M%]-_7!%N.8$:Y@)=PH7%TQ@IM=OL]9A0L!?=<:()FM;H+7+#[0:*RS(.)MV? M/`W#:Y0/,$X+XW!33`=;OJ3\NH1"K<&;K')S(7N)&),[II[PD#+AKOV.L@U#P:]>X^]16,6DDWCF/H!1V#(-@W!L#%Q&-)-PZRF9SPPS]=F M@P0V)B_!M.UUT(#IG/;]Z`ZY#S_5-I!H_,5\VN/E=K/NB;=&XH\AY`2S;Q7D==\F M"&97OF\_?ZF=3NT^^V-BV,G6@*;UVR><3&\[EWSULLOB#(AWD!YV7R)52/"6 MBY6WW<_+M=,4=@^+9;OKP=1]O,ILHLU_J8_!NUE5VDJJ@B$-V=.I[H9*%8RL MZ\Y&A;85[FVT?F+5*U'9FRCXAF_%SS!?MO6)\%\QLGPKJF68>T]"3YUW-)P; M<4RJ@T^NB6F-Y#4PP;1S>%\5[Y-AK/;I#/2XX%SMXZ>3JV8F?&[VXY,K:)I\ M7'36"CWPM\H&,VJ?;(0L!R6WL^.LA,AU+/L)N;WX8I6_,.GUI7+>,$,]K(=W3,68F3E1#J."=FUU MU%XU@/43,SJ4684>YETY:C4G2\Z^*YQRC[Z[@XF?J1S"-<"^44%,,N[Y2^TD M\_%GTP)[3N/5VO4MX>#W27/T_&#ITA'''H]:O]E#6HP>V8N)$UOXOD\>`Y"JP6'19=G]'K<7Z)K)>?PP%L#19=P'+314*#CL,I401N6BW&"1-RO,R"%$W ME&%AN.L/JR\GN,6?#'%T.J$L7HU;94:5( ME8B%0P]4"YB$(+5YD%H31QZH:T]-OT7<&+?ATF=,7HXW@3S$D.Q=-,%4>W?) ME>8VR3UAORND.9#FZ,P>"DES"MBW"VD.I#F0YF@YI@8I"#-T26&0)JC MD'MN/O]I_F['D=1@8A"M(<,V(4I#D:!ZK]ICF&!BE(FZ_EA#0'TAQ(<]1A#X6D.?M<5YM!B((TQXP8!6F.QH%J[VF.B4$* MTAQ=8@BD.<6[Y[*[-J(G*<3\(#BY1\0I'!SF)85KOSJD%X;Y*]S%0E%VJ-IG M](%YT[6#F]KOJ-M[QFQP1]`K<2)W?Q]4*J5Z@%AF]O'Q0UG:/6\V`OF;)CL2 M\[\X:&DPFQ3H]"GS)$JO\.M\,@&[=?,,*Y,2"190R3$/=KNP`L[9M"SF8WM' MXI!3[J"_YRU3[_[[9XWS#G"K'=SJ(#HX<#,#>[.DFU6`:ZKNBL`UE??.Z54Y M^_9.=7I%()L'T0ONEVQFXE<;CA:O&!QL&&$=SX` MY93M;M,K7XIZ&;+F.?C40JW1S%C"L1"S^J,[>79]^QX,"M>55WF,D M3R&7[;MA^+D_F-V60#XL$#H`0L$OCJ0AF>WB&-[[4.6;N:4D'9.:7RX*F>TJSME"G/"M":WJ MOK%&YGP8GKZFOT2,C8)1IR%E$OT#Z@N^:;SU-Y1;=0!L,ET%X^HF]OHPK@[C MZHI-F,/`NDKA0_,!.1A8/P"_A9%U\QT91M:+\VQS1O%@:!U&[;1<`&>T5QJ? M98.70G8+@^O:#*X7;7L872]Z='U'!*2^-J]+7&RWL"O^X3V*'H3/9.0);V,H M>0SU''X6*SO7^T[/FVF+UHMVN;VF)3J!8"]$)]10?+M8^$SF?L3U1?'Q=]35 MYLRA+?0Z@^$ZQ6;9"::T360GV3KCF'2M79[N$]`M>;P,PQX9AZ1H3>!1V7G4 M%KH&)U/ESB.5^RC9E-!(V#XPG]*AEUIE'I/N)=+9A0ZV4]+!@8KK@4QQ'Z!Y M0//`R5+<^:)R'P4T3VD'*HSF*79MDLHN=+"=D@X.5%`/9)#[`,T#F@=.EN+. M"Y7[**!Y2CM0D31/I6MC5':A@^V4='"@XGH@4]P':![0/'"R@A<6&8[[77L2 MG>;^%5M@8SBRZ">4*P\VJ=6J56:7NW3^9C(?6*R>9>*:;AY9["N5`PV[U(QM3%O[O;8MV134J.29(U,SW6MJR1:/9^; MX,)35*;3A=&36)JNW;1M(NDL@NWAT MYW;(WKCO:5J_?<))[(R]9RJ[-CT@MD2.L#N."J*NC1(')C+&J.!8POO,AJ8<(L46%03,@"64BQHYIB3'/K-"'`5@1IA*!=P5P'<.X.[ M"N`N'MQP-P9<1J$O_/,9;P+F`LQE1W3OX8APH"Y`70X;W[)C_6`Y4I99X9. M)ZSJ-#4#4S]@[X?+,'+(/_)BH#<'9.:1/A/^*6?Y6U,-$ M4'P2:NB\H^'<=IFD.OC$>5HCZ1S"5YYPV*_R/ADF[Z`9%YRK??QTXH"3XT!F M/SYQS"8?%YVU0@\HKK+!#(G)1LAR>\UV=DS8<1,S9)8M3,;"K`4IP*#Z,M\M M7?2&,BQ$O_ZP^LCM8?'G.V)VMHX:[>W`3Y?YZ2I+J.2MB=8$9U7&6=?XTP-U M[:D"P7^RAV>"@E6'8\(2(.!WNN`>^)WJ749>R_2`X&GEJ$#PP%N!X6G@0&HQ MO(R/KEYR=_$3EGJW/%\>_`%`?8J,N9F&R65\1L!LZFD;.A#W`VW9PM M:C/SGK`CGTDF1._JQ+!LCY`R/'Z\.(;-H<>1M]F@3T]/DKQ"^-NB5E MQP`A?ID?OPK@7XTHT!L0OS(W:R-=M]3(U:P0OR!^&0;T*L2O?<6O--U2OF:% M^`7QRPR@SVVLS!TAQ6T9W2P4%^'BCXP.10N$N4=Q%(H7MF]Y_`_LV#>436I7 MVZDS[C14C2/;&4V?K:TJ180\]G0L7NNSPQY>57UQ'UMC]S38$)[2E^NLP*5P M<.H0.RA[*V)(?/;_DK(A%17A!^IV0I'UL'ZR7)$IQV6"F3].#J8OR/3%#S&" MZ8LPO1*C,V#Z@DR_M\2V]E([VV`EKPH#.R9LT]XP!$X&3F:$D^UU^5LMDK@I-"@]E]!4:ZD2FO'H]2X)S?FX;Y\E MKQ/C-ZW?/N%DNK-#NOUEE\U!I8/4=NJ)LRV1*O2.Y6+E>T/,>="][$BOA05/ MII`&<^[5G//C$,*@)RG&(4*[YWMLD-Y'4<"Q#(8< ML*C;(H[<'B<+Z6'F=2/#JZ539+`D/Q"HQ2]UFB$%MS`C-B:"0#FWT&;V&-S" MC'GD1!"HY18ZS:R#6V@]Q[X:!,JY14X:^5>Y_,,E7JF#+:F,G;QHW/UY7CR<(:2Y.^# M:J^P2P?$75:QQ!^YX'W$,%]6\V(57XXC$H2%D@2N3P5>_W/+:ZDMJ64H_IFV MCH4JEBHT6H>PZK,_=/"\6<7S:R>8`)A_(X>RF@/*//)/X!7M[JWKB72:O#JX MR3GV^/7'RN'_TAA63[B[UK=*LJ5!P5#&DHTMN4V%?STJGQY]JYV&GB.`O'.S M]B]=1MV'*3I*)AUKI*O6ZQI+MQ\$:*.CY&QLC73URIG&TNT'`=KH*'F8:AV^ M3ZH:2[>G&)"/CES71TY'L6ZZ84[Z6E1\0:XJGQHG8\&W:;$:`L"7M[J3V6S>(CQOQ M-A-70,Y9IKY`(JHQ3&ZFW&R-6QYC:\LV.ZQ*ITVHM-#87;G9.Q@,-0TYS(.GW97!F_*W[&$P&K;=A MMH>+K)+TLS#C)+$;BYI.B(C0T4"Z.HY>X2X6B8<=!NQG]('Y)",)N7-"I[`! MT8TQW2R;M96PCP(;UX.A0T=!IQ2"IOWJD-ZZ'[VC;N\9L\'J?#6]8JJ5SUMJ M)E,9MM,BPT-$[*7P.("#NM:%X3B3VU:WNUCG^F.(78[Y"CR,1QQ",B-SRATA MW=A1Z*V:K(*.TL_C5'71$!>\-G#-OP2#E4,3`\)YX#F3*&Q93'R053RLG9QM MJ9HM6EJ@1M)/^-2+T$<(J!M&![FO:ZB>UZ(2KOOE7-JH0KJZU>FO:V?"*L7K M=L,#D]>(U-@K6K9:I]&H%MY$4P%=/RE>M=GB^;0`!]ULR4%MKSHWZW:4-:K] M7+QFLT5S]:P`_]P,SN4BHO-AP+E<1'3.%<^-7022UT+*TI=A46&CB%T[SV2`Y5VRL$MKF[#[P[H MYN7':NT^-$EJC.'ZUT?&:'L;XR8 M*".L3+(>OCF+C3#LV*Z8@$]X2)DGAR['LX-A_%!NTTGUK#:G@B4MWUZZ(C=4 M5$[SEJ[`S0+5>,*2H^V*D.YT8V"&4P=T,&2X+_?&RN@9[;3#W(.$+IS,@ENX M*^*S:+"#1)_2%5E%\/@!A_%@&PA,$Z3KW[[@]+)]U)7Q/*:KIF7Y`]^18?=* MA!P71U<#\-GBR93(B!&R_/5BG`V>F=!ZV+MNK/OXI'@!RN9LIH_96L]VM_WN8B;3"KEP)`P_\26BV2S`CZRY3;^& M=:-VQL0C5"Z">6149(9"]!:R?K6[(ISBCC^4U"((^D$D[F#V)I[S'^[_LW>E MO8T;2?OS!MC_T%!F@BQ@>4CJMC,#R%?6^\[8CNT,L)^,%MFRN4.1#`\?^?5O M53=%D=9A'935E!I!$M%L=E<]55U'GQ8+NI`+BPWVY1KS7V0)\?S'!5X9_TWE ML"J@LZ3SC;IQ'_*P.(`'K,]YP;Q+K&=2*S:SUBT6R9A56A:C$=;7#(>\DF+P`/:+B;IQ M5.N&19'#-^V)Q4AIBK`4RKFV$K>=-)G"DRN#.2'44(-RZ4C4G*%";L1@62;+ M!5-]WHQC]Z!I++-L:75H;LP'9L48IRUD*[+FYQ;'@6X!IB/',W\L,IOUY1YMM^JP?G2@^=%A\AS8]P_B#Q7\ZI\__>,? M^*&?_XP7Z`,AU3X=V,[+`8Z%A^2"/9%K;T!=\2ZT_V8'1#?\**V+5X8OA_59 M@(I#7PZ([4(FP$2KO]"!?^CV0O\0BW_"\EEB/OG9IPQ/3[85/1Q`^OA15`-O M([$7F#F.3RW$^W-%J_#GT*?F\#GYON<%X(ZJIN7*;S?UF\^-ATG;D^0>Z'Q'7B=OZ>YU_D9Z'*:0$AV_'O$V1>\3)=\"BHZ@,3M6E`?NOCO,K0 MSNK"'.K`/WT23?4\Q\K4U1Y2^ZOMCA0&"'"P`_TKISEYK4FT*+(6$Y1F[+?: M'PM!"SMPE;=U@`D>"Y;K3-AJOJO,P2,H-:B^BZGF;'[UVGZM7GK%7!KJ=:CJ M?V*7C216T_;&M+07D$_#WZNVACY`=0/5#:3K!B?,Y,%8IBOH:^\*]35T!7U? MU\K;%<1SD'N>$;V`ZD\)7:CYXQZB6M?"T,D+#LC/Q\>GIV=GBR)#AO_JVKX^ M"RC;Q=-E#D@U*3@O5MHRRLR_U5,6;@-J,1*,]FOM$9=%:[.SA8&[2MA6@+U] MJR,912K22KP6H20?BM<'W=C79NK#G`QR(C/FAGN=PPKXG*>`^I\KXO]I`I5) MK_J.1Z,#='+IVT])=EGKC#1"Z;S2^5W0^7JG78S2BRA"#D78?#2QE3&#%U$' M"CP"!1[N:I`Z+9,W"=MD=S=J1;HX):>UR:E1+](LET-0*I5;QBPGIW00EAS3 ML4>LY*`.^(JO%([PJ(X]0EV+>#C'D\W[5,I7]!";E&%>35>IS;;*5J]K*H27 MV(NLA,/R#F)(W)1YZ.VS]1N'JD2S,4IB2KF5K1;$W)XNZ$?X([]Z(5/NN&F1A^W5&WY M&)6:D$DF[]5=:3[3@J^'^W"%%Y M!Z4W9DC*S==..`J.E4.>6B%%4I:BGD(IM#5?/^I5HP?>&Y57.#BZ;+GO)OUWB. M6@2PM:+5]SJU0J=_RBY>Z?Q%.=UN^2S"QJ$J42BM)*:46RGW=DNL/,Z^]+GE M-F:0XH0]M>%VU6YFO/-<0!&R7]_!HYM=U;"[VXV5EI9%2XV]MM%4TZ[OY(K+ M&;?(:JC)LJU!36L@>1*V%((`QE*I2ID%<8RE1()`RU M]&"#4TEK7Q$^%K^_@?5N#<++-.>\T:7AZQZ/4$+?0:'+-"-1NG&,4NP5$A?] M4=,$\48A\>D+7ONP%>F,&J'=H1':5J%W\RDU56JZ#C6M%W6_UBY.(Y0G92NB M`]Q0A^(E>GODB=[C_TQO,+##T/;TPQB9A''ICW;L:-U7KM7]CBP^.!_ MHZN,"SVI6\E6)MD:C99:/RZQ!RGGV&GY[,'&H5)+;,LF,:7<2KFW5F+EG'W<:,90U'U`2E#K%52S7>@Y?N40E'0)7"F&`*^\ M,*JR@>]X+W@[!/%Z``\_%7S:)>Z9@4''<^^K$0L&:FAP]]8%%*%]OZ@S9G=M MV%'7VFK846*O5%J/-[X,5^>.Z:3HSJ`7\V MH5[;C9EUZ;-`+(4XH@YU37;SP%ATBW#>0@)UY'CFCR___(F0W[#J6_I\[(71 M$7-9WXZZX34+8R>Z[,/_/2?&:B[[WVE@>W$(1:^2$:F08'-0VS7K?ZZ8R74068< M+XP#%AZ]+,1P]]D.[X"KNQ/VR!S/9]8W&OQ@47@44-=BUN_`96";X=4##0;4 M9,"?29WP*`Y!UF'XC0UZ+*B0V+4%8W_"#[U"+&;:`RCWN5)M5KZTA"D3DED2 MOG?%WV+VW5=V3YU3`"QZX2`-97(3]T+;LOE^NOG8K^IK`>":.:`7UJTW%/AE M_P:DQ!;A]"W2FYT)E$]M6)`(X!UT05TM5-DSA]XO0L^7/K3-?OLT5LFH[F3A MZ1GH,W7^RVAPZEHG0-!"S52KNE&MZ:*A:36.VCSQS'B0%KF"+N%99_"WA;#^ M\H@>L97O@^<49,%SO:/6Z7F\V MU\SW`K#_]^A/%E2E_[(PU_K$&E^W>V8[+#@&L=][P6(B^`HQ"B-=TV0..BIF M$5Y7EH1WM^1K]^CRNGM[>7U^>I-M-E^S M:-=V'UD8'9R`IC]"W8_LPA-NN3O`@U`FB%\W[FJ\]7KJ5D9?G[O0`-?L:SO\ MD?,]9UX`<:I[^FP^4/>>P>,3#2SAA=)"_V;6/?I[%D)1SFNNC@L/5%B\8M8< M#JR-*JAKVM`1O,&ME)!,JBG\G=KN5R^$B"E!C/LU=+4/MI]KXYB&#V>.]Y24 M6PSODQ3L;I@4'1$Q)_X-:>$_AXK`^D37P.#-$_6+!?Z,VL%WZL1LBY$?C_IW MW12L$Y&R6X*FK.AON2&H:PL"G[1]T$U.0[L2AZ'Q(]*&6^=FF>&W,C-=:]:' M!,W1UBI$S9TMZAF0EJ;IFID,<(6R%RPJ`JE:H]V<1M6DQE8B:VZL:HU&;26J M\*0>,3YTB[MUBD#*:$T2W^2&EJ=G;H@:[<[RY,2#F(]2G#`_@%JY48#?#N/6 MP;6@KT+J\C?_^U7@^2R(7JXE?L>T/5D6SV>RT)M!?"&'OQN[$T7- M3N/=N;W$W6F0"D/=#\P-N7=!S4"GTGVDMH-]"`*!&^JP&V;&`5\QV+7^%X<1 M5@S=Z[(/:K2B)9[.=E$$;@*!!08))]E7*2`X%H7@;\<\*`S/7:AO&'>,I0!IA/6MUUF)2/W5_B:&S'^#6ZP#<"L M!7RJ!FU86(@>50W#6%:5EB5XT^C,K3Y50V_,L4 M[(VJ1L>8E!@43>0F4)A?+6K-^J3H6@H0YA%S;33=.)S\Q6B(C_O[GHO)^8?1L,!E\$=,';O_8KOW>:\Q'V"S(M\2 M@_6G&S"`Y6],N'#(`S\?`C@?,/JRO5!F9"::A#E[5@OG%:5"I#8V\+\9DV,L MG45(C,S.6)QBL-I"@U,`,*O8FV9#MEXU#.(V;F_:RX;)$B.S-GM3E2T>+`:L MU0W.LJFYQ+BL9&]:LGFF!5+GAC9Q3D8.ZC=K+E<8A)(9FK79RZ5'?R5'JX`( M;0N!6<5BKC!>M^Z8M;%AFZ.W9.M%!2"S-I.C&[*YWF+0*L#DM+:PAZUBX_76@32W*@3[HW-G.XC]C^ M*W:CXQ[@Y%GL+L]MF99]U_`$TOS8-:.80U/%TXT.<&4(6(?E3GY:YMBG"R]B MI$:RYUV3F]CW':ZJU"&IN$E&WDNR*[$DW@WP9,NKUXVB3]# MW"!'H@;R MZSZ!E%!@A51/8VF?G`ZKZH.S)<=BRS@6&FT:S[0`L.4KQX,8.9T/`6,$7D0/ M(6&XE9S$W;9B*6:MD?06G%RL*.0)P;$?VBU:P34QD'L\-6'NI'^80]EZS,3 M5WTY+_SUL+W0?EZF-7VOIG7R[37KS*BO<*E.067O2*`J>UI M33W?8+O6F@:,LE_+VB\>.I!?Q<4;_R+LV8<`@HE>G5@3Z)T>X/]7#'T6RH)! MX0+S`XA0`B`09(%1"+=AE'PPM%1,Y!XMGI=40\':P<>4\%V[PC1U>WB4RLA= M=0[!2B5'#F#[WUX@$TG,*%>"UJBWP.?)?2$!/\(`C00W&A3#)S"?(1NRT*=V M@(>WQ)P"<0[%?;+B/`2C*PQ+PH@E&.DE9TP0:D*$)TB:V`7/9\&TE["(AS5; MI*[MU[+TXW>Z/NI87F"!?PY>AKT6B@@$+O:_[P-YN"]C9.:'B.)O:WA^!AF( M`S1(3YR@0>Z3(S2(GS]#8\0@L,M;F1-WPGH`9W)X%+8L-7R,MX1@-)6\EJN`# M:<^@J!$:;,/XR&6;^Z->_[B%!F3SH2BW+*DA03]E0I(LQ.()7PX=EJ(-%]%, MHM7'N"O410G"+W[$.>^3:;Z%6H+I-L%\>^38^G801EEO,[13J6-)HJ20%V=\ M.78X-`>!W8M%;(&!F!@+@?"%#X80'T=#L.2'1KV5]TFUFC;+"4)EV)C_ZO*C M`;.P"_(BEHC+Q]LRZJ_\[L['_1]/;4%V'LA>4Y<"`2NH8<[;@#()QMHQ`HG^8.A&<+@;P9] M&?F]HJ&EY4PJD)"`&0KM0Q$C$P'KQ]PB]EZP%->^&&)8$7GNO?8B2&.0GHF# MM3R*4W%X$WYZK@_N&0*V\#L0-WA%4,@7",E"95768%5ND_1&C+6@5$*08"1N M!T.U']T59J>C3R%F45!T1NAY`OX-AV(RK_4]H7<\IT%#XZ#!.2BW5#-#,O1WSRW,TXR'CB(7OO?Y9Q>YE#]IY$4ST(^C)UM4>C!D.=S8:1J;I*?8QI MYDQODV$0]HXGM2]ZW;4)=7!YFNXI,V M>+=3R=WAK[8[DE@2RX?_4J:M(--6^N[FKG MWXH5+9E9V;49/#DN6GR?&\3DX%7NN\7DO$J\OM=L%7H]GARJH-1>?K4OV/&* M[O">H&57HJTM/)%#QS8?IFQC,)),(X]6F_2H^X-$T"JQ&)^%DWNX7-[L:Y,N MU=BK-UJ[>^-LF415ZQ0D*'7GZGJYE?QVM!V\2'''QL-*(Q>EJ$I12R$7V1RJ M+/=-JH'<^1;+>1%UU."M&L7:X<';UIYN=-3@K5+[W5+[@K-V.11A\_F\'#A( M'I?*9"[Q*0,3RG$ M)%607/HQ.ME&XL:RCC<0W<89BM+OQUILY=.Z1U>4`$LNP"U>R[#%VZZ_#L\& M4+NN2]3SWYU?)=-=D^E.[7+:8@.O-A(K(Z!DJF2J#/O8Q*5:L2?!.*%:6OHN M]J@TX"AM4=JB5@.KU<#J6`>I1DP7FD*7@E>U1'*)/:A&4ZT+5DJ_8TJO%W22 MB4Q+'C:_+G@;XP5^\L)6I#6[M6%?5P6B M%%4I:BGD(IM#52.II2ZC4U>JJ4?L>4OJBC1-3HJ3I5H<1V M4G*HU.;F,HA);6XNA9B4X5&&9[O$I`Q/*<0D59`LRPB=>,1KFE_G)L.W$E\^ M+>^5XIE+Q+/7AMLN8:]73>(]\@XS(WY!/##R@T6HQS&;?ZY&+_N[H\?@V2/G?)-QJ8#R-64#1[I-M#`T3L,(R9 M13X8^PW2&XEI=*.\Q7H1,3TWM,,(",>7'UH-+2M3`^\\)S?,M;V`7'@1,&.! M:KQJ%ALU-$,[G/!]HS'W]\8AO[O^@[ZO90DV]COSU]'8SP@V_94@0IW0(WRW M$^!BNY&'_X&',"(!C:#;/%$?`8D":D)WB7!<'(')0CBQ?NAS(]0 MK-_'O@5?!8T9\H!>"GTSL/FU M]OEWHQKFZFI#:RM4#M3J%-^G4QM5X$3K= MR+9L)X[L1W:3AN2GSZ836\PZ@U``>T`<)96=TL"%7A9>L8#W$6@J?J4>B\%> MR_%3@UY9K^>9*8+`=^-YHI_;TMN8V7G5H:X&FBO"B>L-HZI.;G.QPWFAY;EX-7:\MWO`9M8/O.!@R M2EUFLI_&1NF'1R_ISW_;+,"<]>4K>V1.+I0ZA00<QU5JUR0!.('638*9ESEWHO2$O MH&\8NTYID3,VK743LNGBL1M/?K:Q!S?T^G@V("&8,O;@">E?29#;=`]NZ+75 MM.ZR#^]]+Z3.[X$7^^#(H+%=F>*WBQ#R1HYFE\T4P*H`OAYI+:#PS9G7G!#G4P^L[OQ MZGC,-16DC8(IH[=['^QV(^JJ-]OC=DQ*.&74Q`EQ5VFPVW3D56^VEM:\HSBT M71:&7?.OV`[YK.X5"_"L4'H/_>V[ATL&SI,Y:%$*9]7'D>W<&= M]J*[XWYP]4"#`359'-DFL')#)S-K9+FM5;YH^YU.9\3GKHO@^OS@#X[`>MH^]0<]V>;25J>ZR_Q7>W3Y0%VQ2 M4O>%Y_)5'Y[C9*I/^^X[=H?QF:E7';]PYMX?NV*[T5B>NGG$<,;=MI)`_S:@ M;MAG$.U;^MMS?.O%IJ[/@\Y4\HMF'#I1(^7\77I4&WI4,A"Y3A#02($>Y>KH M!E#)O0@`CG$5&8088O+ILC_M$TPK9RO-8O//(VCC^^MZJ M_0XHS^PII\KVB'IV,DF5$R>SF7\FR1U[]]3]?^."2,CB#D5J"-(/^^E_`$A) ME"5;3Z0(D->9VA-3$DET7Q<:C4:C<5!]6-T-S^"8]]0(?N&KM@D4CUY M8>]0>[9W2'B7$X]%S%&[6.@<$+F517Z4F>;.=Z*X/OGPZ0=Y,K\B5V<79^18 M?/.*#(.0T,DD#![4F.$]RKTUY[/=/N(!-N4CPAXEN0WJ1-VE-OP(T7@T%3,K M^3WEY.?667O=3J"GZI+M'@>AW!!$_71G+5^Y#6@@''U'Z%R81!:Z-B>3!4V2 MB="RL-=R[P_Y(ACDDXNQ_"%5^Z:&<2A+'!/V,!&7G+@17[A#6/)0[4!*=OGQ ME>T7C5ULTW"ZD8>(1\6>>"8-Y>.2+$GYW%62S._BD=!ZLOUPP,3K?;73;#4# MNVIS83L!PU%;GD8"Y.GNK6R847`OP<@5STT-Q]GTE\&]S\GY^=GY/Z8X!F)D MC(16U,N7]RD*J9]%S<:)=U`8J[^D'LZ10.5CN6'JW=_/OLBP1'/'2C$Q'7Q8_VS"A M??&V>]5S50]26],&S`ON,^\C2IXM'WTO]".>I*CD"0,F1!^QY"WR'CI]_\Q4 M[;K'-*>CT/(?/3+N2+K3O]'XQZR(4Z)JFWE>NG'\[5'C2%WS";6GU^G]Z?Y] M6S"63CA[/?WC3?)@TFW(C9YOLEY/J[NP#WU-,:256]Y[[3.K-H>U%7X`Z*#` M`T`3H$P]6'#[^K1B;*C`X9CKZDUT#99Q[V)L4^-30"G7#0NY'KB,ZVP9UIWM M.9-^L/#T3I3+(KR'V([DQX49$#V*FQ3?L?K:5)#2M>QE?TVQFS++7@K\&OL; M5CWP+]_`5LV,_A8$CIQ[',QHFD&777VL.;@8^\)=V]I=D?/&)QP0/ M*6)[Y,4:/&P]%=)XJS,;*9)^6;Q57#'0J%K>>R"U26/C(:<'%/Q(;U5":M6 M)_GPU;.9M;?I4K),4YVWC491Z`[B)'\S.8/BB3PJZ]D)A#&*R%^QZ'S#1]5^ MSB94G?8@8]"WOAN]E#^4<_?/V-$'ZA$0A=>2[DA+E4OBT1OF*^ZS>^?Q&F?WL M1T'XN.J'W

/$V,;6%P+TL6O[P'8DG!$_JH MM#MO[%0SV3>MDG2^KV)^KQA1-[M=]*>9M+L9*=C/E^RG[\=I(KU<\.94[D*1 M5F75EAUI"=G#A-EJ"U"0[HQY`ECVK!^Y%R=%F3VHLVZ8.IB&GY%_TI6[B%:] M-J)_,I\(46PF]XC\3D63P\?,(3]J@TCK9+H%*3V>8D$DU1_36MWR/>F>D/L@ M]AQE4=7A/`,F7L2%5R.LHDW5F."XPR%3$J@S>.0K0C81HX%4F$CY"Y;(4(0B;'3 M5WOJ$G$3DSJ(J.O+WTMB#@7]`ZDE(8-KRSU0B>L@7GC/Q,BOW/;IGJ%5V[2F M7?:)(J7=IA-U)2U!?]31UC!EH;W.%OE-_]&7?K+%*T1M,R537N6.>4($`E-DC/_""V\?9=&O` ME!U^,NE*IUMR5R]9.--P/N%0H_-8&$-Y_WPG9V:\<'U;VBZU0U.2]MYG(1^Y M$S6A$WQ-;07&]"+']!F(N![(XTW%-">>J/K:JEEI.VS1/063!*%N8S&ZRZZC]M$J?U(\0MCX M0)CGI1VMJZ21W?U.F!D^HZP0*/:30]1$*T4+P\?I=EDF3UZ5A'WD;M(ODL#$ M\YN1Y6;8O6S]$^-,YUWX5+3W(]<<8]R=I3) M$@]54$J7G,@UZX5!YJG)(.(.UUN`0+Y*R$3$0YQ9)6P:K1ICGGTX?W[,:F6- MX19C5B][VW;CE=5X8G\3H6[3NN+S&B@OCPI/B;B,_K//E0Z&PV3X4"> MLD?4?%U!-&$JMT"]F[JB`^1H[E640?*;GVQH_JMGF^S`U;&G=\ M]@"R@Q3D[!V]:T[/AWBYS-2>`A:GP`_"C1%??,P$PLNK%WR^=,Q2L:(6J-8D MJ)$>K9'$KTM3:V?IT+EB13V06N?GQ);)66NCLK2Y2ZR%C@NN][Q)?5;S%)OY MXDO@WUX+-_A2!O8.K=[S0L>MEX4]I)*?L[[%:G?YR)`#2%F<6J?;T*[I0^;+ MK_-EU?(\L$Z[4%6ODUPKG1=9+KM1J#FNLIJW-!W+YR%70]&?9^&W+S)`]O14 M^L/2N=A9VQI1B]3QXIO4L"#/!YE6%"G14%O]C4X@*$YVO=2^7'3[L]KB?34M M5OJ>>M2WV=6(L4B\=;[`-X^P\/>/"Z/;>0S%"^G`=(_DCJL[Y.JK[^E M15^?(#Q5U69=J]?J5Q[F`UNK5K%C0D8N0Y2WHS=NMOZF2^HE!CLVJJF_OXCE M:-%DM^X`JIO[B)GOR@QK]@KMU"O%/;!VUP2(JJSIPX2+5KZZ['C]1N?<%2!R M<6I6CY^_N-Q5.ZGA8EW4E>(6I]WO:7+?=YG:EZYP)=F])T(W>FD]#IQ/T M]MIVKA@?#]C..=G6KJ@UNDM'P)6@T+4G?;8;[27[G%L[O[/0#82_K!)SV25+ M_EU_N.W&=#C?D+2K&U*0"-L=M7JZ[(+L(4,P'KO)^2_R`=.L0%O.'AZX^]IW MO;='41BSHRW)_4N.[WE!-9N_!F?!F9J1J,Z"LQJ+A\%]$:/B;9*R*C/V/OIW M;ACX$GGJD3]H%+$09\,5L4LT25H?49YD0TXWS,B4QV3;620_D#M=9)[X1.;] MRCS@"95[H66^=W+D5!8\VV/4CR?J8#6NRJ82/Y;.EDSSG&>?ICGQLN>+MZE0 M?)*N^3T6+E%`?KAV0.0A6"$9,IG0["59^E&R(U[N@4O>Z='[Y$:YX6?>&O]V MWGIE&N@X==>>MBG=:'8JMXPX\Q;.SA>3VIF7@?7E3CZ5IKTHJM(&H_:(")>3 MJ:LD15Z`1I/SG.5)62Z[FV\6&"5*#H.!VN@C#!J7^W"573LC7V6Q`&&87">6 M)ZO)ITY?./V1E#F[<9<]V$S\]7-[SLV%!/3%M-M53Y/9L:N>:'66'HF$[>)Z M9,+EP$NV-Y`[*@;_6,SC/>J.$[9[`D-9G"^0^,CTY@3A^6Y3Q5&>;)U2&[1E ME0S!,'=&-=5_11]=>E22-KU@A*<GF&I4?_71;6F.)(VIK3F<%=]1.AGFO MLNU0DGR0+,3)'OI[[+/Y;:V&2O3NJ#8+D3A;;N^LA2NV57:6FR:;D&Q?4:\. M67)ZHM#'O,$J,T6PV2GQ2/Y=''UGEQX`D=2A)]^=/-R'-K)?B@!(_:7!"G3/ROR-7[@.-IN9@*+?5I:5$A(X;Y31XH^GB2@WW2]7P]@UNYD4)]2M^$4>C M(%0[C;:9Q;:66M:Z%) MR9MV;\U6MW^ZGZP46OVC_!9S59_.<3WY`U;OW_CN)'5['2[6[]> M#-\C)N9P=RS)@/K*HF_#:_HP2V;Z+K=F!OY%IFC9=2#75X+9`3(]12S.=^>XT$S M>*2%&!?P2,^E.I;S]E=),0HQ25G62U#25D1U/3FA?[ZB:G$Z`SA_'C.U( MJT8W&O^8E>-/:JS:S//2(L1OCQI'ZII/J#V]3N]/:T';0E-TPMGKZ1]OD@>3 M\^Z9>/:;IR9J4;H7RMNOK)[<;(OY<;`HU[S[+QM M_(%'.^NZMTN5[OODY8/`$_Q"]&?'[]4>ZPF%\^#247PNE& M3OVZ#$X_*6<.TP;3IDQ;9]U1;CU%>UBV_"S;A\0%%/[>'+=/02AN6CYS=!"2 M7Q87'?9YKTR@M3.EE:Y#ZG-/^<>%OOEB5D6WB'.8T2/1(_?CYU<696J_RBFC M7'`LM$O(&3?+^#/4SW@SWT,W"`M]_14+[UP[8X`^R%2>Q>84:HOD(C.L03[6 MP/RC5K6R!IGQN<@N\"\_9$DUQ3D]?I.UX`M]JQCIYW,JM5U=G6E4Y"MEAG.4 M\3JNF!V':H\$NG\.W3_7(]70_5>ZYX?MEYKI8NL.1#EYP+8T#WK]%_2T(;B]18WWZ@!X,V1 M,/]R@]+;H^3?V7Z7S&Z8H1?0Z+4<;V;?3BM)'+=.>LU>D537'_)B5LG0**:R3YCE&"G2*$CI%MZ%II[!Z;@^>Y\;RI*<_W9'DCS[64DEB>7&NTIK27'G;N`=:T M<0S`[%0*)9@=$U""V8'9J11*,#LFH`2S M`[-3*91@=DQ`"68'9J=2**7K4T!):Y1@=F!V*H42S(X)*,'LP.Q4"B68'1-0 M@MF!V:D42FER%%#2&B6=4KU*4U5RO7^F6+5J#'Q;=RPC&;!A$#(2RJ/,.7>' MKJU.T-&[FOVF;#Q\);\2TT7[.6QR`3B%[J_AG:KW8R&]OBF'.%G`3@ MPRGI?S+G&\/,@@%@P`YU]DJTY=UN`^AHBXX%;+3%)H=]>Q7&IH]Q[5#U$8MG M0%[QB+I40[P8"QDCG@E$,(<,PV!,J&TGAYB)#X)GXQD5#^>7<"9!H7)7V4B! M-6`-6),/:TIT5IM-`%HI0"T`NO.D44M`CZU6OTA($6_7&?Q"BP`!>IVA;^40 M@`7V:T\,T1+[/2O#OYPJ4S7HM8M"F9E<9)Z'6+JJ##H"$XB!W"!WM1$#N4'N MRB(&6,ANH[&Z!SGX#Q@>"H?QCS.W02.29##\!3*JL%8TG3>S-B'KH-JZ0HQ*+N@ M5KB`J""J$;B`J""J$;B`J""J$;B`J.:FFM0*%Q`51#4"%Q`51#4"%Q#5W$2\ M6N&B6]5+XY/JZE(T\SWUJ&\S0B/R>^RSN=9;C<(LIAYYG_NOGV]T/I4.LN;` MDY\+8$-Z[K>6-6):)]UVJTBJZP_Y;JO8Z!35[13='BJFH4N@2V03FDZLSI[) M,.@4Z!35ZA3623./W1[H%.@4VW8*=][%S!D\KSS/<]A'I@7R8#E8 M_L)6KD:A]:/!\YKQO*DISX_WW!2'6MFHE8T".>6KRLHS:42,&,0)XH''4!6G M@)`.8-(;)A@>&)YJP03#8P1,,#PP/-6""8;'")A@>&!XJ@43#(\1,,'PP/!4 M"Z9T30LPZ0T3#`\,3[5@@N$Q`B88'AB>:L$$PV,$3#`\,#S5@BE-JP),>L.$ MLX!FUQMGCJW49`GU@Y=R1] M\^R\;-[OM!WT/GGY(/"YVOX0WX_X_/JC[S!G?GF0^IJP+CA$ MK2A38XQ"MK9+*%.M!U-1IEIO4P='JF!'JK/&7EF]\D?X(ORH#_$X]FCDWF4\ MI$]!*&[RET@S",DOT[_W?V\8,M]^G+_U.J0^ETT)BGWSA?.?F$=CH7F.;H%N ML9HD7UDTU]J%'<4T=*E7*"^_!)RSS"2&^IDIS/?0#<)"7W_%PCO7SEB!#P&/ MGC2G4(,0,L=%E\RG2Y8=S2MXI"J2A__R0R9$_F\V@/`;=?UE9N;Y5C'FS:,9 M-/R3173@%2OHQ[]B-\J,OU?,CD,WC>%6\%/OL\ M"N/53F*>[[ED7"!+HZRUH9E1]P/EHT(;\,D+[N>O^R=S;@OJ_Z6[B8B/:A=U MJF]\=,-Y%<*C("J("J*"J'E-BT%4$%5[HEIY[ML%4;68MVBO$#,G.45$.8[= M3,!!-,!S`Y^_TMH,:A$5,V'?1A%\:3:L#M@!=CS+CC;8`7;`=H`=L!UUW;,$ MVP%VP':`'1JQ`[8C%W94,=>J,-N!+(#DG$$$=[4([M9W%6+#&16("J*"J"`J MB`JBFH4+B`JB&H$+B+IG;`9$!5%!5!`51`51S<(%1-TS\`ZBZD%4),FNUI<@ MYC,+`'F=ND&F_[->7"IQ?8?YT6MRJGY6Y,K2XD+2>^I1WV:$1N22V6P\8&&F M$I]U0N1*$Z&^(_]H%69$]3CDI/@2IY8NLN9`G9\+8$-Z^O2S&MI0/-G&S`JD M&B+>'(D!XCZDD[='R;]'TV8[[MVT&4,OH-%K.2+-OOU%?"W_/FZ>G#?;15)= M?\A?%6(`T"G,[10]JX\N@2Z!+I$=)YK-P,&\&RZO/\A9H#II7GN;GA;K\H'G-:-[4E.:=_=>AM$#^<-M,BE]B M,G.ESCS#J+VJK')30X#2YD$:H*0U2C`[,#N50@EFQP248'9@=BJ%$LR."2C! M[,#L5`HEF!T34(+9@=FI%$KI\A10TAHEF!V8G4JA!+-C`DHP.S`[E4()9L<$ ME&!V8'8JA5*:'`64M$9)IU0OXXL15*ODP.?QA-H1"89D$'/Q&\Z)O"O@;B3/ M\2IL##0CNW`JT;;5`$O,";4:.>P!KC8Z.9=43V`[7)=5"OKI0=8"J48AI7KU MSQRV)E0;''3/6C,@_Q-1P``P``P``\``N("HH*H1N`"HH*H1N`"HH*H1N`"HNX9Y0!10500%40%44%4LW`! M4?<,;X.H>A`5IS%M&86ORVE,WZ(1"T6W'D]"-F(^=^^8^+6X9N38"SA_109L M&(2,A,SV*.?NT+5IL5F3>J3P'CXE2,OJF\?]9J](2`N&L;0B^I4`OXU"V@4` MBB5_L`:L`6MR#`?H.'CT6Q@]JH5HH:%'J1884#U/?-L_RA1?:9J M>86*JA40NA@+[".>B?AV,&:Z56I/GN("H(*H1N("H(*H1N("H(*H1N("H M^^97@*@@*H@*HH*H(*I1N("H^V;B@:A:$!5;3+>,PM=EB^E7%A$[#D/Q'7/ M.T"T4H@>M^$_'2#\I2/T>V[OJVU7UG:_YIY3(>S7+#7N8F;XRCQK4;JJ#$J; M`&(@-\A=;<1`;I"[LHB!W"!W91$#N:N8KP3$0&Z0N]J(@=P@=V41`[FKF)T* MQ')81*F%JO):6:E6WNI[ZE'?9H1&Y/?89W/=MAJ%65FS%F'7260=5J(<,/^Y M`&2[9YV22^FT3KIYI%[J#]]NN2&@L1DT[O9RR&73'SR0N,HD;IY8'52H`XT- MI[%UTNSGD(BJ/WR@<9$T[C9*I7'W/(>BKYBS@9FY,_,2EU6B`F6"F MALP\WO-X.A2,1L%H+2V8]@JQ\ES$%_::.$$\\!C*\.P:&``86H`!4P%3H2\8 M,!4:@0%3`5.A+Q@P%1J!`5,!4Z$O&#`5&H$!4P%3H2\82<088&@!!DP%3(6^ M8,!4:`0&3`5,A;Y@P%1H!`9,!4R%OF#`5&@$1GT/D$DNJ>#-[.8TI6GZ[2K) M-Y5R(?]MG8PO235KZF1=TR:Q;T'Y#@Y'>>5 M>-I$-N2$^.(5U'>(3?F(#+W@GHR8@*17$6WKDV([9\H%2,:(872\6(MU!U@(^P9(G\LD') MP3ZN30;,9T-7?.!17]W-WXB',?(UB!BQ+(6"[.12X^+%CM"`Z_&S3:@V[1X) M&P3B;X\L!3=YOOMENQ/)7OSZ2\Q/;ZE@YX?L842?E;9E8Z_90_3>"^P_W_W] M;X3\.O\UC[X-?PL"AU\)W0H1?9G)^(,-WQY=QJ%BTHTE_FLVK/;-=7#3O6DU MU,41B7TW^>&_Q!_6D1#>=L?4XV^/3KM'[]J=;C,9-[)M6WC;#DUI[]*49K/? MS[\IJ58ZV:9TUFJE>7Y>F%:V:TJS:6VO%7[A.Q^3KLMS)$N_UVNL:DOV=;LT M9B>ZM%O]0AJS$V'ZO>9*E'+2S);L;;>M[1ISR0;19Y]'82R'ET_49A=J_%IH MU`6_^3:\:=VTK/6MZ`OB=AI+^#SWGOU;?+-X\\6#RV_H(+KY$OBWURP< M7S%?C#32U/++6!C>9J/9N(B:9XW&=Q;:XHX_V'C`PG4J[G6TE\W].I6MTZF: M;'/039#2:N1#RL]"H)#QZ(?PR)1;YJ3-H+>L1)HVL_)^_OKIZ%WCK-%\ M3M27A-!'^(UYO%KX3L=L\3>F^FKQSW,1?RCF/,[[Q,G^+GQLT4'"R/VO&J.$ M(R(G%U\29WYS9R.CCJ>/YYM447=[DZROGR$SC6155]W^@^52G*TP17V7T=2K))@J)_X?0N:X435\ ML^5HV&[:,%.C^[)PZ\YZ:.69YL9M/7"4Q$9CAI/M_;V2*&J,1JVM!Y[=-/I! M*"MT![%\!G__^'$\\8)'%E9BV&EOX$D_([\Q:MMW;&FU]%*2*1UT$XMGNMKV MY5:GW2M,27))S(Z8\X-%<>A_4XV\$$YW5(UHIK6!B_*\"DQ2WKXD:S:[.JG* M,%=8*YKI'-*TK)9.JC)LM-32G&DY9C8[&XR9!^^2QO!L`V>V&LK;VYXMIS[E MJ:KI.K7*,JV"0];:8#Z>%5IO!>W-GL[!U6&88V5MX)6:HZ!]^3+-3CMX[S%E MX&I62D'[FY>R>H\I?+$V6!,R1T%[FY<-?.9MM/&51=_372KIIY7Q8YH;#-RK MQ3=%:?NOMFX0VC5;13OP:G;O;#_;MPF33?5O+^S(O5-[T:[8[2PY=O;[Y#,9 MYG7]6/P\O2_P.1B[&6/+T_WY!N,P=/^2[F53$O4S9UOM;S!#+U[YILV[-G", MS%;:ON-;&[32R<2"L.7IOJV%IV>R[O<9WK10OF%QH@TFNF;K;._96TN+X4TS M6I5G8FM/V!(]BQ:47^+PII-?IXL=RF.#I=E*VSNG,8%.TLR]5EHOL':3;Z#*J MKL_2J(YZ]L]8:932;TSAR@;KB*9H9V^KLM_X,PG%TY(JM#D6%.VNV-TP?].. M;=BR`.*JE,GGVQ"Z=^+S._:)NN&_J1>S;\/YARI)>459+ZN9UO5:JY%69P5, MZ]^98%:/['K()=6?E0H5= M86'(G*12\35]8+*8J++N/YC-Q,L''N-/IG'S5LVKSOUP^9\+"OZ4U*W^F):M M%I?W-'2>/.F?S)&UO"\9%S^=-W3^HN1S05*>_G3^QDU#;"LBG,!F?VR^REKF M4WCV$#*PV(75:FMR-1^&MC(6)W9G_]T64A#>_3XA=TQ;V?CL\:R?0K97[$L M/K_8ZNEO,[_D/V1!^%!`:J15*P^MV6\^^Y,XXNH'38"SL5E[P8XE.\5V,6$+ M54[OZ62#9W!9=TN6W7K_F-JV'RPYK(&/W,EJB-(?EC!LK5@;.A"^F[OCW?+L M^?*4K23_M[5J-Z[V2LC3_=5+`]7QL'(P(WT@HXGOVUP^8:-$*.#Z&F31X/GJ MBPT4;:/N'?SJH=ZYN]MX#6ENT&6RVCM9&G/ZRI*IXU M5=,?7-AV&#-G^EC7*/_*6E6DLGREP]$RL:O`XS(`I+7V[&HD!C9Y$(\'RE? M-^DKBS[[=\(+D_>5Y2JUV^7CLG&LL-/(YZA`ZU5(1!CE(. M5F1%,B<0*-15[:Y(8BI=Y7!4S3-4<%.UAPA.:FO;A>Q285%+40&/F#IC0&U5 M&GCN;:+@%^*YTS->]QR1JA[5S<>/:T&)]UY@_[E- M.O*[__&B-XY[]S^WT1N2_DUX].BQMT=C&HIWG7IL&+UN3*(WZ77HWHZ2#X[D M77__V__Y/_+&R>)MZ@=#T9#3(1V[WN/K:W?,./G*[LF/8$S]Y#ON_I>])E9S M$LV>I1XFOYP^SW'YQ*./KXGK>Z[/DK?^#QU/WO@#/GDC?_Z+_'VV,;],UC5M M$OMV%"O5G-Z'0N-R[!":W;C-C6W:/+_1FBE.'I-,SHF2Y*<'.?%_0SZYONBU M+O5(!O83,F<#)]1WB&02450BZ7#"=U2#Y,DI%?W??RT/4&8A,'L)LP\LC(0Q M(A>#01!%9)AX'H3'`^XZ+@U%AR1*C>(A43#[7H[RTB.0'T@'G+#45U%=53HK MG(B?B^;*@[C9PR39A"$_2W['Q?-F3YO=+'JV^$9\+$@1N;8[D:9+OIF%PGQ/ MJ/]()K%P;Z@\=G+P2*)1P-EB8^_51T.I6*%5P;NTJ?([&C+B!Y&XC9%_G5V= M$2?P/!J>97"<_74]8CPCS0FY=Z.1O#MY*E71!"E0),CFWY*?K;,N$8;/D]LG M:$1^CWTV?UJK<4*D>5)D%S_M9']ZR6QEBC,_M]3/VZK%\[D*H9S8E(_(T`ON MR4A83B%4,%3RW`GQI\-I^M'LIYPXHF-MI'O9/OG2D-E!Z,A7"E+(SGDG.^=* M3!Q[JJFW\L!,]3@O.264JJ8^HY9[H0TR8*)AMA<["G.B]@&)6R9A MX,224#SP5'ND;&+^P=0?LV]EJ^4O3L@M\X47['F2'V$0WX[4#WUA&$ATS[P[ MI0HFC3YC/AD+B$?\.0ZD0,MV*'V+AK'AD,G12KR%"[X)N22G)$;NT+4%<67C M9V!+&,]V-`\:6ZZ#&:C4,"D;Q/-3);I2'Y-0>)&AX`?Y&(?!A%%_P10+E?Q.Q?ND ME7UD_HD4;8:?U./\_HRI3FY,Y%[QV,T$G,/Q/)I*^F7&2",S;]B3<>1D(TE7 MMO'BQ0'C^0'B9`K(B'ER8&F?6;.114#/8WNT37>!H=K;4`G?)#MB3Y6?[<1< MQ@].!2''XN-!)$=&FHXN:7?UF1Q$IG&`I-;YJ.^*5T_-]Q-B MJ2%SYMI*5@S=!^:""7\NHO"\6YLXL=.7IZYM9GXF#2'G<8ZG%GP2=!E&IYRY^&I?8;&UV9CG@F6 MWKM.-!**;_PC>8SX-M&V+1S_"77DX/[VJ'&DKOF$VM/K]/Z!["[AJ2U=XPEG MKZ=_O$D>+*C0.!,/?_,T*+LH7A3.+I-KY34(&RM?$$7!^&BQOFC:OB0$9! M&$$K(63OZ&5Y6UTE;TJX*)B\MB81\0.?D9\NS^5_9/JE8MFSWR9/5]_SP',= M\E.R]C'[0;)2L'Q_J:KN;\D_=>M]\O)!X#F99_6G[9?Q^#EB*C`_OSS-#.!J M3P0H#`H;2^',\F\!/+:,YG%R'>8Q(AM.[1*)?.SZ<\32Z`U_!9N[SN8VU]C< M1J\*Q-3*YBY-F998.@C)+]._]WV;G(ZA&Z`;:-<-+IE]MA`:*+H;M-$-=I'1 MZH/Z.5,_S=*<`Z7R->>7'^A$AN/`5YAM[;@+[P7=`-T`WHL^W0#>2UV\EUK% M"057'LN;A0_F.?<"9;UT,=H`$``> M'L!-_`B`IAEHZ'4`$`#";)8(6GZS$G/F(`-J_WD;!K'OR-S%('Q-?OKPX>/' M3Y^TFYTT=ID!/TFG_;R0M,_OZ82O2V(O;%:3F^8U,1O+%!,=RFKJ(F@>]/EY M+S*L4%#GK-]_24$;2F<]*060F-4CX@QK1YLG[CZ;R`8V:?.3\A MSAHW9+X-WCO`7AX]E%Y^G$RW:!C6ZK%F@34+`&@Z@(=:=-)$(B,Q0B<#@`!0 M6YM202N)E?BJK\1_VKQ,YV*1*81.6NUABEM7DCQF6'A&Q"71D)FS"?L^=20DXR.2&9PWQ@8,WJN^?U[;E; M881DP.H1H'*F^UNR4<"VPUA8ZT/DYYD!N+YK9#I/GQ2;DO,V%S>I8F=J_N.+ MGILNFKT&=EU4$EFK`V1KO@M`SWF>'@J&C1!_=[LP$94$UFK!^-?;^!]^IJB' M[LJ?0^J638F=7$AQ1XH[`#0=P+KM43`1(W0R``@`M;4I%;226*6J^DZN2S9X MNCY%DQ4J$@R)SR)Q\QWCD:ITXOKBRV&Z]XO'`^XZ+@T?$C((R2:HB#(`R#>]%X+*$9 M,\'=2P^[TV?!,2QV%0VJVF&P*>^,5\`%9H/9%88+S*Z:&ZF-GD`I&,MJP05F M@]G5A`O,AAMP4$KI%$`J355YQ9]T2Z-`"OA@Z85I6FW9)KVY M7LL3WP6JNZT`;H'+C#77(T:&@>>I#<-$Z9;P>"S:*'['222^IG;DWKF1.IE^ M5K)H@^/JG]1"LBD?D:%X47IJAZSROG_!)%43WF9A1,4/DMKP8J!Q[X1.[X1D MKD]]VZ5>]N3%$_FB>^9Y\E\EX#B(Q>?J45Y@*SAD"]+B\\=I7?I7Z@>W\D7' M7L#Y*UF%WJ..Y^S"]9+XC[OH]]MF< M1JW&"6DVK([ZK2S3JZOXMS<9^\?!!X3N99 M_6G[?Q,V>@Y98JSGUS^8'0BC^%_FS#_+_EY5I%\B]B`DOTS_WK=]'X+Q)&0C M,:@("PU'%T,74R[+K;$U:F3-/](N!GSBY5=LL@^]B/CFV7[>10L M=3ATL%WFY9TBZBKK)6..4^TR9'PR>X9+6N_N/!LO.VN&2ZN%X3+GX?):!@+F MD/VA0@"%CG\?97AA_L:G<0;T$O02[7K)E?N`/H(^@CZ"D02]!+T$(TGE^XCV M(89#Q,ZN(AHQN319"$U*5Z$>$0S#K6N)=#W.1FY%`SPW\+$LL7[87WLR7;?L M&GB5LZPRO0'$!#%U)&8;Q`0Q=20F+":(J24Q83%!3"V)"8L)8FI)3%A,$%-+ M8L)B@IA:$A,6!Z.T>F`ZFUX'IB%UNM;JGAZQY$/U#P-7)'I,P<&*Y MQ,,#SRED=J./WLI?7=1I#1&YX4CJ0%('``2``!```D``"``!(``$@``0`"(W M'+GA]OA+G0CFH4#_%PI/$70!74`7T`5T`5UTITN]\N2*8H0^6BH_KJI3 M]!19<5C.PG(6``2``!```D``"``!(``$@``0`"(K#EEQ]%^&_ZJ*S\R*=.\4WD MK6'!"0M.`!```D``"``!(``$@``0``)``(B\->2MU3=O;9N3OOW@:>$W)+(A M=P"Y`Z`+Z`*Z@"Z@"^@"NFB9^7#<+_0T.Q-2`.J<^()"Q#6'OP'\ZXQ_$]8_ M?T>G22#CSVM"-.OUW5]$RGMYE, M5]RMX>N`?RFY;=;XR;K&3F+?CF(:N8%_*@W2:TD6`=1N?-V%K-WG1, M0[9NX[$\IR,2M]_1T*4#UW.CQ^E'F=^*3X;N`W-.U<,==>J'^#@*2-(SN#S< M0][C!?[MJ6C(F`R8;X^$EOY<;!D_R^A[]I<40+7'21[NJOZ$0T M8LA9%`G-JE>QX9#9ZFQB^8/IIZO4,'O&V8X(@WQKR&?3,'R4$"BZ".+Y3H8^ MBF0V"R-A.`6/?.K;+O7$,WD4QO)H&"ZI*7[S>^RSN49:C1/2;%@=];1+9K/Q M@(69KRWU=5NQG(^">W]*PF'@><&]8H0T/&=D51/%ZZCGD4#<$#[7J,DD#![< ML622^)D01Q!+72Y(]RRC;6'%!1LG-(QDS_$X0) MEWV%K;AC\5XWBN7GJU]^,9`C#'$"EBS4R$1O\53J/ZHA3'PZ#(.Q^,J?L%", M-(W4M7%U[>IW> M/PA"AX5R6/:$66&OIW^\21Y,^BTU@BYY.Q>LT2Y$JWH-4_Z_5+7G/= M`Y1\7*/FV7E..LC)L]@O?-99,X%J]LX:;>$*)GR+@LEK:Q+)[LK(3Y?G\C\R M_5*Q[-EODZ>K[WG@N0[YJ:'^;_:#,%'.TOVEJKJ_B_]^G[Q\$'A.YEG]:?N7 MAI;YA1QC"N!LJXB4';TYVP!G\^3L2I]G@;?M0J:A38-Y^V3ZN<^0:SB52R3N ML>O/$1,-\*2G6D3(I&)^P;K`JM6$C$2.0<)\+% MR(/^3=`_3_I_HFX(ZIM!?5A^6'[0'_2ON>6OU?QT>5?*;O'@S-Z3,VO#W2?J MAX@9:YE@F1K$2F$S&^,TQ3`)@`T&T#T0`"H-8#Y^4KF>$9%[-"3S2,@5L^/0E2D;KPMSITS/3MQYYJGGQJ?##`"U!+T)T.L'.GHZ0*\1 MZ(E[:#KH98?4FHVSIJ[NX<>_8IG1SV>N(0)M&_6+5ONP$N6!]<_Y8RL8V^W^ MH]3]>NV3_OE>9T^8&,0`/3>F9Q_T!#WUI6?)UK-I-4%.D/,9"VWD$ MMW6>O7R3FS,1RSY8L*-,8V#U$+[*/U`-1`U$%'T4B!J!*.+'.J=DYN&!70<1 M]R0"4VTV,MPESY5<[\7-;EZM4-+LGK>9> MAW$#38WZ9NNDO=_1ZD!3(S3;)Y:U%YJ)4U4]-/4-@>GL@$W/9/DP/9/E4WHF MR\=I4<34`(^F\"#WJ^JY7\??Z:/T M8%X5[\*8[@I7*R7AN+?7`4WKIK35"ZSG'^@"_%6'7]_>;[6`/_#?TS&L$_YE M!$T7CW]/#T-[(<\P^F?\H2Q0ZR75MMMK'1PO/+S?A0=-!Q`]$``J#6`B,U5 M/39WR/5%!.=TFIY9C1Q656H)J;8!-T!:P5YJ`5)`BIRO&N5\I M(\&`LS")\[G^)([XB?C7]F+),&*K':F1^"1=8PUIQ/C9CAK+Z2R^6L$;>%YP M+Z%078?P>"S:*'['%=825TYB"6X4D#&C/`X9L5D84= MJ@Y.:+3`&O$[$LK:X:%\C7BBRT6KY.,S.ESQUX!ZU+=%DT:,1:^K1HF,"SBM MI=GXQ\P%3,"PF>>EMOCM4>-(78OASIY>I_>GIXZ*L="C$\Y>3_]XDSR8G"Z*5Y&S316N% M:7\-IJW>6:>)4Y&W\LG7'%K\7@YQ<\B"X?QO=6#R["HYW7AV^4%^K5>1B.=]L&K:H5GF,5_<./?\5N]$BXS"M2 M64=:!^#UZ1>'3N_,`^L"#BYNG*NLAPW%*.C0]VZ_.0<81`51]22JU]_,PIB%IIHF(;T*$B[N;,DNH57_^%[AV5^15D MZ/K4MUWJB4?P*(QE2FIQ,RS3Y^GY!V?*=?=:>WI(\3`]I)A-#RFV@[3H-F+].UF?,@>05J=7WUAWR1ML M*S<8F!B@JVMGK3Q0YG76U7F\""[JX[#M)>WN]GN!`/K7S#!&(37;9F$,+B`J MB&H$+KIY6:4K!$35$Q<0%40U`A?=IBBE*22O&4Z]#B^Z#B+JD0M5_[(PU]/T MU8YM# M"J#]G@M&9?0#++OM-*?5@X7E+\CIH0?-PR`Z^>.:JRJU\7E%[T0'(4X0RT,@ M-@W?`:;-1Q7`I#=,,#PP/-6""8;'")ATFI9JKBH8'B-@@N$Q`B88'AB>:L$$ MPV,$3#J%!8U/@M%M7V:53\P\W.J.43N"S#D>$P"66!`9``)``%AF=6HS`,S+ M,ZI7=35YS*_42O,PQU-]#?]*W/U5G&`'M07L,(Q5<6"A__EO)62XJ-E:X"%RO MD^?TK-HX82Q`R+HB?;7R.)G75[78.&8&*;!,K5JY5NX$M M@@AU#LK!)@!;V`0$%A%8?)E`'\1G0B;Q?AE!Y*YP1H4K&O@D9)[P4!T2!600 M(,U8W=H$X(S@`#L!@(ZZ(N)"X@*HAJ!BVZ>3^D*`5'UQ`5$!5&-P$6W*8KQ)3#J>`[,%Y<.7,^-7(:\ MB'T['#8FF+T?I]7--6]8#RJ`]OK3'G'Q.J5;H#]5>QBQSKO(,@+MZT7[G)?6 M]"!"^8MN>NA!\U"'3NZVYJI"`6(C8$(!8B-@@N&!X:D63#`\1L"DT\Q0N$R"RNUQ5?+4'1G(/Z80"];J!K,UD'Z``= MH!?K(YH.>E7C:GGXB!__BMWHD7!FQV&QV\3,X,HVBS](6IZNKY29FESC(FT@ M:?U(:DS,!B3=A:38*X@>@!Z`'H"X?7WC]CCT1.>`3YENI-6P4,*BLM$\`P8? M1(&K;10`+HP"5@FP2O"$0#A/N,ET'\-(5@O+G>N("HH*H1N"BFY=5ND)`5#UQ`5%!5"-PT6V* M8GQ!B#J>?'+!.4->Q-Y]#66[32[;W>KE&MG7@P@@/4A_L%Q[/6@`RH/R+]KY M;AND!^D/3WKS%MB0&E7>2IL>>M`\OJ&3JZVYJE"#UPB84(/7")A@>&!XJ@43 M#(\1,.DTZ=1<53`\1L`$PV,$3#`\,#S5@@F&QPB8=`H+&I_=HMN&2QQW4KNM M/CCN!`!JEET+``$@`*SWSL9ZE4W[1-U0ZB1F)!B2$7-NF4.\P+\]C5@X)@X; M1!5?-4'&C/X9,V6FB5DGW58/"<&@_>%ICT0QS6IT\YV?5!@J#`6+65>FLE0?*O,Z*4HQ8L"C4_'\0 MGPF9Q/NES\9=AX4T<@.?A,RC$7-(%)!!S,7MG(M?C`>NK[Y'59.\C9.><99F M&]4[<+!#Z0XD>`/>@#<83!!B+-)C-3.'VSS_HW15&51U%(B!W"!WM1$SQY,K M754@MVF(@=P@=V41,V>:5MLMIOJ72?_BTH'KN9'+D"ZR6;>227Q(U9NFZI4: MTCII6#5.EP%1MR$J8O;5RT%!#S#%5%LGO5ZSOLE2(.K&1&V4[%/DNTQF!DU+ MFB:9.:?4U:'47"'E%Y`#&!J5B0,8,!4P%0:``5.A$1@U/*07IL(8,&`J-`(# MI@*F0E\PDD`/P-`"C/J>J)Y<4L&;IW'`Z;>K)-\I(+=.QI>DFC5ULJYID]BW MHUCM$CR5T<_7LB2$0'6WR/`N8>&/?\5N]$@XL^-0I140&C(R"5W?=B?4\Q[E M3D9QR9DCRS3^\>A1GWP]^_<9$?W5]6DH[AV)6_A91AFSOZY'C`P7ZCQ&XI/D M(6SIS?>4$X?)ZH^BM0X94/527]VS\("),!VN[3V>1B%UY&\6FT*H\Y^8RQV9 MPR!4-X@/H]"UU6[,[';-]#OJ31_-V50J6I>8LJ\3U MQ1-%(TDHFD;X/9WP$W(_"6;?2>&$]N,Q\Z-M6"*;M7*[[7,("$[)!)T)4UDZJKW4%=@NZS\2/6K^ MLK$8:![%W>(AXDLAA%*+T(:?;97H`T(1HC]*PL2>;!H9AL$X^_.0W<:"6X%@ MHGR%['1"X@U,P]2<);U7:/7MD:6Z)WG>7&;-'\E>_/I+S$]OJ;`FES,,/L\A MN/"=?S)'6ID+T2'N5->[%*SR`AZ'[)H]1.^]P/[SW=__1LBO+S[I-^KZ7P+. M?S#;HYR[0YJDWW[\/FS'P6??<$,]G$X9/*5['L02B2_,@6M M7!/ZP89OCR[C!.$;2_PG%\YOKH.;[DVKD5RD;;E9U98?+O_SXL'ELQ^E=7<^ MIB3_E)#^#S8>L'#VHU0/EXR+GZI7+SSC:R"8E'S%GMZ:2'05B:_D^[\$]O+] M:1L^I#UOJJ[D24E>O^8,N&''!KD(#%R)POO^"!L[2=A:M/?;<>CRQF)+GCZTWDC=N#5AX!' MWX978M3:D$M@TF9,^IR.PC]$*Z[$&)POAV3!ZW_+L40+$DUE_?@@!DS.-B.2 M=5X')K4Q_+P[M2Q`C>$GE^&G"29A^,EC^.G7@4BI']/)$JE3N]&G48OAYU!8 MUWKX:?=`)8P_>8P_IU:[#E1J8P1Z=]JO1=#D4%#7>@!J-4`E#$"Y#$#=EIY4 M"FY]][_,^>Q_DTMH'^22,1L)N=0-!8=QMZ"`>.MG_TYH7=Y7%`W6>Q%;SV-W M4:\Y`&)(V7I(.=UZ>FP2A;:/I1EG`[:>DU8;/YB`[4W`UJZ`213:/IQAG`G8 M/IA0;0!A`[8/;5;:D]Q^1FF>#:B#'P<;4*0-V#I.F0.#9NFBWX;R?G&S$N1' MDEDM1>!7,HWZO]7ONDTVTL_TJ:'R[^O\-"(O]R9QQ( MOI^D'%B9VW\1D=]CG\T_:#5.TN:K#04/PI)%S'LD_>[\-T*WGLST3[=SW+-0 M;=-@X5V:Q#^,(V%\$LE7O_>S+WXWINGY7+=4[A"Y5?KT8VE5I187U$2"..*1 M4(7:].#+_1$LM%VN-C/0YZ206R:HW/O@B?&#OS:[&V1,Z[1V<.,?LY)+:M\5 ML9GGI5O/WAXUCM0UGU![>IW>G^[FLX5>Z(2SU],_WB0/%FB?B6>_>6K!%Z5[ MH:;1RIUQW<.7-5HJXK0'*'EM).[GM#LP4ZM+=G@6'K`"V^;EK5MG_7:IY:U+ M574_OY,R^]/V?YL;0O`3_-2.GQ_G`W,ANZLM@_GY9,/T]J4!NW4\V?7KW"54 M'F=A9D^/^OXEF#\MS]AK]4X:Y_T3JYG;N:W`6#>,F[V3=E.6,\ZI\GPR/)B. M<5[#1!4'@_]5[6$.H7=39MN6OM';7];5<9=JG]MEYGH,/@"K,63AKYSF"F`$4IA.YC"!I*%D5 MD;&+F+16R_-]7,[JP1S MT&K/02]N;^6B=:0*`X:NSUT[+4-7Q.S3]4FZXHXYZ"&-.4SVU&27:9B[W1K/ MP$%38VAJ6;6//R27J/^<8Y*AK+T;J:.E8S^_Q.?E+.I`UCB.F?-MDE8WGN9IR]W:X@>3@%/OVW#E3]\S6=LY2=F^ MI@_;9%6O*]C6;RZ7+,BWM;JHXKG<_/?4H[[-KD:,11>^84X.\? MI\WZ3+(M046\K6^1.6?C'K1Z+VLQ\TVK5^B%X3?_#6/_LJB;\-\26SU6MVM-+!Q M(TL6O*J4K0)@S1NK,4-L?E$"8GO@L*)>C7$P-'L9&*87&G2<]R'U'>8\TW^V M`*HO@$J[B\E(K=PBN$/UBT.)G5`G,V#NYXPLEDA8VS.[FPF^?2/+EER'KEG( MF%8%Q%:6\U@G>6^Y5'PU!*\J5:L`V&ZSW M5:9J#I@`1>A)",S9MSCZ+L0/G(T"$ENZK>?+)T`4T.*R=+*3>]3.S2_4426[ MC<.Y=18=55+D1+=XE8A?)55AGIE!YV@M3EN;";VN28>5JJHCV(H"50:`X3#W MY@N[I=Y'\93H<:'`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`F"JEXYLH[_BF:&H3RT=[CB1#-S:CTGJICIH2I%`UR_942 M?.2R$HC+1^(GBV,`F:YT$,YNY;"T^F2JA!,ABZA2I[L5Z*)18L23/>!VJL'G MSK^27'-D+2\!LK3NXI83]6&6'AG]I4Q18,\:*6/IHF'J*"Q5"F20/F..M2JD$4I)Q$/I,))'C]`',21(3&WZCJ'K"Y_$%;28!(*4 M+E-BSAL&DDST;F$+?$X5S#.++`%*H%`GI*C>+NRI^JER'8D\ M]2Q!%_\-"DEL_0XP4AY,-V=J\YSNZ.A&\2B^U)YX-M04$>P M-IY,@C":OT`\C%'QK(24JC_)U@A#,,XT2/!H0+F[NK=?KVCWF#[*TC9)8]+S MZ^*)?%MS6M!FQ9,^B#YU*^X>/$YE2P[@$VT3*EVC'QJRC`40U^)*&D3Y^[3+ MRSH^2N2T7>I#T1$GR_$59!]!VU7B5+]OBB#;:P$+=!^#C]R8=` M%DR4!8-DR%P>421+XI#9W$"^^2,-92']9Y0W(TDJ60J0$PCI_$`%O,3H%L7" ME&8M0.IC29Q=_R[P[I+7N?ZJ$3*8N6%G,])X/%BDG^@/\5`P5>7,JW8(4YC1 M;\:TA4GE'ZE)FX5R*)$:5://2?([96R31XA7C$F8=,;$J+7DC6(84$10]`W9 M7[&KWDM3@DC9)103P>%0_EX^QDV.HGW6)MN4C\A0'DHH",`#8?]D*Z<-6DDA M]?IUHDMJ22R>%&[*XB$?([N0VK%TDKXNVY[T$8XK.!IEOTFYZ:@I4UIY*O`E MF`GYTQ5+V;(K>4*9.KWR0^"H-RM1FHT.#'HQ9Y%>"/YY&>ND_" M',ENJQXLS&"F$%JJ#[5V0HY=%7!Y-;/"$K&IFK:RP.IUSS1->9FN.AT]:0`? M"4-\JLR7.SLT?;-*;.AI.C%_$-A4A".>.'\\]J+%T=7- M.H-T(.9.,ZXPGDQ/IYDO$N#$]U#>R'QVE3R7SRW9_`FIAYN=^BH&))[IE"S" M;`N+*[]TLJ&RN8\V9<_4:B5VZIFXVHFRMK(Q@GO*+N;EF5X^T[IT2JM8[WE! MZH/(CJB\21[-S+3PP>)QXM3%PE$*E!\H?JUB`ME&.6R@IC72"XQ4,$@^6OYL M50QD-(NA9!U;=*1"S/+OPC5>M,K**+>>,\I,D'O&"/&3?[LL#1$F%Z].TLGK MO3I!7$7]!/(RD+(2;'D".@WM45J6=3+/\WT^5+=<[G1;P3])!A(^EBR4_79! MGN?F5HD!\>36AF2B,4S(>+$;&J.(L&2=)*5Z'O6OL2W5)TTCH3#X_XW[>;92-5M+.9[48_H? MH11AE&929NY7+N-4E:EFIZWU$Q#D*^3"R',O2,PDBY+&9'A`1E0.3XS)N;7X MF9\.'B/F)>&4[)#VLLU/%RB)6J',H7>D/7]$^9-9PH2ZJ4(3ARDS#Y(MEH`$ M`\^]3>#.TC!1K>P-"RI8)>M,Q[N:_)R.**[+(+"`=KIL(.UB%JCIB/VOLZLS M,F0R<]1+XM!!R(2B23*#DTX*4_Y->CV/[BQ8@A-)]'LF'BC^G4:8?*&!A+3>?C,<`BE#SUE]$:S4N'30>!GJ[

GV3BFG*I2?Q:]B[I)/^V) M/!L'?'EH5%I,PGW/`K&W69+F>A@(E_1>#F<).,(!E2+^5RTML7ELC;_@?[^N MFEW))$2D)SLT&O^8G;60*,H6O2T]'N'M4>-(7?,)M:?7Z?T#:>U#>?:21R>< MO9[^\29Y,#FWSL2SWV3S+JS&63^;:;'NS*.5!SBTVV?6]L<>Y7N`PQZXY',R M2?.LU\Y'!SE1=:?35V;GGW;6G'_:;)]UY6B8/+:FD1R&&#DI\MS^1^9 M?ID0[;EODZ>K[Y531'Y*\IUF/TCR@9;O+U75_5U.A;E/7CX0TZG,L_IS$RD\ M[$S^@AIRYMTX"G)VB@EZ"7:-=+KMR'BO<1,4KG=!Q2 M&7TDN=[X$,67'`K#NTV)G>38]>>(34]2+.8@Q$K9\[6GOC?.SF'/5#Y:>3(6K_>1L&L>_(`&\0OB8_ M??CP\>.G3Y4\;E[6CKJB'EL^_CTO0Y>;/DL^+WMK@U>HW$MG3!].$0`=H`-T M@`[0:PAZXB.:#GI>ON*N'F&S<=;4U2.\7-IQ\^Q.&Y4YN'+308'^I!D,V[0W M-9N'E2@/AOQ<`+;G9[V<-+&SZN2_H`7KV@`W%L)ZDVB5,/R)^ M(--CWQXE_\ZRVS*Y;T,OH-%K&6F;??M+6C>H?=X&.4%./ M]UMZ!-[-F3KE'V;7>5*5;@Q`C+T601AC9A+@#7@#WH`WX`UXHR=OL-Y0B-.\ MEQYV9\T":8K=(`A5F9:F!\1`;I"[VHB!W"!W91$#N4'NRB)FSC2M-%7E-@!R`D#.4%.Y(2!G&:1$SEA14]\S)PE MZFJ;-%=(8MIRBP,)LA,GB&715PU+E>D.1F)=`8868,!4P%3H"P9,A49@P%3` M5.@+!DR%1F#`5,!4Z`L&3(5&8!P^5&7\$G^]B@S.SH(Z_A)P_HJ\5^>#DVOZ M4-C`I4:QB?BBJ#B)+I(Y9(L>=_;EI M`GJO"HO(@<2FU;7,"KV7/_U!Y4`$4JH:2#%F MOQEX`]Z`-^`->`/>Z,D;K!F@%[BI*S>1UP5NZLI- MY'45/7DQX*\Q_.V])BGK0NO5@U\[=]+,9!CSG,72587:-:8A M!G*#W)5%#.0&N2N+&,@-E;#@JM/FPLN*DG-U&V%#RN!(];.61'F0!?.4M?M9A!ZCH>:ZX05,K0 M"`Q4RM`(#)@*F`I]P8"IT`@,F`J8"GW!@*G0"`R8"I@*?<&`J=`(#)3JVSK2 M5:]2?5]91#[2T!=R%5=*18_$%)UV#E:Z=A-`!^@`':`#]$J"KE.R:?DE)JJ8 M+8K2?,B%JF4."7*AP.,*\+B5`X]A8\'-(KB)5&A04U-J6IV]CA='@3T4V$,< MI3)5E@JMKP=`#P]HH27S`&@)XW6A5?"`:`DVM]#"=F8@JIUK9F8ZB'E&H'15 MH2J,:8B!W"!W91$#N4'NRB(&ZK!X> M[U5_!LE#X+$>/&[GP&/86'"S"&XVD=@&;FK*3>L\A\4K,\A9TN3%S)F>KK9) MH7'))!6^>1O^FWZZ2?*>`W#H97Y)JUM3)NJ9-8M^.8AJY@7\J8YZO1]07 MW]WN%@_>)1A\/6*$4]$1@R&)Q-_.4NV104A]1USO5(-$O%H]=NB&7+3+?2!C MT8@1EZ]K-JP."1F/O4@\/OUAR.S@UG>E1N1O*)F$+*(/Y):ZZH.?FV?]9H,, M7,\3/SDA\COV,&$^5R+\+#M'>_IUVC1"AQ$+R<)CK+->JSO]W=F.$%9:YA% M!0?)?^7/DJVDT_;)%V=?2D-&;$]\ MZ0Y=^8AGVINVYD,@DW6X^*'X2R6LJ0:]IQ[U;4:N1HQ%\AE""[_'/IM#VVJ< M))U`OO^2V6P\8&'F:TM]W3[+D&'VE]2N3?F(#+W@GDM!`MM5[[UW10\LHBM+ MK;B^[<5.@H30H1B?5)-^>A`-/7_#G]/%523^&3-!(*&$#[+9GU2SX\D4-_D[ M^65&O^B5!?7*8>`)[8O7$E>@2D37$DU\G/;29_K$JA[P>D1[$%F8D=;[>'C6.U#6?4'MZG=Z?^K.VT#6=; MY,'DO'$FGOTFT4KB-B^Z-0@$_.L M_K2UQZX_)\PX\0YX$2E78KZ?DQ.?4V?Z/[ND1VR>&]XZ:Y6;&UZJJHN@ZI(O ML<3204A^F?Z][]NDGX)N@&Z@73=8Z3<7W17:A81UK(:Y7>%)I&;[G*2IZU*K M\O_7(754S(.Y=]*YY"?$9U%A=E:/33\'R,K4IOZ"IOF:5G/-)K`R,SE;YW-& M@//@?!TXWS[OYT/ZQ(O0@PCE>Q.5]!GD]DSQ@SO1@B!TBZKS;DPV_*Z3L#*[ M>[.5YQ`'G(K;\-3.TRR;`12F\AFU#7F2Y&BYF(U'$3,SX,RS!Z6KRJ#5 M&"`&ES3O@X?[=*[&]B$6

E2+;NROV)W(36@5CU%A029=O,=:6U6AM9H=K+65/F$S8ACX[$=RCZWOM:LRF:A:>:R`_#].!C7KZ M;T'@W+M>00?;P$,L2.[JCP[@C4XSB_,.LO@PL]C(.ERNRN_.I'P-WYN6<499%)A#QMN]^UFS0.O!>2!?7&%1\O-:JCO=F.PU!26-D_Z MS2Z670\T%)OIM^AJIS172%H?'`>X:@#&M!`YP-``#)@*F`I]P8"IT`@,I!Z4 MN)14>$;XDO^^1M?U"L+KM.9<:FIXT?$(@%Y#T'5:D3`NCF'$7J'DH#]JVP+> MB),)?93'/E1B.H,(;8TBM+U.QR[@;^PEY>VPYCYA#/I0/7.)%SS*TR%( M,!#J457!GSO$/1,8]`+_]C1BX1BAP?KE!>3!OO]!C=FZA1VM1A]A1XU'+3-G M9.;9@])5A6Q2M@)!1R3S52J9K]8A5]#4%)KV M^KE.ZLV@:4G#L9F^BZY62G.%8#^Z/F!@/[I&8,!4P%3H"P9,A49@U+AT17*I M=ML^\=BGWZZ2?"?7>9V,+TDU:^IDH6G3-B>/%>]\>V2IQY#G=9*5D60O?OTE MYJ>WE$Y>7ZIX$/5^"X-XPC_[MA=+8HB/;?%$UX^9\VW"PB0)0G[J!3P.V;68 M,[WW`OO/=W__&R&_SI]VYSK,=_CW9%OS-/]-/DO<\8,-WQY=\)MOPQNK>=.R M;N1:]Q&)?3?YZE_B#^N(.,QVQ]3C;X].NT?O6MUFTLNSC5[YFEW;TKUI-613 M.FN;TNGOU)2/-/2%4OEW%EZ-:,C>4^[:"PVYC!,5WU@WB59NKH-9NY94U,XV MK'GTKG'6ZHO5N#6E91#4HUU,DV:`FYIPT20U"[8`UMUR`!67.O M!EVZ7APQYV`L2M^W1Z-V95*CR$;MRJ;6`325)Z-6-VHX9';T;?CQP1Y1_Y;] MH!'[YG^@?'3A._*?CW_%KG`GF*Q4L3O1GIK1T]93*[I-0PH2X65E+XG0LW*4 M064<,O:#>>(>Y\M\W2:/\;/7ZRXU==T+]V_?QIKL=#6%PZ6LX]8S?:S M8N7>S@.I0Y@2-W`^!6'ZD?R=M46?NDE;>*/>>?TX81,#"HW??6__O`&I<*=^B;C]1-_PW]6+V_O$]]:@O7\]8I)QG86UG7O$V MEN9=NK(P<](SJPS)/"29%LO)2'J=3',7YFZ:3U\R,J5!@4;C'[.5$S4I(S;S MO'1>^O:H<:2N^83:T^OT_G2J;P>>1R>4<;SG'2067*SA3UG81F9PYTUV5#-GI@T&'_8Z\ZJ[N\2 MM[E/7CX(/"?SK/ZT_;_'/ILCUFJ])=A!5#?#.K#\L/R@_Z@ M?\TM?ZWFI\O9ZKO%@VMY=$U>OU` M1T\'Z#4"/7$/30>][)":SO689.9_]$CXS#5$H&VC?B&+T:&FC7BX*HVRH1C% MG*-XTC_OURV(`7IN3,^RC_D$/4%/?:UGTVJ"G"#G,^0L^R";_P6V= M9R_?Y/$FB&4?+-A1IC&P>@A?Y1^H!J(&(HH^"D2-0!3Q8YU3,O/PP))Z_E]F M!\Q=LD&$$/).!J#,;G[<.>F?M_R>M)HMH%F1OMDZ M:7>!9E70;)]8UEYH)DY5]=#4-P2FLP/V*0A%BWR2U)^S'XGX0!86(]-B?^2# MN"ND=H2LSP/.V2J=%E3CB3JR/FL(.GHZ0*\1Z(C:53WK\P>SF7NG2IL6>N0F M@G9%3B5;G1R66RH,3\E1.,"C=>]IYA%3`SR:PH/^7D_B@X:#B!Z(`#4&D#$YJH>FSOD^B*"-/%>]\>V2IQY#G4<[*2+(7O_X2\]-;2B>OY0%]Z@R] M]X_OJ4=]FUV-&(M^$_[[1"!\+:C\W@OL/]_]_6^$_#J[R_7=B'UQ[YCSV8^H M?^L*K5YPSB)^8=OQ./9HQ)R+<1!&[G^I=!1%1_1EO_C!AF^/+OC-M^&-U;QI M63>2J$4AB&C$OH)V]N;ZU&?RMSI=ZX=_LV-J:%-N]?G`UC[XL[7&3O M91PJ3&[.;YH=I<2;ZT!>=).+],$W[V,N!G@N+/A?L9O$2"X>7'Y#!]'-AV'X M?43#,;59'+FVD.>*_L'&`Q;.;O\ABRVH&Z:?_$$?W'$\3GYW].Z[U?U_FP@] M%\-8P45+%P1OUD3P_U5^LACY[UA(;]E<`9V2%"`,AS53P-R*;*2!ZV`BI"B? MO?O(\&\6!A,)HP9B)%)TI!0S>[F%]6@V3&GXD]Y?5N??MMW/=MX]!4@*]$SK M\UR'U.?4EBW\C;K^%S&^O6=#\9MK^O"B'.VL'"_[`<)U.;661MG-VU&,`(M` MK!-@.G'408#V+@*<=G(38/KU-W^:KRS3E6?S?Y6V_-EGPR$33[MCTABNI](* M2WK)0O>.RD=\]GD4QO+4T!\N_W.AFV2;<'5/)T\&Q57/X#/Y'F5;7?_V!_-4 MB_C(G2P\?4$H\<,G3T\_O61<*)+.3/W\Y@UL&;QV4'NQ MN#UCR@!;4;!=48]]&R9GI,T/TMT&I'7M;C9Z3\W$VM<7U]H;A[DW7]@M]3[Z MD7C*S(_ZX]&C_A-0/_MV,&97D5"N?$\V!GGA.Q>.HUPQZEVZW/8"'@LDWC^* MBTG`J:>BE%P\PHME.%K^1K32]6/F?)-NIV+9[/67[(YYPAUU_J#AGV):^%Z8 M3HZRPU)G[SQ M^S:6^KQ_WLWO;55C^%WTJ,!Y-B#4S3T@]*)`/6$LN\\+M*KI M^PJ96]!GW2#06YKBZ"K6TSC0.LFL/"3SE\+9\X%DMCJ[C2_Y+LTOFBT*9W*- MDG7O4YELI!:_TVN5Q;"XV*_[@T'$0BWN# M(;F=HA"R21"*>2VYIYS\?'XF_%@R$%_(G`0:D=]C/\.J5N.$R'ZNL/O9:IP) M'SO[ZTMF*^N5N<-2=[1/R/W(M4>$/4AO5+QNU@#;HYR[0U=\)EHP8IY#AD%( M'.7$*AMYEL%@]M<%)Q,:*EDB(9^3^KRSZZDW2\:).TL&B3]+;E.'EDP6QTHR M2*VS4*5ZQ-`-N2#C)*E!/%H*?T)^%OXL&:=B9Y4I=>CZJ81TL84^B\1' MDN.$!YYS)KB_YC7#M'"Z/2V<'LEX7!+?(-3Y3SR=O(FA(6249[4Z>"1T,@F# M!S%F1,Q[)#\W6YUIFQ48,M$Z#NV1N(],A$(8H9XP]\M/%XT.;))3/W`Z?,%UL(UG6$]?4+&SUUUBY@^+-TRGXJLN$-UI^;9^5)3 MI_[ITCW/:3!D2FY?*DO>\)2A2IO"^DAUNN,)=4.EQC/8W6+L[JW*1YC3FJ8I M&)+#[GSP2PS#B>R(0@31,O&7`IPH]X@KAD3,'OF!%]P^)MP6]K<_M[[*<+Q@ MKE^RS?)[.D\+F[52T4>]JW-F;?ZJG]L9*B>_?O[M9T3JZ?GO4^7QZ="A^L5< M=5Q<"QMP+YF_XU#R0A$P9ZR>`?<$B2@XG# MAFKE[]232W^KR)6,P(D]5?W?/Q4LL^7S0\89%8.!@B]MZ'AFY<-$=#IOCQV, M!VX2)S]1!'EBZJW6?(!\V8MXB1@7`YDG/'<_S]\(%@@3.DY(ZOMQXM/,N=IY_VQ*>=WM-/^TD?Z+2>?G$N M)'JI^Q,:LJDX0K[@CH6D*8%J-N;:>10X<7)\GRX%$YJL!0L32]17KS8RY04E M_&XWL5P]*?T\&Y6^/$WEVF\A8\54>?%=J]OS/762+FQ;VB$Q@EQDG*/\FO=\ MM/K%%JQN]/7<4RRFM<*;?*ZYJ]^]V,XDKBV5_BD,QA^2L+00;!Z73A::D]]= MTP?&/SX(6QN$CC`[X>/GB(WYU\"7`H6!Z&1R/2XME)5?BL+Y^=(2?X$-UU%# ML]"5:("8M;B.^JUZ]L+Z:-HJ_W8:8=TLBE4K!;=WH6"WTZ^YA@JF8*T4O).I MM[JM&O72EQ-9BN%@O32\4U;!^?("8;2+*!J>MEMR&PM+\]633$[F?'>+E;F$'KY MSL+WE+OVU4@&87:W'.VLQ,VC=XVS=G,;61?:48`0&W7S92&:?9V$V*A/+@O1 M[^DDQ$;]9UF(SD'I=.EZ<<0<#7I%MB6%"'*HGE&X((?J'8="I/`>LJD@JQ-H MO[+HVS#?K5'6>?/E4?+EEAQ$AI6)^+/$RWC`7<>EH3GYW\-@(EH0B:G( MSMFTRLG5"8S=_/2EO78:\&E+E[K7U5^(^G0*:VFU2H-.L>7VQY+Z=7%3#:NU MFRP;>XE["[:CD]707K"=G"[KS'K6Z3J48(5Y^'N0,1^'K$BOO_&LCZF3<+N2 MLEN8<.)7V&%@:CZCW&$@\XRR^P&("ON3P"B+YB"#OXA,TJF26:ID,A2] MD=BS^2P)9KV1A&SH,3M2"8-+V7*S3>5$_)PE>:5I>B.Q1:^]%9^ER7-)[%?^ M8,*$[QD)MW6#I/5HFZ9.WTSE;>(W7"5/_MP]GV7.9;*_G^94X"H3YZX3%?L9--7 MH\QS9&')Y(WI+H+H5+Z-#&/?X4H=\J%Q)"8F26+MO\[(U5DFI58JPID5/U`I MKDQ,&GSQ).]1---5F[C3;$7.J)#CXX*2GVG^B4JB35I[LBZ]E8BQ*9CR>JIY M.[CUW:FR?[9Z617(9TLU#)C/AJZX99Y7+7-5=\`M`\C%8/!OERUFI69P&4X1 M3=%-FA5($?GR*V8@)M.0K16\5/2^[IR-:D48>^ZD"9*+H@J3+ MVR[F^S[.R#8]81TL[9.9J7G2?WOSC29Y*E[>LB9E>I:AO-(.Y,[,]AI2-LX/ MQDIQR_Y[\_9(4=_[Y2=2"?=,;@SD:_K8B7Z=+)/PCKTTQ7A`A,;1*)#[KIC: M$#'M$O^)0Y<[KCWM$K=RPY0:G.YN`LBCRA$_9@LTF4;'^[#X2B>*5F:E[=UF6:_*CP*Y?)/G6N_*M;GG M7YU7*[+SJ9S86F$XMWM_[JW?(O,Z]\8O_ES8UGS5W;7.5^Q`6__27)JY MQ=DO_15.U0ZM5*L*J7^;IYNZ(IECX5T[-&2GJ5!KA;^\;T-V\A_Z*[R'G#2R M99WT%3UR@X8DDZ'9F4Y%[%K^@XI7N=03XIX:HLK_PEW&O+Y;X8K@A<%(9A*1+NB^$/\?IY[?7T(*EH5JS\Q;%O MN?KZ^\=YF7-7S%I">_3X1:XZ+(C\,5VV_C:<_7KVQSP0]R2),O../\3D*$X\ ML$\A^RN6U=-65X//_%*&`N)0ULS<,`5RU?QL(YWIH^C9;S[[DSCBZ@?-VNMU MN8M6D[_/VCY3]*PG??-7Z^+1$.K&?2Q#1CJ91;HXW'R@8?CHRI,TDL*@%VH- MZUGZ[MF;7Y9,#XULTYM-4<>+7>^P_'BQNQB@D'SI<0!M?''I0+B1T:,I%'G6 M@]U,-FWTDBM3#%)*=5RFBBE=2_\I9QW/UB3ESC<61H__9)[S*0CE443)07?1 M7O';YJIUQ@U>FD\[MRC8F&,K'^4AD[)^M@SS[G$U.K7[-B4S9<. M^MT557ZV:,G3\,_63.HN'SN4??A6K]V<&+WE4IX;O/4'O9\&IO8C0&=5`;X5 M+]FM'9LO<'2?U_T&S?C?(/SSL_\]+:>\%PMZS^MCX2T[MF3SU*E5ONAF#4F2 M$9/X8@'EN%83=M5+]VG:3LL_UDH3DG?3=CNO=B6O"M+:ENE%*X>`;9KV[=YG MSFS?O-H8])*_]/PIDE^H__7?JSV5Q87_SM&[[GGOV68O-VBQZ5/718R^%[YS M)?;RR5?KWKAW^[98$5R1HK=S\_)PXJQ&I[6T@KS\ MCAW:L'F%2VMYA7V+%JR8+-5W:4;J^P5=KFAPZ7K59IL>P>;BU'#G94XK?A0EFGEZLZ[>7R]/I+ M\X%=VU&8-)M/()8KYI4K3!Y.:3<%*`>AUGF/.2Y. MMBVK/"DKX^%:W>4,8ZVTJ*-#6[#2M$F*Z/3/E]8=M9`S3SO2;2TO6QY*R,J8 MD;;5*(TIIEJ1''26DRO9:J_P)5>^9L>F;+Y"VN^^Z*&M:\E\;63/!=+F\F1[ M^17[M2%3F7EZP_7CA"UV?K4L<26)I=SZ#8.!UK-*/&CKU<;QS`-W3ANQ65A^K!(EV&LGKP:"\5:,M?3:/7JU8T,FY"05RK+D< M\"^A\9J-/P>;UQ4';+N_7$B@BMK1WWZ4;F(K1*!*C#Z M133M&YO/K!>?Y,I38+[22,C_;9A]P32;3JC?^>&@9\4 MJ/GX,$E.E-DP[K2\)K6)>"]JY(_-M^#TMI"F__8,^N.-X;(Q65JR>;"CB MUIIQ?9,TTU['E^=%7-1,JJXOS+^-1M^&LMJLV@,BNO`'RD>?O.!>75N[%)F8 M[\K][/,HC*6H/US^YV)@*0B9>^M_?+!E^5LF+N]IZ#PQ/:N>Q'^CKB\%>_\H MFZB&0R\I93QR)T_&R[DHLVC5[-OTT\NT(+MXP,+-E[-"[1<\_>F\$2E<[[Y; M_3_F8&RLU2=@N+ZLQ/NX,A=XZ]72Y<6BI\_?^NV;[_JPEL:\[5XN$WU#B>-W M%MJRA]R*(>T[71=MVRT%N;E\S$[[^8:_T+1%F;ZR2*(M>OV=ZS#G_>._N&3` M)]>GPFSXMQ?RR(BD\')^6?RG5J^WM!EZ\Y84(L&6)1K/EZO+YBQ`XE04!4%W MN?S-YNTHI/U;5O==:R]7"-F]((0)LI__SY4#('NV?GS65 MHX[[R_5U%UZU=2MV.X"SNPKH/5JQ6W=I+%=SSD49VQX"O\IJ;M2*BSOJ>DGY MS+2P9F:?B#H1+T_JK#0OVS2F`$EVI-^J?EJR)#M2>/D8V/)%V;$;+$V-]I)D M9F(+L:-68_DF MOYO-(BY=>NL'\AR/[<[U[2S7)ZJ,3CYR67E9;>/?Y^CCYG)EUE9 MTUOR9GGS8F64\F_*;7FFT)8:69X;YJ>1G;R`;F_)GRFX145;\,9R;6&])3J` M!6_VEM*C*J.3G"RXU5WRO"JCHITM>*M1H']7LE)VL^`K"J#D/J9M>;)1JU5@ MY]ZK#O>.)KPI_L\LB0[AA"_/#"NCDYQ,N'$=X1`FO%=AI>SHA'>+=Q"WC/HL M9Z\7W**BG7"K7>#4KPB)#F#!6\O;1RJCD[R<\.7:,I51T>Y.>-\PZU"X!6_N MX@N%M]1W_ZLD61#KPG>^AXS+5`AY^6V8+LM3;]9\ON*@WVT\^'?R'.'LF<+B M[\43M4\]-HS4L=KI=>C>CI(/CG!&^!YGA'\-(D8L,C^%NOV&J(12>=)U%G<< MT%[``>TC1J@M^N.$^C+K4W1K&CMNQ)P3V7T<><:0(_]*>Z.X&$X[GWC/M/>1 M$;UC9,"83R8AF]!0_&X2ASRFHCE10,+88WRN+GE&>7+B>W+ZNP!:'DH^SWQ6 MIYA/,_:(7$=S.9?%9L3G)_*W(1L&(3LA3D#\($I/5A>B>/+@;,3`07-XF?>-[C]$YY9CI))5\IX:):E3GLG1S?CUQ[-&MTX(MV)`W*_NP5\9FLTTK#1ZG"2=(3R)"Z MH?A]J2^8%A[A)YGF3P+NSO2@SIP?>L%]%JTQ==A*T3X+I7+"X]M; MQJ5.HA&-Y$LYR\(^D(V@2GF"(_^1=):ODX?9JQ:NY$I6Y:M.H+_P_5CP] M$-HAGX1NYBVS&J?_O^2H>?&"1T9#PGSYM$NA+3DTS7_9LD[D6?7ME0)*YJ_G M]12C*.TG\NSI*5TGTVQ!U7F4CGD\X*[C4EF=6^`^C)AHG>>.W23M4][IRBR_ MZ3U12'U.E=($PS8P(LKLS/JYZ,MOCZRCV:`UNWOA3G61'=NF%YFQ.>>A]\G` MKI+W98(YBFJM*$NU_(H=FK"Y M0CJ]9Z#:J`5YU7CJ=I;7@5>]9;>&;!,3?@F/%]LAQD,Q&HS$V*SRU94O2=EF:K(?I.:QK=\^7PD8&R[Q0, M[*Q8_#BX[.^5!_R#V1X5KO'0M1/W;X<.OAP,2#8BRA<'_BP8,/V5&+_BL73= MF2->-MTC\RD,QO.-+-_"_RM<.'U!NM/EHT?T M5=O+BXGZ#!_+9Z;42:?[]^3^\@:SVBAPG[[<7SX11U^]O;RNI$]GWFJ>4365 M[M^7NRNR)NNBP#WZ\O)FMX-H;5Z'@,][35(6@.WB2*\U65L9K(U:=Q!A=PO7 M&"KL;DFG9LJZ4T#F=/E<,EVDS;F[;C6Q7]>PHD7).7=,0V7;KBDM; MU0\C8EKE)UE%LA^OYPNK%_YJ/Z"`T72["-+N32Y/+;MUZ>UB'";J9;="-%O. M%TU4S$Y&9#OG^Q!J*#[8NJX?V2JO>_R`Q7$5[_Z'O`H9)&; M'CFTTFX5D2&S78!QCT:7J)D=5P.VZEEF:F:W-8?MYA!F:F;'3!V#.9.O8;&V M&N"W:>0A1=_)LJ^4Z683NO3E?1=^KZUE;KW?F+/G[2W)(44G.]GGD)V.RMC177LRFAD)\O1 M[&R<5)BO1C(U.G(J/]'I/%,59.6K]FC2YIO9SSNK>^"F+1)?!HNEW3X^3`0F M+$^KN7K8?/;5^SF=07K\XMV[FB)OX6[?Q.'U5]HD]!F!Z, MJF)TSQUYO.^QB-;R\MOZ%N3:XBVUVU@VJSDU6*%4[!F(I\LA_"T;4YPDVTZ) MET:$O"3YP29Q:(\H5R<'SPZCRA&&IG6^%.I8WX!<&[QM+?[V2\39JL'?AI>N M/"[1=W(]W7/YM+\5+]RO1=L6OUX:+S9NT75P8?\5BWG;M,`LX[^%P7.U;L]O MFIV9QL1%=S&;8OH,] MXYP>5T[@5H^!WWS M=A32_BWUOUP0<>?V!SQBXXD7/&:B=-4HS9U3F>LG=:ZEPDX_SC1&IBK;L9ZT M5.DI]=Q;_[4\.)Z%.A>_/ICF?\SBQF0B(\:J[*_+(UF-UTFR8,@@4?S)[`-) M4+5V+8AYHFK[CIDCC;/Z6S@\D:RO+!^WLKJP,%3B$>(=(;.#6U\&I-(BR<)U MCV6A[7G%YEDQXV@4,D:$SQF-D@K8W'V87B8UCG^/?9:I;]Q0MZZJH3RF_Q'? M/)$N%5\^>2*)-^^JJX1;O,D5]\F6>K*`]&NS2[%G#,B]ZT0CP97&/XZF=9-5 MM@*QF>=-J"-#B&^/&D?JFD^H/;U.[Q\$HSW]XTWR8,'>QIEX M^)NGAFI1O"B<72;7#KE3W5B^((J"\=%B>UN6>FC:OB3D.L1@#'NV8,\Z:\R9U2E?WB)LRK6<@:>X`N MH,MJNERY#R`+R`+;`KH8:UO@OL)]K:G-P&P\/W/U4<;GYY`]#=2#L^`L.`O. M@K/@+#@+SA;.64QKE`H,IW&)I#V>X^7Z\[]%4SR9M/(*EG:=I6VNL;2-7A4H MJI6EE0F#(":(J2,QVR`FB*DC,6$Q04PMB0F+"6)J24Q83!!32V+"8H*86A(3 M%A/$U)*8Q5C,&D7?!1&?";U3^\_;,(A]1VZ/"\+7Y*[S=6(\>9(C!?W(9V\/4K^G6VIS6RX'7H!C5[+`6KV[2_IYOYN'TP'TVO! M]":8#J;7@>E6IP&J@^JUH'H3_@NH7@NJ=T%T$+T.1#\'T4'T.A#=ZH#I8'HM MF+ZGEY[KTD9)3,]KB6?WA9P-EW$.O(CS62ZQ,9Z6[@Q\,@F#_S`[RI30#`9" M)TG=SL*6:\P@T:X+V&5V_EX/Z&B,3@Y."-`ISD7,8=H/>(J#)X=%)D;=C@M>'3:"`7W/X"TVD`?J:HV\!?L!?5,I%]>#/*\Y4Q6B2/%B5CH,PJ)K=`G30\``D``"``!(``$@``0``)```@`D9YR\/24 M9N.LJ6M`X<*.8AJZU"->P/D)\5E46#P!.2DZQ27;J,)3,42;;2!:+43[V(%? M,43;0+1BB.:PLP6`Z@0H1M&*`5IL\A40-:XP$8I8[)\EH7-0XWOH!B'AF9KD MY-@.F>-&NR4B(:P*`4HMH,RC>&?UH"PI$K*7EG97TH(C.W5( M"*;7@NE6"QNU0/5:4/V\"Z:#Z75@.O;2ORIDJHY>87*O0(T!,+T>3(=+#Z+G M2?2NKD1'30H-EWK,7#$SSSAJKRIE6_-:^18=A#A!//#8QDO?@&ES/P8PZ0T3 M#`\,3[5@@N$Q`B88'AB>:L$$PV,$3#`\,#S5@@F&QPB88'A@>*H%$PR/$3#! M\,#P5`LF&!XC8(+A@>&I%DPP/$;`!,,#PU,MF-)L*<"D-TQ(>9I=SU+%DDLJ MN#:[.4VSFWZ[2O)-I5Q(<%LGXTM2S9HZR:MIC6V:EE'_C!P7`\DR,A1$XL2- MN.BRXFV1:Q.'#<5-#ADP7_P5$?$HGQ-JVZ(/R]H"44`^_[A2=\I+SQV[45)K MX"PC_NROSW[$0E_]@'IDPGPN_IH^-&3J.>)M"\_GXID>#4G(;F/OQ6>3:"0> MX89<".\^D+&0=,1),"3-AM4AU'?D'^T3\G.GW2/BH9Y\N?SXYU:K,?W@1+R( M3Y@=N7?,>SPA]TRT2U93"-U!'(G&B28]HQ7YI&9[\!+PZ)2- M)U[P.&8"N#%S7%NH1]XO:TF(/Q=?Y&XL:5:4LTU8..TY"8,$2]X>68HBY/F> MF>UI)'OQZR\Q/[VE=/+ZNQ!Q+N'[1!HNS]KR`AZ'[)H]1.^]P/[SW=__1LBO ML]M"-F1AR)RK2'SWG8;?PBM!+^;\FWHQ^\["JQ%-=2H>$,-WQY=$MOPQNK M>=.R;J0.CDCLN\E7_Q)_R`\<9KMCZO&W1Y^_?CIZ9V6:N='[ZEK3GN0= M>[1E"P7MW11%.?+`W=>^Z[T]BL*8'6VEGB/R2P[/?U;D%8\/;,8<_BD,QI?" M*(HA+A+6Y]OP?=<#+'9YU_&2>&<&^M&"="YN0Y>>MU).^^N:S;PLO M0!D79;2I^(G-KD:,11>^>YEA4L8GMK$7L'%%&.>+('?AM^"?S; M:Q:.+]D@RA.L=K_SDB2K&_!\@W^P"54>-?\VO!)^3+11F]O9-J\8DQ?;W.\U M7VKRLTW(N]7;:?K4ZEC]G-NM?))O$V58/SZPT';Y$Q=L/TTWF]V76KSR]7FV M=DLN6ZW]6RL&JNCQN[#:\MV'8\EJ$DX2E%(Q9^",:3D(UD,.J.)3[9AUA,0OQ(3*?=P!$/_3:\ MI@];=/69BS=S[F03HT?YJL"75D20?LIG' M=MI<4EB>:C!

)EOU'7_R+ZE7(>&'=O?=74\/_&U'.'C\*;_D#YZ),7W/^3 M.;=L0T=YR7A#Z5FE_\L/Q>Q#1EH^^])?4]8M!:*&"F[K9S:LI1$3"B[>;/2@ M]&+-QI)/8[*"5X?U2C4;G25O%@HNWFRT*V4W\M?Z_G;#6IYWF*SBE:&WDN[C, MS:]!Q$B/*$E^>I#&X@U9@)LHUZS@!-0JY\9^]M-I8`G@X\EX]DFQ:39C(/."-K4F5/ MB"UN%@ZE_$`)^2`L5<2\1_*S=;Z8SQHR.[CUI;=T(G]]/W+MT=(]LUM1)F)C-UA?-FNPKR,W(M MU1MXPC67./%X+._ZKWB7U#M-#&_RC!9PEPV)-NWY8."-/-8/D?` M'\7J;GDUO5FT,HRE5M0WO\<^F_>^5N-$O>FUV18B,^`D&R2$1_2/6;5=M2>` M"*B\=%O$VZ/&D;KF$VI/K]/[T]TIM@"/3CA[/?WC3?)@TFNIK1?9<:W37MAE MH5[Y?`';E1LZ>OU\-_QI?U9^V]MCUYXQ)^RY_5<#. MF]99.Z=#.#/%I&TF,Y5VZTWRK5N7%=_X`%BK>];JFB_ONMU4)LOX9!O4.ONS M7$![:GP*."OU)35E3DK=U:';=;^3'!'E_ITDXY;0B%PR6\5V,D.CI8;&=F$V M1(_=>\7WK4Y;%UDU/:+`:I_U7SS&84,!"SIUIK^_:=4#_O)-;-4,Z6*H83J? MFLV67#5W[FCMA>GK(+;11>TLS-FUOPPSV*4KJJM#4YY04@@9MB4 M2I?:/YB1/1_:6KWB@TG9QL$KA*A4B*I1[I3TO(4I::&VS`<83XPHP=`"CA)%"%RT]+IG.+[WJELS42E+H7D@7G*;VS=(& M-TL*I+:J/3&]>RB33]/R],KG;I_F M/2M-9#*?3U;F!;:?>\Q668%)EF=K)6P>#UY.];19&%'Q1G%3/*33U;!]$T"3 MELPS>\_?$T2/*?"-+=.69TRRP[&8UFQ1>BL""$$1(PX+KWU`UECEI^\*)9\ M>B;/=3&1%6F62+/<9G"7$Z-R(YQ(LSSTA`UIEOI$TUHY126,3;/,,W!O8BP: M:9:%1JKUD%7C&+:^:9:MSOZF50_XRS>Q53.D2+.L:)IE,X=.;P8Z$Z09JFU M&=#3+3AN-XMT"TSP!+>++FAG9\Q<&3+/8I2N*J19FH:8.5,J75:(,2-#FN5. MWAC2++?)!"HU$+7W?M_:S4EK,1+H:ILT5PCR+/4!`WF6&H%1PDBABQ>=7"+/ M:KXLSE[\A5/,]5FN6?/ M)L,A)0TI:=O90:2D(24-*6E(2<.B*E+23%MC14I:#C-2;5/26OO6`--F^:1\ M"ULU.UI2*=;X\L]1CRO$ZR,I+LQ<*QOEN?QOO">;X?TMW` MFY_7.SOW?/$Y`8]4:S@+[Y@Z'YT.HL7?R+-DY<+8AL>@KSIW>ZGA>HG6V4RT MYJK#F@\D6G(R_.QD^R]!DLH,?TVO*(>XXD\!V-UW?2R M89T&N!O22U`(?K%0B7`M&L6+=FFW%Y#;DVDV91T MK9='_'VDR<][V8ET+P_T>@BV(>?.6P;(LBGC\NH_%_-#ZB\S9]1K.&%8XU6_ M+,]3180?@Q^\JB%SG3SG)FK0;/^]92ZYZ\+:^FS-V9J;/S/MW& M<<5N5;[2@M-SX7G?9$+3],L-NVO3ZAY:G@^!KU;WU6\_"]$6!?F6;&;Q;[>3 MI-\Y-T22#8&55NERMHGG>UJ4?$.3U&I43QD?Y^6VOR]4V]Y.-U9[V6`;KYNO M\U+CVVFCU5HVM\9KX]_I-KDMB=%I+#EB^ZNBO@=JRD&&F6YSR2LL M6IQB1IEVN[DTV]53D@.,,L+7KYXRNTE1]MXU>P\R%B]UE+\V7AM[#;( M]+K%.1^+T]\-5@2Z!0PR+T_%"YW+6-;!Y2EH+G.>DD1[20XQEVGVJJ>,O.8R M*^(YQNMFC[E,O[A9;UG:V'$NTVX6T&G:NXPS':N(_KNR*0<99CJ]XJ9F!QUE MVIWEA0<])3G(7,846`\_RIQ74#5[S&6*\#)+UL:.1K80D$S?3 MZR2->"'/M=!4SR<_?/&AV6UCF2;/1,ADZ9)6=[X1[I2H<>VS[S6O?=Z<"59+G)HCTL6WZ6[4.R..7>92S6IR`4-_E+?!V$Y)=-O*O-WAN&S+B;+PJM@HP>B1ZY'S^_LF@.V(4=Q31TJ5=HEY`+T"SCSU`_X\VH[NG3%`>YWLN&1?(RFR\C'^1\34^4#XJM`&?O.!^ M_KI_,N>V(-.#`)$*$!ENC4JT/0<[MK%BP^2Z,T0:O;.>^<34:I@LZ!P'$!/$ MW)N811Q2"6*"F+"8(&8UB0F+F0LQS3^G3C=BPF*"F%H2$Q83Q-22F+"8N1`3 MBZIF6,P:Q=R7#T&]9J](JNL/>3&K9.@4YG:*;J>+ M+H$N@2XQ[Q+-$ZMWCDZ!3H%.,>\4UDGS'",%.D4)G:+;T+136+TV9L[@>?5Y MW@+-0?/JT[S9`<_!\]QXWM24YWNRO)'G6DI)+$^N-5I3VDL/._<`:]JX`Q0# M@:HVMZOE+:D#I/U.L6C4&OD4C%A([&$]"-F(^=^^8^+6X9N38 M"SA_109L&(2,A,SV*.?NT+75"3IZ5[/?E(V'K^178KIH/X=-+@"GL'UY.>Q4 MU3]#^]5.9F-;''.ND),`?#@E*:+_]""+"!4W"ZEV3P8#:LV`;JFVO-MM`!UM MT;&`C;;8Y+!OK\+8]#&N':H^8O$,R"L>49=JB!=C(6/$,X$(YI!A&(P)M>WD M$#/Q0?!L/*/BX?P2SB0H5.XJ&RFP!JP!:_)A38G.:K,)0"L%J`5`=YXT:@GH ML=7J%PDIXNTZ@U]H$2!`KS/TK1P"L,!^[8DA6F*_9V7XEU-EJ@:]=E$H,Y.+ MS/,02U>504=@`C&0&^2N-F(@-\A=6<1`;I"[LHB!W,4%=T!ND-L458'3"0O=P#ELLFZ%DW"P MN1C@8'-Q\1$_PS-.T,YF\`Q"7(8 MGD)9-1A+FLZ;&?O0=5`M72$&91?4"A<0%40U`A<0%40U`A<0%40U`A<0U=Q4 MDUKA`J*"J$;@`J*"J$;@`J*:FXA7*UQTJWII?%)=78IFOJ<>]6U&:$1^CWTV MUWJK49C%U"/O<__U\XW.I])!UAQX\G,!;$C/_=:R1DSKI-MN%4EU_2'?;14; MG:*ZG:+;0\4T=`ETB6Q"TXG5V3,9!IT"G:):G<(Z:>:QVP.=`IUBVTZA#KG6 ML5-TS[N8.8/GE>=Y#OO(M$`>+`?+7]C*U2BT?C1X7C.>-S7E^?&>F^)0*QNU MLE$@IWQ567DFC8@1@SA!//`8JN(4$-(!3'K#!,,#PU,MF&!XC(`)A@>&IUHP MP?`8`1,,#PQ/M6""X3$")A@>&)YJP92N:0$FO6&"X8'AJ19,,#Q&P`3#`\-3 M+9A@>(R`"88'AJ=:,*5I58!);YAP%M#L>N/,L96:+*%^\%+NZ!J%'6H8RT,' MF51*F_D1"P^84;MM*4#3Y06FP-1$&8$I,#5=7F#Z!-,*R`M,@:F),@+3FF/: M-U_>0Y5B+$-&A"G0M5=V[=::OMUKGIV7S?N=MH/>)R\?!)Z3>=9L?^B5^S!7 MVQ_B^Q&?7W_T'>;,+P]27Q/6!8>H%65JC%'(UG8)9:KU8"K*5.MMZN!(%>Q( M==;8*ZM7_@A?A!_U(1[''HW MA]3GLBE!L6^^67@'.6F<10 M/S.%^1ZZ05CHZZ]8>.?:&2OP(>#1D^84:A!"YKCHDOETR;*C>06/5$7R\%]^ MR(3(_\T&$'ZCKK_,S#S?*L:\>32#AG^RB`Z\8@7]^%?L1IGQ]XK9<>A&+D,? MS*,/6HUJ]\&2.L,"V1IE+4V-#/J?J!\5&@# M/GG!_?QU_V3.;4']OW0W$?%1[:).]8V/;CBO0G@41`510500-:]I,8@*HFI/ M5"O/?;L@JA;S%NT58N8DIX@HQ[&;"3B(!GANX/-76IM!+:)B)NS;*((OS8;5 M`3O`CF?9T08[P`[8#K`#MJ.N>Y9@.\`.V`ZP0R-VP';DPHXJYEH59CN0!9"< M,XC@KA;!W?JN0FPXHP)10500%40%44%4LW`!44%4(W`!4?>,S8"H("J("J*" MJ""J6;B`J'L&WD%4/8B*)-G5^A+$?&8!(*]3-\CT?]:+2R6N[S`_>DU.U<^* M7%E:7$AZ3SWJVXS0B%PRFXT'+,Q4XK-.B%QI(M1WY!^MPHRH'H><%%_BU-)% MUARH\W,!;$A/GWY60QN*)]N868%40\2;(S%`W(=T\O8H^?=HVFS'O9LV8^@% M-'HM1Z39M[^(K^7?Q\V3\V:[2*KK#_FK0@P`.H6YG:)G]=$ET"70);+C1+-Y MCDZ!3H%.,>\4UDG+:J)3H%,?59W@+-0?/*T_R\4)556YJ"%#:/$@#E+1&"68' M9J=2*,'LF(`2S`[,3J50@MDQ`268'9B=2J$$LV,"2C`[,#N50BE=G@)*6J,$ MLP.S4RF48'9,0`EF!V:G4BC![)B`$LP.S$ZE4$J3HX"2UBCIE.IE?#&":I4< M^#R>4#LBP9`,8BY^PSF1=P70Y7H6-@69D%TXEVK8:8(DYH58CASW`U48G MYY+J"6R'Z[)*03\]R%H@U2BD5*_^FJ<@PX=!G)\C?IU2).I:L!*%TA.))!3UQ`5!#5"%Q`5!#5"%Q`5!#5 M"%Q`U#VC'"`JB`JB@J@@*HAJ%BX@ZI[A;1!5#Z+B-*8MH_!U.8WI6S1BH>C6 MXTG(1LSG[AT3OQ;7C!Q[`>>OR(`-@Y"1D-D>Y=P=NC8M-FM2CQ3>PZ<$:5E] M\[C?[!4):<$PEE9$OQ+@MU%(NP!`L>0/UH`U8$V.X0`=!X]^"Z-'M1`M]#0E MX'EX]Z[0@Q0K#*B^9Y[M'R6JSU0MKU!1M0)"%V.!?<0S\1[FD&$8C`FU[7@< M>S02'P3/AHTJ$6?'?C`=W7LP``RH,@-*]!PZ.P"QBK`V,YAO1(X)E$.@[NCC&54#<:2(A9F9@+IZAV5KA#L,]$3 M%Q`51#4"%Q`51#4"%Q`51#4"%Q!UW_P*$!5$!5%!5!`51#4*%Q!UWTP\$%4+ MHF*+Z991^+IL,?W*(F+'82A>3B8L=`/GL(F#M4Q1UG5+(?:3'F#E5E?PL9^T M8H#FD38(0#4"-(]4PUH"JNL>K^YY!XA6"M'C-ORG`X2_=(1^S^U]M>W*VN[7 MW',JA/V:I<9=S`Q?F6506D30`SD!KFKC1C(#7)7%C&0&^2N+&(@=Q7S ME8`8R`UR5QLQD!ODKBQB('<5LU.!6`Z+*+5055XK*]7*6WU//>K;C-"(_![[ M;*[;5J,P*VO6(NPZB:S#2I0#YC\7@&SWK%-R*9W623>/U$O]X=LM-P0T-H/& MW5X.N6SZ@P<25YG$S1.K@PIUH+'A-+9.FOT<$E'UAP\T+I+&W4:I-.Z>YU#T M%7,V,#-W9IZ#E^"EAKRT&@TP$\S4D)G'>QY/AX+1*!BMI0737B%6GHOXPEX3 M)X@''D,9GET#`P!#"S!@*F`J]`4#ID(C,&`J8"KT!0.F0B,P8"I@*O0%`Z9" M(S!@*F`J]`4CB1@##"W`@*F`J=`7#)@*C<"`J8"IT!<,F`J-P("I@*G0%PR8 M"HW`J.\!,LDE%;R9W9RF-$V_727YIE(NY+^MD_$EJ69-G2PT;=KFY+'BG6^/ M+/48\KQ.LC*2[,6OO\3\]);2R>LK>\2V'8]CCT;,^1:-6/@A>W;, M9W5TS)>`\VNIP&OV$+WW`OO/=W__&R&_+C_LD@VBQ5\26[107/Q@P[='EW%( M(S?P;RSQ7[-A=6ZN@YON3:NA+H[>R;9FVYW)3$N@22R%Q">]3GK^`IWW1;3Q M$J)/?OCB0[.[JS--GHF0Z8RDU9WOUWXSS[W+PKMAY\GE`4\5`CDA)^2$G)`3 M),\F)PWSL2SEY2XZ**_L.EBY72X*Z:RAXV<]7>9#M\G MKQH$GI-Y5G_:VJM1$$:G$0O'\SGE9_^.\6@LN,<+B"(T5=&U/-26V9YDB\:R M<+<9MWQK<8?;6*VS5DY1DYWE+8(X3^MMG8`JH,IJJEPRFXT'+,S0Q2J"+M:9 MU3"7+D]"CON,2?4X;[T(JAZ[_APQT0#/#7S^"J8M)]-F.#&ULJHRW`UB@I@Z M$K.-T7V_T7UYF_]T:,^K#'*FLN^9]9*B,K5]U0\WU55C]\7;F0@?_XK=Z)%P M9L>A&[FLN/FH'N6EBZ^$TM2F3GP>_"B@2HK5/&OD<1BM:F3>!53:)]U>R=6 M\QS!6]"^7K3/>=:N!Q'*G\_KH0?-_5*=[*3FJDK-;(D[[0'3YI8>,&D-$PP/ M#$^U8(+A,0(FK9QDXV-TND7BEF8=:S1:Q14*X_=C;9?Y5'1T!0`:#F"%U:3W_X/("T[IA6JM=3A4V\-A(#",`3($I#/O2PB4R]C2($R*U M]"#VR!CE@"U@"[*!D0V,L@Y:14RW6D+70E:D2.ZP![7915XP2%\STELY53+1 M*>6A_+S@*OH+JO)"):8U]=JP;Z&P0JUPJG`N`NHJZ-A-2U<(MJOKB0N("J(: M@8MN`RHBJ4;-C%!7`8&DV@>2VBU$3T'ZFI$^KU(BB)ZBJH+!=E)S56%SLPDP M87.S$3#!\,#P5`LF&!XC8-+*2=8E0I=43EY?V2/FQ![[-KQD@^A: M:N=:S/S>>X']Y[N__XV07U?],G3O:.3>L<\^C\)8;0'^C;K^EX#SS_Y51",F M/_LV_.3ZU+==ZGUGX3`(A<[L^>.)+=HL+GZPX=NCRS@43PS\&TO\)T\*O+D. M;KHWK8:Z.'J73C1GDF0FG4]/R4ZO$_NQ0'#-,3[@`>/BR06<,-YLGG7*7D_? M`Y6\3&]>.M!B+YQEK5E_:_:5P(:OOVEU(*6TI7/(CCUA5E_-KW\P.[CUQ0W. M_+/L[UA2RS&CYA_C%:'D39)[CWT??R0Y\O\=^ MYOVM!GH)>HEVO>3*?4`?01]!'\%(@EZ"7H*1I/)]1/L0PR%B9[,%OT)H4KH* M]8A@&&Y=2Z3KP2J;5L.D;;SQ3K2U83XQM;*L,MW]!T^*WXT,``$@``0``)```@``2``!(``$`!6 M'L!#)1)K(E&.,1US(CA%5'K?,+*S15RGD4-QXT]!*-KC$SL.0^;;CV08A/L5BKV@U8/_!]#HPO0FB@^AU('J[!Z:#Z75@.F*76ZWNZ2%K M'D3_$/"(!$,R"0,GEDL\//"<0F8W^NBM_-5%G=80D1N.I`XD=0!```@``2`` M!(``$``"0``(``$@.1+"@N_A1? M#M-LC!Q5YNOYPK"L86LH)VH7A'X"UTJ!?J:HV^U`7^= MX2\T]QGPKX>_U(E@'@KT?Z'P%$$7T`5T`5U`%]!%=[K4*T^N*$;HHZ7RXZHZ M14^1%8?E+"QG`4``"``!(``$@``0``)```@``2"RXI`55]^LN,_R-"+&(Q+2 MB!%^3R=/*Z,.J1M*C<4,I5&Q^*!)J!ET`5U`%]`%=`%=0!IOPHQZRYAJ>8@\3YG-6B/^FC\K*CWSJ%-]$ MWAH6G+#@!``!(``$@``0``)```@``2``!(#(6T/>6GWSUK8YZ=L/GA9^0R(; M<@>0.P"Z@"Z@"^@"NH`NH(N6F0_'_4)/LS,A!:#.B2\H1%QS^!O`O\[X-V'] M\W=T*IM@ M?BF5;=;4R4+3IFU.'BO>^?;(4H\AS^.?E9%D+W[])>:GMY1.7E_9(^;$'OLV MO&2A>TA(*;0 MA,VNA6U\[P7VG^_^_C="?MWP\<\\-N!NY`;^)^J&_Y8[DV M7<8AE3^[L<1_S8;5N;D.;KHWK8:Z.'J7&N*9\!FCG.![*JVR`CF]5E9]D=2: MTR(C4VK]1,>=#32*[,1FGI=VV+='C2-U+49/>WJ=WC\(0H>%LJ=[=,+9Z^D? M;Y('"UO64%;AJ>X6Q7MA66.EJ6FVRE_'V0.5?,QMLX@E59O)Y.HRIN2]-4Y9 M*W7*$L)%P>2U-8F$*^4S\M/EN?R/3+]4+'OVV^3IZGL>>*Y#?FJH_YO](.G0 MR_>7JNK^+C[!??+R0>`YF6?U9^MEPE3.$5-&A M\!>7#EQ/.`@%K?":S.,G'N\^([+AU"Z1R,>N/T=,-,`3/BHO8I96,9N[-I;3 MJP(QM;*YO\=^QLBV&B=++!V$Y)?%J>?N;Y/3,G0#=`/MNL$EL\\RW<`JO!NT MT0UV"NWV0?V>C)\-P?J:L18-+_\0"ZN*]U"I.N&)#TD[+=IEM1V?6AAN/U`^QM*=G;FVO^GM!`2``U&OK:^I' M`#3-0$.O`X``$&8311$..@ M]/EY+S*L4%#GK-_7=7^-U6C-R0"Z@^Y5I[L%NF^#YC0@KX6@>=#]D@U9&`HW MP/7M8,Q(1!_$^ZCOD"`:L5!X!X5F?^NA2!A(&,AG#&0/]A%L/R3;C2]%H^CT MTX-<]"]N=4P/@L'3V((7WP,>G;+QQ`L>Y>9=$@R$Z&HW+C\ASAHWQ`O\V].( MA6/B'6`OCQY*+S].IELT#&OU6+/`F@4`-!W`0RTZ:2*1D1BADP%``*BM3:F@ ME<1*?-57XK>:]0.0 M"LI=K3%*:_-&C,L."=F$NC(2-F$^9\^EA)QDU[?G M;H41D@&K1X#*F>YOR48!VPYC8:T/D9]G!N#ZKI'I/'U2;#KH"=W5"K5L-;[H MN>FBV6M@UT4ED;4Z0+;FNP#TG.?IH6#8"/%WMPL344E@K1:,?[V-_^%GBGKH MKOPYI&[9E-C)A11WI+@#0-,!K-L>!1,Q0B<#@`!06YM202N)5:JJ[^2Z9(.G MZU,T6:$BP9#X+!(WWS$>J4HGKB^^'*9[OW@\X*[CTO`1PIF5:?'J_,[-6:R(Y-JO4 M=9=NKMN70%/0M`B:MCI]T+0NB::5PPBF1"-3TFGF>A@Z:%I1FG9+IFDOUX28 M"M&T@B->';=6U"),HFL7U5PAZ7G;><76!=F)$\0#CVT<7`<83\_V!A@Z@`%3 M`5.A+Q@P%1J!`5-1^KQ!;X6`(1A,-`8#@XE&8,!4P%3H"T82K@486H`!4P&_ M4[=PMRYY*=;X\L]1CR MO$ZR,I+LQ:^_Q/STEM+)ZRM[Q)S88]^&ERQT[VCDWK'/\W,&/_M7$8V8_/O; M\)/K4]]VJ?<]X&[D!OXGZH;_IE[,KME#]-X+[#_?_?UOA/RZXN%"`0&GWF]A M$$_$4VTOEOP3'\OSZ5T_9LZW"0NI?*K\.ABSV8O?4T^\EEV-&(LN?.=",%?^ MC'KR;B_@<295D MU9-9'4P8D`Q9D@;I=3($+?0:W8ESJ*8]O?/%MV3S1#/JG:D[8Y](JSO//7TS M7ZO-,GZ]RK:Y`Y)`$D@"22`))($DD`220!)(`DD@"239_([5T_%,B"&-4#8: M_YC=K*)3Q&:>EPKS]JAQI*[YA-K3Z_3^-"IN!YY')YR]GO[Q)GDP.4]"?5DU M68VS_D+$3[WT^032E2'$=OO,ZI:<,;M'F"2O0'NOG?NY`+:@-@MWU\KNQ2L[ M:\Y!:+;/NNU2*RZ4JNK^+C'L^^3E@\!S,L^:];_K4HEVO>3*?:AX'Q&C=-_[[.GJ\[_4FXR^>PY[E252Z\@I@@IH[$;(.8 M(*:.Q(3%!#&U)&81%K-6\Z'E'?K3R5"M#C_\RB)R13U6Q)DCB:'3HV1D"09/ MS_/HBB]C!=`!.D`'Z`"]@J`G/J+IH.?E*^[J$38;9TU=/<)+=L>\8,(<(AK^ M)XLXN64^"UV;D\F(AF-JLSAR;>IQ0GU'_,\=4X^,&/6B$1G$7#R7\P+]23,8 MMFEO:J+TH-+$^5DO)TU4^Z1F](!J]X`-Q2BF*OIY&^0$.?4D9[/3!3E!3CW) M>=YOZ1%X-V?JE'^87>=)U<5@\&^7(<9>CR",,3,)\`:\`6_`&_`&O-&3-UAO M*,1I-K.LF'FFIG15&92F!\1`;I"[VHB!W"!W91$#N4'NRB)FSC1-EZK'R"K+ MA`FN@XAZA5E5,Z(`6-?=3A/("4,/0`]`3AC("7(B)PSD-(NN)CYBQ1 M5]NDN4(2TX;#SK0`([&N`$,+,&`J8"KT!0.F0B,P8"I@*O0%`Z9"(S!@*F`J M]`4#ID(C,`X?JC)^B;]>108_TM`7,G%R_"7@_!5YSX9!R,@U?2ALX-(C%04[ M35"+#*`#=(`.T`'ZOAZFZ:#GY3Q6,3\450>1)5+'+)'CSO[<-`&]5X5%Y,!C M'7C<.X>-!3?UY&:S`6Z"FWIRT^I:9H7>RY_^H'(@`BE5#:08L]\,O`%OP!OP M!KP!;_3D#=8,4#G08%-3NJI0HL[*(F;.-,WX M;0557`!!Y<#-NQ+6=759UT5>%WAP7054P M@`[0`3I`!^C[^IBF@YZ7^UC%+$_4_T.>"$Z8WE$U!]F!CQY0W1Y09J94&P=, M@YN:[*(@9R M@]R510SD!KDKBY@YV5+&Y^I7<6D`)?4V[TI8\-1EP3./-0X3T-LMF`D>F\+C M5A\V%MS4DYLH6PH>5X+'K1RRHTR`KYREKUK,('4=CS57""IE:`0&*F5H!`9, M!4R%OF#`5&@$!DP%3(6^8,!4:`0&3`5,A;Y@P%1H!`9*]6T=Z:I7J;ZO+"(? M:>@+N8HKI:)'8HI..P+H\`>"NPACE*9*DN%UM<# MH(<'M-"2>0"TA/&ZT"IX0+0$FUMH83LS$-7.-3,S'<0$U"ZJE`5QC3$0&Z0 MN[*(@=P@=V41`[E![LHB9LXTS?AL]2J&V5&L;O.NA-5#758/C_>J/X/D(?!8 M#QZW<^`Q;"RX600WFTAL`S0YW62E9%D+W[])>:G MMY1.7E_9(^;$'OLVO!1M##CU?@N#>,(_^[872XJ(CVWQ;->/F?-MPD(:N8$O MOP[&["JB$1LS/WI//>K;[&K$6'3A.Q>"7/)GU)-W>P&/0\:OV4/TW@OL/]_] M_6^$_+K<@$_4#?]-O9A=<,XB+I[SQ:4#UQ./8OP/1N53G&_^#V;'82A:]IYR MEU]+/&>/)K*IXN('&[X]NHR3QMY8XK]FP^K<7`.A//?O-4=8O2O1!H7FFNVIVSUH%CS4N1]3U` MR%L3+EK16F_368MGIGG3Q]P.VS.TM5 M=7\7'^@^>?D@$S,L_K3]JOA;PY9,)S_+4?2^94:4^>7Z4@JAVVMW/W$ M8]QGR#*NI+],UJ($:+(UUW8D7NW M7"HHSU?\D=1F+:9#&^R!H4.7WZ&O1#/SHA#@O=.RKS*\C0]:EON]03C^!1&,N4U.)F6*;/T_,/SI3K[K7RG)4`7*TB M;P8,/HC85MLH`%P8!43T$=%_0J!/02A:Y!.YAYCY]B,9!N$]#1W"'NP1]6^9 MVD(<4KM`3]0,%NUJ?T/TN3).4P"W,]35_MV"8W30]9]#"J`]:'^X MK'@]>`#.@_-K3'TKUQQ[/:@`VN^Y8%1&/\"RVTYS6CU86/Z"G!YZT#P,HI,_ MKKFJ4AM?XDDZ@&GS404PZ0T3#`\,3[5@@N$Q`B:=IJ6:JPJ&QPB88'B,@`F& M!X:G6C#!\!@!DTYA0>.38'3;EUGE$S,/M[ICU(X@\RMU$C,2#,F(.;?,(5[@WYY&+!P3APV*..%7IU43Y-0@ ME>SE&*!CX)F2<\ M5(=$`1G$7-S.N?C%>"`\5/D]PHSFA2ZL[CGBC-6-72#."`Z``S#8B"OB')BR MQ^O2%8)B\'KB`J*"J$;@HIOG4[I"0%0]<0%1050C<-%MBF)\"8PZG@/SQ:4# MUW,CER$O8M\.AXT)9N_':75SS1O6@PJ@O?ZT1UR\3ND6Z$_5'D:L\RZRC$#[ M>M$^YZ4U/8A0_J*;'GK0/-2AD[NMN:I0@-@(F%"`V`B88'A@>*H%$PR/$3#I M-#/47%4P/$;`!,-C!$PP/#`\U8()AL<(F'0*"QJ?Z*+;QDN<]5*[W5@XZP4` M:I9H"P`!(`"L]R;'>A5/NV0V&P]8.-=SRSHA,HOK=<572U`TYZ!^&$"O&^C: M3-8!.D`'Z,7ZB*:#7M6X6AX^XL>_8C=Z))S9<5CL-C$SN++-X@^2EJ?K*V6F M)M>X2!M(6C^2&A.S`4EW(2GV"J('H`>@!R!N7]^X/0X]T3G@4Z8;:34LE+"H M;#3/@,$'4>!J&P6`"Z.`50*L$CPA$,Y3KG+=_&:W5=\8NE$Y@08,!B8&Z.K: M62L/E'F=%2#QJ` M\J#\BW:^VP;I0?K#D]Z\!3:D1I6WTJ:''C2/;^CD:FNN*M3@-0(FU.`U`B88 M'AB>:L$$PV,$3#I-.C57%0R/$3#!\!@!$PP/#$^U8(+A,0(FG<*"QF>WZ+;A M$L>=U&ZK#XX[`8":9=<"0``(`.N]L[%>9=,^43>4.HD9"89DQ)Q;YA`O\&]/ M(Q:.B<,&4<5739`QHW_&3)EI8M9)M]5#0C!H?WC:(U',G%`T^I/^_:DZPPAH M#]IC&*G@PD+Y\]]*SG)1BK'"U=VL5B?/^5FU@<)@@)AU53IKY8$RK[.B%",6 M+`HU_Q_$9T(F\7[ILW'782&-W,`G(?-HQ!P2!6001*5Q7(;1IB(#?(75G$S)FFU7:+J?YETK^X=.!Z;N0RI(MLUJUD$A]2 M]::I>J6&M$X:5HW394#4;8B*F'WUL;[(4B+HQ41LE^Q3Y M+I.90=.2IDEFSBEU=2@U5TCY!>0`AD9EX@`&3`5,A0%@P%1H!$8-#^F%J3`& M#)@*C<"`J8"IT!>,)-`#,+0`H[XGJB>75/#F:1QP^NTJR7<*R*V3\26I9DV= M+#1MVN;DL>*=;X\L]1CRO$ZR,I+LQ:^_Q/STEM+)ZRM[Q)S88]^&LJ+BOV5! MQ>0P]0O?R:0+_,$HCT/F?/-_,%F,0G#G/>4NOY;JO&8/T7LOL/]\]_>_$?+K M\J._LN@]\]G0C3X$/'IRDRIA(2Y^L.';H\LXV15Y8XG_F@VKW.!,K$>1/,$A,B@4NO$Y.PP/-]H6Z\!/63'[[XT&Q:2*;),Q$RO92T MNO-4DS?S2'86]ZT7&?=XP%.%0$[("3DA)^2$G)`3Z0ZWQC]G-*KI';.9YJ:AOCQI'ZII/J#V]3N]/8\9VX'ETPMGK MZ1]OD@<+=3?.Q,.7M+@8^WDA=6YE`+9EJ8>6FBNX1W0RKR!T)R<=9%)";4%[ M%NZNE=UKQ5C6FFV4K6:^2R#;;Z,L5=?]_"HR]J?MOV1#\5-GCEH:89Y_\-VC MA53/`WE!WCW)^P=S7)MZ<]2HGV'RI6A?]LOBB)S72%0&D9^L[F$PACU3]JRS MKJ1!IWQYB[`IUZ.0L;G>_A"_&&'X`UV>H(Z7Z\__%DWQY(EBKV!IUUG:=761&[TJ4%0K2RLW>(&8(*:.Q&R#F""FCL2$ MQ00QM20F+":(J24Q83%!3"V)"8L)8FI)3%A,$%-+8A9C,6L4?5^N[3X-O>=U MDMCL<*STS*MG%57FX5A7++QS;2:Z,\]L'_J?S!$L9)!L+N*$T=!G#G%B60*+ M1"-&)BQT`Z-WHG/5?/.1O0P$+.4FCVP?3P?1: M,+T)IH/I=6"ZU6F`ZJ!Z+:C>A/\"JM>"ZET0'42O`]'/0700O0Y$MSI@.IA> M"Z;OZ:7GNK1AZO&]NVT:SRSD;+B,<^!%G,]RB8WQ2*WBD,`GDS#X#[,CYDP7 M;T@P$#I1QXOH7;M"WP7L,CM_KP=T-$8G!R<$Z!3G(N8P[0<\Q<&3PZ(2X"D, M'@OH:(P.3)O&Z#3A%VB,3FO/<:?TZF/(C"QT4OWQ89),H4,6Q:&OIM4>]0E5 M1X06-HDV/4:SJRG0,^IV7/#JN`F1UE<[<;TJ^%LMX%]C_)N='$)OP-]<_)N% M)HT`?\WQMPK-`P7\FL-?:"(-T-<<:8J1I.^LHC0<1!& M[G]5%@8)AJ\+BR%5.U*4\P;UQ%;HDZ8'``$@``2``!```D``"``!(``$@$A/ M.7AZ2K-QUM0UH'!A1S$-7>H1+^#\A/@L*BR>@)P4G>*2;53AJ1BBS380K1:B M?>S`KQBB;2!:,41SV-D"0'4"%*-HQ0`M-OD*B!I7F`A%+/;/DM`YJ/$]=(.0 M\$Q-E"6%`G92TN[*VG!D9V[$J:[ ML:4KI&8'41J#"X@*HAJ!"X@*HAJ!"X@*HAJ!"X@*HAJ!"X@*HAJ!"X@*HAJ! M"X@*HAJ!BV[[)TM32%Y1^'I5![\.(NJ1#P''KLO<+:"6F M,42M%B"M&J0-[.JJ&*3'A2):O329:J&?QX%RZ,\Z(5KH`1D`M(1R)#FU@"[,\"!TH-A@`2?&A4C,S++1U024KA#DQ^F)"X@*HAJ! M"X@*HAJ!"X@*HAJ!"X@*HAJ!"X@*HAJ!"X@*HAJ!"X@*HAJ!BVYA=&S?-"J% M\2N+DN,E3DF:Q"@D/$06H^EYL9O*:C5UD34/NOQ<`!\Z9_V^KAG@V.P*IM># MZ6UL+P33:\%TJX6-6J!Z+:A^W@73P?0Z,!U[Z5\5,E5'KS"Y5Z#&`)A>#Z;# MI0?1\R1Z5U>BHR:%ADL]9JZ8F6<5LJUYK7R+#D*<(!YX;..E;\"TN1\# MF/2&"88'AJ=:,,'P&`$3#`\,3[5@@N$Q`B88'AB>:L$$PV,$3#`\,#S5@@F& MQPB88'A@>*H%$PR/$3#!\,#P5`LF&!XC8(+A@>&I%DQIMA1@TALFI#S-KF>I M8LDE%5R;W9RFV4V_727YIE(N)+BMD_$EJ69-G9C2M*DZD\>*=[X]LM1CR/-P M9=5/LA>__A+STUM*)Z^O[!%S8H]]&WYET7OFLZ$;R:.G^;7$\)H]1.^]P/[S MW=__1LBORS?]8'9PZXO6.)]EQ05WZ#+G@G,6\0O[K]@-Q97O?''IP/7/F;/X<%4G05S\8,.W1Y=Q4B?AQA+_-1M6Y^8ZN.G>M!KJXNB=%",K4B;' M,T$ML8D2NO0ZL7$+G;!0L)_\\,6'9JM59)H\$R%C0DBK.Z^`\6:>Q9I%?CWG MMKGCJDFR?,=J3SKC,";S.$O,XF8WJZD+L9GGI<*\ M/6HO/YUYB9N+)LFRO"@@0)$#E M?#"1+7H?"W>;JOR?;?:$367B.'W;#3.(;X343]6U<.#U1%.$ZD53QUF!/;D?RX,`.B M1X2Q^([U\EYX;*-^;?7/K!N MUL&,IAETV=7'*K>C=W/HZ&;@`W]I9W_)9Q%YXC'!0\K9#.CI"33.&GM6280G M4%U/X)(-69A,J.Q@S(2->!#O"YDM8TX.H1&ATH1P5ZX"PSTPSCTX;IQU]BP= M*;N_"5.\[6*&)1D$,].*=.W+I2MD:Q>A%LL$Y>.BVYQ'EX1`3)G6#B/7040] M,@F9YXY=GX:/A'I>8*LT.!(,R9"ZH=17C!`S0LQU#C$WS\[WK-6)B64!!M;, M<O$FS6M"J*NW8?7SK=*B]?IJX=NP MQ@5NPVJ=M1OF;MG9?N&_>]:JP+:S=>&Q5JVW8?77'*A7M37R"]L.8^:0`?6H M;S.9)GC);!7TF:N]99V09L-J%V9#]`C'%M^W.FU=9,V#.T4LD[?/^B\>^EGF M,GGK?'_+J@?ZY5O8JMG1[_1Q+%[-"?4=$D0C%A+J_"?FD?I4:^=+7U>KS,Y^ MO.ND&WM0#UB`>7CYT58[X>'JG+OD^V]\!22`))($D MD`220!)(HKO&R#_&VC'R MCU<5B+?Z^YM6/>`OW\16S9`N1*")/1(MSY9_=OUBLV_,((^)B]IVTY?TJX#T\>0G?.0M70+CMM[EH5_6303/,'MH@O:V1DS3)#W7):EOE M@>_S@*<*@9R0$W)"3L@).2$GY(2]CH<>KE8#UGSX$[M]CJT.ON;5CW@+]_$5LV08J]#1?Q2A=5=CK8!IBYDRI=$G3 MPHP,>QUV\L:PUV&;=-Q2`U%[%]VHW9RT%B.!KK9)02FQUN"]CL<,5N97ST!YL$823N_^P/@W"L=C.\?TR_W&73@R:[%`H&]X`) M7N?+"5Y6?\$(K'''5EJ59O>LU2S9_]P#E=Q\#H/S;);B:9:U)J#6:I_US,_J MVUG71>3Y?671'+$KZC$^OXR"^=\?'T1#?>K-/_D0A2P3XO]# M_&*$80YT>88N5^X#R`*RP+:`+H;:%KBO<%]K:S,PZ\[/7'WT'>;,(7N:*@/. M@K/@+#@+SH*SX"PX6S!G,:U)IS6&T[A$TAZL#DK%[.NZO3&-WEDGSQ0]V-U"`#%!S+V)6435%Q`3Q(3%!#&K24Q83!!32V+"8H*86A(3%A/$U)*8L)@@ MII;$+,)BUBKFOEPI8!IP+Z!ZW9GUDJ(R)5+4#S?551X%,CYRN6/0Y2/FD.\C M&HZIS>+(M:E'OH>!$]N%E+%+3*`>=7N*+YS2U*8`EZ8E5804K1=UM*&`Q1PL MV^N!ZJ!Z':C>:[=!=5"]#E2W3OH]D!UDKPG9V_M6,0?9079#R-[;LQPWJ`ZJ M&T+U;@-4!]7K0/56ZQQ4!]7K0/5FW]I_%4PN!IH/=H#$\OCZ`$X"D*GDY_KT6O_-(AS9DNUROY\=*EMW[`(]=&LF-1 M!D#/&)MU8B&MKX*@YN'.`E2=0&V>-'M8Y:P;@X;+`!/ MD3M@XX`MZC\;P=+HYQ,8`3V'P-/>"IXZ9 M`H>4=O'KM5_O.HBH1WZP21#*4PL8 MN6*W8]$:[-K+W2!JF>C:/NFW:,3" M2L2%:Y94G$>%(@.K;>`#4M%%]>`U#.AVDGP!U.7``( M``$@``2`!0&(G8/%2JMYQ@M2LY":I0DN("J(:@0N("J(:@0N("J(:@0N(*H& M4U1CE`.V@"U@"]@"MH`M.K,%N\FVCLS6:S?95Q:1*^HQ[![;5];FB^F5AY0U M#U[\7``?1/_2-@6UV&5@`':`#=(`.T"L).K;'%A+@-3-.;IZ=T%Y5S3SS=$0'(4X0 MR\INFR;J`*;-9VV`26^88'A@>*H%$PR/$3#!\,#P5`LF&!XC8(+A@>&I%DPP M/$;`!,.3495>H61CU`:&@6%@F":J`L/`,#!,0[69LSQK_/:=*F[2^1"$DR"D M$2/#V+:A9X9#`/PWGAU!S'$)M8@15,\2$"J%:2]O0RO3MDCY6_NKV2HA47BZXB%C$>$/4R8SUEA<18S MZ()%2@`(``$@``2``-"D-<@"#'8Z[C MJQ$-V>F`5;-&+A"?%91(X'2$_!^B5`!^@`':`# M=(`.T,U9H+0:A>8G`-(R(C#G.433ZK3F7"W\NZA#4S%$C]OM0JN65*]':Q?5 M,?.<(/-,1NFJTFLN8(S:P#`P#`S31%5@&!@&AFFH-C"L.(8E9]R+F<"J$^Z3 M+^7D[/EODZ>K[WG@N0[YJ:'^;_:#,-'D\OU`#.0&N2N-&,@-Y$Q"A6:0LZ2( MGIGA3UUM4^D**6/2:8QRP!:P!6P!6\`6L`5L,4HAS3P3,X233IP@ED5\-\W, M`!A/9H4`0PLP8"I@*O0%`Z9"(S!@*F`J]`4#ID(C,&`J8"KT!0.F0B,P#K_$ MIDO.?7))!6]F-Z>KEM-O5TF^TT+B.AE?DFK6U(DA3-9)K/J%V>CU[0#C[RUE\3JL[(TA60YDOYUIH9'^:M#]# MER<]1ZW5IG^K9>[%1Q.K?]:0#R0KE3=3\ZQ%D]BWHUAM7CB5B^JO1_),*O]V MQ?ZC1;NU14+"FPPQCA;[1!;NS*]V;-4VZ05)2Y:.9Y_WSLEBYW2>@[KQ`M+R MN_E?6T*^@'(6?]V0W,)LRAN3/5;I^)@\YF(R"8,'=TPCYCV2=H-$`6EWR(2% M-A//#88D&C%"?3^FGBI;;@=HW MG3UC\9\@^?O^'B M:^ZJ[\6]?SQZU!>M"^P_A:$3:B4.LT,F[,W,:%$WE`J.UBL&B4#&(NI..BA?9?L9N\[83RLP\BV8M??XGYZ2T55+NR1Z+Y'OLVO&*W8Z&Z'TPAY-]^]H=!.%8*?/^8 M?GG-'J+WGL#CW=__1LBO*QXBAX3W)V@YZ(51UYT:/ MUU+:V?,4=N+B!QN^/;J,$]QN+/&?9-7-=7#3O6DUU,71NW1DF$F5&242HB23][ID, M23Q5TZ+K^,)&E)7+`MW.6:M;\LZ;/0+3BX#LNC32/.OGM#22V58E8VLLW%TK MQ94QL%IG_7:IY;-*575_EW6I^^3E@\!S,L_J3]O_+8YX1'TI%/@)?FK'SX\/ M++1=KL)"^?/3.K,,YF+;),+J\GS,=0^MURNW7>#Q@X6SMIHAR;(G9TZ-^ M8`GF3\OCEEJ]D\9Y_\1JMN8:`,;5PKC9.VDWK9->KY,/QLGP8#K&>0T351P, M_E>U1Z[=W[&0WLJD@#%U93E/XKE#1HZWFGLG;Y#?O78CH4Y[Y3L?&0V71YUM M6_ZJL''+#%;O:KG*M$_ML_,\!Q\`59BS<-;.Z_I/2YN#HO)@2P$UM*SF64=;C[QEG36ZF'"!]O6B?;-[UL\ISH`Y M:-7GH!>WMR&[I9',Z(Q"U^>NG>9S%C'[='TBI/)D&B+FH`'2Y;87\#BL[+:$ M8C8V/[M]:2=;N(LA_!H(!])JD?E6HO8;DL)+,OM8=A0PI_R&NJ"QL2H)W=B"8L@WA+(K5C\+*/%V5^KFY7<0.3=M\QGH=KXQ0//$0T+F1V) MJR@@(8NHZ[&0RXUB@<=D8^3%*.`3.=^0?V;:(=KM>F[D,O&Y1P>!L!M!J*XF MHT@Y M&PL9*@.7[)5-^D0B+^5D&'A><,]?[\@U=(.MII\?N43!Y6(8(]_%$#:F-HLC MN2F;?$^)N/>T=-$&?I;6RE=:$"^1K.6K^M`@%,03C5(]0,S`)XN-FW.D M,?(B<6568#1M.'K)07K)ORE7,!<0.\ZOVSWA^`O]SPY"86NE:\Q\)[A+A3L1 M+PMCZ1F+[B72>>OBIV!+,Y`QL)XRS%<^-;"PYQ;;;))KYJJ M4SWOH^A"41@H#S;P@MO'.R>JGLI)6B1%CJ@3CZDB)IER*J[L M?,FL67PCQ/J3B4^>N//\B3_/YW-P,;5-BJQ\/?OWRK'W>N1F?J[*HX3"D@0Q M%Q/CE$.S$E(;S&]F)D=Z#_.R4]Q](&.AFY$R>XD]E.9+G1R?V"+YX>QN=Q[3 M(0,A_3T9B:8-&/.%W_J?F*?%7L3]TFBI^VV/)Q2:"03Q7S(9!+K+),EOA+;6I2UO$J$O^,TVI>'VDH4V_1QPX5 MDHH%)J'W*$<]:MM!G)0UDX719,DT:0EE-G0D_B M[B9.<#9@(Z=+L>@#=F9,#=E?L1NRU(*NZ&332*4S"T`G[ULL41?>4+55A@VI](QFTL^GV!_0]:=Q>8`DZBM^Q. M9X!D)BVRZ$R")+.+?@IDB7:TE257CTG27[^7DM^/V+$EFY)/YT-CR>;CG,-+ M\O*2C#@M$B.3&+XPPH7::M<;NK7RLYJR]C]Q=R7<;KED/Z-^QB?/@0]'Z(4] M.6@ORV%I.6_'H?'\*S0\\FB&'-#`;`R"[X?.Z)"I27^Y%'R)+TGEQTYQ@5%; MX%TSF2=&Z?0Y;W_E1HK(7DA[`NPHEV8&T'Q*(V=BZ&:G_XW*.6^SIZACMO,X M2G2VJ>0)KB0P]R).%6G&/H\M,S%`]C+/FK>XR,U$G6F8%V6LXZGF."!CF7E` MQ\>%-;G==5GL1%Z'*[-#K:\YHT?*)^9N^J4939R\](8-LG'I5':YFYH/OTD6 MOI=#GFMORG!WO8!2Y+/;>&3"M[;;PBXN[/&0A+:V<$B",MX%NTG,U-(%X`/< MV"G>*0G%G34OQ"YT15FS@4+33RT3V]#?%%:R9AOZ5Y9,C56X;V+R,0DG?U\^ MY_9[\N03C<2I4U^RXPO"AK`/+NSKT5!J2L/#P6H)@BWN*/\*G+>`#OE([):Q M;D.C>?CZEF$[[A\CQB:X?,\0"L<"V0"X5M2T8OF+X>K0V M`[/NXLS5)5]>G5#V[S28ZNLT&9J%9J%9:!::A6:A66BV9,UB6C.SK>QY2#&%"F"(*4XN0.J1^ M#%)7FBT+8H?8CT3LNFI`[!#[48C=4B%U2/THI&[*D#JD?@Q2U[0VI`ZI'X/4 MU9:R^RJ.&/0??C6GCFLV&UU$(M(ZM;BKTH>=E5M*`4L+(*A$@K2=3#$(*GE0 MV-1:)@@2FB"S`&\,""J-H%8!TRK04QH],EJ/P/1813@E0$]9]!BMG1:]B@N' MK,YT^;B"'S>YO!'!CKL9`#%];$I305A?#4DM8C@+4D4B56VJ%E8Y:T>J)A?@ MN`&I(I&JR0BHK!FEJH7^M&:4&BWTIG6C5$;```(&7O%S+%SM7IJ7HQI:J:(S MTU*Q%"`R/68!&RQ`3YD[8`H8]X"@\@@R9`T$B4N06L2\`?24YWQ!ZQ&8'L,L MP#<&>DJC1]V)GF.,%-AG;;>?`H\*-X=/U:>^!P?DR$Y_JPPO$"J$6@E>(%0( MM1*\0*@0:B5X@5`AU$KP`J%"J)7@!4*%4"O!"X0*H5:"%]'PSJ!VI1AN[]FI&JM)4=)P-7SM295SE4C=2U:9:Q!X0D"H2J4JSU<;N MO4-%)5;"ZW&=/+*H%G[A(PLJ+N*$(=!3%CVFV@(]XM)#\Q*(%0( MM1*\0*@0:B5X@5`%F*)6!ARH!6J!6J`6J`5J$5DMV$WV9L_L<>TF^\H2Z<[V M&7:/[5I7]=7PRGW6M0A=_+,$/5#[$C8$U6@JN&$+8C\6L6XJ#MYI^\NK9 M">&A4HN,TZ$&(KEARD]VVS10!S1M/FL#36+3!,,#PU,OFF!X*D$3#`\,3[UH M@N&I!$TP/#`\]:()AJ<2-,'P3$$EEBNY,K!!85`8%"8(5%`8%`:%"0A;=99G M*[]]IXZ;=#Z%T2",[(1)W31P$B\,8LD.7*G#`M;U$HD2H"=.&)=X"50U8@2V MM5.U#O\`@2`0!()`$`@"!3U'^YTB%W!53Q4VI/RXEWG7@;DLX'Y*<"D$EZJZ MT\4\X%(@+A6S@$N6ZL=E49Z'(SLX)`Q.HLDEU#$NH:ZB!U7P`3=(!^D@':2# M=)!^%*0?.-H,\=#S;??2*]L[=K27!.8B40I(-T MD`[203I(/U[2#SI'*/?RI_K-'FI&O]X"_4=,ORH;X/^(^5?,G;9:KHLWJ1__ M13F/ZN@B.N^'4>+]E;N%PBZ/4[&#GL>W!-EQS'`@R9:VXP@F!2`0!()`$`@" M0:!XZZB*@8,/:L,EXAMJPZ4F(^RH+ERJIKR[)Z)^7!;E;SBN8)7KY)%%32E@ MB?2N@_`4K%^"=)`.TD$Z2`?I(+TZ"Y2*7&I\`B@]A`>F78`W[9C6G.O%OXES M:&K&Z#M=+_74DOJU:.&\.M6\)ZAZ)N/@4(DU%Z@,;%`8%`:%"0(5%`:%06$" MP@:%E:>P_(Y[F@DLN^$^?\DG9ZO?YJEG[^/0]USI!SG[;_R%*$=R\?=@#.*& MN&O-&,0-<=>6,8@;XJXM8]4Y$!S7R0L8*?DI#+)F9R?,E2[M**`*QE(W"OL2 MO4J\(*4'TO6`179^U_P%ZX81D^[M9X;]G-L9S2.(H@&!(!`$@D`0>"0$KJN1 M6A!I^QP;_;.$\0V-)`^\TZK=*B``"^*$.$L)#C0*B/>%."'.4H+1FZ;6ACPA M3S'EV6[O),[<55@-<1[(HU=-]Z>HMNG@@!QBTED9<*`6J`5J@5J@%J@%:JD4 M(&J1@1DT2)?<,.6'^&X:F0$RYF:%($,(,F`J8"K$)0.F0B`R8"I@*L0E`Z9" M(#)@*F`JQ"4#ID(@,O:_Q"9*S'W^T2;=C'\\7+4U<+]ZI/F-9AM M7>XJKN17J.+O)G^]D;,9FJ8)W#<5;[!K_(?Y)JAA!Y8G1EXCNU38ATF1P'E[U*)LI2Z7D2__S.UHX1%DILRGB%_D7A]ON-F MF&$OLODFG-[RG$Y7F.0YILXFS?AU&PQK4G]KTH$U*=^:3-T_0.U=E16#_N_X MJ4N%L:6>30_#W`[$-K4I:MRV-."7)^87)YYW^/@Q&PC\\$R_;K^/Z77L9>_I MMU]>?#N@TH7.'V22"#G)94[$R#*,S8OM11S#-$O<"3,CP@T9_1E[[G`W']DE M/]OX1[;'ECII3+6+J83.GZF7Y]:4GAX]YU%ZLJD$9*N\S**%W6Y,5>N\2`[9 MI!ZO5!R'CI>E]>0EC[EUC)B;.L,R4VJ4Y7=6N,T:_SAGC%CYT%!RK:\>L$XG M)$U_^/DLC4]Z-JGICO7Z!-@MRW@)>I^]V/'#.(W8/7M.+GS"_N/?_R9)/T]^ MX),Z>K^R@-#USP/WW"5+[L5)E%7\\GG``B*(W M*;ABZ@AN`JFP45Z[SB$9U/<;-R\7+Y"LW]@M_=,Z'=E_#X'K`OWM) MICAYN0J(EI2_C7_E(T+FOJ%N#\/2/&0IW[\,V/FS%S_8G>3AEE&ZGD/IW?'. M)/M"_(7U.RR:1T2;AD1N?#1-V6I9Z^`HHJK5@73T=`Y6CE]\>_=M,V`-R](- M7SS1S]&*>P55`8J!1E_,?/AY37H-CC:XN^P,_?&$L4U6> MT7)-S:-H*LI2&$NI8$&J6LPG)W`?^,W(\.KK+]0!6+JJ6)91@`Y75:PTW/Z; M^8Z9>_Z=>OH>&[YA-V2BV#[0U*?15`E+\[2EE0+D:S4MK7W/97K+^C2_HY$5 M/S\ELODDJ0ZWNITO2?U?D8OND+:HZ MCW48)?SY11A%X5-VZ-FB[!3U05,V\EOH6DM=M&8+>6Q3B,U]%"UST$7ZO;V)YE M+I,[YJ21EWALP_+KIK7:#*PNO]<+O*[GT.CO$U_$H@GUMV"R9'QO/U^P@'4) MUZOXEC`-`QJ,O]S0\-"C0?EEG&3+UNXM_^EU-T_BM_")11?\R,]=M&:HBV[/ M4@M;/C#?!H,"@#&UO0`S*>P<,+R7?0Q]ET5QKM2=;+:J&.JBGVTACRW*L'GG MI$ MSM06S7$AY=I37=]`D;*)2G:O*C65<_=_Z=!6WK$D\;-!8=:M!&E,0[J;*/SN MQ=F!M)LO/CVXS'OXC?5L_S)(J*0S!O\N[<2>ZU%W-C+V4]V$$_9I9$O-,QN; MVKX=..SND;$D6S9SLZ5RVY\L$<<7+_2!^D+;IVE\.HC'H/#O9*OQ*7,GI^J. MNU6JUX!*D-C1RPT-@/NVP]*$QQ'1"[Z8OF$_I,@+FGP3J'-\##ORC.O<>_ZF M-K,X=55:9JNM&\J4.W5))MN48K.5A=RE*[=54U6G)]!O*\0JU\GFUH-&[`M& M;S&++8JP<:-N6\I"FUY7@A7=6NZV(J5GD2B?1Q$I:)]+VJ>V$$?P)E#+XN.- MX1`+8Z`=*C$WCQ\MUGWV_)2OHV9M<6K:OT/,P>P:HT9L&)JJ6MI,3=Y8G!+J MLE%HS9*Z*):LFX+592-Y+:N+W#85P>JR40#.DKK(.@VS2Z_+PJ\N[-ASBFTM M-.;-PG36UF1Y80JOQ[8M13:-]D:,[*D>V[82659;(M5CRQ:BMS7+VJBUOU:/ M?YR<_!*&21`F3+IC6?CIR4G^BF8^'SDRJ]-E. MPFB4Z&/$`?CABD8J)U33UNBY;W>83^/2T?,'O^,WI+.9I$RVI"R37\\U':NE&\#P%P! M@"D"`.8>`+!6`&")`("U!P",%0`8(@!@[`$`?04`N@@`Z*L!4(H"0%T!@"H" M`.H>`-!6`*")`("V!P"4%0`H(@"@;`7`*,V9(M*@)4PC9YS1)D.,^<(-(9HQ M1,]]GY[SS78L./EVU_A8S/ZC^NT]^OELAIP#,:8L8:R:^T^7X3GWC(^SZ?G/ M9QPI^N/_4$L#!!0````(`(>#!$_SWM'^X9X%/1L[R)M]W@OH M`%`;H;V?_O77OWSZVV!@71((?.A8DS?K'A*"7->ZQ&2)"?`9`6LPB`K^=O%X M9SG8#A;0\RT[JO6"_'E2[X(@9P8MZW3_Z&3__'S_<%7[`E!6FM$39([WCY)? MXO:Q]]'Z\6!X<'QX=&I]^'AR]O'PU!K=)^7N&0=3)"OH(N^/C_R/"6O0>J7H M([7G<`'NL"WX^;PW]_WEQX.#EY>7_=<)U2TK=!(7)SU<*WTRTE<]NC@M_N[)]'Y`?*H#SQ[58O1 M1`6M;)7?ZE74SM&'#Q\.Q*][3'J6]8E@%S["J26^??3?EO#S'D6+I?]\#$'W`%')Z=''+V?WCRF18Y-"ZQYT"/:9O]@V(7.5R[R:_CZ34@'H,B MW;-X6[\\WJ[U"TPFV/?W;;PXX#\?E"`K6%92P<%[\7R)%TL"YZP(>H:W;#`N M8,WL9[9@BB0N@,O1^#2'T*^#[W5ZIG"9U@:@\QL7O]0-\A3=]^/Z"E';Q30@ MD/\+>S[R`NB,ES!<(>@5]`%R%5E5)M8&?V-_#DG&2"K)H91<&SS>((^-'03< M6[9&$+&8,Z$3],SD_PSIR'-N`"+_`6X`[R'@-6*=#'7YK]14&[)YP-2_9C7P M&^_K!?3@%/EE\2TAU@9_3W#&^W+K33%9B/%6DK<"0MI\V<"U`U<0N6._1;SP M!FLW#%*2@Z\^9/68/,[#ID5JN5U&?_3AJPTBVDBN"I5<+Z$-PS_EUL MK_7,Y98J)NM*C<@)4E-`)X(>L^5G`"RY(3P\@*Y/XR]<_\/!X5%DFOX0??X] M[N4#)$]S0"`SRI$=-^2""72%@U!4]J"%;H>SYAVF](;@1?:Z\14R57\#KZR[ MHJ>BSSFLE:;W^]G)Z?GP^/S\_.SD^)3]?3I,220%Y!%9%PX@B9C9/[>PO8Z0 MJ,0!#1;AV!H@!K2X_I1U6:JEJ&W<%,^8.)`PWW+/"BAC!2]Y?>#N62\0S>:^ M^&5)$";(?_N\=VP";"Y#?IFP5@SK@T5*I3,0*<=I!(QCHX&Q*9$KY`;^:BF0 M3(1)Z?8Q+1W&45]KG`S3%,W'^H9F*TR(4KZ[,R5J@T:!3H>@4I;;G9@:&>)7 MW.8H?Z.,F3AF)=R`A[P?,!&X\GV")H$/)B[\AK]BCP]W!A;6M=FMYT/F>_JE MP5ZF,?-&1*;N]<9!;8)0F4W-!-X%9#YQ%.AA2P>DUZ\^`8P?Y`'R=LND3VM& M7^D6S8/@.R*L#+SKE;2I&(_XY;V7K`09)7<14_6J=1M8JF(R%1!/P(7T$3Y# M9AU_A7D3U48I\X"@JH9M!:JP9JKR+C'U>:C]^G7)@YAY0WFS6)?4I\2;U#P? MM*C`\?0+Q@Y]PFY>E&*CE'GJ4U)"MNYD?-4_]+;V4-B'WT<+;G+\3S`ZGK(U M`'@SQ,R.$:709VM&9)ADAQ(VU%:9WLXKN!D)J#C9;0SB1T@A$^:>*K2,N M7O*=HTA4":,C^\\`$>C<>@\$VY!2+M.<`5^!XLYCIRD91.@Y,0T]3U"8G5^@ MQ\#O,FY'S@)YB/I$[*1'#.?994J5.X.)"NQ&ZA^:IO[8W2C6\T8I\Q3:OB.F M(B)C[=\"+5Z/B2M_ADQ$E MU)=8A)A3TQ"3""GJ?)3\6+C#L55Z%S'2^.Z$FI0,MF'4DRYJR%ZPE MV#,U`I+)B@*W5P'AXVD.*!P'_@,D"#L2B#31E'E0JHR4;?"]F^!V(EDJD]78 ME!M[[.4>U$3M:OHB_0&3TSEF;P:["80,*Y726< M43;L^(E/;GKD`$Z;BD&L;O6NZ.""%@WS!E!);:<'3'4)F+J9S687(L[<`/<2 M+Q;8"WE:-[/C+'?H/`!Q]FI$F"L^$_7RMK^K$^XDDAH2B[J-^NE@XWC8^YP9 MRSY-G5):[O&QXU+'Q];:L[2/;[>2E;`EH7BEK3'UMN96.!C/AJ?GI\='P^&/ M1T?#PP\MAM0RF.,6C<1P5*EJWEST'HK,":F5D96>?W)B'HCR8]$CSQ'_BP#@ M_#<(=SXJP*Y\8^8!M31D]-!7L\A,M=>*1/#`/PA^12E^7)Y`'X7V1A3=?'"9 M)&K!:(76>@O2NF5F;%BZ2`BC9X!Z%R7;7H$R3MNJN/"+]IC=B__Z_K/@*T(+@]FCOQ+0`A?$<2E97E!*Y6Z MIJJQ2%G;"B[/JJF*?YJS=>0;)(M53FC>M)%5M!MJ5>;,U&23D6WC@'7Z$=J0 MH9+9`FPQETRR!56ZH55M#DWUFC@J/4;[+?\PE0A[+G(711;C M%X*#91+4RLQH5`D6E"'8#3S4S'^$FS/3<'.'O9F:FYI1TE1-9^E3M?NF+K3, M.&`X\]_X1JG/C[/_&:!EM&&5H[&B*KND.FT^3%UD$8 MFX2R>?T1DU=RA0T/%;P@U\UUT.15S4-*_L)1FA]38V`2_>VBCE3T8)RWE7(6 M>6J`JL.\*KM+&E)GP%0G1\.'BV]/B-@LW.^O2G:70-`(KQ%>SDW#RQT"$^2& MB8&>\^1C^X\Y=EE?*;<)_+<\#UE:K65FBB,^VP7-`ZBJ9M8\?S6^3/4@DDWT M"TP(?DD_09:72+`J:;0&2R832+@S58_QMOD#>!-)A00X4"V5(*-&A_2JRZ6I M`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`@M)BD#KF+;ZXNL%1?.=1OG5>6*>7*)#Q+TVI-$?](O:4R.82 M+)$/W**+%%4)]!(86L*0)FP.3'A6:/6R)G]J83R-PV"R>X:D]7H`D'(RD"9? M&H&+PF=8H\=>BQYBO8!33&"2HYY["*/65GJ`N?>06(30#V8C-$>TX?"K$);, M(&`>KAH*2ZKR;FKT(WJ2E'[#(YN)A4#=FYK4"9B'B8HZS<@>JB8,:;2S+3,Y MYNL&$W&9+W3$S"DW>N05>X0*32$8>Q-7FHDK)*3B!X29E3$S2F*)H^FZX`B>R*/<.#AA#T7IEMR_A(\2:2J,>B MF_3Z%1(;T7R+0U9O321G/YZP`"+=:5'-36 ME9]RQ1EW`;'GS(9B5O/J`*,\JI%3L0>`*"D$8S.1'A)X)]?02=2?*MDC?%D#:T4S^D],UEK1M?X>4?['GM&'PDJ\29>7 MEU^&TO=W#0V;*"K@H8&G#C=FC\*@0^LVI0:O<>KV5^R+#<0[#+SUQ\_S<]#J M:Z,3Z"N"369&6L/RVPFHII+&XS29GZ'K,'N>)X<6SW9*=7L(K?)R:3B*!B8^ MQ\'IX=G)H4`!^Z`S$!X(\_^1<_W*CQY!9C&%MS2EKG1FHR.\-R)D[3F?G57F&K0+$3X*RZOJK(9"V$>:?!O>*A^PH4O\.ONKBZ-@W&+[0>58=;0NH[SBK(J6$3KJH+4F"C M9DY;=9/O$[;>178JVP&M3VAE+[?/F=3*D]LEYM_OJ1PCQF%5C#3U>DY7[=6- MISWK"Y-'!+N#L,8#XT42:QAV5>T)^@1#DW2ZNEX4SW,["$82M-J:M"M;77 M^'(Z'5X)\PAM%[#I?HKL<#&07.U?@:)Y$U5-2-EZ[J]&^9AZ2&B3"WZL0>'Q M@\B`"=,E)5"KLXE>8*]Q@6EE7@/WUJ,^"40R]17K^3.C^2Q6]1N` MB'ANYUZ\OP/CQ-2AXIKXX7"XN28FC5JI5O]II=JU@.=8O&5+-&W%;2=KIC4T M?-4,0XR)\%;\%Z9J9I9O)17UF4F9#Y`H2^@)V@$I.LZ<7\&\N4*JF[6$43W& M3%U@XIM@>'[\:J"%DACYB2QR4^N4:N^XJJMP:>I=;BL^DOXS)W*=N;Q8I4+5 M'==X:19W(K,LY8.K+T2R2FV_:"^;JC++F@=3-=WDO6:O-!<9MP;%-\$PHWG" M3$`1@16AIUGX9!9%3A1_BJ63]])P"4I=@$!=;._H8B5#A6KU+D"A$J\[L7JE MK;&$QY^A,ULQIV>XRHET`1@U<%PR!Z:I&$7F9H3>^=BCH^W(/"<[6-&U8L*[ M$I?G[^%ZT(FZS9.$O\(HZH3LZ.LESGU75+UZ.RO!9N^>('E&-M3B*%7'O*&M MJ[_UV5^755-MPFU.X@E,2]/I2EU7M917<\V[35;X42_;A\XC]`/BC3W^K3C= M7X-$UW&@R;G4Z&OK#I1MSM8?$N3ON/F9 M6O,N"720^G*A0JQ?2-&0@Q$Q#IY MCW`EQ[RTS^V2O46#KDP:/J&9.>*+7[:_?BT\#Y(Q*52BUUND-",YITH59B*6UQ">V;U=JWG,%9Q M_-\,Y6O4[C46JLI)\ZGQPGW/3P>A%J.P`/OR?U!+`P04````"`"'@P1'DD,N MK^`N``#L1`,`%``<`&%B="TR,#$U,#8S,%]D968N>&UL550)``-=(,%572#! M575X"P`!!"4.```$.0$``.U]VW/;.)/O^ZDZ_X-.]F6W:I/X$B>3J9FS)3MV MQE6^?;8SWWY/4S`)R=A0I`8D'6O^^@5XD4@)5U[`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`;@K_*QL4% MSW,.URLG6Z'ND3?KL41(?S%5+O M5A_P!*5!TH]"E+2+&;-_DS`[\E\QN@5U/I_V[LK*Y/%K@D,?^\O?DH2/<'SP MZ>!X]':T(L?^4:,XRDB._CTG^A\6"T?&'H$@"V784W@_`(NU:?')9%.+,7W!XU<22]C2]EJRLE+',:TS MQ3Z3DGKQQ31<""+J8_KKF\.2VH1&LX8(%/.++#A-8S;O:,XY1,$P&#ZR`=;8 M^U+;@=;04[3O";?-_4L-FJ%65H%2,+5+$/WQ\?CDTX>C3Y\^?3P^^OC3\:>3 M$Q>HE9N,.]B$C+9"UTRB`AIMZ[Y0J)M3:@2T>L9EK^7$ MC9A/F':P_QU;27N]DU.A'_4@]'6&W,C^F(UZ1TE$_X41C:T0$'=UBL-Q#SB( MV0*P=2C,%F;AX\L$SXS,-&G7GJ#+CM46^X6&M>JF8673K4&8GZ1^YF%]=H@Y MST/>[#26NS96?V?'%^S_^H91'\@R-V22,7'*9O&]W0%D107"@MJS7JR8G?,/ MGB2+3$.%W_HO[^L'ZFX.V;K$&?U)^\,!4YOUDW:5[&A%=_3O!67@Q^T\">,A M84AEWF`4\.2OAV>,N2$Y]GV28[/B.3Y=L'_,HQ@%7VF4SF-&(DAY-J%8PJJC MNK/1FR\F,?;>3:,7II(DERK[85V8[%=_7.$I"L[9^,E"<(@7MH!S8'>L!7S] M$$JDLZW?%+5\<.&Q%,);&.B?4CI"H4WOROD M5/O[D.=5O:1J4]4;J;MFIBDB#ZX&'\`>DAR&!K"'7`L;@%);S?H&S;#2?=^8 M&I#XB]M/O*IRC26WUR'`QNS6ZI6C*-07_(*#:([]:T2_XR0^I8C[?+[B$%/B MQ7?/B,Z0A].$>"B(R^L=4ENG'3D(<:R6GU)I2;431/WBCR@H*?T`=9: M`#D*;>CJEI<:VB2O9BAR$@Z[9&MZ<1VC@LX.WA[$? M7S`I?.$WWQ.2\*)%2QW>6)*M>CJ%]*0-I$;L0$/O*Y/"513'MV&^\)S_F;+9 M789\^EE)`PEV!OV<(O>Q#7(&S$##S4#9\@),F.T>"=M'QI,)"0B31HNO44[1 M*=:?>OY*Y6SV[>#'C#XW`M@D7PC?$$Z1]_V63<#+"MY%-'FD*,Q+I#U@^L)^ M'W\+F5#&4XIQ885ON(F[H.H4X)^:&E6=L.HY(:) MDK-3/(EH402VH<(T&<6MYC3RB_7&.T`5,O4?C#TO2MDAAJVRF6U[%3$+*/??LY3235/3 MLJ];L%NYX@PYZMF&M%"Y.XKGB/CGKW,#[YE3J* MC$UG([O5B4:^/*?R@+8LY$6ZLQW1V#>M7"O:$'2K+*W@-G8O-F<0VF>>[U"5 MPY`H"5?MC[`CX1;A1G[&9HQ!0]9"1]>?YVB_;F]2=)M*T\@3V0F?6ZP&Y8,M MA^WQKY!R"WQ;-V,#!N'LRXIC1Q=[M0%YMV`WSICKENDM_N1S%FZBT%.>WUI1 M=*L3SMQ]&WQ"4X,&I]'NCN^N86_E^&O$'S2X&[BJ[]!"45BN#4&WX+?*UFO# M)IRM/WY`05;/Z9]HBN.S:#8C,;^WM-JL/(^R#E<$/9&``=+6`]QH0+=JTSAJRB<\HR=SM:8 MCJ?B5I^<.!>[%="NK$O:\TP7A-UJ4RM'9A?L[HIN=*P1KF^9M7)L-F<29,'Q MI?M'6W'\R+;B^.@(>,WQ)>#*5[S6&NTK>)M=NMX7VM[B0MO[FL]N:C[OB_)N M85%>^1+G6B8`=,]JUOO:N=!JG.X+FNX+FG:%LV0B7/%M2I]V0Q9"U9F><&\F M$&B^AYTN*K5N(FSK.W0U#;Z)$DG^5FW3J^QMXZ\DVRJ2G!:%2GFO5T4NEYYA\SHO\:H'@?*'O`J'P M70](FC&_%5^V==D*O27:Z2`0U@*754%`VZ7[ZB"-+=H>OKR_6V$1Y::Y87JI MN&UHKEB.`<0"'D+SF@MM*_3N;UT[2VXP#[G&=5IVJY_LH:Q07&9'H.""A"CT M"`HN0[;PSHK\R"S9QS"-Z/C@<#V-J#K`:#G"J#+$,J,(>CY1.ILANN"K1UGL M]KL!>2K,+ M?4HL98TA['7F"EH%3L81`&2R^]65-Z.4R,@:0PAE-$-&QE'W9F,VTATE;&\E MP>(4A=\?V2KQ!3/3B20\I_A;_$@Q8D;SXI0$@=Q@;$H(0A3`#J0VW((+%'&A M8[^H>L`+YL:54Y+@KPK[L2&M`4Q,6:&K!B9F0Z:!0J_T$LC;`[$Y6RFS#E0X M5VP[`PZT[=D_F%"MTKM<4/E,:Y-76D'Z;A`L5:WRUIZ7U+($`*[<%(CBA.*$ M4%PI(F2+8"-*$(Q<*U`;<0D`YR_X*;D,V;13/F6E';39<``C1U;0L9&1L\D1 M.$3T80YI%24(#@)^OJZ]I@#IY;C)(7E)`7O&+WGL3?E5:? MJLL`]I^LY1\M?E;R=Y1I/^ M0S/HYQ1$>U^]$D0#]J`AN:_3H-<2^Q.]4DMVOOI"F8Q_%LV>2)B_%91Q,64B M8C_%Q"\?):,4L=]FW\;9,__Q,AS/^#MEMQ-9%_[>G>R55R,=C3R,_>+;XO(B24K9^EQ*0VIO&/5TJ@^REYD:ZH,1@ST[]6LZ=(\] MS.;A7T0TWT/+B5R&0LNP"0&G@,D>/[($K`F?/>-6Q!+0E`W.C58:/Y/Y;SCP M\PVJ/BL!;);]W7JK9&\5-8#-DD]HJ^ MQV:'KRL(>:!-69;@;W#:V=;\4$,NRSKS]U$07$3T!Z+K_J8N"$+8^QVJCE`& MT%S$EKQTHQ4P;/KVWT8+I>C=JZR:Q"J[*Y.\),$KS@/#]]@+4!R3"?&*8JEB M77`UZ!:M(AK5<24Q:&N.BF<[G>N$(H232[=K42MQ0-.6]:GRK\)`7&<1(HS[=#@'A&-2M/G4K'V@*9B*@NXAF."8))4]IP@\%CY$RVZ@U50@W$-PM M2T8B&2KL6V;%C;T_4Y)OQK%=R/=D,^1;$AU5J6Y+M/?!>\9^6LT8K')QNJC\ M2_GVE369(2\25&:CB/=*6\.)]#9%3Y3"O\$F@!5=-#?^(\7J6@,&_8#$?S4J MJ0-JC:E=A@QT=+A+&+N/$8NO24SHVJ,G#TA:YDC5&((+R%CKEG?6./$7>>2(5:_S,$]X"U1.LL0#MQW?-L3H4) M5?D[H#?I.C":*HQ!@4$9%ZZU`&+Z;"C/AH`!!6>OF:!FJ7C]EK2!L"\*-&/M M?E%UQA#DC%[U-(N'I"V$_50C=\G, M`'O"L_*VL@,>O/VKV9T=S@!!6 MM%4RQR+:`BVMU6#)+II,,&/*MZM()2,!H:Q9!SJBX!`JQ!5NJ_5:?H]XH:OR MEGJLV76:$H-04:PI[+:\0E6`BOI66+J=7+&_/3ZC\'#Y-`E?R'BMZB@(*BQ> M($)_1T$JB[CW,`Z$PF,=K!9MQ;`%&M5XTSP;VK#130!"+;4AK1J=?'99.8LF MZD)1?0X(HB3S=S8U8?:\I[@]'?/F4MI0A-)2\XE/B*UUI?LTZ_Q7B2!E=D(O/YF74%4?':]A1K MQAHT+#OU_/``:^CSNCM3WH"!*;@_J@Q,(9:2Z<>-^68[G5MHY2=GJ2Q2ZK5^VCRIR!KA>Y M8E"W"@PO1:@/V>RR.F9? MW,ISX\RW(1G7K1IVG++4HUQV606%"9Q#Y=:Z5L'^TI^ZELL6A? MG8F+NPFL5UZ[2*=WH&;F5C-;)D6!DMPN+Y^;_#H^SVR.[#;3`&#^E%0RNZR( MPGW#E2ZJ!G>KCAT%0EP)!ZI&5O/_:701T1FZ#"?\?QE^9LFAID3<:DC'H0Y3 M)AT9<-5+W.5\QF&8Y@]RW."$/TRLLK-,"4#*B+33UG7[R)1CJ-]J_8H6OZ## MEIK:9:TQI;Q"0W:S-*O5<#NY31->*S3.;EO\1J;/5C?=F@_B]EOO+Z#42@A; MH$DM0A@%LL(T`A>>!>T,W.H@R#"31D*[K:`EMVZ4L3*:6\4#&&ZJ26,+E$RR MRI>,683']93<*D>OU\0UG`Y5=WQY(2'<6/+LRH]_W"P_7M(>H=`?K:B/\?%Y5665\K=&@+T>7"OB0EYTR>CE:W`=0/7$A"L*WH<6L`%A,BPDIBTVO MM0%2$--(M6I@U-G81N'7BEU__GSRZ>03G*K>[0`1LM:]_^4\YH]KD/@9^_6* MUG%<'-1*5+YU'NH0(]B+PT0U*U=U%*VU>^`[78',;%I7.`4#;;2(<C MH]XBJ,)#VNJ5G+PT2L:[,GE&%#EM16G_HJ`F;-H!3OM'!?>/"NX?%=P_*MA$ MSOM'!?LY'P_PJ*#0!##=4&3NNH8TW+OR6C%;>E\;;\3;Z@N4E\Q3OBZH[S;D MVM=:%E-B0[PH.J!(Y\SN@$:QM=QJ1$1ORE;\A-2)C?GLT M8BL?)#AP#K?="P7]A$CO<9S0U$OREZX"%%I>+/VT>;&T1G*4T=R:VZ1+7V"- M":8!]SCS`9Q%L3A@VHC"(.&YZK3X9+*IQ9B^*,.GNE[#!U5;8%B+]>DX!;#R M/K(!UMA39M\KVD,)OYII914H!5/=AU0VEDF.C#2S7=D:0B16JT!E<$3)B1LQ MGUB)^012(+:5F$\`!6C7KK]<\9&X0(UOC]5[`+KRU6ZS4'()%S?E9J'I`V3# M,-!(`Z``54#H'"K0%1*ZA*_[>@F=6=KL[.[Q)\&*&UY\[L6Q7IT@9](3@AUA MI+1KUK6>,P#8\67_=I*5T50B)6@'P?"PQD7`!P`4'G`0\*`KOPB)@NRB[8R) ME!='3<@++M1&C9`E#0AY9-;H6?((`%F%M;7A3%.Y(J1=A[M7:L-:#40;4W1; M<\_JY_QG1*?2FI;BIA!6UZ8(BSF"YM:OS;+TP7@>#OA%=OZ6]YQBCZCRR*PH M0%AP.P%4QR@X#[_IW:=/FW>?5"[^'B\\[9W\>R?_WLF_=_+OG?Q[)S^8LW8W M3OZ>'UL1C7W,/K\[/BQ/,9&7:3+O"L&4:X6&F"T`>\$^_K*/O\#:RWPBGZ@W0QSSO,QO3/4/S\@),DR.JD9570 MY!4DVY&"<-"V`*P=LZ`_MQV+CTF*AW:T=((+C3&SFY6"K*CYETV!&S8P?*3:>C#U=K-KX>UCYQT<]0 M0-Q]0IVOG65[X7ZO06V'`IT%/HA604T7/Y_-@VB!CK]$8\9L-EPV4PUD5-9:P@8:56N=GJ3<0+@VUF;WSQ#7-#\A(V9O(G"G,_S/U/&SV7(/6G9=YKQ MC64QLSX'A.!Q!J:+!E+;'95,.4#%5A*/7Q`)^-9P$=&,U\X54C<\$ MXT!X7PRFW@F$!5+OGO0L/ND_K;671.XQQR^[4Q,F%'E)BH)'3&='*LUT/9,A MZ_LZT%W7XMPU[:Y\P(9"..Q)NQO-9,A2Q;"UNY$X06IW-V;1FA`*\>`[2CQI MOH2KT8,IS(KQ`IMR=U%R"6@XG:B8$2,04`J,LPP>P$D]RS M[_OA!YHK5S198PA[C8G&U6O@B7D!@`D[A6.VXIZ_>L_<65#4=5`BH^X"8=.Q MQ4?-$0"43E&`0NZ"P=BD!*B\^0`[C\3=:K#SR-D`"HERSU%U`++CZ-1,!PZ@ MO:9#>$"?6;N!K/MSJ_`2]1<\P93RU[!YTMTK;U<;L]4]%G<4SQ'QRWJABIG<8P^SI?I)5A^W-34()H,Y9JU8!;`RCCV/ MIMB_(NB)!$S8FIJZ\N80;@::P:;G!0`N#\\137@6[!?\I/;)"5M"N!AGAX:0 MC1X6NBA.`3+.)J;[Z$.X86:Q&';+/(#/4.1U MB;\RUJ^B.#Y=%/[,K.`OY_.9S"W=@";$!CBF23[IA@Y"$R8!@"V8FTE82]0> MR!&NG?H*8EPB7G<).="G.P=H0@U9\N+`%T'THYBX^F4.<5L(9T&MGM9>YA#S M`0"-&YQ<9HE>7`--(%%U@'#>L\)%Q0P`<);I:2;`R!I#.,U9@2)C!``@E32^ MY2RO-)7,-'V&*U)FQ(S8'@1112S&WKMI],)8YU\P!_&X^)G#=UR!+_]M9?XW M43[G\2Q*-VK=:%M#6.:,P=-R`RW;O+2";L-J=+6V*#"C"4\FV./LA%A:PJT1 M)0C+I?67V8C3GI_5N&;2FZ6S*QQ.D^?;R2,SD;-Y^)=AU1S:N"EEV1>">\P8 M+TO>H'V:U^BU$:0-^D/PEEE_AA;\08-VQ>N2U=O)ZI=9T$IKX*BZ0BATU,+B M4;&V95B6[ME%,SPKW2$4`.H:TPI[VW=O:6DL:B\N'?5P<6ETM#57ETR];J<+ MR3N>IPM9%J?9K:C^)P`EQK)M"=6=>6S;ZLX^5QMHV&6?JPW!`;_/U=[G:@^^ MN?T=$@BT^$+9$/>Y"8`VR5W,3=B'KB$%X_:AZWWH>A^ZWO5:*-H0V1#6Q[[, MRK[,BN5FM445'SHHQ`&WXL/NU$OIH##'MM1+D:SD.PNJ:(=A+W-2--JQ^)-/@"@4/JXBSNL M1K[]M;80MC!K-"2\`$"D\&J?I93BT%N42[N);U_6!\*IV!HA#4\`D%)NQ5?& M2=[JSA"RO4W8:^=J;VZC;.N[U$H9K0HD7X;915E>1YGB9VXQ\`Y<5.=E;NY= M1#GW-P;I=ET.!6'9[TE%&\L$;EZ?F,L`Q3&9$.Q?,+&./2^=I0$_V]V>7;(- M,NI:T9H/!V$'ZT_9FLME^Q(.E\+5)AP>]Y%P>`P\X7`IMM-%M?3"5QJE<[9G MJE(%S;H.&MHY712(9"\1H)C$"H>,MA><5#\;U(31'QF+`/:0Y1Q7WR)?Z/++ M8+'2LV+6%8B#Q5!)A?`I^=M]#$$73N@)5[C%$BA=9*>K.;,3L)]/6L"1)A?% MD@H$EYR-EM<35BR9!0#S>9R0&;,1;R?+>=IB;$<"PG&O*)/C9&^&X1MJAE: M>MX`X+9ZQQE2SQK[1AJ<)M-$),!$(IH0&U0BR4[=*H=7;!6D^`&09=Z8$^#6%-%@#VF?4UI#9+LRBV MJB<0%[R%3@M!5+&XZR!N829"%\!"348033U>KE%F-_R572$$9RP46@?K)H.0 M0#Q=K$Q0@BD3UO/B"K_@P&R;578&&+3N>:=5B@,2[%7]W)RT]8JMH`%O`S90 M>.TW+>?W[XCRMNS0?2(/=;O>[:0RB^U;^P5L=7;9#8*:+IW:)V1%PS(ZM,3L>!#-=6+1+S(X!8;8+]OU/A#,S);%K==9@@#4/A<48BYH^]5]6Q-&QR^( M!)P%]NWP.DNKS'>)=JDZ@#K5]*4T*@%`3C)9RY.+[;)+E+U!G8Q<$_`3#@NLD+=JL9IVE,^)OB9]'LB>0UQ[F'@_'.CI3LIY@P\:(\'UF] M6#2BY%1'/@^D(XTD`TU1*C(QM_QTG=SZ`P^&,A8T4ACJKL`5ZSO-BY>'_GGX M0F@4WQ_/7^?9%B:TH08@=]@#D.IO@?`1Z1A@:C!$S MFT?5'T)XL,WRJV1N"W'-%;0YKF5_"`'!SG$MF0..Z]CS*-LDQDE9AUD=_3/J M"R$:V`I/&6-#.>V88B7GLWD0+;+JZ3AD]!)+3]WAIJ>.DWV[HCLJ"6^+=^[! M>\9^&F0!.29@[!<,W`4HC%><*IUVEC2&">BJ)B;XJS)=OA$M.!Z^1IC7`[J- M)`!@Y1;-7)U!+VT/Q/_72K-UH,)Q!-[E0LFG59NI,J]>WPV"ZTBKE56<]"P! M@"OS*$%`^65+DS1[`1)0@."2M0&W$)`.?EW\RP4'T['_(FW+&;[ MD'N^%#NI<6\XQ35:[YW&/$-`-Y^/8*;*35/?#::F]-1BU/.XN?J#C:#UB M"K7J13%OOOIDY^\4^P4/4:A^CL*H)P0+R523!7"JF8,#7^X[21ES=N"I^D&P M@UI`IV(-`'";%D`U1TSW>KI1WR$?3[=@KH:=G86TK7RO)1@!66]$\ROLPLLZWS"!_/\=8Z]!/OW.$EI>)LYS/),=6-H520@ MI$KT`[2*:_BPCV<138JWZFXG7YDP8QZ9E)90L*(`(7NB']`53&\;YG=\OI6= MYXQBGYBOYV;$(.1;N-`$&?_PE4(LBY9F.(S$C'Z`EW'<<]JC<")5)>2SB"7' MJ"8$(-RY;H-@$Y[A?ZY9?3#RE&9.GM-%GE(C]7U9]!_R=-5',*-L"%LA#:SOD$S3<'7IM2`!.3=?N*U/;:IY+HWB.]HQ+9QMMO1Q=TS MHC/D8;;1>]EE03_U$OGE2>.>(#S.[32_M(2->>[CY/*"@VB._6M$O^,D/J6( MVS=?F9U&B1?7IQ.7U4RDZ+4C-[29:ZFUJX-,&Z8[6\!C[+V;1B_,-B;YVLU^ M6%^RV:_^R"[MGC/U3$2%'X0MX.2N#;"C"R7B'+5\<.'.N?GG@;="A9:5`JW/ M%X`1\Y`^Q<0GB!+)S7Y5PR$7+IERU/(9!'/N?B]9.T!O!-$K^X2\J?ML$9.I MN[7L85W.9[+A[IU['#"._<>H9.5V\L!V-N'E;7V7(6/,IH";<=*S:[F80.$X M&\?W.$Z#Y';"_A\%:1[@^)U]V%'*U.;U+HHS62I`L:XRA?`7BL9%Q(+UHF&-(:,)-NB;\D:-'2_\>J3T30D?['M M"+V6=[7SN!O37(I1C+_@_/\2="UI#!DNMD77DC5HZ#X0-O4)\5"8G&5/#EV& M$HXNV?:&8C;3IV!1%IPH'\'TBT(4.8EO<[96G49IZ$O4H>]!APQ6V^I/W[+X M.RC<5?3#O<)5!QVR^C@$A:O*8JAH>G']Y3*<1'2664IV`?7CS8!Z07)4H;DM M(?75A9*"B7L\Y]D3X;3"S.FB^*-9H1(+2D.L+)E&*J+1E;_#"1BWP*GZ45=X M`[#&9[-1^C1K+8#$43?T9T/`@*[1%>7;E$)>:P,A?BG0C*J4UV8,0R1NTH06J6E:V2O:0C";E!JNF'L/^?,$3<,H9A!J92IO"L',48I4/O7N)?H[ MBKTT0%0K3UE#"`4NE-*431R`73$.@JR,K]&!5]880ET)*0"ZR0,`06&[7FE* M\IEU':XBGPUKXH)\%H;]MI;E>T`!CN_Q"PY3?(-EY3XV6@':F.WQ76<&6I[, MTB>V2@[5N0&K+0'M\-;8"!GJ.>M]Z>L:A_6:$?%&Z3-]'$)EJ*;K ME)PK:'`QVY,3QWYVA^@4,7OC+)KQ^69<%E.76]U&G2&4B&H*I2F//:^!]3)R M3+]0..59EWDER?-7Y24^P3+9DMZ0::UM5M*6;/<,3@'\W!V`5DQ"6VSKM[E$Y?A/,1,!SMMEJ=OGKPE%3(PD1'21 M282QR'63B3O(9);O--+MM<<1W3J[#[K>HGN43-^;01CR5[27&]+X!Z)^?+_, MU+\,+PB-DW^DB+(9W6'JY5Z%C4V@&1VWN'?DOFG!;Z-["[^\SZ5-\DQ_]IO_ M!5!+`P04````"`"'@P1'P<1=X?E\```1_`<`%``<`&%B="TR,#$U,#8S,%]L M86(N>&UL550)``-=(,%572#!575X"P`!!"4.```$.0$``.6]>W/D-I8G^O^- MN-\!MW=O=#DB9=>C[1G[SNQ&2J6R%:LJ:239LQV.&Q-,$IG)-I/,)IEZ^-,O M#@"28"8?(`D2AZH_NJW*!,XK<7XX``X._NU_/N\"\DCCQ(_"?__+NV_?_H70 MT(T\/]S\^U\.R9F3N+[_E__Y/_[O_^O?_I^S,W(14R>E'EF]D,\TCOT@(!=1 MO(]B)V4$R-F9;/B_S^^NB1>YAQT-4^+*7D]^NLW[G<>^MZ&$?/_MNP_?_LN_ M?/NVZ'WN)*PUH\?)O/_V7?Y-QC\*?R+_^MW?OGO_]MWWY,>?/OSPT]OOR?)S MWNXSTV#MMS4,_/"/G^#_5HPA>4[\GQ)W2W?.=>1R??[]+]LTW?_TW7=/3T_? M/J_BX-LHWC!2;S]\E_>J;0'_.LN:G<%'9^_>GWUX]^USXOV%,+.'">>MP21K MSB0LM7[ZD+5]]]W__GQ]SX4_\\,D=4*WZ,5H^@U<3MJ?2"7YO/OQQQ^_X]_^ MA5F/D'^+HX#>T37AG_V4ONSIO_\E\7?[`&CQS[8Q75>S#N+X.^C_74@W\)." MA7X$"[W[`2STW^3'U\Z*!G\AT/+7NZM:+7XLT9*=N#I:YOU.Z"/&`W2^9G^5 MU*+/*0T]ZF6*`;L&TER:PE)`.W)+!`,88U%<-I2S2L]@I+[]X<-;;@7VP7]] ME&ZT#+W+,/73EZMP'<4[/D*7JR2-'3?-R'#A.1W=;AUM!)H`CV5<5L>)W4P& M]F>+=62+[]R(#;M]>A;(WXMW7\?1KI,&0HI(O\]_!:L>HR/3O*1V3)/H$+NT MT[!0M>WX@^6BLXZ`T#0\^_6^@R[_(V-"G-`C@@U1^/R;D*[3H)5<.<>UDZPX M6S9U;!QG#[C[M^]HD";9)S"^_W;V]IU$PO\F/_ZO^Y1Y+DCVX*P*_)#FJ6V$ M=/0V*P5CM;H%PI'9(FC?<9B3([]S@O\_@I''0)]>L3^3-A.H#>:LYC,1380V,1B!*.-7!0S*A[K>;Z/$[C_IB-+(_C@_0DW-P094`V6F'W@4;^;$37+$`]_E_ MT9=:U4_;H1]\-:J51]]1(]3#KT[6@>-/DB6<+F&$IQJ!64#ZP,A6*'WT->+Q M5J5(-LS4[Y".KDH1!Z\R@-K4(^F6QG[$EE#>1S:I-VAZW&X&8ZM2M>-!5FJ$ M?+15RSIXV`FR;'WK$2`\U0A<,N8>"/`I<#856A]_CWC$5:J2C;32ETA'6+6, M?4=63HT`N:G&T\4ACD$#/W&=X._4B>M!K:$IXE'6IF`VX.K:(1U[K>+V'8:2 M,!&4"9">'.1D&"HDN:/[*$[]<`,KZ,/QQHE&<\2#4T?1HW5$95ND@U1+Y*&K M"CE><_)$T)]VK'[R`QI?,!?91'']XO:X%?J16:E6>4"6FJ`>A]62#AQ^G"C) MJ$X,D-%N%X7W:>3^<;]UF,%N#BFKTW-G="/R1UE#Z"S(8>J`>LEN!# MX9/S()S)@@@V1.$S]JIIKJ47--4X3C55?BWHOY*/1H")F.[*\D"GR/IS869]'1FEPZ M<<@F>HLC^-X):')''VEXH%]HW<@];85\Q-:H54J**#=!/$+K).T[,B6I!6'$ MCD>>$652&B?T>D*-&`W":8ZBSB.-5Y$EA4@:D/(.[AI0M@L[2T(?7:#`ZR_B;.#;4'UM`/V.2]D87UW3AC2&#@#PSU?="9<&Q>">?;YBH9T[:<$ M!BA)#NY6\ON6+!-&F`GB.LDV,\""T?$9@4`L`=B?CN?!A2O'_0.HA6S>]_F" MA#QM:4B8_.XAE^\\#@P#O*KR-(YO4^QXPU!M@]AI:T4=LK66B$OHDN0X3ABE3M"V96A4L0?@F"VW85$.>Q"@ M)ZW1:UU%2YV_5+9&[7(-ZJM=5-$/L>$W2]AVB.4TBB)(W0-92 M<#RN@G7GY].`R[BZ4>NY`5MD`-)C5KE+)92$\0`4B=IW_&7 MT;,'N90';I#=\0^WD>+OJX@>9&,&5&X$6`GP_@%67&> MA#&UA0=3V@4RX=;2-O39W3(JE`2,!7D#^0$6$>,FW=+X2Q1&Y65`<[3Z0%YHM+/U^N2A>$EN[Y_3Z)Y-N47J3'A:3KRU%`6ZTE MM!^3(W(R[D@I3$%/4< M%Z0LZ4BK)MW-0S1V*% M'%_'-+"*KF/P08RMHZK;NZ9(Y<6?!:E`W.JF1(A'N'QGT2&K3,MOUL.%$>-[ M]/HWTE%:/,?6-T%AVYJ+@'P_$(QH>0E:::7LG.,F9%_OH\0);M:5#?N`;!_B MU7=06_"_(PGD*-_'(/5;#LW]$2-V+S4, M;@_47&A7@1?=9H'>UNI$-BUO`30",D/CK`2$I2ST22T#(XCV#.+M`363NO5. MS'$;Y%!;J9**I:4&B,&R6LXAX[.,B,>H=NO$%?>CIP$Q\[K:O0`S,WTT(ESS M&MF_QI/9]);&O,;XN9/X;DNIVK8^R-%12V45+1L[($9//;D'QT&,O*A/OR"< M`_D]XW'RBNHT2#JNWD+'DO99K7Y@AF7%675DQF3ETG-!>Q^\'5-![NX]S=+M MM+M$`C$D]-5D_/-I\"/A6I5N9&,A.;YY%%LHV75O_)!X;&'MQ`E4%20)\+)X MEZ'+(K([Q'2C-RNPZ6&JOCM>\P2@/CJ-OQH\' M'9A5!H==`DG\(-2H8NO"!C%X-,MK?"%C9]]D'"7+>[/(??*C'QQ2ZG7Z#0G3NF=ZSG530LH_>%OBB`YR]^]MFLY; M$RH1Q!#17Y=IMBY1=$9<+I2G!7T]#+7@(V*6<)1/ZTP;U:@ M@[-I33S7#0MIA&ZA)GY(:E%38Q&$&$K:)!YAT8-C\\*4HJBW+Y3GX#_Z\`!3 MZ!4&H"Z3L]9=-;LB]]TN!B@706_OA]BK.XG?/_X6RWC@`LXM^2Q*+B^9V7IY M<0HSP/MF.?E111@;^N6P6]'X9LV%36X.:9*R`([! M6M,Y1%<:R.&BETE4W.A$`#&`]-.CKPMEW(AD1P0_6!,(CD1A.>H12!NB3&N7 M4W.H@%*R"OD5GE1<1]E);^V&*XT53*0*F(\,ZC<@(V33(0C-S[.]>=+ M$_X2U'H-[Z!F,'@&A%A@(80CJG36-DEL6S6WE1J-DIM]L6-B'>MJY@QURTB= M.KK-/`U4D*-83[-H1%MU)!#C4U]-)HJXK.[<3&V;+E'7;7!(R`PP:!FFOB?% MO*?N(?93G\J'B*DG3NQV^T,J7RP^WBQ;[J)#6)?M8HHV.P$7#E.J`%@)>;\XC_#=E]-0%@48 MWC/[\/`3GF:'8[YEZ('=8KJE8<*DE9\V)_EUIX(R9*O:3U6+@T2;BY+QMOI?<8,1;^(!;C+>ZC=CL1%-?;-+) MLNZWS$J)$>`=QFW&R&O`S+K0.X#53+'7A,8FP??-E7SP"82#Y`8N'L=9T;PL M(9$B$B[C8A+\[?A$%D+#@V48VA^Q'\4DH?&C[[*?#YZZ%U^X,?7\]*A"+_SQW]^]Y0W^^_OO"8-Y!KS?BW__ MB_C/N^SCO^&$_>6CXP=PVL)FLGLG4+8&C.!\1_(S!O8^AM1%\BZT9PK=O50< M,5#.Y3E;1_$9KU2K[/Q-&!EKE/!"8]=?PY@Z@?\G]8YQF"'OSHG_H.*@FO[S MX*H=``-W;,';5@X!SM;3,9SW&'/D&FJF48M>/%&(D&ZI1[S2Z@B_I%)19+W5ERV+WA_T^ MR"Y^=#(?^Q=;4>[D\V,87B31M&'567['A)]Q.+T.Q.MCWAYHV(7-_)&RE[83 MH6AUP@_"!!^,MKX0$H%9UQJ)/BAR?#3M^)&N_9!ZV=E\T_D]/[@W@[D#N+X. M_!UJ]AY8W)?E_'%YL.838737O*"90+4U\W_13?"!_!XUO0<]:AO(UAF'T^M` MYZ$Y/".PF3\*3YJ!TA%YT63YF,+<28VMA,>'X\R?EH0?]$A;Z':QA9(3R16\ MYIV]_,VO2SK)]E,0/8G$`'%)T0SV#N;].M#8S$_0`Y^',9X_8AO2?R(,5U!( MB@L)+8#7('&Y##KDSH#<>2J2O%L\$W2W_,,HECY-[QR8O(0S^4C[7L/(MZ!F M`>NF#6G\GA-N<#:N(J*;3"BOC4YJU&EO*?$,4'R06MP/^"4*()$CF[IN0F6A M$OL)^^HC^V>XN66S2N1U1]=AG&8*M`;,JX.Y`]C,$'Y-:#MBZJIRY4;*5PI[ MH;Z.LJ$AQ"1"3B($18C.-FT^X`X34M1MO=0PPB6D6>-H%X,9N7HT3V3LI);5 M"T?H`&X2TXURQ<@RQBFUM3[YH1.Z+#AF@;O/$T"TBZXU=46.65T,4%->K;8? M8@SJ)+[A0FKG#J/'%EKW6TI/DN(G/+A@44B:M&5T'S="/IRKE2KMV9=:(!ZB M-8+VW@7GY.RG/H^AE6TG$MF#J98OG;:=A4O5J'CJ64<-T3M8G;S#1N1")LBF M2!S.M):9=H+Z3Q:O>K+8$NJALO]J]L7 MN8-V,D'ILJ5.1\0.W$W^08^JP8J%_Z$P6A`G)1DOPIF-XN)[OA=U&3964[-N MBTM8TZWE'N"(=F"1>YRBML0YW?AAR-\"7Y._4^?D+'H:X)_8#GR13PM&%M?T MVRA.'VB\NPH?J=RLJ%L&5C=%#OA-"I;6Z!7M$,-YH[B]KSP"T3/F+#NBD+5S M%7U"!1?D`:2Q50]I;$W]^I]RTLQ/>,,BN:,N9:BW"J"P@`R,ZX+QYB[(<4=' MX:/TR-KVB'%(2^P!R8B<."FH\V3P?,%HRV5'U?HA=CQ*XIPTPR?V?PEQ@B!Z M@LU045[LPP_ORV7%/KQ[:[^:&&!8R&B_,(.T;/'4-$7NUTT*EI_E/&V'V(\; MQ>W_=*8D*JYPV-[=&55'G]K"ZN5ZEDI?.5 M6L[!_:H%-N"`&6'"*2_(SW&46'M^=A1E0=7)O1;J[A?T;Q'U?A;1RQ M6;O5'8\;S\4=*Y6L=,=2RSFX8[7`!MP1"$.T)DGC\$>SVF8J[@4]!-YXYSQ] M=I@Y?"=H=<:CMG/QQ2H5*UU1;3@'3ZR4UX`C,KHD)XS##8VJFE-"X'\L[M8( MS6?D;8I"=6N_.?B6*J:9M9Z=/6.C"O$]8;YY*I=WEI/+2[D)-0:H;(CJ5 M.TGO+K5"[%@-P@Y+Q3[*E['Z@H-9_6YCNG=\C]#G/62!,AT]NJ:,MI?52>?) MSXLB'5K=(;6=TW:S_N@G^RAQ`A8_'/9YK63V*91%]L,#]6[V-.87#%M./880 M1.[JPXUUFD+7AQIBZ#"@U,"DUVA-,N:$KF*L"D%R"<0%),VO/BLVRU#Y' MV&Y+`T]<]>"B\`QY.Z'0O&QB*0>YT78S0]56H)P+]IF%LY&A2<\-C9T,\R5) M.9W8GBM=1^%&+W.LNB5RMVI03W6NBF:(7:Q)VKZC$FA.E#36%@F,H9Y"2[G. M;VOI-;*&]M#D-HY8()*^0-&7=!EZD(:[!YGXCFR--5H[(<<8/:55N&GN@1AY M-`7OOW\@R"]XU2-16#AG,>JV?EL(,)'BQQH[*:^PC*+6YT>ZCZGK\U4&^SN@ MJ2C]M%3*+M6:J2ZR,D<>.4B8-F1-4DUS1)?B*.8EA/D>>DM!O"Z*;^2+2E"W+0TE%8*Z[!?82J M)?9(,8VU8]91E89$X;T:T]`ZK)LR@2%EROBK@(H]%R;CY;/<2H7#[%W=Q*__^H[8Y(?[X(/O,DYD8S5R2/14^4E36L%1UI! M/IR(8P)O[BA<3:FD^EEX1A*O[&>=N,[*S\05?A#[SZ-W#^V4>`QH+GD5?%;JBYTZ([< MI[H:HI2UH]D7L5]V5J'W(4O!*-^"3E^L5W.PIO_]UHFI9/57)><)!23H5==M M[#`?M]>HLUO?>AZN;;H6K4(:3]G=$?7-5%186"S3DI=Z.X_B.'IBD7YKL<52 M2^2NV:!>9:G%HAEB9VR2UD!UOH]T96EC;&3%5CE5^U4';YT7N"?(*ZOI%1VL M[H'<_S34K2HY6-$>\'"GL=>[O9! M]$+I'>7Y7*>108V-=/HA]UYMU54?;NV$V)/U9>\[NC,.9[%@0:K"7SM./;[R M]T[@Q%S1)R=[2,R-=CL_@9=WK9>S<-WXT,'!6SLA]VX]I4\/D^MZ(/9K3<$' M'B\+^H@\>A*U':EV4#"P>.7V`A)36M6YM>^0NV:KJT3JWNC%BMVR7><`: ME\\@\B'?!U%6R?8"=R1EK]3L+.L.FEW>ACV_9M>L;HG<*1O4JZJ8H#1#[(A- MT@ZOF`!4BW.8STXZ9GD![?())G7-=-M#%G\40D9_D*OO56Q^6SDV-5C`;3A5 M[&YNQFPUI[2OK)Z;*MEX*6LMA'5>)NK=6PFQFAG(,P*A_6@ M=59H.0(`6JX%-X)RY8)PUQCV!-48LO4^6&UC[*[7J&3=8F<65\):!#:UY"EN M-V-<_(RBN-W%#C\^4!!"[ZYF70?D_MFN[,E!6V5KQ'ZJ(?2PDZ;2Q(GB$N$7KGF"5L9Y(QP_\8Q_?9<$[1/U28((X<- M<\8SL;DQ"Q@RJ)RU+0[;X(;`ANHM4"N;'3JE;^=MINGF@`M(\A+U?)>A=\$- MLJ&ARR2M,6US#^2HK:&N"L<-S1'CK([4O??Q"MH\M"E1MP.):-2=\&[0R0W& M'-9NQ=G9,DUC?W5(>1)X!+#&)&?V9*)LKD)F4YJT7?PSS@0Y-HQCU-)E)J,< M$"/02(KVSFY6Q/FKO).L!GM2)J(*1=*(E,4BF5S6[T!B,V_-)6>+ER=O8[D8 MYZ;ZS0D.M,:6U2V10U6#>N5"N2?-$(-&D[3]R^)FFS*TFT4^W^R=F?DW>+MV[?PO[Q/")W\ M2N-,NR:)PE;/K6B&W&WK%#M>$CK M//3]XF_"0Q4OE1:!5SN2E-]4[S@YN9K)N?$9.?B+,P;[_B;GY#S_^ MN/B7MQ\6/_SKO_Y_\.'?Q(=_6_SX_L?%CW_[T9ZO/\3420[Q2ZNW5S9$[N_U MRJD>?]H*L<\W"-O_6K$@6?)[L_[^HU`LI!M^?W):_4H>+[;__)"DDE'^^LZQ MV[Y_^^/B_0_O%^_??\A]]E]_6/PK\]KOWWUOSV/O:.KX(?4NG3B$B@VE!S[6 MONO7[2=H=43NT?K*JQ[>W@NQQW<0OJ^'9"Q(QH.\*3^`P]E8*FD_@?ZYVN)H MF0J`V%*R.B2,]>EK9%9>YN+GZ@S,]FRQ3\/$?Z3BQLQUE$"=_YOU@_-<8\/N M5)#C0$^SU#RGI4,",4+TU63`K;0<&T3^28EC=EOM#3#]1KR0$:WA\MHH`+*G ML1]YEV%C6#&UB!.`ZF,ZWM'?"\<\=]0$M3'-FGT/A44^<\2.!62.:S_U`C#J& M%422ZX$EMK!B2Q&/X`M$VLKYUUA5HQMR>-)5O,OS%8@A15MTL\]56+_R.XZR MPIOQOU"Q#(+H"79L/D7QQ^BP2M>'("MK?$==ZC^VUP_L2@.YW_NV49-WY?(^-'\LK?!4?;1=$F-8NH`Q[G=),%<3(!$O*&K8A$VIG- M'<1RBMVM$]_$]SQ9AI_IW]*8XUZ-.;4[(X>-;D:HSQRMZXD8*#HJ8"R_E'$B M#"L$+Y'*0A@W,M1X+C';+R_5G!C7B\X**F;&#Q]1+4S#U=R5<5'N%Q:),IV,%;>88:N7%:V MS8U%ZYFY\)'0IMUWQ$SS7JYK7-W,;<4%#^LNJ^36:T[!S3V0.ZV&NC47068T M\^I(;>9Z")(Y=P*%$?FLO63;$W3.;FJH?FFRDU'O<;5W4?- M:IJ45+3NFZ4K+$+?&KM4MT3NDPWJU=ZJ$LT0^V*3M*;N5=U7CLMI/'`,_=KN M5=GV0[[)!D=I-^L+)]E^"J*GI+7D2F,7Y)ZIHW`Y)::^/6)?U1*[_Z`./1HF ME)<:2J+`]_A&W2G@MAI!BC3.V63IL)5,J9D]4+>`%\V3WQ#/PXB-25YB.XHN*$?4&:PXIK,0V0&DT9B MA1RUQC1P*1=E!#Z(D6]4=7MGMA1"0?)K+A:_+%FZ/PE?SPU%YV#R.#=YR$Q. MLQO@[!OXMPL6!_B>[S:KDUYC]J@ASVJA0J/=.K?(\8 M9BK%[#M656*6GN"=2IT)`Y@=I.[_R:6X65^%*5/&7P5TF20TK=NB:^V$W+OT ME"Z%!XT]$'N@IN"]YP^%/.P"%`R(X&!IKIU6:S]G8'-G#W86SYE\'MS7IV'2 M-!O6-D;NN,2*L>!D3*%OY\^9F_D"->RZGLM.+"9=L&QNLLZ1=OQ&9E;DTXHG18D,8,Z*D& MC#*NE@(W;,:ZC6GJ/)--/YM--]UD)KH)[YF(-^OL?G9V<;)N):?3#_F4H*VZ M"O*MG1##MK[L@R!"`BXD3I$)E`\_O,+(U23O3$--.+2>3IH M8V`.V3/T(Q7_O0I/+Y'6F$RS*W*`ZV(`%>-T^B&&N4[B]QWR&1/R)F/S#>1K M55RFM@5UDYCAY/(T)G<'B`L9M_K7_]KZS,[!*U1N]FREPZQ`WD"ZU+;^E$8'8.W6:,9N^NZSTK5V]5PK#?BR+< M2BH(/_OAY87*+\-3P_51AN#":$;BA!>0QC&']-P:>W4B@!PCNANC7QHN8HSH MH<2$:;=V"J[9L`E/L=4Q@76H$+L=!C+YFPG-$SHTC*,!(0U4Y@M61&,FX+PODM\DJP^ZHZJ%,M6"8T M"F>0^/Q<%0XC]I(3-P2M,\24I9TBEU)/'DIS*$L/,;U9G\OGT6I7,7H]L2.$ MOOKEJD^MW3!C0@?I^V<<"!Y9IDO.!9R@X&.K(-34!H"WL#R>\^%GV;:KFO<' MC9A`ZZ'TJ8V0::Q:`E&D5.C-GP2#B$]^4UOFKAL)[%C8PR"-\5)#?\SHV$<- MDS%3P2]_7Y&O/C*F:**F,0US'#>MQH/-Q<'2/6.G*8L=J`5B-'N!RN2D^:%3*@C7XG,AI$Q;BR]#($ M_Q3%JIG:,Y"U.F*''&WEJ\*^^EZ8`41?^,$A'KQS\J;D`-]@2$*>P`1O;IG< M6_9G\@W/PD[$;=.,`4FH>XAE'H/5H_T:6_"L@XK3A6X6;:`R3V!H,XL&2M21 MF!]DM&HR"GZ([*"J,RAD<#*:>3CA.9SP#S[+Q(\3W8W1[R0?,3KT4&+"DWM4 MR4"CVD3CE!X=:'SR0R=T#:0%-1.:)XAH&$<#3!JHS`]4=)09"5QRUC-("QK3 M3+5I054&LID6I(1B=W0O8[2;]?TVBM,'&N\^TE5M1I!F7^2XTLD$=5NGM1T1 MHTX\]WBR.Z2IK0+)$6]65]'X:8#4-1VG!%*-"M?!Q'5O6:"#RW"FP&' M*V7\`QM,N#")`>#<0P6!(#>"5V&$Z3Q?!44-?V]HCMS+VQ15?;NN+6*/;A6Y M[S`NS>JC^J[^AN-$RF+Q465_E0DHSU5NULHS7.T;L_4=D?NMOO(U9P\UO1#[ M<@?AC9PP%$QXXIGRWAR"$X71+)"=3_(4*O7M*QQA.-?R9L^SX2Z?:>SZ2E5SN-(,LS\W2#MX MEN;58B55VW.R205S2CRC>0ZGK.^?&9KB'!#[QAXWH3\KD?HP7_@-O&C$S1D#WTB7_&LJM6HC;330HY^P>SURW[,9AT M\GDQ&50Y0?X>>EOVH2G:R,''J`E55#)"&#%.XG/-TU4EC-U2'@L M)HB20TP?Z'-Z'M2?]HW`YC6[:8-AC7EL!8_7ZKQ-JO:^Z*,(M"`ED?B"'.AZ MFJ7U<(BC,:_K M],6/0OHF.)[#6SOBQI,.\O<=\@5)!AS%DN`J7$?QSG)\N_0\7N#."7+!%+GT MI^H^=)![16_3J![2F0AB;^FO2^\*C#G':K_!-;=.;Q_,R,+3*+=1X#&SB0=6 MOT0I;9E06SLAQPP]I56`:.Z!&`TT!1]44P=R__VN5&C&_)AK:MXZ;R[I0_BH:TM>N]S[8IAG;T2#IP03&:CVP"C@V?51YE4 M*S:;BGV\YAFKI0MRQ]916'7JIO:('5I+[-XG%MF3`FJ]<%1C6'\9I]UY?N-: M<\&FUW->8WV4<[ILU"M\<"W'IC8$#O?_.8J\)S$1/ELII*_"JAXL+?0OF5. MZTH#.1CT,HF*"9T(((:&?GKT=8R,6U9]7O*3KTY*:NV-H3JM]Z,S97<:81\J>`Y.)9*M6 M#D8UT2(PDV6`*13D99;V-$SX$EY:XB)*TN0>RB.![%Y6"T([7Z2@8\9H MU1D^?2@B!B)#BO7UM2OV6X8IG'F(.DBW<;2)G=T<'.Y<-8A&"N]`JJ_%Y9K- MULOGJDF^!J=KT6Q(\JF6\ M%Z002;SF^LGQ8_*;$QPH^4P=D&!>/M@:-PPC^?J\L#EB&$#O=?FAP5@A9ZYZ M(G<^R1_M[H%5N\T1P*".LY]F9KK@]Y,VE&G1(6SH2@,Y1/4RR5'^ISX!Q"#4 M3X^^WG/-_')3%!2X#!_].`IEAO]G)P7?1^XG&NG0W8B\!D]I2Y7N0&'NOF(T MC3IC)TI>J0QQ3>&,/ MQ#"@*7CO*N2,_-EE3I]D#+`-:/TIL4O_60YSS8E0N_/L!O\8(%_FE+L!KHEO M6G/@@@5QG>G!>=9>1#;W0.[Z&NJJSM[0'+%[ZTC==P0SJJ(>]*43ARP^Q#5T MVR:QEB[S&[R-4U53^WD-7Z.G@W"1E5''-0>-JC0BI[VG&YCY[N@^BF%]V59L MH;XY,QO#FO..1K<9C>Q1 MBN+(09XSP34936D"''[N;JEW""B\T]:A^*"8M/-BP^=.`$^5WV\I39>A5]1: M*NS7FHQH1Q+L.&3OYRGAVO1B8,9)B];H#3I29O$X9/'#6SXA ML`_Z6D@U"?^MZZ!^+!Y(07Q4DP(\C\+`,O!ZD9'/2%.2;BEQ`R=)_+7O%N?!KA/'+P#&CSP!B]&" MAHZX<0X-`M]9^8%(;7.A1)>?0'/9L,SXI.[\:+,CSA^G8=YKG_:.YCC;$QE2 M"Q]V.R=^:1FG6QIXA*UW")/88@TYQ7QTU3Q9:79!.O=T4;@FTC]I/X^0O%YL M(QC"R%L'@DFT+H>>R3:*TS,FT4ZX=A1NQ+_\$$F(G<*@ULO718^'/A]*U[# MLJ)2)E3R[.CY?:G.!AP&F:T:/WJ1G`7$#-/,!`HI$I#Z4JU9T5I\<&7?@CSV MEF\\^RSN5@P:<8.Z)8/ZTJ`!&'1!0LJ?C):?IG#(B`'\[J@;;4+_3^I=>7`3 M=.U33Y1CXN4/8_:OT+LNHC+V'5MK>1W!T!27V8"C4;-6@Z41%K,`3[.:FH"" M0B)2B)15>,N$XE&/(A:1'W^+FU-'Z*=@HS@D%-<]1!7$OWF<"7KA9FH*FN-A9G*,'G!'$L59H#F;A) M$AH_TN6SG]28L[T7Y]\`-#]>88I7\7U"V%@2-K>S(GU6G; M^PRZ1![*'(*+?J:[%8V/5&YOC=3U--7,3G@;FB(_J]61O/=P9.L%6-VD+W]- M"-`E<6E@[J%")DDCPCZDSHYUI&RQ$?O1@1^:[FC,RV`4612P#13%'HVA$ULD M'5S*&B;R+,O?[>/HD;%868]4%<.-8CA_=38AZ^>[R8(PD5B$YBV%=.(,B&AS26^2,)64CDZ,_1M,D`3!E?UFR$2-ZIA"H\_\+&\!S;D!?C4A;<, ME0-_$Q*H+?`4Q8'WY'NT"A8IEW%:`&EHE-*`N;#!ZT8X"X`J4#IG' MBU?:%YN%+)A@3T-WR?WCTD0;1GE]PT9@#[*/R*+]F)39_`&PFG!?AS)!A M]$26*$:W8@HD.]CE#?UK%CIFBR3@@@?'^W#1V M40_"R\&O(VHDOV#`D>)!!_7)!_X`P\U>O&4NI>V89C>`\&S09JCQJ@&H+]59 M8-)@Y4RXH_H`BRK&0KX\(B599$787Q""F#U#)#FF2,M#/L)\^P](Z M`988X*VR6OU5F%^'OEGG)>5O(Y&Z!\7C>>WX+C>KS'"9#?`9-6O=_2T#+&8! MB68U-7-+K/)Y"C\L"BA`L^(UADRNA?KT`C[,1&+IHQNGN^B0%1E7/XBASD"@[<5GWE#;W[0=P+8[D_G" M[0!=S;X!M"`@"MZK;UBLITY7GO+\SX9;C]]S@_GJYN)*A*76ZV?F$\GYBUK- M@)<_8)*U86"'[LBAK:LA5,32[8L8B#JKT/NMK#P26Y#5RU$MD(P=&H29S"PJ M<)1+U8@0K+C6E:A1&-K0*S>[&95(0_VRSE(EPP-%B)U\`UU9-V MF5&=M'1M-B0.B7,CKT`X#)#ZA69OB13W(O7!LJWW;&!0RPS5`-?8=1;0I:>! M"9]AG(ADA?;$=%QK@`4@L8(76"O=2-DY_V`?>8QQR-!C):TDD@=Y@B$\RZ,\ M4[2C7IXPZ(D'Z4J=,*#+<8UNI8[V^8O\LL,Q:T=JLT&?7F:J.5#M0FH6Z-1/ M(R-'IR<%\!7>?*&9M<"'8O:LEDB;`"YM:+2)G?T6-W'O4%,+$_CO&(??1?UW3C!)<\!*PHPE+=`JE?-Z@#OE?Q-4+_:)*R[QCF M](@@:*AQS9]"*`U,?Z&R.[ M@=VM-_)[V#V5Z7\E9P^WFB&K$+93PP/XBBB##_3AKY`^Y=4EX%;SBL))#)<+ M5@F\OG2TVSOA"X%?E'^P.KPP,HX@NH]]MN+(GL3@AS_9[6E&8N?$?\!)T"IF MJQ$*FQXA91V2DRI"F0S3WJ2>^/>XEQ9JM0+\$I]?X)8Q6Y5-?ZUZ8K-\.1Z7 M^0A4A]4PHTT$YMU6CU=($868Q7=HJ;MXI+MF]9C4T@!S2&<64H=3E>U]:B!?Y@U7J M?6.A='30?G*P("7^=C8-K%EKR>]UV0>ORNB6H:L?`9+?QM&C[_'40/>/&ZAB M2.\/>S@@?V!3N+@#=T_C1_9Y\BN;TN/E)J;\V*EBNC!#%2DZ&39;%O@:((D\ M`C:IH;E0F(G$'7&?"9675UXY<+^=BT<2(1])YBJ'ML[$)L=JO?1;4P\SZYNE0N&)EPP\+B]%`T= MD$]IR$H(+PE`A`2P09')@!&[+1BM/-S:AIEA-+]9?XG84H'>4?$HWD/T0..= M'SHI;31%K3$'$$2/YT.-50;TOM1F@>B#E3,+Z;`_S>5ARV?YE"5;$*>92`5H M]P1_&UAOS<02MQB2"P%()@%YB$@N0RO\VX)[VW8[&8OEH3C&!##YSO/2=7DY M(F9IRN^31FQ9(G;^(0GX"SU>#XS%`^F<,JI)>VY0Z*1`] M%61,8YB'*.7E=')>QE;('2#O-J9[Q_>"IRYN\T?;,H*GHY^>G[7FA)J%1S`?4DN*+`"VY2IJ`J>?(32I(]=?VU3[UI]Q3F M\H.7Y\'6:9!(84DF+8_R9<9")E5N)N"SL5<_DU;O6\0HQY/L;5 MD3^+K8PL=(%7N^`&]^4_#_Z^XD33,&FD$_,8!NRY7U%+%_%:P:AZTRTE,ED6 M_.VZ5+AS+M!<]B7&LRB4GMI+ZJ)0<$;:XF)$%/,S,KGDI)"BD@D#]8__!9U7 M%]`?J34P@=4-G"3A<2U/E)!Q0U;I,4UC?W5(>:FG-#J*YLF6!FJZ:RR_AZ!] MC3U*-F3%OF&O8#^'`-:0H6Y+(VL6$>85\]IPX[.Q7PG99B@B16Z#YNH91AZ3 M>QW18ZU64^X_9R)(%!HO3C1Y?<.XY10[.-(.V1[1#BH(_FFY:%\'V_P<11Y< M[7PWW,PJJ=>#32<&Z@E*.9W7@4:GZDP'0QEO],!CSDAU*D^Q^&S8?S2Q(-4A MCQ1.QC)DCX5K*^W7LYC55Q7]$=2@`R>YTI[;6=/X/U_7E77;^=$,5MP3&+5R MJ!:'0#-:G0N+?&&XWIC%-8PBTBG+H+GZ)J4>D7L=\7"M5A,FG&9+\ER(<2`+ MLK-,Y96:MAHC=29I9?-COM4L9G/?[M)<:'RS[F"D&C/WHX0_.P*1'="Q82.1IXH29KI@L,SMOW5>&E[B&$00.>@,-];` M^SF2&F((,J#4]#=OB!0!_3ZA:9.)NS1.9H9]M1FFV#M,[IV`E^7^3V=#DXMH MM_.3!#[/5Z>N&[,.RNN4PQ;"_1@B!:CIC-UCQ[$'M]>S!SE$>:2[DO+IU36) M5H&_D2_\^&)EYC%:C-EFR_[KI,3C%^SAF46!+(29(@$:HB(X%"QR7$$`JMQ) M4RW($QAK`4)FYE(WD(3%U/=AT>YAVOCY.^YJ)B23D7`AB2(E619[F]+JBJ2H M-SIM6/Z^]P"VDBL:)>EE_O*I?)WU)O?IAIWBZRC<0.$$8Y.Q:5%>QS0]R@_4 M)]?5I!RO9VH?QRS8)_WC!Y.5(*#N7ER!?`%3_`SJG*%`ZWDFJ,&K^LQFUL?UD]T:]Q5[&X6*74P<2@P@AW1R-V4H=8NP+RW$ M&X2#5>K]8&C!>#ZG%=:L)8XL%.3!?&[Q)4HKK7!5?H_Y8_&.\7*5I+'C:F5T M#**.'*P,F['V>*,_:<109EK#*>]GE!\`+SWQ_7LFF,5G8SM`W1U]I.R#X8YB8,,YIA^E^LU=5.^=M3>F^E+:XX0IFNB5L!J(S0W M>-+6QS08,<9$<);;-)-MQF@D:EFP4P&U62$[\D9N;']C[-A8,*D%S:KC78TN M2`&AB\+9<6E;>^3'FMKB#W^K4AYG\"C".3F.E#<6BS./!8DI/)0FB@,Y)*%[ M)X:TH=)AI6POHP_ZG,9.%+/EBQ._$#^E.]9SS?R7>!0>2H"SK2AF%-0'D^61 MI[Q3"9HV<(FE-&^"(E[*#TT3 MXHGG&_@3)%MFG+/HD,K'2!9D`T^*R(Y,J,P\"_'P"&2*D#=,=+C1&;-%6)S` M2YZ,+W7BP*=QT0P81W!*E"1E0OS&I_>/0Y+N^%,H<#\47MR&QTW$*Q0U,DQ[ M#COZB)2X^:D^FK5PE#FZUK#B1AF+_LP&'03F-V&V#U$S83(-;M9LMFO?HC?+ M!.ED-:Y16\/:WASF%N\.5]1T(/PSA^GK#*;S_<;:J)@768*O(59$LHO?&#"? M+->;[-XS*._*8XXP,-2D71:WG1C,#00&ZSGN8KAZGZX%%7"NE::10UC.Y)`'*CVU63(#E(9?G*F*L8H?!>$ M\=B5[SW(\Q^.LW?,JL$!,`[> M*_:C^.],-M;F5N;H5D6*PRDB11"#YLJBQH'DD,>.IK3KZTM';[:'U0NUE92) MQ8/)(4B+&^0\1,QDS%IGV>D)!(WPACN/)B-Y"/+"5)CXSIEM(TO^Y"HW*NPK M9#((4]Z5S,CE("`(;YJ+,GU0B<5V-0.2VZX\!(MA=C0:Q55,?N-+W/$2IXJ' MA&\N""XAW\/E?ZOGBG!]TV7SH.5+8/>'W M9JELB'PPURMW_#9WN17B`=L@;/\MF'Q<`DWR.U!%,R0OV))C$\7R!9'/=+>B ML99M:CK.:L@V*5\_A*MZS69(-PIO:HB7F9#?!9N3,3_-"=*D^K,IYV.T8TL% MBPX.;U*F+_?4/<0\S&MTZMK&R!VY64G5>:M;(G;8%H%[[VUSLJ2@:]DOQU4S MR>G:#T3!AD9'K&V,W!&;E50=L;HE8D=L$;CO"!4U<4ISAE5''%/-A;'- M:T[N-O;98NHDA_CEW`^":F<;1`BI(PXW M3K9#W8\*\HWI@4KUO\[G\XV)M1\ZH>L[`4GR(@FNL^=Q,87#ICV\:0PGS&(C M;Y])2E9,5)(R68DGA>4I^;]^>_\M2:7$9`4B3[L);$KC:MM2BV51.I:F$`!;S?"ES%^K)C?E;IG^B%!2I^+9A0ZTO M+:0H;\1$I?SL5#Z$RGTQ3?V8EFHGBF:V=P*K M3,8W+SJ8.&L_0[NHJK7M[6![&S:XO>>_4B&$A?/_8)N]L5HRM?"7B6=Q'+ MN%/"/7T_[T<)N>L/,,_)YF0W,H@!8H@V`Q?H30$O+B"Q8:3/U/-=>,./110? M8=86<8MF7=<%7AA^5V/F:3@CAY$)S:^BT01L$8/: ME-KWQ8E,1J((N2`%3U)B2E1!63,N*ES>*,K@U75=$"ZQ':B=PR_QD;IPNLG- MN7;\N'AZS"U,6BKM9RQ7Y98R@[/%W8;>K&$NBI.MO_^%!IXH&GSO!.R+S(85 M!\==^R,%R]ZFR!)2.G5&GH?23Q=#UR'W.7/^WF[&7KS%(XMA'A>G@9N.GU\8 M_VG32Z:UTVW),#*TJ[(*0PL:^VX"I3CCG>/20PH;.#2^_2Y)J_2;-.% MTY_],(K]].5*EFS-35AH>OYRR]0,Z^I(=J.`%+$'F$,-4SMT1QQN]M%BR.U@ MI7)PQG)!4&`MMR%L)7B-9*JU_D! MC`=*^TERL+F16]8SFU#OG%2\]>@5,ZJ6H5H(S,I]=8Q1[]!-O6?CXEI*&'/Z MC!L!=@OQK*>G!)X8D&!4B^0&X"^'[&L5[[TS^)&MAA\=*$3W)8*-(B<0J)9M MC=[RZJ05ZWOMCD@]O+ORV2:@7B_DNW\=E3"P[1=*/DI=7;["9`%N0B@?Y[R` ME'S+)=E3UU_[[#.VN(0M0R^7^$WRS;?P9%0,%:O%ZSHA<5:\5!45N^K3;A%. M9,R"#/H>!',/+)93WK>O688;((<86DT8*C]U&4`+86!E3*7>F^4EYD3A MKEPL`0$(2$`4$1H>7YG@1,&VSR`X7@@F$ MEY^BF/J;D%PQH_^BYE<4F,8\2ORB6`28)O.?]V8G_H"E_S?*DLCX6L,DLPI]&IPD+P?AV8_P? M!Z;-^L4/-Q=.LOT41$^_4&_3\E*$(=*S`J5A!JP'JGYT9P->`]4S!6@%=($@ MI)"$W,2DD(6`,`2D(4(<5$AGR98*^N60IR1$%?F8B6I7)SDQ)@HL;#IAN6ZI MIS"Y33F@5W=5)GH-.[:=I&LR0TDC.*6C.)S/NC1A"$V?USV M+@J"3U'\Y,3'V=Q&"+X.A&DP5@^LJ:`V?]1I4FH2_%GP4$H^]?P[B$&D'+C1 M:`S#U>.2>&19%)8Y\.=<]K*H3"(>9V8&E"U3Y[E?5%3_+%*-"7C(Z"?9P]$W M:[CK*D1DMLL%%!4B[J@;P%,T:]\5'V<&//H9)F.*%.*F-7KI::91.2*_0#.A M`0S5W)$W)C@P>(I`!3009\W0#@!AD=5-B8^D(TYQ.L9+]]0CT)L`X-K"6U"X M?Y6F"8Y;3/Q"BJ1@9U564@B;_4PGXBJ3I*5WIG#_"E>[O>.FI?)27B&5[>KZ M-;;K-C&:H8ATUC-HKI.J^_W((0[M36@U!MS)>+X.PQ;60`R/X1IFUKHIVB)X M'5L#P%YC>232<%)Q1;0%S0RS0`YO8QA4Q3N3]!$#X"AJ]@_+CT)J'N_I[8$L M9,I:*N]YCP>1/PJKAG0#(C6!)"KCBDOGB0**S)[H$?4/"*4P(]G'E'"!+I>#"L7MW2[V#6MUWZ?[SX,N%]?F+\J^F.Z8] MR"!'JKZ&*5VRZT@#,1;U5J7WVT^2(.FB(>YVT2#W[8HS1B+5\NK5(6_HPI;;QHJM-OAH.X4O6VX5SJ M-+.!72V[T2&>\;!\2]6.]HMV]7N?W/]&XXB_BE"9=5W=`JE/-JB3'6`??8W\ MM+E.6@-'PWZXCN*=V(EB"XJ4C2E>/"\B.=-ISW!-ZYK3LY1&/:I.QKS_@6(_;Y*D^0>WREJ*.ZN^`XK:\;U5(0L^CE(VB#*I2_;KF9T-(% M*6AT4;@E=K^>P>T"+;'-+DJO;5\8F$9G1]E+LN>WMPZO4)H\1'*ID,E'DY_C MZ.1YQP[=D/NOKN*J#[?U0>S'VJ+W+GDK&4!L(%F0@L>"<"YV_'ETW?FEP;WC M>X1%2T6*H.+AQ@+O3'3EZ=K_C.(_^#W*O9\Z05&RXB$ZITSUBE.30820^O5P MXV1A?S\JR!<(`Y4RFU3.(&)%F<-P'MQGGH0LQ!7"*'GC)*8B"P,Z57C6M"L0 M2V:\/ZP2^L\#/\458*::I=YXTR]J9FZ@Z1=,BJ'NJ!MM0EX5Q&.R^6L?;,/? M$T_DS.4M0T\M6)\DS.L]>'Y3'/(KWV7U[>']H99`=RH9D$X=5G^2JC7B)`(@ M#E;MV&'PBDX1=T$*@8DJ,1$B9R&R)Q_:+-[,D&(O2"&X^OU">34"I+>[0I[' M#R09\0<340'^!5OZ^YZ\Q,2+2JXILX3W3M_L323F![>M!FE!R]K^\P*[=C7, M8E6)'U$8HD&7\2RB;CVZ48(`(!2)BKOI6J0.P&[Q1%0:!8[)/CQ[_!NYKZ^#Z8STQ@R[AI M6P*B84QF`';F=34;6JGA!7-Z$(ND3"["!,M`4JSU"MERG(1W[/V8J]0I$3<6FL_(3>$YJ\;*+R67SA>T-OU8!Y@?)(_\8 M8VWU-7.?%XB/;01DFWP7EG;X'FF\BJ;;XQOYQT&[P=?;8+))]5O@DS#\BM"[ MVMACH769VU>"SC5*(T-CV=#6L^4S,/PRX``J5S,07:_S>/QU("];L3#3^'EC M?H,?EC@_1Y'WY`=3_&@Z,GQ%^*S]DXP%V:T"?"4HKF\'9,!>""[[+&35)+X5 MDTD_?[0?_P>Z"MV8LK\\V&;);.IP9J]AH3*^`?/!>F*_!=_)\JAW<%/XV-Y\ MFBF;R?KQ$/OA1M3>JOD16KH@GZUT%%8GEZ;VB.<"+;'[#NR,^*+`8T%?%I^S M@ZX3J3S<C^DX7%+:.8D_$+`.O(^.;"D23R0Y1OBY8+QMWW,/0KP2BCY1% M!L3+\39Q6\MD([3R`\A,]C$-_!T3*7XA3NGL$\.YYR<_]%-Z[3^>;%S_FM#U M(;CVUW4YV)I=D0->%P.H$*;3#S$H=1*_=Z(M9W+&N9P?TP%S0G8-*8X-0'@8+XKUFJ->0:94-N'?7')FC"T MATHF4^1+5C%%CL73&'VT'.H3CHCQ?R+%D06HO,H6?*O(.O^4C1'LGQO*A3]H MO;5FBLABQT2T9%0H4X_UG`27ZUE_3>C<\@.,?,_EA._7@M1MZF/#:WFW)G"V[^)=3G'KP1D M&Q1'AK;'\2T7=O[(.$/(.[:9-4L7]/N\&T,[ZZD+[?,,JG(Y(K*_H)KL) M*PV_\QXH&.\+!!1O6FZBR$OX-)#0^-%W:9:9``^L;>%R64S)090%8LT(Z)Z^ M_#51GNQC?;,GV?8.["7(]_\2L0\3E?:(54$<>?W[U5V[M_F;CW)!OZ*:+M&[RS`\.`'@ZA>:WCNG]RU[$4"*!OV-<;R#KM=[)AO='97IO1^=D^1E M+!,@2NCSGKJP>>PDQ!=/C^1[RZZRAQG%ZC\3LG4\LJ(4'G?>[0.:%AO)*[KQ MPQ`*5,NG3$11"SO[R1.9M@ID$P5D%=,SGH0SM;]A42D)!)196*+8_@;YH%,KH5X=7=!0#8TBUN;]EUZ'D=BJ(KGO'!> MY+"/\HE5UL5S:9PZ?D@\^DB#B.>)+TA,-X<`<%)DD`N$W?GL_],HQ+`&-G-E MU:/KVDI<4Z0KMDLP/W0>^^<8[W)\(_MYX?KH5D"VU5F(75/_\!6D.([]TWPI M/8FCU@D\V\>1"S\:LQ%EZ""*52D3QFN9#S*+3H/]*K>O"N=/S#S^.Y!?#WZ? M:HP,JVOJU+X*A#9G_",TSJ>W@)L-=^W6FE5/9K`.I:0T*,T/.77-TV^3(BM;QF0EVE M=%<7O5:U0XZ>M:I5/>Z:-T*,?/6R#GW3E/P.-`DG:NF4?43E()H\"7J&GJF; M=;^'V`F30.SO>O\X)"G?)%09$X6#7 MET?2^E,44W\3RG1I]X6DBO).P8@M?++WZS=2(ON>?LNLO64RRRT35+E_8\<9H(">_,/!(.-#"D9X0&%<(^2J[V/?I>HS7BHPL!`@ MDC_YZ1:NOTJ@>)-CQC>(0.-JMW?\&&2_CI(VE#AI/!-8J%:R"@?*+6?@^#4" M#_?T@C`!RG8]V["6Q4WU6.QEBIR#S"O%HAJ@C:VJ_9RUN6H;]^Z6\0WHS5KL M.B_#MF.T!]CKK4AQZT$J>L:,$^6.]N3#/(DVJ%:]?69C"]_K$V6*J;/;G#P MP%&*A'*Y!H:5\28'D\!Q_X!F^^U+XKNL57)8)4Q*-H_R69)GI#/Y2>"OQ65S M^NPG*52!V--X3].#G[Y,FU&+PD^I M`6+_J9:S[XB3U"S[T"@Z670?Y[G=?8[:8'>?*I5*[J,VP.P^E7+V'FJ"FFWW M&4,G8_L6NBNAZYHC_[XTD'K4()-DNQ2="2#TR&%Z]#ZLZ[8ZOK:5AV#'.J4< MA=9[!]/-J)_JE?\YKC^"T.B&%"6Z*JY.Q6U]$&)!9]&'N7_=Q9H%X5SLS.*C MZ\ZI$"<_QF!_Q:G_)\]X1Y2$W6"'I>L>=@>>N[B4PE=L>`\B-%\\:#&.)D+4 M4)DG9K0I,Q:**'R)RA@=L(QE(-4`CD(88`<1U+3$59?92546%M48N`<9Y##3 MUS`JR'2E@1AB>JO2UW_:[P"3-SE7DK']Q@Z^V+1.S14R]8:#QIU?]8(P<2KO M1.",AQ1HO7S>TS"A7^AS^O!$@T?Z.0K3;8^5D1Y1Y`!FQFBZ,5,[1<3@9DBQ MT6(I-7R00BP(B$&$'$0(@B^VFL!XETGJ[T24Q>N(E8,MFEGK!!\7!+9IYX)I M?V>@_?`4&?D)"EJO"L&.3-0?N"2A5X-7Q_I,"U/`G<%4-`=P,F6I09CTPZPP MB;$_SJ\=3NWUX9)JIH'(!*1>%S:5-+*!3B#`;/#)B+4&(=2_S`FA/K$?S9CQ M);%7AT^JD8;!$U!Z5>A44L@".`'_N6"3$5L-@J9_G14TL;;F;"^(O3YH4HPT M$)I8V]<%3:I"-J")]9D--)FPU2!H^M'F(1\4H[Y/F>CB+JBX@-UPY:BY!W*0 MT5"W?$I7VQPQ7.A(W?]T"6B3G#C)J%N_SE2CM;@NTLU2>9]YCN:RRAKC6728 MWX@^DGN$,5USV6BJHV-<6D]X-5$>12]#[V-Q$"WG[.8KBUH]D?MU!_5+5QS; MNR'V\2[2][Y"F*4X,"9$X9)%K[9O2TYI`C25W9E$:7QPTT/LAYN+K1-O:LNR MUS3%[\ZU"A[Y[TD[W`Y;+^Z`X5D0)9*J-6\<6S^W6C]+O@?0$#]"K2\:0#%< MRE!H'U.HO56?1]Z-PIP\5<\&B6.(I!O`:#]+Z06M+QE@D/+2I#[O;62+U=4\WL.FE# M4^2%K70D[SL^'[:4P)L9ZC` M,X=W-.:UK:*]++L.-9Y)%'LTADZ\B!QE#1-9^,K?[>/HD;%:['KU1U,-$__U77: MF7GJ..XYBC^R2,F/O,O0Z^J3XS@B"ZY"?L%NY02\[&BTYM&8$'-$"]RG3IQB ML<&*;OPPU#:#F669U.F6L[APDNT]3=.`OU5WPWC']8\4#"2%%+=,&*ARM=>! MSIR6@GW4&K).=+>\=*-&@R`OG*[X8(.H7/ M65R\36G8ZKA0L";`FTCFW&Z<_7CO2OPHC!32#?R(6FN_*6UUZ[S(MR2JAI"] M2+*HB'V_=6)Z#D]97$0[..\3*3MQ#)[#I3Q_*=I(?9809E?5L1^#/E+L'\V4 M:J!KC#CBZ-B\CB;JM7,^9RO^W(LJ#5'%(:N74D,I$N$RV2_B+DS#N#1D51ZW M0>YME2JI'E-J@'C45\O9^]"&#S@@9ST=LK\3%R8)/=A#_>+L:&,6Y4BLD+O` MF`8NS3TC\$'LD*.JVWM&`H;DO&46.I>SD&Q8GH44:(#D,WXX`1):SC%%:>[+ M?\+C--GT;3T;]7*W#Z(72N_3R/WC9@\&:LQ!;6J/'-1:5561J;8Q8GAIE[GW MH)64"2=-!&W+":7C:2N4C/:]7T2OW^7TW91ZG#X'@*0Y^:2V-5)/TU2SM!U9 MW70..XXMD@_:^^*T2<('HL.I6]CY&U]!X6F"NNV\C6E_3LLGO(6ROX9^FMS= M_]IV\Z2Q#U(\ZJ3RR>%O70?$$8">W,8_&K_=LDTB@L?/@!]Q/L? M=>N:ZYJ75HP21@X&YHS7:2>CE2IB6#&HW*!=BI:]\I:M\FM;+[J\)C/.$/3$ MVC#YF35,DZM0',HV/1XS#J?7"HOMYC6"D_5L7B-P:FAK#0(6#X+' MM_PI$L?'J_J9@_$!]CIDAE.R?'3\`'*#/D4Q5]WX+];*[M4"L9ZASM^#ZD!YB2C8(Q7)%<7-(D]3A-XF$?4=:N53Q>:WHVV9:DYL-)TQ> M(]ZVZHIAHT&1+H/?F0'L>&8N;2A$JJ'"?)X2(#M?)+U\AIH:"4Q)HR)I%9]7 MCJ2UIC6)I"=,7C&2UNN*`4D5Z>:-I.;-K%#,\!0=AJ[:#;9JGWK^D_J;+3S] M_$AC9T/O*&0A0R7`*$QCQTT/3O!`X]W[II]NJ#[^?I`QGCK1WG-L[\-P7HV*\;;@6[G.8*Z;[&4;:76]BC7U.F-`"&.:!YA5%)C?A M@L]S8VFR7Z7#RH%F=MT#:YZIXD5!X,0)I+.(K:DY)JVT3K=33`;ZW%_Y9-#Q M9QCI@.`KG0RZ6@##9-"\*'@-D\%4OXI>\/_*IP%EYKUBBRL_3'SW-R<)V./9?;G9Q+P&++QT+0WU M")3A<+@BC'\5^_ME&TZPC7_*<`Y(/*JQ1]J4/^*&'8O'51H#&)>BZ2G`F$65 MJVBRC733IM?"8UKP1U!DC\:/+&ZOGN*^1.$C36!]P0L$/42I$ZC?PZ.!7Z+T M[S2]HVZT"?T_:^]7CLD/.1J/;NK*(H&FF2'&XO%U'EZD4(A66U^;WZ$4\LG: M8XLR=H-XK$U*7FA*"@DMUSE$9W#.A1S"."<)KQ\69H07#E\AZ(KZ`)^B6'X$ M[>H"X\F%^%KAN?%'F02S*R7X&H&\V1!HT7V1O2\#%Q`5T5\9ZH_SZ^A,!7#C M/FM*@V(3.`G92A/X.1M[3L]6 M?UXN7*.35[=$[M0-ZJE.7-$,L=,V2=MWA)9H6O;(H6KA_)I^UD,Y0:Q#0SEC+I\)-;J`G!RG>TO`J]"9A6:I'=LFKQ_OE ML[N%1#GV3SBA:_3(EB[(_5)'8=4[F]HC]E$ML?N.8$F<9-2))&_97R?1V3W$ M,0W=%SA]YSK3S`BNG&$M>O.YP[2#0WA*TVM@TWQ:U]`W*:IZ<%U;Q-[; M*G+?42P)$TZ99*2M+^BJ]&U>V?@UM*2I&\%6%W%X].W] MZO='NJ9L9O.N0C?:T0?GF2;+T+M)MS1>)@E-ZU\`U^^)U#%[J)^]#*[9#?DK MX5VUZ)U\MZ4DXT4$,\*Y$2?T".='!$,2P!N8?DIW\!`.^X(D3'IQ22E:D[4? M,J?PG8#LHT2DZ;%F3UO?W?+&SBXZP",Z3@QW;MS@X%%OVG?)IS)IM3F7Q^:T M]V3YY(;PA2'2?%Q%W!`.9V8,+F]CNG=\[_(94D=ITJ#E'76I_PA)?/40.HP: M8E@U8*8,:@>00@Z_)C0;`LF2/\D$:,5H18S9`[5-XVL:?EEI>'N0CL%D5#)? M$*\*^!<*\L>%$/96N$O7C0_4N_:=E1\P1ZB9##2:(T5[7475M6U=6\0KVU:1 M>U\2%X2)0MGR=NIHJ@HL):"AJLHCJ,G/]P87!9%"0O^X$8@1(`W MJ\#?\*BW*4BXCL(-*-DV-XY!'ZG?CF;*?#%EDCCVY=4HNO;UOSNZAQ=$8=$# M"R"V+$K/"NE(5(BGA+`!$X=PGU5FR_DOO5#],&5IB").Z[(,A!*3AOWH#:=A M:X9XS>KM:.2?'8]\#)FGZLOOCA]>1TER_B+O=MS10.BW]?<=TZNUB"&=MVIGQP_YG6#=;RTMC%R#VU6LG1]HK(E8L]L$;CW]0%& M5A3(1N*18^HIBEO;]L1BK9WDRE[[(;U*Z:Y]2Z:Z#W*_U%*Y>H.EH@-B+]63 M>_BUV61!%,_]'5@0SL/Z;>%Q]58J5C`3A!$L1IU`GAGP[=EU[NA#/3RA[K>; MZ/$[,8F#?W^0?X-G?U`\6WRJ&.&+%&S)Y3JR67MKI-ZLJ2;X<4M3A!ZL*_'P M,0SU=>6X%;2G==FQ%?URY)31FKCE]:KJQ/:FX6QW^R94[U.7P@]Z%=+UFKI@ MI9`F=9-S/TI(G=R`>=2)O`<9A.!@0IN^_@0\R1O@^@V)0E*N1G`4OD,UG!)W M.]&`#3,M<[3),*9$GY?.CCU^H"O/=(TE%WWV0W]WV%W3<)-N;]8/_DZHZ%V% MZO[?R>-?7?LB18Q>)L@2?K0[(D_FZ:Y'WX$N.9&`LX(!GS)F)'JDL9)%PT3U MTQ?B*[7>4GC,:1\EAYB2-.*M'IU89B^\@%^L#RE\F4_7"2_ES_Y'V4=0.BZ- MG3!Q7)DC09\A.P=HI]LHH74-F>L%O/"<9+J7KWDU:<_THFKMRG4 M`%>[,^*PMKL.O3U+<,IP)BKCC'^",W;BU^GM\9J1IMAIR%<`-^OB0W[;NG5; ML;$KFO0'`8CXIA8[4$PC!JVC3B77\[S9 MGU7C"<0(#9P/94/\:P6S=]N<]BZIC,"$8?:6"H MJIYH67]&$A;+-^M[IZX,5E,[Y-Y:JUKIWL!Q(\1COU[6WIGTL%5RLR:NFC/R(H8#!K:O"XRJ M-MSA64O5\_T!.'LA;^`LYANDR^)K[=L$+9V1.W&X?C&H,H72096)ZQ9T'I#APEQ\+7X6\F,Y%M-O'=,NB$-X!=@4NLRS)VRB& M38$O&H>Q1EG-&6,&&E@;D7KRF2M^#55W3+2[*Z5:B#I;)?&R8ERB_8+D@A(I MZ8)\L7\WQXN[@9,D_MJGWB>&)LLBA^?FXHJM!R/3V#N`W+\17W;ZN[V83BQLH1:W7 MYJ0GC6[(@4!7<=7YV_H@=GAMT?L.9OEJ=YLQM5V/;NK;(L:M1116#*ALBQI)F>?N.V>O\I3J@JU[^MG77 M>QP]'Z+4"91W^3Q&W0YFC:.?4L$^*W+IM:@[_=6NTSJ?'+>7K5C4B0!R@.IN MC*J;8>V]$4-9#R4&7Z^J+HB[%--T.AKN=;U<-J5)8C")J(>+M21.O5GRJA9# MT*.&R&P1I,DH>BA216&62-*HR$AHDO,<$U'T(RE;QJG`%3S%2M-*LC1`'SE&&S>EZ>VSV>1T&M/1;&(,BY0:-LB0IH%^BND_#W`3 MNG,JZ''/N;A?N_KM*:&E;G-P&0WI3:2&YI3QI(=6Z:V7'=K8 MWVT.HUU#>L,YD@B<_/RE6+?[-&9NLGVYIH_,V[2"VN;.?@['H*F)CO3V*8=@-80(ZK<']($PZ4[_1"XLH>G4K,>"T^1P\OD%J`\-8 M4">"/)8H=P25_^,00<[V;>R[-('*0DM1!^2S$_]1\5J.7=]]W]EWW\_9=]]W M\]WWL_3=8ZD-^^Y[A+YK2N5[?Q/Z:]]UPE06!+M9)306^2N"'R[__=#9?S_, MV7\_=//?#[/TWV.I#?OO!X3^:TIEU7]_#2,\OKM\=/P`)/D4Q?#JPCWL@/'# MYQHK-79`[KGMRJJ.6]\:L=]J"-UW#.>DS]91?)8PXJ2@;L=E1]3V\I\'R'!+ M:C6TDQUZ](QDTBTMM+DW"FUR.O4]\[63LA=5$_ITGW5QAZ(G553\-Z+YGRZ MD5FXQ?RC<$;ET2-;1+@UBO=YH5[U112F?KBA[#>AC=<#:AMC]^5&)\Y M#?UV)0RYPPL1C*QG'95-(-5OS#%J[C&K05^I;OTH+S6?S;"NEMKX.+::!C2E MQHLVE760E;7+QQ`!JGG#C4,N'-?&I9]W(M0A6PGM05'PTAK=A.9"YPK4=@2QI>4 M&).'W57H^8^^=W"">S\]WHT:1@FI MKQHP3Q8K]22#/%P:JE7OO5H6$U%9=]TC.\&#/R*_('LVX?DY.Y(P?@OQD"%$ M4JZRSCH*LLKSH1M0)R2'/60VP[>_ACZTO6>VH&+^O#W0F'6]\]UHVF#+EM5/ M%JJ<,U1.S'B3:_X32/:DX$]`@.EC+EN6R@S`@BKJPK#AHXD-IBS*(NOH9)1. MC^AY@7-0^CC(&D;I-2!ZM7DZ(WJ9S&M!]!JMQD!T\!4G$$Z2?*U8;MC>G;$\ MY\^A?.($39N6:L=R-JJ6U7.E??P0--';\&WLCQ3=>YNBX8"BOO-L5MXZ M.IC;RJ\%$L$1P])\3(/4[;BQ.:QZPVU!=M66004=`@3[6S?O/W_H*)NB(W2( MSO.&CB,=)H`.P1$M=!@R2!_HJ+:,->A8NF[,UK/+-'O-LNDJB6[?>4%&LPD: MX**ZXWR@HD5^8RL5R0<%&HRD\QUUH]AC:PVF`XT?*5DYC)(KMHUJ3O/LG]_= MNUOJ'0*&CA_IV@^I=TY#]D=ZRV1/BDS=QFS6KC208T,ODZ@8T8D`8JSHIT?O M^]&2&\02DA^1#`GGJ"2S(TBBY1M1,+??[&GL`+;P6BH\"_V>;N";A@Q:_=[8 MG:6;&4INHM<5LX-TU*!WD)F1)P5]ZRFS4L$*U1OS9C6Z81_RFHJ7QGI+'\R# M7%?TWL`O&)#J46XUH79TW3OI/+EOPX3+X^8#]:2D4=C\8KA>SWEXN([Z%4[> MU`V_GVM)/]3552:DX&*Y^L\4%BAI'N74K;NZ6!\?&!)U<_3&?O-P\W;5*YR\ MOA-^%]>0?:B#%RS0N?>(VBM:8W#MTU5[L8*^;DG3UNV+W,4[F4!U!FW3NOH(G)OXWJG6O(/3P*(1'89&07_WPNN'&B(;)31#G)N`K`-O%A$^-L-Q%<>K_R>'L9OVSXX<) M9-C5/A?0C<+L,*/5',V04=M]5HC1KH59P%#Y0<(8YTC>")[?X`&,\>RR=-.# M$T/M5W'A,J2H]@3*BM^RA4VL+*HN8NKY^BL*36(SAXYF(W5!D6I*,P:4%H7& MQ1;.O+1-0=X(`0P#C334(XU74=<5S23V$I9(U`V--VZU)?"=>`SG\P:H@1[E:*]:Z%4RJX"''!+:DXP>Q%`ZMG]C9$5 M/.G6&Z%W#U#":%(#N'*2 MG1^A_)K;%)P1XJ$E`PQ(=^8<"6=)OC@[^[7^.UD!)&Z\S]2?&G+G'FBFTNJB M'RG$[C=4(S/^E)"<<^V5"N%R5F]1(3'6HMU:BV9S]5[1W,;1/O9IZL0OMULG MWCDN/:2^R\N*>P-'LAKPZ8U5LC6LL"C*F?ODQ;2W$JZ^B8P]X[`U-9P>#MLTJ<>W">:7(3 M7CIQ"$5.KFLNF;0T18QD;0IFT%77#F%(HR5N[]U!(`RY#!EIBU="IE74I$_! M1LZ=*);[$&51SIG< MT>00I#=K]M\H.(@#ZM^_C_1H>D@-?O3[Z206X]Z6!%-8'F43=*.]$`.%:0_Q)80=7"G.&"UYH M5?(D!5,[.^'3VN63\QC%4"93!TFXG<2;I0=IK7TF"O%AC6P/:GX-8^I&F]#_ MD\7(SK,$[$2D,UV%;DR9OA^I^&^-Z;O20`XUO4RB0DTG`HBAII\>?5U*Y<;# MEXS?0B;_D8PE>9,Q'2=+N!5KIC5,1@@>UMG$4/[[H)H*H":+=2S6.O.9.&O? M=<+T8@MO`ER%-5:Z8L&@DT0A0\^7[-F`R^RI*_F<@"#QZWY/X_/H$'HUO\/H M3)$CU31&+Y5H&Y4C8BR<2/'>E1`*\8@@#FA1"ZG$3T@A9?Z^R(+D@A:/CPAR M"\*E)5Q<2T7F)`N+D*UU&\X[O_YR_R M2[VG9;I0PHZN_4'VZ("LRK*S?M3A5M?$R14/S MV0W7^NL0=6UG-60-Y>A7#EJKMQ50J#J=A^8OT,CIK?G5A_K6R/VS14W5/6N: M(O;.-HF'OTZ4$;;\A,-8BHHB!B+TXP>F&7T$[PN>'Q(_I$GVH%Q3K-?6![F/ M:JE<^8)@50?$_JHG]\`W6.P'?]E[2AK/`H-,.P!7;6<0Y_]0?%: MGUF=AL5HU;=!.UX!G>^]SRZ7/6=\PW/,*WN0/;LO7UC<8[J_.>JE37P7-2VH M:PQW+A,(;OUD2[V.$*3?$S$:=50_`R;-;L@QJJL6!BY2*"SKKEPO,$#85*;1 ML(=%9$-D!6.`]^60QK(.4BO$-;5%#&JM*F8P5ML0.7"URSTDL@H+ZJC"JO&T M5BAC@)UI%357HM1W-F&4,-QJ!9:&IHAQI4W!O,!H33ODJ-(J]A!0\7+B"2I0 M&4WI@C`&2)E236.`\IN3N(?`B5OAI+8A8C!I5BZ#DNI6R(&D1>@A,/(H2:/" MD)'TS-,B<-\1RL@2 M3A?+G*:UH]%J_);KVL*YG7LBMPSNQB@XFRUL1]BK^TD_M"3V,HT9HO% M]_`8P5C(?A'%C+R3TF6H/L+`7UVH""M:FB/U65U%LR"^J2WR4%Y+]"$!/5S: M"5T_@`$)%34(F)@XFTW,GQ8LPOL\[<[G5?Y)%/-'_J!VFYLGD5*//R'.BVIF M#5:4#7.:=8.;0?1Y3\.$DY"7A!9J*3@WTYFL#Z%;%`*1;<43I+Q6T;3+C%%_ MBYPX5[7TS`MG,/7SD1,J7/\K)^)G-G?V$H5%/J4$9/%H1=4N<%-CQ,C8KF1^ M_%+;$CDJ:@C>>X<^"L_B(N2-Y(VM_P!QWM M+)%&4Q9>A?1#H3B4Y'4NWYG2*\S!!SV%22[!2DND,+'*DL;>RR36V0!P\$8OB[#\.`$ MQ22Q?')B+[G+*P%=A9_\.$G_X^#$+,:[I0X M/$RGWA=9!!U'U/F"5!6'RR%>(LE>')&QB,-%(D];W]V2)S\("#,'Y(,'+PQA MB5+IR@\YK35(3/XI1)X64^V84W`5\2OA?(E@3.Y*QN&\B61.)/?I-YBL&JEB M9)5'4>D#?\V86]D.&D4'-OJ/[\PK2H3>$K?XL85BO4R,!2^0HY!%9):N!V MDZ\_1^W> M%:H4#JY\B=[%JV0U[.1\D2==/*1/+#J![V#1R--PA=N3+[^Q&,5)12##%H`K M2+@17\$2:+E:16GZUX1X])$&;+GAD9T3_T$9KU7,&K!_;]BJ,N97!TJWXU@# M62QD:E0Q:=O/+^0:K$1^LPHN9E42O[NYNT79T/@L1L:Y&!@_RW%1OC299"5D MZN\?#2.'&+],&"J_QS2`%G)T-*+:J!%39S"TA(56+9DS)Y([D>Q)QO_H/C5K M("6P>1D+A\DZ3[(&=^W\G1/\0IT@W;9B=6-CQ$C;$XVL<^39WXI;J2QR\T\#Y%ZT,WE^R$9?)--H^04U,O0R]3C&H(;*(YP"3AJO;/^A#$_G\8%3% M_@F[U3NRIUL(M4L\\%`,T30*>Y[N*M3N)BQA_QI;F([,B`,&G[U,[(]TE5Z% M21IS]V^H+U_9$"G0MRNG9E.?MD*<.=T@;/\1O(([$!E-ZZ7CRRI^<7:TL8I\ M0_-9#<]31>L':=%V-D.U0F13`Q9(6RX_/Y6NBV9E>Z\GKJ-P\T#CW3T-_2C^ M$J4T^7B@5^'[M^_?+M/WW[Y]*W.U:I<.W2D@]%EJSF: M\;*V^RSQLET;(WCY_??=`/,]!L`Z<6&QL;(X;!=B7SVH*U+9&#FX;@?0=D?@3CN/\\^`E_ M\(+L..V)*_:-IR,C?7(8=>]81)TQ=?UT=ZKKTMY&_']2?[--J;=\I+&SH8V5 MPNO:(@4?+175_??*AH@WWYOE[3M",ZI$DK5<(WP<)24UFT7"`T9SPX^SG0". MK[V='_I)"O4I'K.J8,V5^[O20.ZGO4Q2KA_>@0!BO^ZG1_]BVIP;D>Q$&DB) M85;OQ?9S`5;LLA"Y'I!)"JD=9<-8+[+W*8H9/H:7S^Z6:4DOHI")YE9OL.CV M00X36BJKL-#8`3$,Z,G==WA+ZB0C3S+ZEIU\&JW=0QS3T.5WO*&*"/-D:097 M,K28KY67\_X2A;*`;Z-#-[5'[LRMJJJ.7-L8L1.WRSR\Z#L4H,ZJ3MMUWBFT MS4O"NZ(J(7_8I-%+6SLA=U4]I55_;>Z!V&DU!>]=44*2)PI] M\6B/9?<=6>^[HR*>)0_^M^\*B:[97^S#["-)@'WR?P!02P,$%`````@`AX,$ M1PHV*;_C2```_+T%`!0`'`!A8G0M,C`Q-3`V,S!?<')E+GAM;%54"0`#72#! M55T@P55U>`L``00E#@``!#D!``#M?5MSXSB6YOM&['_0YKS,1$QF^I+7BNZ= MD)UVEF.=ML=V54\_=<`D)*.+(M4@Z;3JUR\`DA(I$2!``B((,3JBTV4#ASCG M?``.@'/YRW^]+H+)"\0QBL*_OCE^=_1F`D,O\E$X_^N;-'X+8@^A-__U?__W M__K+_WG[=G*.(4B@/WE:37Y`C%$03,XCO(PP2`B!R=NW>I^!F+0F]!B9DW?'Z[\4WX_" M7R9?WG]X?W)T_''R]9?33[\O3SAX%^$Y(75T^G[=B]N"_M?;HME; M^JNWQR=O3X_?O<;^FPD1>QBS;TM\I&A.1EAI_?.T:'O\_G]^7#^PP;]%89R` MT-OT(C21X"L[[7=&E7_G^.O7K^_97]\0Z4TF?\%1`._A;,)^]TNR6L*_OHG1 M8AE06NQWSQC._OH&/"5OJ0*./IT>4?;_[5N.C.+?:>A?A`E*5E?A+,(+)OPW M$TK^M_NKRE#`TU.4).^\:/&>_OF]'"7&F)2@WW?D["$A^*0#.8]"'X8$Q^2' M.`J03W&[_NOM[`+@D$RR6([-%F0MY/D\6BPQ?"9-T`N\(LO,`FIFO_8+PY#$ M'<#D3\\P01X(S(MEZW.VR.@,!'0M>GB&,-$AA"H]&[G4KGDF%BD=V134F:ICD(?G!"\D[E-@/^01-X?=SB:8[!0YH9'I0^.2JL4 M%3%=NN)O$*,70`<8$PQ=`H1_!T$*?T!`>RBSV^H3?9F-9`;+)VK'?XD#UV2SO6Q;3LV/];[B1<.O;8`M]@ M`E"@R1A8$[..OQ.M#)[8:>^TU*4T69LLGI:\-I*SQ>9IR9^0E&6W:2U9E*%H M)Z?*BY`423MLV9;*%!"RBB]EU8DHV6.GM]1:`[&!6.HMF>_RI6%)1AGTG3XU M+-F<[D\VIT.3S8?]R>:#I>\3+=<6>;KVG/I;LMI`S(*WBY:,\:C8<9/1]HS( M)Z3,U[+D/G--_I@S0[^HP[&T)"WXFL#0A_[ZMRBAWS@Z.OIZ-'D[*0B5?P2A M/\FH3MJ]WC`>"9=!Y%7&$E`/Y@@WJ([\XA\B_J9/9($$7E*0"<`3#!@=R6[O ME<:7L\M8C:'W;AZ]O/?/W_^='IZ>O3Y\\>OI1&7<3/%U=$#[!7?(#_N0*FJ MJ[S%^R5SQ7OK/:-@#9$9CA8J\LP'$2DR%6$?XK^^.7XS26,RU&A)J5)_P'WI MYYQPANF&Z\/7_P=77`5MM7-$0S)U#%>8HIOY?$:`3!WR'`_`G#:SIX!2DQENOJ4W]&0#;:>[B,<$(.*]19 M/XWYMD!M\\'K3)FY7&^?>]/;)0H@/B>PFD>8;[I56CFBI6:>2T'+S. M5/@J#K-'O6LJ,U7E=%5JZYBVFC@K],6[??C+^^TKNFX7=VU"I65N\8Z/Z"W> MNC_Y>?V!2?D+I2;1;-+"M[PUBF<@?F+TTOCM'(!E!F48)''QFVU,Y[_^1^:6 MLAXXY]ZOL77["=A^Z`\@@/$]?(%A"F\@;\A;K:R9@I(*H#-/A17NA1]A;0:) MZ>E?9_+A#IV-F[X!0=:R']V>1S&9I]0O)7Z(-J+;TNU6JR'K5H85[DWAOG1; M^XPP7="#S)],KK>S;?^ABU%KP<8$)KS[S`DLXDZ0$[]!0K9LQKU"$`\+('0" M4,^@G-7M'8O7;,A*E^*%>ZFLJ-XH`4&/ZLUWT7">R>.)>>$NJ_6NF]A#.Z:U7CXJ_C#!$\S![4O-6CQB$,1$0X>8[0"%=TL[@+&*N MDAPL*%`8,CRZLLF_>1\:9%A@WDT41M7M3[PMB#L-&1@M../?Z@\-"QO+YY+( M[SR[6"$RV-RL9+.BR%;Q"N.+5R)*(@$4`KRZ(O*-B?#HE0QA*6#B:]AZC'UQ MR"C^2>W=J,WED<_7/+I!"+Z=UL,'CAQ+A=*'?B/:/%E(B^PV[XY> M*A.])0E&3VE"DT(\1IH7K#8?&S[D]B*1`K&=[UA[7J9J7RVJY-'@=6NU[TO$#]%O:ZOM?(HCDFW(?GS,HI! M<#NK;=@&G\K$G4.D'@D4&.Q\)VW5#E__YMN`,Q420T939SX+S`S]?ILPV?B" M46DS9*TW,U*HM?/5=L]J+9P(R0[,G)EI90"OP4E/V&?(:E=GK(!!ZZMN*W>$ MND,'D0D3!Q-,Z\-&E0.\`@-95&KV[?AK< MSE2V,2>A(L^I+J=.RZR:;RA($^@KVC5;O:R#1@?+1H:U8DEH_29KR9H@M2/G M`NELW93I6`>8-BAH:>$TRN$P;1QEF"E1/`C`=9>(H[9.SK?:YN8H9%2X=<3F M*86E?T,OR(>AOV$?>@'YAQ_FUMS5.J`H^9NWY*]8*8:^2_T-HODSG44O9+V< MPYMT\03Q[6PG?8'HN*1$8\AHZ/)\88`%*S2E M!=P=OC:B6[OTNMZU6A/:)Q+:]`6@@)[BR=I`4ZIM3&4MB%8A/T*XN[@T)2+J M/_!`)*52E:K_3D&`9BN:K"G^%?ISV.0+WIGNB-(.'9`X`@R.5$X MDF^IAO6";8UAJYJ_]XF;Y0[IMYGL@5ZE#5)UY2/ MFEQ3)O]>^?Y_C*XJ-51LNX:5?@XT_%9KXUK8$B+:7V(=/[[Q9/1;B"$(T)_0 M_S4*Z$7B)N53R1["**95;K+D8RSIF#I2.WSID$"K6TR.G+]:/P(:>'\],$2V MEH>Q\]%^S<$S0/8'#SX\PTTQPP9[[U36%3FG/2F(#\.6NT0A&34"`=E.$0.Y MM`$GZ-K+V9?5<6MZ!JHTLGGJ-RJF)#/A*:`>-[DD^5?9W"Y.04.944WG@/Y=+>E<"`GM%6&XL2+[;E.G4"#- MH",%:=?\7M(ZJ\_09S7!F[1?:6R=_J5U*%!_,X>.6`=KCO\6X3_6=9B;`%!I M["0`FCETY`IRS?$]^/F#'+DQ.6[Z3NN;QI6N+ M[[OF-+T`K]A$HI>#2D/KU-W%M)-DST@$5?\G/\8W*W/#"MY\QU&Z7(=9U&;1 M;#@7MB;H%*@TBT%7V)5--],R-](.8D)"S4,/2[J.PKG'WGVPOT'" MAX>R2=T3H\C_B8*``PJ9KFZ`HS6GCAQE&H#@ MEK)E%-KYT&*#RVV.Y2CT9&_$-FW=4+4\:XXD,5"XH6&RV4@EDQ('(EW)NH$F M(U+(@?=UX,`3PL$)!%JP2^JR&S',4$-YB:C0GJP;W M&=GNUN&AK3-V)X8=>6`OR4#.5YO?P3I<=-*O$"X'Y,^]=DH]BS".?M(B"4W^ MN9N6-D.BHX]N`Y..:+_P.[T#*Y;>#@,?RKGDUO1P#PVJS#JR:5PLED&T@O`> ML@O=73%RL-'8SSV$M&/9$?^M[!CO>3A5`(FXDWL(:<&O(^\=FP*7V?(IQ@6G MM7N`4&%4UV-'_V8&A7\6^_X(7IO6"&Y[]]"@QJHC[QJ%X\HW^-00`5;3TCT, MR#+IR"-(25X:?4([4G40508$XLASC+2Q>@@&JII1VOE!I.]+]-):V_@$6]_8 M9@AHN0B5Y]J1"P]V1BM)4>YMOK:#Z^!0Y-R1FXZV>VGS"M.9L.N`,R0A1^Y8 MSJ/%`F6N_RP['97"'(8>D18'<8(>KD-)E75';E]VY=:FQ%%C/CJ='W$=B7N0 MEB-717?%:)G(1-G%:EI:!Z,]Z'T7;+*"T?2FW7].(;K.1V$C8+:;C6B1EHJ1 MB,(^H/*((8A3O&H$RV[#$2X*_O4(V.@-U`A*P[+4Y4+0]SMRPX5@RR`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`M[/"2:VI%EQC MOQ&>7875]5FD`7`]59LCTJ87Q/`;S/Z]"G?]4#B8D^DZPDZ#O+J^QU@39+8K M@:)>-#^O@[#/"*\N@NKZY&,QKEBDTUJFYV")$A"(RK'+$K`.<<:NW#K*Q$AD M;._VF;RT.S\\'0[2.LI$E_-2SY$7'"ED9JF&MTT!(>N@INEM4Y5E1R[@[L`J MMT"F'CG:8*A:`UB>@'7(T82$&H_*;C+I^FA@C:U%V/8@]/-K'";5),7D%'V6 MQBB$<QGALKB:GP": M.QX0T-K)PLTK?HXPV&U.C:C5X,6C.,C&0 M<\)6G.5A,MUOS@2$K,.=IILS598=\3PJ+^#W<)FO[+>S=?E<6CM$X@3`[6L= M7C3I7VSKJXG#$?_:BN$9QRE-]W$[*Q>AD0!2?.^,O1N M)I$$BGC-#P<[2A(P?,_5$V9*9Q,BC11[SR`F\Z<4#-Y\VN-T/!P,KOGB%V$.Q(.=*0[\#PE,K41C(RF'-72=U`\^+1S>L1Z66!P08 M2>8-WR+UM(?)B[7SJ?YP(-51)L8RE^X76A>S&?22V]G%*]G3PSF\)[B_#=F; M:.C3?ZA/QPL(!*\N*B2L@Y?J95%G9EW),U;+\1TD2Z6_[3;+P8T*B<'CIC.S MNHR?GM>;>CE,R5*,\8JLNL*J7C)]'46*#)>:DI8M&2C)L'%R8$`Y/@RD'&NS M7C*H7(15;TS=Z)=B]%WKL,?8.)1X*> MLX!_(ZC[,]9M55KA52DMOP_)&7LT,[>>U8;^RR5K/#XZV5W2RO0F%8(6+VKU M0B#(J)2$;UJ^E*GTE-:C-!9QE7N%A:DK6>L6HI:0V$K`H5\F`UQB'M+E,F`+ M*0C6B^M5.(OP0L5^.MU=;,J4)VO2DRIMR]>=+:5O6))8;23Z]I/0T4<9+.O4 M+;^H*-.QX6/"JHTHN$A]V%PE&<5(A.5G3M'AQV*U?=A,E ML#%;M+A33S4`MK5)!]4T^YNZ63?9Y12V50]`G<4!3NHBLH@%N679\F6/&!]K M;DUR:I,MUXQ(?B^7ZVS=G)917'E&=V!S M@//Z>Q3Y/U$09/&"M:EK&Z;WI]WI71"=@-"?;,A.UG0MGN<"@6QX;)CXBC1Z M29`H,\2F%4&-B'4K0RM55Q(@=N=_@$O&/2022;TDQ;3<4'*_,'99>JK[M+5?D58_VU_YR4 MOL?.1?2+$_;)2>F;-B]F:P9*?!'1_0K]><756?JKX:'>AVI!F"U*% M^&1#W>(EB<8.HJ2`Q3E[DY]#LO@J+$**-/HJP=PX1(G'&`4BUBTMK52]7;FY M(_\#7#[NB(5WL5@&$;/LSF`(9TCV:O>XQM^5TGN[(3@I4;1XG:"CACM2:%@8 MFCKU$NE9.R;Y14"ZOW7S7TZ%E7#/3KP.<*X_@E<8WX87`(=D:9.=Y#4>H(S0 MA)@%)5(6S^YU@2OI/5_8HZ?*&]L#:IK*HB[6S5X)%6W5S%#C;8"S]0'.Z;JD M[$5Y7.=%F=$:CMMD/N![N*35/@C`HH#Y\/3G]\/GX MZ^>3DX]?CGI*AO[@/4,_I840E<(&LKUN':ET!@*:G.WA&4):#6/C1;S!2>.[ M2`\CL6[9TH&BF@7.$LGVGML1/"5T'GP\^G1ZQ&8!^45;Z93%P=8Y'KZ-?,-Q MY.Y/9L:J/O47UZ2TG9_N;N?-T4T#VMD=#',J30SX)%Y[9+I8N92T"EY2YG*` M%CPO3DEITG_8G?3\:*6!3'9GPI8V*)YZ7KI(F<\+3^VLIK#:"M"*JG6+A'K0 MDPD)#'`!J8N)4EH\/NXN'K6140-9-YP(D=I@FY8=GX?H3^A?^=3W=(:@GSGW M%Y7>B$U^C<`3"C)7X#A.%]!77$.T?,6Z-44UZ&H?\AC@"K,;:J&TOGS>75]J M`BX&LKHX'GE1G@&U`V6^NDQ3$FM*`P7KUHM.<19=&>5N73@&X[U-Z35O1'`GORSZF2OJN= MG%>[!+M&:U*9T_XIRU))OO-W"'"LA(&ZKLXC09II`R43>Z_5(3"*R$$27B5P M(64)S4KP?;TO8NK5(?W"_(2$-<)5J$=^O MM(1]W5W"VD?Y#V61&\/]RUXP-4._"DO%5M9XN(NR5]LUXE0\BC1\Q;Z%3V]2 M@'V(J_?;P[W@]SLYG5/O#([((&9>BL14ZXA@]>\<.(8U"DXE.26VK^+3'.O133O6K5`M`;:;MJ@?T0D6NM;.364XQ]![-X]>WOL094@F/VP# MF/SJ']=P#H(+,O!D5>.O7-/".B#TJ<4-IF0E9<"'65;5V`%\&":(`\$<9&R@+LY=R%G'11U:K^Z]6L7 MDYW@FH9H`8)?(0B2YT;H\!L?$#`4A6"G!7^'([*YP@3@517)Y`]^ZB7QKS#P M+R->:M#BR(/0CR^)O+_11`<)2EA6BV(^[NQX"CW=P5%;9@U<1VT@TU-I MM"*@^3;,5NZLS,!52*7"(@@Y@&GLYPY^/6\*7QTI_ M13AYQ"#,4H,\0/Q"?A__%A*^IG,,F93K7E^Z4QT^JDP*(D?69SO,=$ED_0!A M.@-Y5D!69&MU.RM>GUI@2H&>JVCJ*H(<1U^LQ]'M["9*R.2XAUF%D\?H$>(% MK9L"A3+@`JDM09>0I%4&.92^V@$E@Q&5&S.T.`>SHJ&[#6]@P0- MQ(>/QSW(H[@4/>H(SA>(GR)[C@%"B65&K%!F9W`6X75)QU8X5?_*@0!6DV`* MY)JYS^\/M[+WAU//BU)RM*?U%EG&HXA8R]DU-WT/([.^^RUM\S>AEUGF*\>VQ1ZNL.QMJS6V"G MZV,`#SMZ[DP4YM`=ADN`_(M7FG$:QM]R)M9K/IM865G83"R;^55W=-G3EXA+.T@,V:DG_^$ZV)[@L-'J"$9%,#K_-P1)2#8`=X7Z^W% M8L.A)9*HYQ5](UK6W"CJ).T.&(U)HX!EUZ<0;4:AIHT]F[U:=NJ,U/"QI)W[ M`CMF'CMZ"D7(3(O214%=>(_X_E"%Q/!AI8WK`DZ6O'GL?8>\(HH.YXB8KK6+ MEP:*[H!-MQ`*[+GV2"(KI.]1Y/]$07#<'71K4@>)-C'WA1-OU^<.D\^Z"LP* MCN,Z[*]&\L-'V%XD4J#.DL1O^W^J8**YB4)/>.G1@>+P@6A*"`7V.L)J2-]%FSM8T\5\@;'.D0JU&%-^FNCM*?8.K`2YL=L3=`=QFF50`,_,8X*R M#T!7;18H#A&62+QS,;P/$PZE(H;=3/P6GQP^%CL248% M5LV$6_1D!):8UOCZU9'J\"%J4A`%#CO'7N@Q"#L_-]35.[M]"M"\Z?GL*V&TK M+B5M:96F9P"VMX5.;.391PG/$KAD7)?FB^%M1!W5ZL=')ETBP0T[=" M>_&*NR)W7J(X"-25&3 M$38$5!,17,QFT$LXN;-4,-Q$:T2L)ID93>6O[.91>TS-I,8/':XY@C9U.5#X MM!:-T>S]@TX4VL9GH?5'K(-MSXE#98XJ=KXLC#E`S7BIZ(60(FXUYP^UHP3! M?@S&'6M;),26AJ32-T:X[T>D1HN7V03V,07Y0."M-7VY\:RHYKR9604!9MR! MX!*%(/00"*Y"LG\M\K@7YGPLZ=9\>G2\[=9<_L!D_85)Z1-K#^$[/@,Q\CB30Y'*\,&E MDW%-IA79`E&"7DQE(:"1:"!^OEHL@9?MIWF$)9M:]S".@I0.G):R(5_^.P28 MM+F+LOI;=6M31XK#!Y$I(1BX*^['_WRQ`'A%3R]%&YVU0LPN^_GW1;7=N&7W1^X=*@Q?,Z(L^^J*/ONC&BSME MN\PC^91P.]YN:!UZM&V=4IQRSX7]J_&<+.5SLM7^R:0O#`YM[FB=FB7UTZ18 M:5X=F>FT3$FR>H!>BEFF$2$LZAM;#@5IC>Y"0X%?1^#`,FMMY">&0WUC=^&@ MP&_OX4&U1B9CX`XCLA^B8'4&PC\>$;&6(+N%I$%0O\6/&`)BS*_.4!#PSSG%Z2T.E9<.C+6_%5@;;:B91WJ-!FD^H3!A9TM M>!'>M_#:6Z=W?0J3`X/%5R!ZH'('0YJ2.>.V(@"AV=+4;1#`44F,TXIA1S"2 M[6L.!2'ZO:VPQ'"1U6??X+LVI54`XH/SWW59YQ8SXN^7)QB3XAY0$O]8@_[&Z M!N'-[UQSN_)WJU34*/"J\=S,B*T*"D"]0]G67X>M'#$;O1]FC0?P7#?EB)7H M:@T"-)]B6O.>PT9G=<)>8/,_$O^43R8U#0=$BS$^JR!ABR_NA;WVA)M M/84J%_=!S;"H:>DR*F39-9SCLJ>;D@W7MS_IBW$17523$4&FB\M`4>;;J!=A M3\O()F_,`PC@[2SSS&Y>5!K[N8R<=LP;34?9J>C@F!30&6CN,=5?W3M!#]EW M]0"Y"$$\CQ9/*&2BR!+DS(DRR$\Q\G,)33$&Y+=LGI\_TQ^OPNDB2LDV,N-U MB6.8''/`O80J_V+'NE$+ MEMR1!,P)3_1HA.-GM/P5!GYF'%29K<&*4G]7H=)="#E2OKH4M/8#A6P`Q?/T M6C(;<9VM[IB..#N-`@47H:5+#,65Z)%C)5[@4ZG"1%,2T]K&+J-&@>,"(#;F ME:IX45X"#V9FO%0DP::Y=8I6T$Z]:J6Y-)J[M:<3?%4`%?\GFFO+WRR,4C@1 M$7`9.(6@'"((K_&DI7KZ`8<.O)K5XJ%^G-- M%).]9XP+_19`&;Q='B-P!,*6&8:C@G1E9Q]D&F3KE>[!`S< M+-N1:H'Y\:(GEKPX/EM=,*%QW92E^UL#(R-HJ-NJN@C&J-5C4U6NL42119`= M=C&B]3G>7,D6)NCS:$$H/=.$&B_Y\Z-:J98/NZ5:&.%)A?(D(SV4$BWED@F9 MDP$-_&NXUFCJU,=`J),]BHDK%EDU!197CU"0%T`5NE\:]3":,W:MM;I6%TANTJ5 MY[3WD!3M2_\C!F$<9!KS_YEF=]G"@$VYSM8!15[)PH5?E67W$%.7O$\9.1)$ M7$506]8=B;DJ2>(&)K^%&((`_0G]S4M:X1HIBR4I,JZBJ3WSCF0>JF!XE#Q)PN4SD@T";\E73JN'X7X^>CBH[5&>1M_@>O+5%HE2#>@:*!X.BDT)RRX'+3T0W98` MG>$2BCE/,55OYLW6@%F=GS@\$!N77M?#_-<,U2&GCH-2$P72Z.M;F(>H*K+:>Q8\?QJ$5"F@+7L_/812A8,\VY MC!5QDU/O7RG*K/E8S5WLXZZ[6$%T4J8Z%$^QFC0(/-]UF2X4.I\^?OWZZ?/O9TT?/@/4,_+``^F"3D[!O$#X.9!YC<>A(:;=52]XE1DUTX%_PYQM*1<<+6ZU<))5<[59/G/3JJQD4$G[UYI2+#`W%K_W3J5&S*PQ`P+IG'/(81L MW$+?M%(+ZY0IECI'2S9OE]H2+:%%6K^[UK:Q4[&"L>VJMID?5Y0+7IN56V[C M@G(;^7'$X>YO$,V?$^A/7XA-T;`PU[9U0-GR?#GB6%YCB%PW..Z*NE@'@?W= M:8EEX`A<[@!+6!`_1OE999-G]CN.=I)RRG:S#C;*^MV%2"N>>[<3:H_9-6\` M?XOP'RSV88D2$&Q"NQZC,T@XKWD1:4_()71HEH)==S3&UQCVP$SC;?*_\%S] M54BXA"YM_+M8<:9FVMU#+YJ'+*C0)_)",T1G&DN^'Q?RF89^.0E/'*<+Z-]$ MH9>YBI7^5N3LH5GPY)^^S8W!163W+T"CU73LF1J5C/,L'T#&G%HUD7H2!P), M-?Z-%K?I&5T=HG1>+7N&%3;T?,9:QID(31:C(]&9`U4[$DJ=O9 M-?G;XS,(CX^.;Y=VK_C,E;-"LE`S5UK%D\= MILYYW\:J>``'`OQ]2D]3N1_+RFSH%&K>1-E76=,'1\QWEI;10D4.()SLG2"< MHW5C%KM!-]OO4>3_1$&P!]`WCL':>;`G$)N=1>W$K^D9@K=Y]!324;!<".Q; MBHF!65N#0Z;+"-QMX"I+R^CSQ4=3;U^MA?I8F8HWL*ZXA]'OC9!M>(?@_V2M,0QBEDTEQI)7W#J1@<.`AD3?9VQ!WGB/F# M\?YS//147O$2A2B!U[3@]=9AYK<8SM+@&LUX%_0R7:W%:H=KF-9\FR[.ZX") MPEQG0I\F&'X!`76RVKQ`W+P]92T(%$G&2GGL!/>?3 M(_0URJV8`(:+N`UW`M!J`R$9YVHO=^7YMT:(=Q%4@>G1>U5FA6`O`OM>SME' M1Y1KD5@!=]<]4EO+\0[3-`G)BE8A2G*C<+G8SW4B]]LC^'4*KI@#3GK/ZA`G M6SXV]ZA[NQ"L_>Z(?5U"*W!OQG_7`=S7QGCT%9PSXEZ7T`K<6^+P:]QS8-@P\ALG3$\)I,P*?,\'X^TO MNS0[^A9;@?[14UAEY]W7!.!_?)P#6B57N%MV?=ZUUQ.SEG%OSE14"4QP!1CFJ:.Y6MA">MN9[=I0DNJQ"S>]5$BE5OZ.D?];[/^G#&=4+;Q_U;PP@.!.M[%5\Q$8:> MX]!,^-U^0+_^V@CP;J(JP*SS4=T2,',VP$)&"HY.390.!(2MQ%``3.>+M>GJ M=^OXSG!G1U`K@O=IMPA>07L"0G^RH3[)R`^E&IY(0FMN&^XB%>4AR/H(B9 MRL+2=Y5&UJT%K515*6O7S)_@9-OST\EZ\,5Z]@#G[.PC**PB[&.=?B74(]"I M-(L6JS@;NK!47:6-O2J4UD:-1ALYM#/G]D5,2SJC^!GZU:)K=SCR4R^)N56O M)'O:I^U&355O'KOP::?.;]($HVPDC5KFMAV\7M4XZ[WX2JTFOR$P#Z.8P+%1 MD;RF@]>C$F.]U\>H+Q8)8B\-`&Y48GW#P:M0@2T#:;'[,)JR8O8;PP,$(/3@ MPS.$U`E]ZOOYRK0Y(L1G*_(?RR@&P7<Z)37K\-4C5'9QJU.H=EJQW^`+#*(E M]'\`_`=,XC,,Z"7@=QA"C+QXJX1T<;3CVT<=R%D'19W:W[*V=(NI=W#IO9%= MW_,WW+J*WP,&MTW*L>5BN9^&'+?6II^5TQA?TP?C8E4PS"JK!)F*UH73FJ9Y M?2?GP*#`IHNEY`HQW*78>P8QS&-HR(XKCQ1A7^<`H\ZMBSE-"VE<+98`8+]=^MT:=N=>QN+&*>[5-?[=5J30MK5"@G:(YB!+PX4"UZ;E5MNXX)R&_GIW(0>DB#6B9H^DBP@GZDRE:'4D<0H>.+16Q.+)*-0CWXC5W M<6FXXE8E3S-\AP(\_(RU`S&F-^%.2C('7N('`CGQ>O42>D-H(/479Y.#3 MF:=]&."[C%+>#5<[8B/TU$23(T]GIO2!((^TU8<\TG9$GIIH]4"PK6+!6ME5O)S-*1 M<;L<;4^)>UNF[J\IJ7'9:2,`JQ3^2#VR)0QA4S6UOG;+; MJ&97P6K\]OX$5_ODO[.C4RQP`Y8%K:W3L9IVJH_UJGP.1[PO[6*=P5?5(*]CF'5R; M/0^)H)_)Y,@S:U#^\ULOL4-]<\^A`$5JN^C*MR.`H6OG[8P5N1'"8Z>=DV"0 MX](1J^$!!@'UPJ&I=D#`4DHM4(CHS4>"7F`^!<2P4*+A)&2Z2\`13R>!<7;= MD,1(IJMUX#%\J:0B!A<1=/X,\)Q;?J:NJ74(::W/IOM&`;^.F"45?HO;.\^# M`4TR!XFE1MCQD,@+7('"P0"GA1B,V3H]/&3*9GWXO)OU0?22:7VJA_$M`---&$YSV5"AB?.CNZ:';5LV/K][CJ_?XB-GA$7/HJA\?,:UZQ!SZF_CX MB#D^8NI_N;J/@N`RPC\!]F7`L]O+.MP8?J%J8MV1S:N.=06`V(T*257*`<(D M"I:0'&Y\LH'BQ!8LN.;\H`<+$GX/EM53KA/"'8/;.8B?'V"2!*QR`ZO+P*_M MTX648\#0+HJN9L?7##@AG-,-T);R+_IWED&C1IU73,">'S$[>]=>C9&Q)V0:@FI-Z1Q+\-0A[9U1D73"8-'D_UK:T# MAIIV:FYS%/ATL2;\E@Q^"U$2WS_\UA2PS^_C#$+:X;\311FXKOX5TH8N`KIW3-;IY@X(<^)Q-P'QPFP)YD:-5H^#VT> MI-2XR_?O>/H"4$#WX\L(,Q%JGP7BSXUS8"\2=3%LI>LN>ILF<0)"6C,M$ZDA MTV?G.R/FS8K20$FQX9H]N>0N7B'V4$P7"J-@W_G."':SHC3J`]$GV)^:)??4 MO$QL%1B_A_1VG(7]A^RI-P7!(\2+$]%TV.](#GS"6"!L`^79-E/JXS"G5&DQ MDI3ML:$IU6(DXY3J6]@&ZL[9L4OI,6:W9)M+'=YAY'%]M_;S]0.?.CT)V$"Q MO,%/%_Y2M(_I(OGU<;KT(6`#=0$'/UU*R\\5V:!1&"/O=Q"D>]A/JM\;I\1^ M1%H\]AT9F06G@S^V5$6XA]/)U@!#S=1\G>8W$,OFH?H3^Z[M['O'>Y$V*]( MBWE@YMG;M5F0^=)<1CC_%6W'VR3V.XAQOO0HYV(2F7DY7T\BLE#@DLOP5^G.:NV>=)WXCEZ;XU"X4^UB)-P,6A9ANM;)N M+=.@R/**)<.N5:&`.9_?8(SFX3HU)D>9]8TMUJF*I[D"WA)U@*5_OZQA;#05*7NW!0X-01(%Q&&))-[N+5 M>Z87=7FJ-B$<1%U6\D>PY"Z]*5 MOKHP;2<`[C!<`N07I4,$#-Y##Y*U[XE7O:`HEL0CI@%4\_#*1DK`D\H M8*\@0FN1U]P=K+3BU)$2+`_/$4YHA,.OQ,A7T=Q?+;* M+_U91FT5+S!;B9F'?+TW6VW9)Z[G/7X]%T>N,S;]VY[B_7<66/4SB89'/`[ M.`<&158=.>"N75]ET%#?V#DD*+#IR,FVY)>\9OZZ(;6OL(]UF.AJ-LKR:-7) M(X;>NWGT\AZQ=8W"X33_F0+AM`2$[+K@WFCGTN&_K=BW4V]GFE^PAO-'(Y7=U$D6M&;?*`#:&F>(98M4.-^ONAX@= M,?,&4D_:&V"\3KK:&&%\8B#">'(RQA@/)\98]AGD;)4]GSX02+-@`6KX6:(Z-[D:15(;N'$X'5BZ[EP"<3W&4;7,;@KC&X:PSN&H.[ MQN"N,;AK]*-SW4+IYJ)G1V#ZZ*(WNNB-+GJCB][HHC>ZZ(TN>J.+WIBFT%X; M5#T#HAU9#\8,B%+*=-^`'+/:M<]J-W3=C]DO]Y?]%;%F'(&+[0PA'VLPXNJ>J05[+[!06M+W,X>`"_)#K?=4$"@=ELEQ:4C MJB^>&/.<05(/KY6V3D)`GE-'3(G\4?$\)2,.O56QS1+H!W?9SAPUJK5(S9DO:S*ATU7Q,B"?L9XC50: MW#&5J-B+)544U-R":Q"%(]BZB!.T(%;][6S-OBJP5$BXC*K.2E.5@[V:EO8BR)C:=Z$F*Q<#>^(FU^-)O^BA-:G6LF_` M3Z7MB"`ER73=*K]F&`JS[=F*-_7#2!+:!ZRZ)A7MNK6]0/P46>*Y<5AI12U$ MFU0:TM9YD*U9U_B)YIDJIHV[I#R!$77=Q>6(NR5?"NMIUP5Y=41&].D16=<$ MS+4KW^9<\-5FS[(/TIYE'TQXEGT8/EJ'$[.*E?5Z:Y:1G1"I8T'.\8W?TUZ(**I,H'Q% M[AUY3JQC/U[/++E$8X*N]@)'4=URP)%BWS7DG*TVYPP$,='%\^H:OL!`;EL2 M=+87/?O?F53%9)6;4^U5(>9OBTK`7.>J:E%QZE$3AR!HT.M=V!4*-2Y4F M+]NA8VO-]%6X3).8S=%C.8-HM\=!($>5?]>3`@2+BWQ&_ICJV M3Y6!X@6&;BY-7P`*J&#)Y*:95S?A8!R< M\CLX"3I5%R)%\3BR0)8=I[8\DF,U3S5![Q%?'67ER)W1&&O0N_>W\5B#^JBH M#SWMD4SN-1?YO"V2UWZ$EK)T=)E940(""$RQ\"ZO0;6#3T08`QXLF;+DPIX M:NWV;PG>QL"3_JWZ;H$GGUTRO,[2F`@RCL^CQ1/*RI312T:;* MT+\(7Q".0OI*!X(?(*%+;Q[+)A=(=WQT=+P=2+?Y`@N8JWQCDG]D'3)G><`< M6706*"DBG=;KCJ<2(J=(HY^S(5U?2P,31;C5-[9N"6FENNI13YI/JT*)=L9] MMKH!"6'V=K;YM2CH3)Z`=4I7T)F$PM7XMA@$.1]"/Q-!#_O5K*:I)M4W,]_[ MHQEX2JCJ/QY].CUBBB>_R'(E7L,Y".YPY$'H$W;B[6W^XG7)EK[ZA)-MR5@. MD6:-;C"A502]`\70GM+D2\+O8#E2NNX94BX;_;U_UJX;6W/EGKI6W<[NR&\1 MD00KT2)=7(4^>D%^"H('E&S;AQTHV8$V<.D;B'TOGYT`\PZ<2]E<'NM MZ$#I0`$C(83>5Q@C]FN=2%!(12)GS?+[NX,D/:P[$JPC/:7:XR?K?Y#X$;#N MB%/JEA"FGH?)-CU-BM)(8N\)B;[.XT:!;6.N$N:NTG1_OWIU3LF\W="<%X:',_03P/F?S$C$\'/ MAW47@+!T?RR\*%>B8=UZ(*?*\@+0G5^KKE#%3-3\51C?V8*6=9#HKN`ZGR== MDK$>/.(H3TY[ZT"@3V%R8+#X$E[3G@G#F`P\X[8B`&'L9U.W00!')?:S%<.. M8(2]1]`=&<,$Y56"RW*4ATT+2LXA29<,'+EK>R#*8T*X73)/NG(NWPMJ'FS::Y@)&F76W,)-=&J9$C&J(X?=S'"^*C#MBINQNTV6O M9K$[BE1?^U"SE_L664DX\C*X*X`;F-Q!C"(?>?EOS\G9H+'PB1H9Z\#5'@@R MH&HA#$MH8O7)?02Z-_#),7A+;LHS<+GI"'$)W&X@%*425L(?F]4(;8B#EE MZ6ARU.H_AEY6U!T/?X<+,05YZ$I%YMJD3'P5$NE0<4BGY1#VZ"?S&1W0 M^D7Z#!`L>_#A&9))$OI3GQAE#)REB_^S%?F/912#X#N.TF5,2`0IC56N?U$4 M.2OOZ>O6+$@*P*FF2>M/3%8YN)H7A,#G:#\?MQ2K_8"OCZDP$%=O%99NP**A MW$\[:@>(516_H M)'M:!S"=.JV>4[M(Q$YT?*.5]Z(E]'\`_`=,XC,,Z(G@.SDT8>3%52[C(N,F M%S)=R%F#HZZ:WK[;T"R2WH%4WAQCZ+V;1R_O?8BR?9'\L+T=DE_]@V5,NB"S M+ZG++U?3PAHTV&5BR4K*@,^XK*JSD=6:,MM_MD;)LF*M*J*1%:NF:@=OW/0I M1CX"&'%RP_$;6J7A1GWMVH>2'/6NZ-K-?>L.<.V[5[-Q\YI:HS^[EF%ED?7N M(LL#"+U9OXB%E2FY:KJ8LU@%%6T8YVU?G+V+8C:?!$A0I>080+2P;\#SL`-NM%U^ M[2ZN1!(7LQGTB)RRA9QZ-%T2=6RF5VT__I68OF^X`,S]"<;%6GI$0%/_GVF< MY89_@$D2P")-_&]A&J?L^/^"XIH5L14-ER#7G7%'$L3]1JN-1/,0_4GL!O!: MY$?*/&3(Q,,0Q/`;S/[EH$B)ADLHZLZX@91QO2],#XA(9(8\$";GK+S]5<@1 MU!6Q0T!,&'X*5D5BQHLX00MJQ>8)&S,2ORW)^GX6I:'/P:#9C[H$VAXDY4A- M/Q.2NXY^[A_8FX^.P.XD*6-^G.9<[?+8^ZMP%N$%HZ/F;7>ZZVV7DYR4:`[% MWRX?^CU<4O?-<-[@;,=KSL!Q^OGD^,O'3^1#7TY/3OK.][D]U))RSE;Y'^6R M?DI3LF8Q::6NF@5%DPBL9G+3U*S:L:"-5::6.G8J5<3N3Y<46Y6-2RH,>J( M$?"#\(L1".ZA%X4>"NA.22778/*).KF&BQ;<]NZ1ICE%>>$Y7ZR2,HG)Z_I8 M!PUS]J*Z'+B@Z3.QM$3><4L-1'4%U"BQDC8+ZN#3%8+0A1:`UZV2CQU;, MV:G2BS@AJP^*R7JEJ%W)GM8HNI72JCKOPK*=ZK])$YQ[WS;TMGPNJ$$ADQ7^U!A M[E3<5AR.K"$/((#Q/7R!80IO(-=OJ]K*/GRTU6(-("18U621]Y__=OW:L`D1 M:GI^V;1T&06R[!J-Y?NDQ2Y_^CT61E(QM6N$BC`56`*^YBPAIQ;/1 M:+2/O1TR*7'HLTP(9R"&_GFTH&)@\LPEPC]T2G1V&3\=)-`UZFLOFTRUA@29 M+2"\$6N]1AQ05"/Y\HF\JIH4\V M\*CXSQHD*?1V%3==19"CY(LM*-&9LKI(AU%71/<,$G'#=4IP2*98@@&1!@H! M7C'I$]G1N4;X"YA^,BN!:S@9^Z*+T.U+;#G#1ST4$OG+^TS)*(L& M)K_Y_U!+`P04````"`"'@P1'6R":FB/3^_5%_Q7V!!%"#/"WF^&@0/XG:9_3<^K%W MTCON#TZML_/AN_/^J36ZB^GN0(,I64?X)IQS8<^QARR)^`S+>^1AL4`V_MB9 M2[DX[_5>7U^/T&3"I#RRF:?%]-\-P4I(2DXFOL37C'M7>(I\5X+%Z)\^AT>,SZ"A_J#W^]WMD^Y>1&PSGTJ^C!G>)MP] M$M@^FK&77OA0]7'8[0^ZPT'$YA+Z-=6(Y@N;&?;4XPF8/.Y2CC[LU.#L[*RG MGZYZ3];WODNHD(C:<0,<3TN[\ZX'3R-"ZGO%A([D/;E+!:%3%GX%7ZHQ>JY$/`.*EOKPZ^--VA`_'4\_(4[!.XJ.1:#_]=GB3D;==/"44*)5@FG3 M!S]HQ7SP.19L)24G2-C4BH1_Z&4E9AOS0="8_J0_+S@6($!;4PW!D#LD,7': MR+5]MP'CJF?E?.&W$7K?!-1+YH$UYD!"7O`-+(`>KHEOD00SU,>-H$ZU8P4- MM;#7@?T"NT^!;8-+!71-@N$S['ZA.CDE`?VEK@('P05U@BXH9H5B4V07@"3G8` ML*UDA7]$XJR5/.N'4.(_6]C*8!O+.>8%*UT)<.O(S="=Y*'3`@N7P!:]]>A= M$PJ+#D'N#>SWN0[-819Q\@)*0-PRHLXU(OP+MR<\4S:[@[KC)9B5$YKQ&N;Q M"D59"5DM5*50A0G0Z']PBY]@XR&7">N%6%6A-&]6P7,JL**<:^*CSB4,Z_+-U0$ M/Y5O:(&NNL)>($'$>/J04#F[MA:1F$"#/5!^5=5"U+Q,BFEAJ9<]J)8V6`-. M]7Q!"T_IOM1?+(*C3^0F`L7LEJ>5N"Y$<#>@ M,IV1B8M'0F"9P\=$:H;I71ZF2)B.]E;BK$!>BU<97H]8I11MZ7-"9P^P2\[! M5$!A1N=]'IV4#$L+:2$I@P1\/Z@*J\"39/;7!\YF''DY6$JHS-#\F(DQ#R' M]'H&(ZZ#?A[7E<@PM9D0:H526P3KG?94.^99@U6-\YT6GS)\GM$;%F.:+C,L M?VQ&I""=H06HXNJV:+#^`=OZD[4U@%0[4FLAJ9?Z>T80ZE1,`(:T)IB&_>/^ ML'+94""PS:(WS@<6HU>1RXSC,(_C^MQ@"VGC)&$QE&NHS1">Y"$TE8&UT#7( M'!;#9J`T0W::AZPPB]BBU2`]58Q5*9T9J?=YI`I252U.#7-6Q5@9:=X[5L_QW7?^K&.6^@:1_!E=><5V:M#AN`\?<,E_[DOD6B\7:,;'+,9'SS9N(6C/_%43J'W6QZR.>6OK:UG-UJ>G'CB#>PE6W?>KOYOHZ5C21W>B*U#]`VZ,W MSXTHE'C#]:$:X:R!PG8C$8C;.2FY6V5!"%M@+@D6O:CO':NW+:T`B;I:9<#; M0Z5@E-15*CVP]E`G%TWJZ@0LV-V-.A]ZV2MFPV_25]'JBVA!,\:E10OOD3;< M7AS<0GW+;"VO&E=7W9/;'1QW!^^.H.VHPXWZD;SFN%Y?&+W?5G?R]_Y6ZHO+ M>8JK44>,UQR7]**01WWHKI@;]J#@(NDJG4BPA9^[*Q'-44G>$%T%$NJ M*HGH[X`6/"]ASK-NQO%Y^)Y%J=ZYW*P:X;#;?P`I_#\8<7&'O0GF*XVKW*BNS+!W@WIMSW_!KG/-.$"X8`)"][J:E_#OG2$^P>(X<8F88Z<:YI49 M]D[5>Q\\D*(I5\Y`LG?J7!$TH[!.$KM,FW**O5/F"Q(JR.5EJI0]WSM%5!$M MCFMHQS!39E'9X!1SCIWHM:,WG0_6KQ'=,CI[QMR[)6A"7*)BP)R_V:[8O3.; MWA\16U]+R>ROHU?$G>)-5!G1WJED0";8)^2F:U6&O5/U@>,%(LZGMX6Z]]$T M)A^QCLAGWWKG' MBO'E8048T<]08L`CD=O2R:R54F:J?S$VS3GO[Z0NA"C4Y0JK,>?46DC M^Y@T+['5QMGA$4Q,6)Q@#F/]:ZK!?ATV;VQ&R5]J9W=-N)#_]A&7F(-15+UC M(LG6C#WT"N`2%L%7#7S"%+FBF5/(#A]E),=W8<&*,D&Z80&[6E..,'D9NWZI M[QF_R0L7@IYH7.U"<.&`"_VKC.BV,^1J#JZL65,ZFU6N'E9<^EQ=29^(+CIQ MJN5;-;?;.1]O3G8UY6L8:FVTVVF"=@6I>[HMK#/&BE[[7@5.]5)"CL4+,8U!31( M,CCR?+Y4.Q!_H@]#=Q1R5%6DX-2V`>OW3;9DYV=ZC@0I`A_ZM)H4(]=5Q1+8 M>68PNV"4Z]UDO*QO(N#@9U-11<))E;*%D[V-OR&>M"&HNO$6(%F[O>@*$X4O MZ,)NO\`MV(0AW[A#_"I/]@B/P M!LYG4)<36Z03,")Z:SY_&6U/*`(M3-*9*$P1\(8P[S(_3Q\8;M>-'%3HNTL$PL1`\H%M,Y]*\8"6 M6D8Z@Y`*I;:/U6;=^3ZH;LN=!)G::Z;J3EZ("H?,'^![\6OL/;QT8QC+2N"9#NB#.:,W,E>).CRVMXAZD]1N)74EROSVK0RF>\.1!/UT\3$"2=P<`:# MU5*C!MYX&HW3FTS&J#:78?P*3;,7QLC&[R6!.[BS$24>:#;&,A&*K-3@+-RTH&YIH_1#Z5@-CEP.A*'-ZFE;3 M3'(@>D;G>4^8$L9A[XG%E8]O0)?C_D@>'_7[X0!-ZUZ?[:#M0>XCQ4Y/:]C# MQ';0]E@!?5;''B:V`[''W?(6T?LO:6VS7Q[HXJ=CG0<.SIL3=WF!Z-=GXN$K MK,^NU8K_JWCF^@ZBY06HF/'ZC;D/!/GZ1411Q4K3(J28_Z!3JW>$JNKN6TQG MJD'Q"W9FZJ!:E5!>N^Q5_SV(9U,-AH/)><2W>JGTCGH_<>2I'.SE7)7# MW]`@^;/:@U>D_F;A]2YV4^`2U%OT%3956-YP)5.,^\!S,*D`:3\>O$(R*.5FHU[.#DJET7)5(IM9BVF'@M;WQ M`L``00E#@``!#D!``!02P$"'@,4 M````"`"'@P1''[K,QVH2``!C*@$`%``8```````!````I(%`'P$`86)T+3(P M,34P-C,P7V-A;"YX;6Q55`4``UT@P55U>`L``00E#@``!#D!``!02P$"'@,4 M````"`"'@P1'DD,NK^`N``#L1`,`%``8```````!````I('X,0$`86)T+3(P M,34P-C,P7V1E9BYX;6Q55`4``UT@P55U>`L``00E#@``!#D!``!02P$"'@,4 M````"`"'@P1'P<1=X?E\```1_`<`%``8```````!````I($F80$`86)T+3(P M,34P-C,P7VQA8BYX;6Q55`4``UT@P55U>`L``00E#@``!#D!``!02P$"'@,4 M````"`"'@P1'"C8IO^-(``#\O04`%``8```````!````I(%MW@$`86)T+3(P M,34P-C,P7W!R92YX;6Q55`4``UT@P55U>`L``00E#@``!#D!``!02P$"'@,4 M````"`"'@P1'6R":FB)P(`86)T+3(P M,34P-C,P+GAS9%54!0`#72#!575X"P`!!"4.```$.0$``%!+!08`````!@`& +`!0"```/-P(````` ` end XML 46 R4.htm IDEA: XBRL DOCUMENT v3.2.0.727

Condensed Consolidated Statement of Comprehensive Income (Parenthetical) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Condensed Consolidated Statement of Comprehensive Income

Net actuarial gains (losses) and amortization of net actuarial (losses) and prior service (cost) and credits, taxes $ 10 $ 7 $ 25 $ 15

Unrealized gains (losses) on marketable equity securities, taxes 256 (2) 344 (2)

Net adjustments for derivative instruments designated as cash flow hedges and other, taxes $ (6) $ (2) $ 0 $ (2)

X

- Definition
Amount of tax expense (benefit), after reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669646-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e640-108580

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of tax (expense) benefit, after reclassification adjustments, of (increase) decrease in accumulated other comprehensive (income) loss related to pension and other postretirement defined benefit plans.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e640-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (i-k)

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669646-108580

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of tax expense (benefit) before reclassification adjustments of unrealized holding gain (loss) on available-for-sale securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e640-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (e,f)

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669646-108580

+ Details

Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 47 R12.htm IDEA: XBRL DOCUMENT v3.2.0.727

Business Acquisitions
6 Months Ended

Jun. 30, 2015

Business Acquisitions

Business Acquisitions

Note 5 — Business Acquisitions

In September 2014, Abbott completed the acquisition of the controlling interest in CFR Pharmaceuticals S.A. (CFR) for approximately $2.9 billion in cash ($2.8 billion net of CFR cash on hand at closing). Including the assumption of approximately $570 million of debt, the total cost of the acquisition was $3.4 billion.  The acquisition of CFR more than doubles Abbott’s branded generics pharmaceutical presence in Latin America and further expands its presence in emerging markets.  CFR’s financial results are included in Abbott’s financial statements beginning on September 26, 2014, the date that Abbott acquired control of this business. Abbott owns 99.9% of the outstanding ordinary shares of CFR.  The fair value of the non-controlling interest at the acquisition date was approximately $3 million.  The acquisition was funded with cash and cash equivalents and short-term investments.  The preliminary allocation of the fair value of the acquisition is shown in the table below. The allocation of the fair value of the acquisition will be finalized when the valuation is completed.

(in billions)

Acquired intangible assets, non-deductible

$

1.80

Goodwill, non-deductible

1.60

Acquired net tangible assets

0.06

Deferred income taxes recorded at acquisition

(0.54
)

Total preliminary allocation of fair value

$

2.92

Acquired intangible assets consist primarily of product rights for currently marketed products and are amortized over 12 to 16 years (average of 15 years).  The goodwill is primarily attributable to intangible assets that do not qualify for separate recognition.  The goodwill is identifiable to the Established Pharmaceutical Products segment.  The acquired tangible assets consist primarily of cash and cash equivalents of approximately $94 million, trade accounts receivable of approximately $179 million, inventory of approximately $169 million, other current assets of approximately $51 million, property and equipment of approximately $209 million, and other long-term assets of approximately $138 million.  Assumed liabilities consist of borrowings of approximately $570 million, trade accounts payable and other current liabilities of approximately $200 million and other noncurrent liabilities of approximately $15 million.

Annualized net sales for CFR Pharmaceuticals are expected to total approximately $750 million at current exchange rates. Had the acquisition of CFR Pharmaceuticals taken place on January 1, 2013, the consolidated net sales and earnings of Abbott would not have been significantly different from the reported amounts.

In December 2014, Abbott acquired control of Veropharm, a leading Russian pharmaceutical company for approximately $315 million, excluding assumed debt, plus a subsequent $5 million payment related to a working capital adjustment. Through this acquisition, Abbott establishes a manufacturing footprint in Russia and obtains a portfolio of medicines that is well aligned with Abbott’s current pharmaceutical therapeutic areas of focus. Abbott acquired control of Veropharm through its purchase of Limited Liability Company Garden Hills, the holding company that owns approximately 98 percent of Veropharm. Including the assumption of approximately $90 million of debt and a minority interest with a fair value of $5 million, the total value of the acquired business was approximately $415 million. The preliminary allocation of the fair value of the acquisition resulted in definite-lived non-deductible intangible assets of approximately $100 million, non-deductible goodwill of approximately $115 million, and net deferred tax liabilities of approximately $25 million. Non-deductible goodwill is identifiable with the Established Pharmaceutical Products segment.  Additionally, Abbott acquired property, plant, and equipment of approximately $165 million, accounts receivable of approximately $45 million, inventory of approximately $25 million, and net other liabilities of approximately $10 million. Acquired intangible assets consist of developed technology and are being amortized over 16 years. In 2015, Abbott acquired the remaining shares of Veropharm, increasing its ownership to 100 percent.

In December 2014, Abbott completed the acquisition of Topera, Inc. for approximately $250 million in cash, plus additional payments up to $300 million to be made upon completion of certain regulatory and sales milestones. The acquisition of Topera provides Abbott a foundational entry in the electrophysiology market.  The final allocation of the fair value of the acquisition resulted in non-deductible acquired in-process research and development of approximately $20 million, which is accounted for as an indefinite-lived intangible asset until regulatory approval or discontinuation, non-deductible definite-lived intangibles assets of approximately $325 million, non-deductible goodwill of approximately $175 million, net deferred tax liabilities of approximately $105 million, and contingent consideration of approximately $165 million. The fair value of the contingent consideration was determined based on an independent appraisal. Acquired intangible assets consist of developed technology and trademarks, and are being amortized over 16 years.

The preliminary allocations of fair value of the acquisitions of CFR Pharmaceuticals and Veropharm will be finalized when valuations are completed. Had the aggregate of the above acquisitions taken place on January 1, 2013, consolidated net sales and earnings would not have been significantly different from reported amounts.

X

- Definition
The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

Name: us-gaap_BusinessCombinationDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 48 R11.htm IDEA: XBRL DOCUMENT v3.2.0.727

Other Comprehensive Income
6 Months Ended

Jun. 30, 2015

Other Comprehensive Income

Other Comprehensive Income

Note 4 — Changes in Accumulated Other Comprehensive Income (Loss)

The changes in accumulated other comprehensive income (loss), net of income taxes, are as follows:

Three Months Ended June 30

Cumulative Foreign
Currency Translation
Adjustments

Net Actuarial
Losses and Prior
Service Costs and
Credits

Cumulative
Unrealized Gains
on Marketable
Equity Securities

Cumulative Gains
on Derivative
Instruments
Designated as Cash
Flow Hedges

(in millions)

2015

2014

2015

2014

2015

2014

2015

2014

Balance at March 31

$

(3,727
)

$

(656
)

$

(2,179
)

$

(1,296
)

$

174

$

13

$

125

$

5

Other comprehensive income (loss) before reclassifications

84

(19
)

—

—

660

1

5

—

Amounts reclassified from accumulated other comprehensive income

—

—

22

12

(138
)

(5
)

(30
)

(7
)

Net current period comprehensive income

84

(19
)

22

12

522

(4
)

(25
)

(7
)

Balance at June 30

$

(3,643
)

$

(675
)

$

(2,157
)

$

(1,284
)

$

696

$

9

$

100

$

(2
)

Six Months Ended June 30

Cumulative Foreign
Currency Translation
Adjustments

Net Actuarial
Losses and Prior
Service Costs and
Credits

Cumulative
Unrealized Gains
on Marketable
Equity Securities

Cumulative Gains
on Derivative
Instruments
Designated as Cash
Flow Hedges

(in millions)

2015

2014

2015

2014

2015

2014

2015

2014

Balance at December 31, 2014 and 2013

$

(2,924
)

$

(718
)

$

(2,229
)

$

(1,312
)

$

1

$

13

$

99

$

5

Impact of business dispositions

108

—

19

—

—

—

—

—

Other comprehensive income (loss) before reclassifications

(827
)

43

—

—

833

2

48

(1
)

Amounts reclassified from accumulated other comprehensive income

—

—

53

28

(138
)

(6
)

(47
)

(6
)

Net current period comprehensive income

(827
)

43

53

28

695

(4
)

1

(7
)

Balance at June 30

$

(3,643
)

$

(675
)

$

(2,157
)

$

(1,284
)

$

696

$

9

$

100

$

(2
)

Reclassified amounts for foreign currency translation are recorded in the Condensed Consolidated Statement of Earnings as Net foreign exchange loss (gain); gains on marketable equity securities as Other (income) expense, net and cash flow hedges as Cost of products sold.  Net actuarial losses and prior service cost are included as a component of net periodic benefit plan costs; see Note 11 for additional details.

X

- Definition
The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e689-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e640-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 17

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e716-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e709-108580

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e681-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Reclassification Adjustments

-URI http://asc.fasb.org/extlink&oid=6522872

+ Details

Name: us-gaap_ComprehensiveIncomeNoteTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 49 R23.htm IDEA: XBRL DOCUMENT v3.2.0.727

Other Comprehensive Income (Tables)
6 Months Ended

Jun. 30, 2015

Other Comprehensive Income

Schedule of the changes in accumulated other comprehensive income (loss), net of income taxes

Three Months Ended June 30

Cumulative Foreign
Currency Translation
Adjustments

Net Actuarial
Losses and Prior
Service Costs and
Credits

Cumulative
Unrealized Gains
on Marketable
Equity Securities

Cumulative Gains
on Derivative
Instruments
Designated as Cash
Flow Hedges

(in millions)

2015

2014

2015

2014

2015

2014

2015

2014

Balance at March 31

$

(3,727
)

$

(656
)

$

(2,179
)

$

(1,296
)

$

174

$

13

$

125

$

5

Other comprehensive income (loss) before reclassifications

84

(19
)

—

—

660

1

5

—

Amounts reclassified from accumulated other comprehensive income

—

—

22

12

(138
)

(5
)

(30
)

(7
)

Net current period comprehensive income

84

(19
)

22

12

522

(4
)

(25
)

(7
)

Balance at June 30

$

(3,643
)

$

(675
)

$

(2,157
)

$

(1,284
)

$

696

$

9

$

100

$

(2
)

Six Months Ended June 30

Cumulative Foreign
Currency Translation
Adjustments

Net Actuarial
Losses and Prior
Service Costs and
Credits

Cumulative
Unrealized Gains
on Marketable
Equity Securities

Cumulative Gains
on Derivative
Instruments
Designated as Cash
Flow Hedges

(in millions)

2015

2014

2015

2014

2015

2014

2015

2014

Balance at December 31, 2014 and 2013

$

(2,924
)

$

(718
)

$

(2,229
)

$

(1,312
)

$

1

$

13

$

99

$

5

Impact of business dispositions

108

—

19

—

—

—

—

—

Other comprehensive income (loss) before reclassifications

(827
)

43

—

—

833

2

48

(1
)

Amounts reclassified from accumulated other comprehensive income

—

—

53

28

(138
)

(6
)

(47
)

(6
)

Net current period comprehensive income

(827
)

43

53

28

695

(4
)

1

(7
)

Balance at June 30

$

(3,643
)

$

(675
)

$

(2,157
)

$

(1,284
)

$

696

$

9

$

100

$

(2
)

X

- Definition
Tabular disclosure of the components of accumulated other comprehensive income (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14A

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669686-108580

+ Details

Name: us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 50 R19.htm IDEA: XBRL DOCUMENT v3.2.0.727

Taxes on Earnings
6 Months Ended

Jun. 30, 2015

Taxes on Earnings

Taxes on Earnings

Note 12 — Taxes on Earnings

Taxes on earnings from continuing operations reflect the estimated annual effective rates and include charges for interest and penalties. In the first six months of 2015, taxes on earnings from continuing operations include a tax cost of $69 million related to the disposal of shares of Mylan stock.  Taxes on earnings from continuing operations were not affected by any adjustments as the result of the resolution of various tax positions pertaining to prior years. Tax expense related to discontinued operations includes $665 million of tax expense on certain current-year funds earned outside the U. S. that were not designated as permanently reinvested overseas. Earnings from discontinued operations, net of tax, in the first six months of 2015 also reflects the recognition of $17 million of net tax benefits primarily as a result of the resolution of various tax positions related to AbbVie’s operations for years prior to the separation. The conclusion of these tax matters decreased the gross amount of unrecognized tax benefits by approximately $35 million. Taxes on earnings from continuing operations, in the first six months of 2014, reflect a tax cost of $7 million, primarily as a result of the resolution of various tax positions related to the branded generics pharmaceutical business.  Earnings from discontinued operations, net of tax, in the first six months of 2014 reflects the recognition of $109 million of net tax benefits primarily as a result of the resolution of various tax positions related to the developed markets branded generics pharmaceuticals business, as well as AbbVie’s operations, for years prior to the separation. The conclusion of these tax matters decreased the gross amount of unrecognized tax benefits by approximately $134 million.

Tax authorities in various jurisdictions regularly review Abbott’s income tax filings.  Abbott believes that it is reasonably possible that the recorded amount of gross unrecognized tax benefits may decrease by $525 million to $635 million, including cash adjustments, within the next twelve months as a result of concluding various domestic and international tax matters. In the U.S., Abbott’s federal income tax returns through 2011 are settled except for two issues.

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 51 R15.htm IDEA: XBRL DOCUMENT v3.2.0.727

Incentive Stock Programs
6 Months Ended

Jun. 30, 2015

Incentive Stock Programs

Incentive Stock Programs

Note 8 — Incentive Stock Programs

In the first six months of 2015, Abbott granted 5,518,363 stock options, 660,787 restricted stock awards and 5,774,560 restricted stock units under its incentive stock programs.  At June 30, 2015, approximately 86 million shares were reserved for future grants.  Information regarding the number of stock options outstanding and exercisable at June 30, 2015 is as follows:

Outstanding

Exercisable

Number of shares

37,098,123

27,421,775

Weighted average remaining life (years)

4.9

3.4

Weighted average exercise price

$

31.06

$

26.83

Aggregate intrinsic value (in millions)

$

669

$

611

The total unrecognized share-based compensation cost at June 30, 2015 amounted to approximately $249 million which is expected to be recognized over the next three years.

X

- Definition
The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 40

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 52 R13.htm IDEA: XBRL DOCUMENT v3.2.0.727

Goodwill and Intangible Assets
6 Months Ended

Jun. 30, 2015

Goodwill and Intangible Assets

Goodwill and Intangible Assets

Note 6 — Goodwill and Intangible Assets

The total amount of goodwill reported was $9.896 billion at June 30, 2015 and $10.067 billion at December 31, 2014, which excluded goodwill classified as held for disposition.  As part of the disposal of the developed markets branded generics pharmaceuticals business in the first six months of 2015, $894 million of goodwill was included as part of the net assets sold. In the first six months of 2015, foreign currency translation adjustments decreased goodwill by approximately $235 million, while purchase price allocation adjustments associated with recent acquisitions increased goodwill by approximately $67 million.  The amount of goodwill related to reportable segments at June 30, 2015 was $3.3 billion for the Established Pharmaceutical Products segment, $286 million for the Nutritional Products segment, $443 million for the Diagnostic Products segment, and $2.9 billion for the Vascular Products segment.  There was no reduction of goodwill relating to impairments.

The gross amount of amortizable intangible assets, primarily product rights and technology was $10.8 billion as of June 30, 2015 and December 31, 2014, and accumulated amortization was $5.1 billion as of June 30, 2015 and $4.9 billion as of December 31, 2014. The December 31, 2014 amounts exclude the intangibles that were classified as held for disposition.  $738 million of intangibles were included in the net assets transferred as part of the disposal of the developed markets branded generics pharmaceuticals business in the first six months of 2015. Indefinite-lived intangible assets, which relate to in-process research and development acquired in a business combination, was approximately $134 million at June 30, 2015 and December 31, 2014. Abbott’s estimated annual amortization expense for intangible assets is approximately $680 million in 2015, $660 million in 2016, $650 million in 2017, $570 million in 2018 and $530 million in 2019. Amortizable intangible assets are amortized over 2 to 20 years (weighted average 12 years).

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16373-109275

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13854-109267

+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 53 R14.htm IDEA: XBRL DOCUMENT v3.2.0.727

Restructuring Plans
6 Months Ended

Jun. 30, 2015

Restructuring Plans

Restructuring Plans

Note 7 — Restructuring Plans

In 2014, Abbott management approved plans to streamline operations in order to reduce costs and improve efficiencies in various Abbott businesses including nutritional and established pharmaceuticals businesses. In the first six months of 2015, charges of approximately $19 million were recognized, of which approximately $1 million is recognized in Cost of products sold and approximately $18 million is recognized in Selling, general and administrative expense. Additional charges of approximately $25 million were recorded primarily for accelerated depreciation. The following summarizes the activity for the first six months of 2015 related to these restructuring actions and the status of the related accrual as of June 30, 2015:

(in millions)

Accrued balance at December 31, 2014

$

118

Restructuring charges recorded in 2015

19

Payments and other adjustments

(44
)

Accrued balance at June 30, 2015

$

93

From 2013 to 2015, Abbott management approved various plans to reduce costs and improve efficiencies across various functional areas. In the first six months of 2015, charges of approximately $25 million were recognized, of which approximately $9 million is recorded in Cost of products sold, approximately $2 million is recorded in Research and Development, and approximately $14 million is recorded in Selling, general and administrative expense. In 2013, Abbott management also approved plans to streamline certain manufacturing operations in order to reduce costs and improve efficiencies in Abbott’s established pharmaceuticals business. In 2012, Abbott management approved plans to streamline various commercial operations in order to reduce costs and improve efficiencies in Abbott’s core diagnostics, established pharmaceuticals and nutritionals businesses. The following summarizes the activity for the first six months of 2015 related to these restructuring actions and the status of the related accrual as of June 30, 2015:

(in millions)

Accrued balance at December 31, 2014

$

135

Restructuring charges recorded in 2015

25

Payments and other adjustments

(42
)

Accrued balance at June 30, 2015

$

118

In 2013 and prior years, Abbott management approved plans to realign its vascular manufacturing operations and core diagnostics business in order to reduce costs. The following summarizes the activity for the first six months of 2015 related to these restructuring actions and the status of the related accrual as of June 30, 2015:

(in millions)

Accrued balance at December 31, 2014

$

39

Payments and other adjustments

(7
)

Accrued balance at June 30, 2015

$

32

X

- References
No definition available.
+ Details

Name: us-gaap_RestructuringAndRelatedActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.P.4)

-URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 5.P.3)

-URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140864-122747

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section P

-Subsection 3, 4

+ Details

Name: us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 54 R16.htm IDEA: XBRL DOCUMENT v3.2.0.727

Financial Instruments, Derivatives and Fair Value Measures
6 Months Ended

Jun. 30, 2015

Financial Instruments, Derivatives and Fair Value Measures

Financial Instruments, Derivatives and Fair Value Measures

Note 9 — Financial Instruments, Derivatives and Fair Value Measures

Certain Abbott foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates for anticipated intercompany purchases by those subsidiaries whose functional currencies are not the U.S. dollar.  These contracts, with notional amounts totaling $1.6 billion at June 30, 2015 and $1.5 billion at December 31, 2014 are designated as cash flow hedges of the variability of the cash flows due to changes in foreign exchange rates and are recorded at fair value.   Accumulated gains and losses as of June 30, 2015 will be included in Cost of products sold at the time the products are sold, generally through the next twelve to eighteen months.  The amount of hedge ineffectiveness was not significant in 2015 and 2014.

Abbott enters into foreign currency forward exchange contracts to manage currency exposures for foreign currency denominated third-party trade payables and receivables, and for intercompany loans and trade accounts payable where the receivable or payable is denominated in a currency other than the functional currency of the entity.  For intercompany loans, the contracts require Abbott to sell or buy foreign currencies, primarily European currencies and Japanese yen, in exchange for primarily U.S. dollars and other European currencies.  For intercompany and trade payables and receivables, the currency exposures are primarily the U.S. dollar, European currencies and Japanese yen.  At June 30, 2015 and December 31, 2014, Abbott held $14.1 billion of such foreign currency forward exchange contracts.

Abbott has designated foreign denominated short-term debt as a hedge of the net investment in a foreign subsidiary of approximately $431 million and approximately $445 million as of June 30, 2015 and December 31, 2014, respectively.  Accordingly, changes in the reported value of this debt due to changes in exchange rates are recorded in Accumulated other comprehensive income (loss), net of tax.

Abbott is a party to interest rate hedge contracts totaling approximately $4.0 billion at June 30, 2015 and $1.5 billion at December 31, 2014 to manage its exposure to changes in the fair value of fixed-rate debt.   These contracts are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates.  The effect of the hedge is to change a fixed-rate interest obligation to a variable rate for that portion of the debt.  Abbott records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount.  No hedge ineffectiveness was recorded in income in 2015 or 2014 for these hedges.

The following table summarizes the amounts and location of certain derivative financial instruments as of June 30, 2015 and December 31, 2014:

Fair Value - Assets

Fair Value - Liabilities

(in millions)

June 30,
2015

Dec. 31,
2014

Balance Sheet Caption

June 30,
2015

Dec. 31,
2014

Balance Sheet Caption

Interest rate swaps designated as fair value hedges

$

103

$

101

Deferred income taxes and other assets

$

17

$

—

Post-employment obligations, deferred income taxes and other long-term liabilities

Foreign currency forward exchange contracts:

Hedging instruments

87

107

Prepaid expenses, deferred income taxes, and other receivables

9

—

Other accrued liabilities

Others not designated as hedges

270

150

Prepaid expenses, deferred income taxes, and other receivables

66

130

Other accrued liabilities

Debt designated as a hedge of net investment in a foreign subsidiary

—

—

n/a

431

445

Short-term borrowings

$

460

$

358

$

523

$

575

The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges, debt designated as a hedge of net investment in a foreign subsidiary and certain other derivative financial instruments, as well as the amounts and location of income (expense) and gain (loss) reclassified into income for the three months and six months ended June 30, 2015 and 2014.  The amount of hedge ineffectiveness was not significant in 2015 and 2014 for these hedges.

Gain (loss) Recognized in Other
Comprehensive Income (loss)

Income (expense) and Gain (loss)
Reclassified into Income

Three Months
Ended June 30

Six Months
Ended June 30

Three Months
Ended June 30

Six Months
Ended June 30

Income Statement

(in millions)

2015

2014

2015

2014

2015

2014

2015

2014

Caption

Foreign currency forward exchange contracts designated as cash flow hedges

$

5

$

(3
)

$

48

$

(1
)

$

30

$

2

$

47

$

5

Cost of products sold

Debt designated as a hedge of net investment in a foreign subsidiary

(11
)

(7
)

(14
)

(18
)

n/a

n/a

n/a

n/a

n/a

Interest rate swaps designated as fair value hedges

n/a

n/a

n/a

n/a

(63
)

8

(14
)

19

Interest expense

Foreign currency forward exchange contracts not designated as hedges

n/a

n/a

n/a

n/a

(85
)

(11
)

(101
)

(25
)

Net foreign exchange loss (gain)

The interest rate swaps are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates.  The hedged debt is marked to market, offsetting the effect of marking the interest rate swaps to market.

The carrying values and fair values of certain financial instruments as of June 30, 2015 and December 31, 2014 are shown in the following table. The carrying values of all other financial instruments approximate their estimated fair values.  The counterparties to financial instruments consist of select major international financial institutions.  Abbott does not expect any losses from nonperformance by these counterparties.

June 30, 2015

December 31, 2014

(in millions)

Carrying
Value

Fair
Value

Carrying
Value

Fair
Value

Investment Securities:

Equity securities

$

4,898

$

4,898

$

212

$

212

Other

17

17

17

17

Total Long-term Debt

(5,894
)

(6,323
)

(3,463
)

(4,113
)

Foreign Currency Forward Exchange Contracts:

Receivable position

357

357

263

263

(Payable) position

(75
)

(75
)

(135
)

(135
)

Interest Rate Hedge Contracts:

Receivable position

103

103

101

101

Payable position

(17
)

(17
)

—

—

The fair value of the debt was determined based on significant other observable inputs, including current interest rates.

The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the   balance sheet:

Basis of Fair Value Measurement

(in millions)

Outstanding
Balances

Quoted
Prices in
Active
Markets

Significant
Other
Observable
Inputs

Significant
Unobservable
Inputs

June 30, 2015:

Equity securities

$

4,682

$

10

$

4,672

$

—

Interest rate swap derivative financial instruments

103

—

103

—

Foreign currency forward exchange contracts

357

—

357

—

Total Assets

$

5,142

$

10

$

5,132

$

—

Fair value of hedged long-term debt

$

4,104

$

—

$

4,104

$

—

Foreign currency forward exchange contracts

75

—

75

—

Interest rate swap derivative financial instruments

17

—

17

—

Contingent consideration related to business combinations

169

—

—

169

Total Liabilities

$

4,365

$

—

$

4,196

$

169

December 31, 2014:

Equity securities

$

9

$

9

$

—

$

—

Interest rate swap derivative financial instruments

101

—

101

—

Foreign currency forward exchange contracts

263

—

263

—

Total Assets

$

373

$

9

$

364

$

—

Fair value of hedged long-term debt

$

1,637

$

—

$

1,637

$

—

Foreign currency forward exchange contracts

135

—

135

—

Contingent consideration related to business combinations

243

—

—

243

Total Liabilities

$

2,015

$

—

$

1,772

$

243

Equity securities are principally comprised of Mylan N.V. ordinary shares.  The fair value of the Mylan equity securities was determined based on the value of the publicly-traded ordinary shares adjusted for the restrictions related to the resale of these shares. The fair value of debt was determined based on the face value of the debt adjusted for the fair value of the interest rate swaps, which is based on a discounted cash flow analysis. The fair value of foreign currency forward exchange contracts is determined using a market approach, which utilizes values for comparable derivative instruments.  The fair value of the contingent consideration was determined based on an independent appraisal adjusted for the time value of money and other changes in fair value primarily resulting from changes in regulatory timelines.

X

- References
No definition available.
+ Details

Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6441202&loc=d3e80720-113993

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4C

-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5624171-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=35706170&loc=d3e41620-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4B

-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5624163-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5579240-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4D

-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5624177-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80784-113994

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=35706170&loc=d3e41641-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5579245-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4H

-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5624258-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80748-113994

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4K

-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5708775-113959

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4J

-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5708773-113959

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4A

-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5618551-113959

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 1B

-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5580258-113959

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4E

-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5624181-113959

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 25

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=35706170&loc=d3e41638-113959

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(n))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 55 R34.htm IDEA: XBRL DOCUMENT v3.2.0.727

Business Acquisitions (Details) - USD ($)
$ in Millions
1 Months Ended 6 Months Ended 12 Months Ended

Sep. 26, 2014

Sep. 26, 2014

Dec. 31, 2014

Jun. 30, 2015

Dec. 31, 2014

Business acquisitions

Subsequent payment related to working capital adjustment $ 5

Net cash paid, net of cash on hand of acquired company $ 4

Minimum

Allocation of the fair value

Amortization period of acquired intangible assets 2 years

Maximum

Allocation of the fair value

Amortization period of acquired intangible assets 20 years

Average

Allocation of the fair value

Amortization period of acquired intangible assets 12 years

CFR Pharmaceuticals SA

Business acquisitions

Cash paid for business acquisition $ 2,900

Net cash paid, net of cash on hand of acquired company 2,800

Assumed debt 570 $ 570

Acquisition cost $ 3,400

Percentage of voting interest acquired 99.90% 99.90%

Fair value of the non-controlling interest at the acquisition date $ 3 $ 3

Allocation of the fair value

Acquired intangible assets, non-deductible 1,800 1,800

Goodwill, non-deductible 1,600

Acquired net tangible assets 60 60

Deferred income taxes recorded at acquisition (540) (540)

Total preliminary allocation of fair value 2,920 2,920

Cash and cash equivalents 94 94

Trade accounts receivable 179 179

Inventory 169 169

Other current assets 51 51

Property and equipment 209 209

Other long-term assets 138 138

Borrowings 570 570

Trade accounts payable and other current liabilities 200 200

Other noncurrent liabilities 15 $ 15

Pro forma financial information

Annualized net sales expected $ 750

CFR Pharmaceuticals SA | Minimum

Allocation of the fair value

Amortization period of acquired intangible assets 12 years

CFR Pharmaceuticals SA | Maximum

Allocation of the fair value

Amortization period of acquired intangible assets 16 years

CFR Pharmaceuticals SA | Average

Allocation of the fair value

Amortization period of acquired intangible assets 15 years

Veropharm

Business acquisitions

Cash paid for business acquisition $ 315

Acquisition cost $ 415

Percentage of voting interest acquired 98.00% 100.00% 98.00%

Fair value of the non-controlling interest at the acquisition date $ 5 $ 5

Assumed debt 90 90

Allocation of the fair value

Goodwill, non-deductible 115

Deferred income taxes recorded at acquisition $ (25) (25)

Amortization period of acquired intangible assets 16 years

Trade accounts receivable $ 45 45

Inventory 25 25

Property and equipment 165 165

Other current liabilities 10 10

Pro forma financial information

Non-deductible definite-lived intangible assets 100 100

Topera

Business acquisitions

Cash paid for business acquisition 250

Allocation of the fair value

Goodwill, non-deductible 175

Deferred income taxes recorded at acquisition $ (105) (105)

Amortization period of acquired intangible assets 16 years

Pro forma financial information

Additional payments upon completion of certain development, regulatory and sales milestones $ 300 300

Non-deductible acquired in-process research and development 20 20

Non-deductible definite-lived intangible assets 325 325

Contingent consideration $ 165 $ 165

X

- Definition
Annualized net sales expected as if the business combination or combinations had been completed at the beginning of the period.
+ References
No definition available.
+ Details

Name: abt_BusinessAcquisitionsProFormaAnnualizedNetSales

Namespace Prefix: abt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, and other current liabilities assumed at the acquisition date.
+ References
No definition available.
+ Details

Name: abt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherCurrentLiabilities

Namespace Prefix: abt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of tangible assets, acquired at the acquisition date.
+ References
No definition available.
+ Details

Name: abt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsNet

Namespace Prefix: abt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the amount to be payable for working capital adjustment related to business acquisition.
+ References
No definition available.
+ Details

Name: abt_BusinessCombinationWorkingCapitalAdjustmentToBePayable

Namespace Prefix: abt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_BusinessAcquisitionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of voting equity interests acquired at the acquisition date in the business combination.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1392-128463

+ Details

Name: us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessAcquisitionProFormaInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (e)(1)

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4845-128472

+ Details

Name: us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 30

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6578-128477

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 30

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6613-128477

+ Details

Name: us-gaap_BusinessCombinationConsiderationTransferred1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (c)(3)

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

+ Details

Name: us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liability recognized arising from contingent consideration in a business combination.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 35

-Paragraph 1

-Subparagraph b

-URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 25

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476

+ Details

Name: us-gaap_BusinessCombinationContingentConsiderationLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of assets acquired at the acquisition date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4845-128472

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4845-128472

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4845-128472

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4845-128472

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4845-128472

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4845-128472

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of deferred tax liability attributable to taxable temporary differences due after one year or the normal operating cycle, if longer, assumed at the acquisition date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4845-128472

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4845-128472

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of intangible assets, excluding goodwill, acquired at the acquisition date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4845-128472

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of identifiable intangible assets recognized as of the acquisition date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 55

-Paragraph 37

-URI http://asc.fasb.org/extlink&oid=35744172&loc=d3e2207-128464

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4845-128472

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of inventory recognized as of the acquisition date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4845-128472

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 55

-Paragraph 37

-URI http://asc.fasb.org/extlink&oid=35744172&loc=d3e2207-128464

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4845-128472

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4845-128472

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4845-128472

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4845-128472

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of property, plant, and equipment recognized as of the acquisition date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4845-128472

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 55

-Paragraph 37

-URI http://asc.fasb.org/extlink&oid=35744172&loc=d3e2207-128464

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

+ Details

Name: us-gaap_GoodwillAcquiredDuringPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquireBusinessesGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name: us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_WeightedAverageMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=abt_CfrPharmaceuticalsSaMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=abt_VeropharmMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=abt_ToperaMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 56 R21.htm IDEA: XBRL DOCUMENT v3.2.0.727

Discontinued Operations (Tables)
6 Months Ended

Jun. 30, 2015

Discontinued Operations.

Components of discontinued operations

Three Months Ended
June 30

Six Months Ended
June 30

(in millions)

2015

2014

2015

2014

Net Sales

Developed markets generics pharmaceuticals and animal health businesses

$

—

$

494

$

256

$

983

AbbVie

—

—

—

—

Total

$

—

$

494

$

256

$

983

Earnings (Loss) Before Tax

Developed markets generics pharmaceuticals and animal health businesses

$

(5
)

$

79

$

20

$

161

AbbVie

—

—

—

—

Total

$

(5
)

$

79

$

20

$

161

Income Tax Expense (Benefit)

Developed markets generics pharmaceuticals and animal health businesses

$

—

$

44

$

12

$

11

AbbVie

(4
)

(6
)

(17
)

(42
)

Total

$

(4
)

$

38

$

(5
)

$

(31
)

Net Earnings

Developed markets generics pharmaceuticals and animal health businesses

$

(5
)

$

35

$

8

$

150

AbbVie

4

6

17

42

Total

$

(1
)

$

41

$

25

$

192

Summary of the assets and liabilities held for sale

(in millions)

June 30,
2015

December 31,
2014

Trade receivables, net

$

39

$

498

Total inventories

23

254

Prepaid expenses, deferred income taxes, and other receivables

31

140

Current assets held for disposition

93

892

Net property and equipment

2

125

Intangible assets, net of amortization

—

804

Goodwill

—

950

Deferred income taxes and other assets

—

55

Non-current assets held for disposition

2

1,934

Total assets held for disposition

$

95

$

2,826

Trade accounts payable

$

279

$

423

Salaries, wages, commissions and other accrued liabilities

13

257

Current liabilities held for disposition

292

680

Post-employment obligations, deferred income taxes and other long-term liabilities

—

108

Total liabilities held for disposition

$

292

$

788

X

- Definition
Tabular disclosure of disposal groups, which may include the classification and carrying value of the assets and liabilities comprising of the disposal group.
+ References
No definition available.
+ Details

Name: abt_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsBalanceSheetTableTextBlock

Namespace Prefix: abt_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of disposal groups, which may include the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss), amounts of revenues and pretax profit or loss reported in discontinued operations, the classification and carrying value of the assets and liabilities comprising the disposal group, and the segment in which the disposal group was reported. Also may include the amount of adjustments to amounts previously reported in discontinued operations such as resolution of contingencies arising from the disposal transaction or the operations of the component prior to disposal.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1510-107760

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e957-107759

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=8077374&loc=d3e2443-110228

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1474-107760

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

+ Details

Name: us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 57 R26.htm IDEA: XBRL DOCUMENT v3.2.0.727

Incentive Stock Programs (Tables)
6 Months Ended

Jun. 30, 2015

Incentive Stock Programs

Stock options outstanding and exercisable

Outstanding

Exercisable

Number of shares

37,098,123

27,421,775

Weighted average remaining life (years)

4.9

3.4

Weighted average exercise price

$

31.06

$

26.83

Aggregate intrinsic value (in millions)

$

669

$

611

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 58 R41.htm IDEA: XBRL DOCUMENT v3.2.0.727

Financial Instruments, Derivatives and Fair Value Measures (Details 2) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Net investment hedges | Designated as hedging instrument

Gain (loss) on derivatives

Gain (loss) Recognized in Other Comprehensive Income (loss) $ (11) $ (7) $ (14) $ (18)

Interest rate swaps | Fair value hedges | Designated as hedging instrument | Interest expense

Gain (loss) on derivatives

Gain (loss) Reclassified into Income (63) 8 (14) 19

Foreign currency forward exchange contracts | Not designated as hedging instrument | Net foreign exchange loss (gain)

Gain (loss) on derivatives

Gain (loss) Reclassified into Income (85) (11) (101) (25)

Foreign currency forward exchange contracts | Cash flow hedges | Designated as hedging instrument | Cost of products sold

Gain (loss) on derivatives

Gain (loss) Recognized in Other Comprehensive Income (loss) 5 (3) 48 (1)

Gain (loss) Reclassified into Income $ 30 $ 2 $ 47 $ 5

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DerivativeInstrumentsGainLossLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4C

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5624171-113959

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4D

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5624177-113959

+ Details

Name: us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The effective portion of gains and losses (net) on derivative instruments designated and qualifying as hedging instruments that was recognized in other comprehensive income during the current period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4C

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5624171-113959

+ Details

Name: us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ForeignCurrencyGainLossMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 59 R5.htm IDEA: XBRL DOCUMENT v3.2.0.727

Condensed Consolidated Balance Sheet - USD ($)
$ in Millions

Jun. 30, 2015

Dec. 31, 2014

Current Assets:

Cash and cash equivalents $ 4,048 $ 4,063

Short-term investments 7,129 397

Trade receivables, less allowances of $362 in 2015 and $310 in 2014 3,553 3,586

Inventories:

Finished products 1,869 1,807

Work in process 303 278

Materials 563 558

Total inventories 2,735 2,643

Prepaid expenses, deferred income taxes, and other receivables 3,573 3,680

Current assets held for disposition 93 892

Total Current Assets 21,131 15,261

Investments 243 229

Property and Equipment, at cost 12,433 12,632

Less: accumulated depreciation and amortization 6,695 6,697

Net property and equipment 5,738 5,935

Intangible assets, net of amortization 5,785 6,198

Goodwill 9,896 10,067

Deferred income taxes and other assets 1,330 1,651

Non-current assets held for disposition 2 1,934

Total Assets 44,125 41,275

Current Liabilities:

Short-term borrowings 2,867 4,382

Trade accounts payable 1,000 1,064

Salaries, wages and commissions 759 776

Other accrued liabilities 3,288 2,943

Dividends payable 358 362

Income taxes payable 589 270

Current portion of long-term debt 32 55

Current liabilities held for disposition 292 680

Total Current Liabilities 9,185 10,532

Long-term debt 5,862 3,408

Post-employment Obligations, deferred income taxes and other long - term Liabilities $ 5,952 5,588

Non-current liabilities held for disposition $ 108

Commitments and Contingencies

Shareholders' Investment:

Preferred shares, one dollar par value Authorized - 1,000,000 shares, none issued

Common shares, without par value Authorized - 2,400,000,000 shares Issued at stated capital amount - Shares: 2015: 1,699,703,688; 2014: 1,694,929,949 $ 12,566 $ 12,383

Common shares held in treasury, at cost - Shares: 2015:209,262,223; 2014: 186,894,515 (9,716) (8,678)

Earnings employed in the business 25,162 22,874

Accumulated other comprehensive income (loss) (5,004) (5,053)

Total Abbott Shareholders' Investment 23,008 21,526

Noncontrolling Interests in Subsidiaries 118 113

Total Shareholders' Investment 23,126 21,639

Total Liabilities and Shareholders' Investment $ 44,125 $ 41,275

X

- Definition
Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

+ Details

Name: us-gaap_AccountsPayableTradeCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3-4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a(1)

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 15

-Article 9

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 15

-Subparagraph b(1)

-Article 7

+ Details

Name: us-gaap_AccruedIncomeTaxesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.14)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 14

-Article 5

+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e681-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14A

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669686-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1107-107759

+ Details

Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),19)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.17)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 7

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 25

-Article 5

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 17

-Article 9

+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

+ Details

Name: us-gaap_DividendsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph ((a)(1),(b))

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a

-Article 5

+ Details

Name: us-gaap_InventoryFinishedGoods

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6386567&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryNetAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(4))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a

-Article 5

+ Details

Name: us-gaap_InventoryRawMaterials

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a

-Article 5

+ Details

Name: us-gaap_InventoryWorkInProcess

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1107-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

+ Details

Name: us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1107-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

+ Details

Name: us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of long-term debt, after unamortized discount or premium, scheduled to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_LongTermDebtCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying amount of long-term debt, net of unamortized discount or premium, excluding amounts to be repaid within one year or the normal operating cycle, if longer (current maturities). Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

+ Details

Name: us-gaap_LongTermDebtNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.12)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LongTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 27

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 7

+ Details

Name: us-gaap_MinorityInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e7018-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

+ Details

Name: us-gaap_OtherAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.8)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

+ Details

Name: us-gaap_OtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 17

-Article 5

+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 24

-Article 5

+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.13)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),16(a)(1))

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 16

-Subparagraph a(1)

-Article 7

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 13

-Subparagraph 2, 3

-Article 9

+ Details

Name: us-gaap_ShortTermBorrowings

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Investments which are intended to be sold in the short term (usually less than one year or the normal operating cycle, whichever is longer) including trading securities, available-for-sale securities, held-to-maturity securities, and other short-term investments not otherwise listed in the existing taxonomy.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.2)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Subparagraph g

-Article 7

+ Details

Name: us-gaap_ShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4I

-URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4590271-111686

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4568740-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4568447-111683

+ Details

Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656

+ Details

Name: us-gaap_TreasuryStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 60 R10.htm IDEA: XBRL DOCUMENT v3.2.0.727

Supplemental Financial Information
6 Months Ended

Jun. 30, 2015

Supplemental Financial Information

Supplemental Financial Information

Note 3 — Supplemental Financial Information

Shares of unvested restricted stock that contain non-forfeitable rights to dividends are treated as participating securities and are included in the computation of earnings per share under the two-class method.  Under the two-class method, net earnings are allocated between common shares and participating securities. Earnings from Continuing Operations allocated to common shares for the three months ended June 30, 2015 and 2014 were $783 million and $423 million, respectively and for the six months ended June 30, 2015 and 2014 were $1,309 million and $646 million, respectively.  Net earnings allocated to common shares for the three months ended June 30, 2015 and 2014 were $780 million and $463 million, respectively, and for the six months ended June 30, 2015 and 2014 were $3,061 million and $837 million, respectively.

Other (income) expense, net in the second quarter of 2015 primarily relates to a $207 million gain on the sale of a portion of Abbott’s position in Mylan stock and $79 million of income resulting from a decrease in the fair value of contingent consideration related to a business acquisition.  In the second quarter of 2015, Abbott sold 40.3 million of the 110 million ordinary shares of Mylan N.V. received in the sale of the developed markets branded generics pharmaceuticals business to Mylan.  Abbott received $2.29 billion in net proceeds from the sale of these shares.  As a result of this sale, Abbott’s ownership interest in Mylan N.V. decreased from approximately 22% to approximately 14%.

Other, net in Net cash from operating activities in the Condensed Consolidated Statement of Cash Flows for the first six months of 2015 and 2014 includes the effects of contributions to defined benefit plans of $547 million and $330 million, respectively, and to the post-employment medical and dental benefit plans of $24 million and $40 million in the six month periods of 2015 and 2014, respectively. The first six months of 2015 also includes the non-cash impact of approximately $1.1 billion of tax expense associated with the gain on the sale of businesses. The first six months of 2014 includes approximately $70 million of tax benefits, net of cash refunded by taxing authorities, resulting from the resolution of various tax positions pertaining to prior years.

The components of short-term and long-term investments as of June 30, 2015 and December 31, 2014 are as follows:

Short-term Investments

June 30,

December 31,

(in millions)

2015

2014

Equity securities

$

4,672

$

—

Other, primarily bank time deposits

2,457

397

Total

$

7,129

$

397

Long-term Investments

(in millions)

Equity securities

$

226

$

212

Other

17

17

Total

$

243

$

229

The short-term investments in equity securities reflect the market value as of June 30, 2015 of 69.7 million of ordinary shares of Mylan N.V.

In March 2015, Abbott issued $2.5 billion of long-term debt consisting of $750 million of 2.00% Senior Notes due March 15, 2020; $750 million of 2.55% Senior Notes due March 15, 2022; and $1.0 billion of 2.95% Senior Notes due March 15, 2025.  Abbott also entered into interest rate swap contracts totaling $2.5 billion.  These contracts have the effect of changing Abbott’s obligation from a fixed interest rate to a variable interest rate obligation.

X

- Definition
The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.
+ References
No definition available.
+ Details

Name: us-gaap_AdditionalFinancialInformationDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockSupplementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 61 R27.htm IDEA: XBRL DOCUMENT v3.2.0.727

Financial Instruments, Derivatives and Fair Value Measures (Tables)
6 Months Ended

Jun. 30, 2015

Financial Instruments, Derivatives and Fair Value Measures

Summary of the amounts and location of certain derivative financial instruments

Fair Value - Assets

Fair Value - Liabilities

(in millions)

June 30,
2015

Dec. 31,
2014

Balance Sheet Caption

June 30,
2015

Dec. 31,
2014

Balance Sheet Caption

Interest rate swaps designated as fair value hedges

$

103

$

101

Deferred income taxes and other assets

$

17

$

—

Post-employment obligations, deferred income taxes and other long-term liabilities

Foreign currency forward exchange contracts:

Hedging instruments

87

107

Prepaid expenses, deferred income taxes, and other receivables

9

—

Other accrued liabilities

Others not designated as hedges

270

150

Prepaid expenses, deferred income taxes, and other receivables

66

130

Other accrued liabilities

Debt designated as a hedge of net investment in a foreign subsidiary

—

—

n/a

431

445

Short-term borrowings

$

460

$

358

$

523

$

575

Schedule of derivatives gain (loss) in OCI and earnings

Gain (loss) Recognized in Other
Comprehensive Income (loss)

Income (expense) and Gain (loss)
Reclassified into Income

Three Months
Ended June 30

Six Months
Ended June 30

Three Months
Ended June 30

Six Months
Ended June 30

Income Statement

(in millions)

2015

2014

2015

2014

2015

2014

2015

2014

Caption

Foreign currency forward exchange contracts designated as cash flow hedges

$

5

$

(3
)

$

48

$

(1
)

$

30

$

2

$

47

$

5

Cost of products sold

Debt designated as a hedge of net investment in a foreign subsidiary

(11
)

(7
)

(14
)

(18
)

n/a

n/a

n/a

n/a

n/a

Interest rate swaps designated as fair value hedges

n/a

n/a

n/a

n/a

(63
)

8

(14
)

19

Interest expense

Foreign currency forward exchange contracts not designated as hedges

n/a

n/a

n/a

n/a

(85
)

(11
)

(101
)

(25
)

Net foreign exchange loss (gain)

Schedule of carrying values and fair values of certain financial instruments

June 30, 2015

December 31, 2014

(in millions)

Carrying
Value

Fair
Value

Carrying
Value

Fair
Value

Investment Securities:

Equity securities

$

4,898

$

4,898

$

212

$

212

Other

17

17

17

17

Total Long-term Debt

(5,894
)

(6,323
)

(3,463
)

(4,113
)

Foreign Currency Forward Exchange Contracts:

Receivable position

357

357

263

263

(Payable) position

(75
)

(75
)

(135
)

(135
)

Interest Rate Hedge Contracts:

Receivable position

103

103

101

101

Payable position

(17
)

(17
)

—

—

Schedule of assets and liabilities measured at fair value on a recurring basis

Basis of Fair Value Measurement

(in millions)

Outstanding
Balances

Quoted
Prices in
Active
Markets

Significant
Other
Observable
Inputs

Significant
Unobservable
Inputs

June 30, 2015:

Equity securities

$

4,682

$

10

$

4,672

$

—

Interest rate swap derivative financial instruments

103

—

103

—

Foreign currency forward exchange contracts

357

—

357

—

Total Assets

$

5,142

$

10

$

5,132

$

—

Fair value of hedged long-term debt

$

4,104

$

—

$

4,104

$

—

Foreign currency forward exchange contracts

75

—

75

—

Interest rate swap derivative financial instruments

17

—

17

—

Contingent consideration related to business combinations

169

—

—

169

Total Liabilities

$

4,365

$

—

$

4,196

$

169

December 31, 2014:

Equity securities

$

9

$

9

$

—

$

—

Interest rate swap derivative financial instruments

101

—

101

—

Foreign currency forward exchange contracts

263

—

263

—

Total Assets

$

373

$

9

$

364

$

—

Fair value of hedged long-term debt

$

1,637

$

—

$

1,637

$

—

Foreign currency forward exchange contracts

135

—

135

—

Contingent consideration related to business combinations

243

—

—

243

Total Liabilities

$

2,015

$

—

$

1,772

$

243

X

- References
No definition available.
+ Details

Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13476-108611

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13467-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6447952&loc=d3e13220-108610

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 30

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13433-108611

+ Details

Name: us-gaap_FairValueByBalanceSheetGroupingTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4C

-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5624171-113959

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4A

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5618551-113959

+ Details

Name: us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4B

-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5624163-113959

+ Details

Name: us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19190-110258

+ Details

Name: us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 62 FilingSummary.xml IDEA: XBRL DOCUMENT 3.2.0.727 html 236 286 1 true 70 0 false 4 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.abbott.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - Condensed Consolidated Statement of Earnings Sheet http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings Condensed Consolidated Statement of Earnings Statements 2 false false R3.htm 00200 - Statement - Condensed Consolidated Statement of Comprehensive Income Sheet http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome Condensed Consolidated Statement of Comprehensive Income Statements 3 false false R4.htm 00205 - Statement - Condensed Consolidated Statement of Comprehensive Income (Parenthetical) Sheet http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncomeParenthetical Condensed Consolidated Statement of Comprehensive Income (Parenthetical) Statements 4 false false R5.htm 00300 - Statement - Condensed Consolidated Balance Sheet Sheet http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet Condensed Consolidated Balance Sheet Statements 5 false false R6.htm 00305 - Statement - Condensed Consolidated Balance Sheet (Parenthetical) Sheet http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheetParenthetical Condensed Consolidated Balance Sheet (Parenthetical) Statements 6 false false R7.htm 00400 - Statement - Condensed Consolidated Statement of Cash Flows Sheet http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfCashFlows Condensed Consolidated Statement of Cash Flows Statements 7 false false R8.htm 10101 - Disclosure - Basis of Presentation Sheet http://www.abbott.com/role/DisclosureBasisOfPresentation Basis of Presentation Notes 8 false false R9.htm 10201 - Disclosure - Discontinued Operations Sheet http://www.abbott.com/role/DisclosureDiscontinuedOperations Discontinued Operations Notes 9 false false R10.htm 10301 - Disclosure - Supplemental Financial Information Sheet http://www.abbott.com/role/DisclosureSupplementalFinancialInformation Supplemental Financial Information Notes 10 false false R11.htm 10401 - Disclosure - Other Comprehensive Income Sheet http://www.abbott.com/role/DisclosureOtherComprehensiveIncome Other Comprehensive Income Notes 11 false false R12.htm 10501 - Disclosure - Business Acquisitions Sheet http://www.abbott.com/role/DisclosureBusinessAcquisitions Business Acquisitions Notes 12 false false R13.htm 10601 - Disclosure - Goodwill and Intangible Assets Sheet http://www.abbott.com/role/DisclosureGoodwillAndIntangibleAssets Goodwill and Intangible Assets Notes 13 false false R14.htm 10701 - Disclosure - Restructuring Plans Sheet http://www.abbott.com/role/DisclosureRestructuringPlans Restructuring Plans Notes 14 false false R15.htm 10801 - Disclosure - Incentive Stock Programs Sheet http://www.abbott.com/role/DisclosureIncentiveStockPrograms Incentive Stock Programs Notes 15 false false R16.htm 10901 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures Sheet http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasures Financial Instruments, Derivatives and Fair Value Measures Notes 16 false false R17.htm 11001 - Disclosure - Litigation and Environmental Matters Sheet http://www.abbott.com/role/DisclosureLitigationAndEnvironmentalMatters Litigation and Environmental Matters Notes 17 false false R18.htm 11101 - Disclosure - Post-Employment Benefits Sheet http://www.abbott.com/role/DisclosurePostEmploymentBenefits Post-Employment Benefits Notes 18 false false R19.htm 11201 - Disclosure - Taxes on Earnings Sheet http://www.abbott.com/role/DisclosureTaxesOnEarnings Taxes on Earnings Notes 19 false false R20.htm 11301 - Disclosure - Segment Information Sheet http://www.abbott.com/role/DisclosureSegmentInformation Segment Information Notes 20 false false R21.htm 30203 - Disclosure - Discontinued Operations (Tables) Sheet http://www.abbott.com/role/DisclosureDiscontinuedOperationsTables Discontinued Operations (Tables) Tables http://www.abbott.com/role/DisclosureDiscontinuedOperations 21 false false R22.htm 30303 - Disclosure - Supplemental Financial Information (Tables) Sheet http://www.abbott.com/role/DisclosureSupplementalFinancialInformationTables Supplemental Financial Information (Tables) Tables http://www.abbott.com/role/DisclosureSupplementalFinancialInformation 22 false false R23.htm 30403 - Disclosure - Other Comprehensive Income (Tables) Sheet http://www.abbott.com/role/DisclosureOtherComprehensiveIncomeTables Other Comprehensive Income (Tables) Tables http://www.abbott.com/role/DisclosureOtherComprehensiveIncome 23 false false R24.htm 30503 - Disclosure - Business Acquisitions (Tables) Sheet http://www.abbott.com/role/DisclosureBusinessAcquisitionsTables Business Acquisitions (Tables) Tables http://www.abbott.com/role/DisclosureBusinessAcquisitions 24 false false R25.htm 30703 - Disclosure - Restructuring Plans (Tables) Sheet http://www.abbott.com/role/DisclosureRestructuringPlansTables Restructuring Plans (Tables) Tables http://www.abbott.com/role/DisclosureRestructuringPlans 25 false false R26.htm 30803 - Disclosure - Incentive Stock Programs (Tables) Sheet http://www.abbott.com/role/DisclosureIncentiveStockProgramsTables Incentive Stock Programs (Tables) Tables http://www.abbott.com/role/DisclosureIncentiveStockPrograms 26 false false R27.htm 30903 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures (Tables) Sheet http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresTables Financial Instruments, Derivatives and Fair Value Measures (Tables) Tables http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasures 27 false false R28.htm 31103 - Disclosure - Post-Employment Benefits (Tables) Sheet http://www.abbott.com/role/DisclosurePostEmploymentBenefitsTables Post-Employment Benefits (Tables) Tables http://www.abbott.com/role/DisclosurePostEmploymentBenefits 28 false false R29.htm 31303 - Disclosure - Segment Information (Tables) Sheet http://www.abbott.com/role/DisclosureSegmentInformationTables Segment Information (Tables) Tables http://www.abbott.com/role/DisclosureSegmentInformation 29 false false R30.htm 40201 - Disclosure - Discontinued Operations (Details) Sheet http://www.abbott.com/role/DisclosureDiscontinuedOperationsDetails Discontinued Operations (Details) Details http://www.abbott.com/role/DisclosureDiscontinuedOperationsTables 30 false false R31.htm 40202 - Disclosure - Discontinued Operations (Details 2) Sheet http://www.abbott.com/role/DisclosureDiscontinuedOperationsDetails2 Discontinued Operations (Details 2) Details http://www.abbott.com/role/DisclosureDiscontinuedOperationsTables 31 false false R32.htm 40301 - Disclosure - Supplemental Financial Information (Details) Sheet http://www.abbott.com/role/DisclosureSupplementalFinancialInformationDetails Supplemental Financial Information (Details) Details http://www.abbott.com/role/DisclosureSupplementalFinancialInformationTables 32 false false R33.htm 40401 - Disclosure - Other Comprehensive Income (Details) Sheet http://www.abbott.com/role/DisclosureOtherComprehensiveIncomeDetails Other Comprehensive Income (Details) Details http://www.abbott.com/role/DisclosureOtherComprehensiveIncomeTables 33 false false R34.htm 40501 - Disclosure - Business Acquisitions (Details) Sheet http://www.abbott.com/role/DisclosureBusinessAcquisitionsDetails Business Acquisitions (Details) Details http://www.abbott.com/role/DisclosureBusinessAcquisitionsTables 34 false false R35.htm 40601 - Disclosure - Goodwill and Intangible Assets (Details) Sheet http://www.abbott.com/role/DisclosureGoodwillAndIntangibleAssetsDetails Goodwill and Intangible Assets (Details) Details http://www.abbott.com/role/DisclosureGoodwillAndIntangibleAssets 35 false false R36.htm 40602 - Disclosure - Goodwill and Intangible Assets (Details 2) Sheet http://www.abbott.com/role/DisclosureGoodwillAndIntangibleAssetsDetails2 Goodwill and Intangible Assets (Details 2) Details http://www.abbott.com/role/DisclosureGoodwillAndIntangibleAssets 36 false false R37.htm 40701 - Disclosure - Restructuring Plans (Details) Sheet http://www.abbott.com/role/DisclosureRestructuringPlansDetails Restructuring Plans (Details) Details http://www.abbott.com/role/DisclosureRestructuringPlansTables 37 false false R38.htm 40702 - Disclosure - Restructuring Plans (Details 2) Sheet http://www.abbott.com/role/DisclosureRestructuringPlansDetails2 Restructuring Plans (Details 2) Details http://www.abbott.com/role/DisclosureRestructuringPlansTables 38 false false R39.htm 40801 - Disclosure - Incentive Stock Programs (Details) Sheet http://www.abbott.com/role/DisclosureIncentiveStockProgramsDetails Incentive Stock Programs (Details) Details http://www.abbott.com/role/DisclosureIncentiveStockProgramsTables 39 false false R40.htm 40901 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures (Details) Sheet http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresDetails Financial Instruments, Derivatives and Fair Value Measures (Details) Details http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresTables 40 false false R41.htm 40902 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures (Details 2) Sheet http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresDetails2 Financial Instruments, Derivatives and Fair Value Measures (Details 2) Details http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresTables 41 false false R42.htm 40903 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures (Details 3) Sheet http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresDetails3 Financial Instruments, Derivatives and Fair Value Measures (Details 3) Details http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresTables 42 false false R43.htm 40904 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures (Details 4) Sheet http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresDetails4 Financial Instruments, Derivatives and Fair Value Measures (Details 4) Details http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresTables 43 false false R44.htm 41001 - Disclosure - Litigation and Environmental Matters (Details) Sheet http://www.abbott.com/role/DisclosureLitigationAndEnvironmentalMattersDetails Litigation and Environmental Matters (Details) Details http://www.abbott.com/role/DisclosureLitigationAndEnvironmentalMatters 44 false false R45.htm 41101 - Disclosure - Post-Employment Benefits (Details) Sheet http://www.abbott.com/role/DisclosurePostEmploymentBenefitsDetails Post-Employment Benefits (Details) Details http://www.abbott.com/role/DisclosurePostEmploymentBenefitsTables 45 false false R46.htm 41201 - Disclosure - Taxes on Earnings (Details) Sheet http://www.abbott.com/role/DisclosureTaxesOnEarningsDetails Taxes on Earnings (Details) Details http://www.abbott.com/role/DisclosureTaxesOnEarnings 46 false false R47.htm 41301 - Disclosure - Segment Information (Details) Sheet http://www.abbott.com/role/DisclosureSegmentInformationDetails Segment Information (Details) Details http://www.abbott.com/role/DisclosureSegmentInformationTables 47 false false All Reports Book All Reports In ''Condensed Consolidated Balance Sheet'', column(s) 3, 4 are contained in other reports, so were removed by flow through suppression. In ''Condensed Consolidated Statement of Cash Flows'', column(s) 1, 2 are contained in other reports, so were removed by flow through suppression. abt-20150630.xml abt-20150630_cal.xml abt-20150630_def.xml abt-20150630_lab.xml abt-20150630_pre.xml abt-20150630.xsd true true XML 63 R38.htm IDEA: XBRL DOCUMENT v3.2.0.727

Restructuring Plans (Details 2)
$ in Millions
6 Months Ended

Jun. 30, 2015

USD ($)

Restructuring Plan 2014

Restructuring reserve activity

Restructuring reserve, beginning balance of the period $ 118

Restructuring charges 19

Payments and other adjustments (44)

Restructuring reserve, ending balance of the period 93

Additional charges for accelerated depreciation 25

Restructuring Plan 2014 | Cost of products sold

Restructuring reserve activity

Restructuring charges 1

Restructuring Plan 2014 | Selling, general and administrative expense

Restructuring reserve activity

Restructuring charges 18

Restructuring Plan 2015

Restructuring reserve activity

Restructuring reserve, beginning balance of the period 135

Restructuring charges 25

Payments and other adjustments (42)

Restructuring reserve, ending balance of the period 118

Restructuring Plan 2015 | Cost of products sold

Restructuring reserve activity

Restructuring charges 9

Restructuring Plan 2015 | Selling, general and administrative expense

Restructuring reserve activity

Restructuring charges 14

Restructuring Plan 2013 and Prior Years

Restructuring reserve activity

Restructuring reserve, beginning balance of the period 39

Payments and other adjustments (7)

Restructuring reserve, ending balance of the period $ 32

X

- Definition
The change in the restructuring reserve related to the amount of cash paid and other adjustments during the period.
+ References
No definition available.
+ Details

Name: abt_RestructuringReservePeriodCashSettledAndOtherAdjustments

Namespace Prefix: abt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 5.P.3)

-URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140864-122747

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.P.4(b))

-URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section P

-Subsection 3, 4

+ Details

Name: us-gaap_RestructuringCharges

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.P.4(b))

-URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section P

-Subsection 3, 4

+ Details

Name: us-gaap_RestructuringReserve

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan.
+ References
No definition available.
+ Details

Name: us-gaap_RestructuringReserveAcceleratedDepreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_RestructuringReserveRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_RestructuringCostAndReserveAxis=abt_RestructuringPlan2014Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RestructuringCostAndReserveAxis=abt_RestructuringPlan2015Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RestructuringCostAndReserveAxis=abt_RestructuringPlan2013AndPriorYearsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 64 R20.htm IDEA: XBRL DOCUMENT v3.2.0.727

Segment Information
6 Months Ended

Jun. 30, 2015

Segment Information

Segment Information

Note 13 — Segment Information

Abbott’s principal business is the discovery, development, manufacture and sale of a broad line of health care products.  Abbott’s products are generally sold directly to retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices and government agencies throughout the world.  Abbott’s reportable segments are as follows:

Established Pharmaceutical Products — International sales of a broad line of branded generic pharmaceutical products.

Nutritional Products — Worldwide sales of a broad line of adult and pediatric nutritional products.

Diagnostic Products — Worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites.  For segment reporting purposes, the Core Laboratories Diagnostics, Molecular Diagnostics, Point of Care and Ibis diagnostic divisions are aggregated and reported as the Diagnostic Products segment.

Vascular Products — Worldwide sales of coronary, endovascular, structural heart, vessel closure and other medical device products. For segment reporting purposes, the Vascular and Electrophysiology Products divisions are aggregated and reported as the Vascular Products segment.

Non-reportable segments include the Diabetes Care and Medical Optics segments.

On February 27, 2015, Abbott completed the sale of its developed markets branded generics pharmaceuticals business to Mylan N.V.  This business was previously included in the Established Pharmaceutical Products segment for the first six months of 2014; therefore, the 2014 segment information below has been adjusted to reflect the classification of the developed markets branded generics pharmaceuticals business as part of discontinued operations in the Condensed Consolidated Statement of Earnings.

Abbott’s underlying accounting records are maintained on a legal entity basis for government and public reporting requirements.  Segment disclosures are on a performance basis consistent with internal management reporting.  Intersegment transfers of inventory are recorded at standard cost and are not a measure of segment operating earnings.  The cost of some corporate functions and the cost of certain employee benefits are charged to segments at predetermined rates that approximate cost.  Remaining costs, if any, are not allocated to segments.  In addition, intangible asset amortization is not allocated to operating segments, and intangible assets and goodwill are not included in the measure of each segment’s assets.  The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and are not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.

Net Sales to External Customers

Operating Earnings

Three Months

Six Months

Three Months

Six Months

Ended June 30

Ended June 30

Ended June 30

Ended June 30

(in millions)

2015

2014

2015

2014

2015

2014

2015

2014

Established Pharmaceutical Products

$

977

$

744

$

1,874

$

1,425

$

172

$

160

$

339

$

281

Nutritional Products

1,717

1,731

3,386

3,362

389

302

739

585

Diagnostic Products

1,177

1,189

2,270

2,306

304

279

580

501

Vascular Products

722

765

1,420

1,503

280

303

564

524

Total Reportable Segments

4,593

4,429

8,950

8,596

1,145

1,044

2,222

1,891

Other

577

628

1,117

1,216

Net Sales

$

5,170

$

5,057

$

10,067

$

9,812

Corporate functions and benefit plans costs

(104
)

(103
)

(221
)

(161
)

Non-reportable segments

62

106

117

172

Net interest expense

(17
)

(17
)

(33
)

(37
)

Share-based compensation (a)

(57
)

(48
)

(205
)

(164
)

Amortization of intangible assets

(151
)

(133
)

(307
)

(260
)

Other, net (b)

108

(191
)

66

(442
)

Consolidated Earnings from Continuing Operations Before Taxes

$

986

$

658

$

1,639

$

999

(a)

Approximately 40 to 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards.

(b)

Other, net in 2015 includes a gain on the sale of a portion of Abbott’s position in Mylan stock and a decrease in the fair value of contingent consideration related to a business acquisition, which was partially offset by charges associated with cost reduction initiatives.

X

- References
No definition available.
+ Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 34

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 41

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 33

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 32

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 35

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 40

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 42

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 29

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 31

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

+ Details

Name: us-gaap_SegmentReportingDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

Business Acquisitions (Details) - USD ($) $ in Millions			1 Months Ended	6 Months Ended	12 Months Ended
Business Acquisitions (Details) - USD ($) $ in Millions	Sep. 26, 2014	Sep. 26, 2014	Dec. 31, 2014	Jun. 30, 2015	Dec. 31, 2014
Business acquisitions
Subsequent payment related to working capital adjustment			$ 5
Net cash paid, net of cash on hand of acquired company				$ 4
Minimum
Allocation of the fair value
Amortization period of acquired intangible assets				2 years
Maximum
Allocation of the fair value
Amortization period of acquired intangible assets				20 years
Average
Allocation of the fair value
Amortization period of acquired intangible assets				12 years
CFR Pharmaceuticals SA
Business acquisitions
Cash paid for business acquisition	$ 2,900
Net cash paid, net of cash on hand of acquired company	2,800
Assumed debt	570	$ 570
Acquisition cost	$ 3,400
Percentage of voting interest acquired	99.90%	99.90%
Fair value of the non-controlling interest at the acquisition date	$ 3	$ 3
Allocation of the fair value
Acquired intangible assets, non-deductible	1,800	1,800
Goodwill, non-deductible		1,600
Acquired net tangible assets	60	60
Deferred income taxes recorded at acquisition	(540)	(540)
Total preliminary allocation of fair value	2,920	2,920
Cash and cash equivalents	94	94
Trade accounts receivable	179	179
Inventory	169	169
Other current assets	51	51
Property and equipment	209	209
Other long-term assets	138	138
Borrowings	570	570
Trade accounts payable and other current liabilities	200	200
Other noncurrent liabilities	15	$ 15
Pro forma financial information
Annualized net sales expected	$ 750
CFR Pharmaceuticals SA \| Minimum
Allocation of the fair value
Amortization period of acquired intangible assets	12 years
CFR Pharmaceuticals SA \| Maximum
Allocation of the fair value
Amortization period of acquired intangible assets	16 years
CFR Pharmaceuticals SA \| Average
Allocation of the fair value
Amortization period of acquired intangible assets	15 years
Veropharm
Business acquisitions
Cash paid for business acquisition			$ 315
Acquisition cost					$ 415
Percentage of voting interest acquired			98.00%	100.00%	98.00%
Fair value of the non-controlling interest at the acquisition date			$ 5		$ 5
Assumed debt			90		90
Allocation of the fair value
Goodwill, non-deductible			115
Deferred income taxes recorded at acquisition			$ (25)		(25)
Amortization period of acquired intangible assets			16 years
Trade accounts receivable			$ 45		45
Inventory			25		25
Property and equipment			165		165
Other current liabilities			10		10
Pro forma financial information
Non-deductible definite-lived intangible assets			100		100
Topera
Business acquisitions
Cash paid for business acquisition			250
Allocation of the fair value
Goodwill, non-deductible			175
Deferred income taxes recorded at acquisition			$ (105)		(105)
Amortization period of acquired intangible assets			16 years
Pro forma financial information
Additional payments upon completion of certain development, regulatory and sales milestones			$ 300		300
Non-deductible acquired in-process research and development			20		20
Non-deductible definite-lived intangible assets			325		325
Contingent consideration			$ 165		$ 165

Condensed Consolidated Balance Sheet - USD ($) $ in Millions	Jun. 30, 2015	Dec. 31, 2014
Current Assets:
Cash and cash equivalents	$ 4,048	$ 4,063
Short-term investments	7,129	397
Trade receivables, less allowances of $362 in 2015 and $310 in 2014	3,553	3,586
Inventories:
Finished products	1,869	1,807
Work in process	303	278
Materials	563	558
Total inventories	2,735	2,643
Prepaid expenses, deferred income taxes, and other receivables	3,573	3,680
Current assets held for disposition	93	892
Total Current Assets	21,131	15,261
Investments	243	229
Property and Equipment, at cost	12,433	12,632
Less: accumulated depreciation and amortization	6,695	6,697
Net property and equipment	5,738	5,935
Intangible assets, net of amortization	5,785	6,198
Goodwill	9,896	10,067
Deferred income taxes and other assets	1,330	1,651
Non-current assets held for disposition	2	1,934
Total Assets	44,125	41,275
Current Liabilities:
Short-term borrowings	2,867	4,382
Trade accounts payable	1,000	1,064
Salaries, wages and commissions	759	776
Other accrued liabilities	3,288	2,943
Dividends payable	358	362
Income taxes payable	589	270
Current portion of long-term debt	32	55
Current liabilities held for disposition	292	680
Total Current Liabilities	9,185	10,532
Long-term debt	5,862	3,408
Post-employment Obligations, deferred income taxes and other long - term Liabilities	$ 5,952	5,588
Non-current liabilities held for disposition		$ 108
Commitments and Contingencies
Shareholders' Investment:
Preferred shares, one dollar par value Authorized - 1,000,000 shares, none issued
Common shares, without par value Authorized - 2,400,000,000 shares Issued at stated capital amount - Shares: 2015: 1,699,703,688; 2014: 1,694,929,949	$ 12,566	$ 12,383
Common shares held in treasury, at cost - Shares: 2015:209,262,223; 2014: 186,894,515	(9,716)	(8,678)
Earnings employed in the business	25,162	22,874
Accumulated other comprehensive income (loss)	(5,004)	(5,053)
Total Abbott Shareholders' Investment	23,008	21,526
Noncontrolling Interests in Subsidiaries	118	113
Total Shareholders' Investment	23,126	21,639
Total Liabilities and Shareholders' Investment	$ 44,125	$ 41,275

Restructuring Plans (Details 2) $ in Millions	6 Months Ended
Restructuring Plans (Details 2) $ in Millions	Jun. 30, 2015 USD ($)
Restructuring Plan 2014
Restructuring reserve activity
Restructuring reserve, beginning balance of the period	$ 118
Restructuring charges	19
Payments and other adjustments	(44)
Restructuring reserve, ending balance of the period	93
Additional charges for accelerated depreciation	25
Restructuring Plan 2014 \| Cost of products sold
Restructuring reserve activity
Restructuring charges	1
Restructuring Plan 2014 \| Selling, general and administrative expense
Restructuring reserve activity
Restructuring charges	18
Restructuring Plan 2015
Restructuring reserve activity
Restructuring reserve, beginning balance of the period	135
Restructuring charges	25
Payments and other adjustments	(42)
Restructuring reserve, ending balance of the period	118
Restructuring Plan 2015 \| Cost of products sold
Restructuring reserve activity
Restructuring charges	9
Restructuring Plan 2015 \| Selling, general and administrative expense
Restructuring reserve activity
Restructuring charges	14
Restructuring Plan 2013 and Prior Years
Restructuring reserve activity
Restructuring reserve, beginning balance of the period	39
Payments and other adjustments	(7)
Restructuring reserve, ending balance of the period	$ 32